

- Abbott, J, 910(ab)
 Abdel-Dayem, HM, 1396, 2014, 843(ab), 867(ab)
 Abdel-Nabi, HH, 14, 959(ab), 1000(ab)
 Abe, K, 1019(ab)
 Abe, S, 1019(ab)
 Abel, W, 117
 Abi-Dargham, A, 911(ab)
 Abraham, V, 832(ab)
 Abramovici, J, 1005(ab)
 Abrams, MJ, 710, 910(ab)
 Abrams, PG, 1099
 Aburano, T, 2024, 957(ab), 1020(ab)
 Acharya, AS, 986(ab)
 Achong, DM, 256
 Acito, P, 915(ab)
 Ackerman, RF, 1819
 Ackermann, RF, 908(ab)
 Adachi, I, 1023(ab)
 Adams, HR, 945(ab)
 Adams, M, 974(ab)
 Adatepe, MH, 263
 Adelstein, SJ, 384
 Aden, MD, 1132, 894(ab)
 Adler, A, 997(ab), 1044(ab)
 Adriaens, PJ, 551, 1032(ab)
 Affleck, D, 881(ab)
 Afriyie, M, 973(ab)
 Aftab, N, 2154
 Aggarwal, S, 1548
 Agid, Y, 1481, 1019(ab)
 Agostini, D, 471
 Ahn, CS, 964(ab)
 Ahonen, A, 1255
 Aigner, TG, 1383, 945(ab), 965(ab)
 Akamune, A, 893(ab), 933(ab), 972(ab)
 Akansel, G, 2110, 868(ab)
 Akiba, A, 1005(ab)
 Akiba, H, 958(ab)
 Akoun, G, 81
 Aktolun, C, 464(le)
 Alagona, P, Jr, 1723(le)
 Alamos, F, 838(ab)
 Alavi, A, 269, 590, 751, 1964, 2036, 848(ab), 849(ab), 857(ab), 858(ab), 896(ab), 897(ab), 898(ab), 902(ab), 929(ab), 940(ab), 954(ab), 965(ab), 992(ab), 999(ab), 1012(ab), 1013(ab), 1588(le)
 Albarède, P, 409
 Albert, R, 900(ab)
 Alderson, PO, 570, 1042(ab)
 Alexander, GE, 940(ab)
 Alexander, M, 873(ab), 874(ab)
 Alexoff, DL, 853(ab)
 Aliabadi, P, 643
 Alioth, C, 833(ab)
 Alkire, AL, 974(ab)
 Allada, V, 977(ab)
 Allen, EW, 981(ab), 1034(ab)
 Allen, LF, 23
 Allenberg, JR, 907(ab)
 Allie, D, 1269
 Allman, KC, 2067
 Al-Mohannadi, S, 2014, 867(ab)
 Alpert, NM, 908(ab), 924(ab)
 Altehoefer, C, 886(ab)
 Althouse, L, 972(ab)
 Al-Tikriti, MS, 848(ab), 945(ab)
 Altman, KI, 1725
 Altmann, A, 1982, 1019(ab)
 Al-Zaabi, KS, 978(ab)
 Amano, M, 1008(ab)
 Amarenco, P, 858(ab)
 Ambrose, KR, 1028(ab)
 Ambrosetti, P, 1766
 Aminian, A, 1021(ab)
 Amino, S, 1019(ab)
 Amis, ES, 1042(ab)
 Ammann, W, 157
 Ampil, FL, 1047(ab)
 Adams, HP, 231
 Anderson, CJ, 558, 1685, 837(ab)
 Anderson, JA, 1003(ab), 1010(ab)
 Anderson, PJ, 2090
 Anderson, R, 927(ab)
 Anderson, T, 839(ab)
 Anderson, TL, 990(ab)
 Andersson, L, 1654, 954(ab)
 Andreassian, B, 835(ab)
 Andre-Fouet, X, 953(ab)
 Andrews, D, 964(ab)
 Andrich, MP, 852(ab), 976(ab)
 Angelberger, P, 108
 Anker, JP, 903(ab)
 Ansari, A, 844(ab)
 Ansari, MS, 847(ab)
 Antar, MA, 928(ab), 970(ab), 1040(ab), 1041(ab)
 Antich, PP, 974(ab), 990(ab), 1003(ab), 1010(ab)
 Antico, VF, 2094
 Antman, KH, 1594
 Antoine, J-M, 956(ab)
 Antonino, A, 2222
 Antonucci, F, 895(ab)
 Aoki, S, 844(ab), 966(ab)
 Aoshima, S, 6
 Aotsuka, A, 917(ab)
 Appelbaum, FR, 863(ab), 941(ab), 960(ab), 987(ab)
 Appelbaum, JW, 1099
 Appledorn, R, 956(ab)
 Arai, H, 1019(ab)
 Araki, N, 1029(ab)
 Araki, Y, 951(ab)
 Aras, T, 1027(ab)
 Araujo, LI, 1669
 Archer, CM, 850(ab)
 Archer, S, 423
 Areda, J, 876(ab)
 Argenyi, E, 1917(le)
 Aric, I, 1041(ab)
 Arimizu, N, 324
 Arnilkan, O, 1027(ab)
 Arntz, IE, 936(ab)
 Aronen, HJ, 867(ab)
 Arsenaault, A, 875(ab)
 Asahina, M, 917(ab)
 Asano, T, 333
 Ascoop, CAPL, 1727
 Ashida, K, 246
 Ashmore, RF, 995(ab)
 Assis, RVC, 995(ab)
 Atkins, HI, 305
 Atkins, HL, 1717
 Atkinson, ER, 423
 Atkinson, JB, 826(ab)
 Aubert, B, 1006(ab)
 Austin, MC, 877(ab), 930(ab)
 Avet, P, 1269
 Awad, I, 970(ab)
 Axworthy, DB, 880(ab), 909(ab), 910(ab), 934(ab)
 Babaian, RJ, 1001(ab)
 Babich, J, 924(ab), 935(ab)
 Babich, JW, 2154, 910(ab), 996(ab), 1024(ab)
 Bacharach, SL, 1209, 2058, 2226, 881(ab), 938(ab)
 Badger, C, 960(ab)
 Badger, CC, 863(ab), 987(ab)
 Bading, JR, 1373
 Bae, R, 926(ab)
 Baer, L, 906(ab)
 Bagdades, E, 1022(ab)
 Bahassa, FS, 1047(ab)
 Baidoo, KE, 899(ab), 921(ab), 1032(ab)
 Bailey, DL, 901(ab)
 Baird, AE, 877(ab)
 Bakir, MA, 2154
 Bakker, WH, 652, 955(ab), 903(ab), 914(ab)
 Baldock, C, 1041(ab)
 Baldwin, R, 896(ab)
 Baldwin, RM, 1836, 1964, 848(ab), 911(ab), 945(ab)
 Balériaux, D, 868(ab)
 Ballinger, JR, 970(ab)
 Balon, HR, 1393, 898(ab)
 Balseiro, J, 2059(le)
 Balter, HS, 1949
 Ban, T, 886(ab)
 Banaszczuk, M, 921(ab)
 Bander, N, 913(ab)
 Bando, M, 1016(ab)
 Bankole, A, 849(ab)
 Banks, WR, 830(ab), 975(ab), 983(ab)
 Banzo, I, 955(ab)
 Barbaras, L, 947(ab)
 Barbarics, E, 1033(ab)
 Barbaro, NM, 967(ab)
 Barber, HB, 851(ab), 879(ab), 1002(ab)
 Barber, R, 983(ab)
 Barbet, J, 912(ab), 1000(ab)
 Barbour, MM, 951(ab)
 Bares, R, 1001(ab)
 Barkan, AL, 1608, 834(ab)
 Barker, WW, 1459
 Barkovich, AJ, 967(ab)
 Barlow, CF, 838(ab)
 Barnes, D, 950(ab)
 Barnes, WE, 2214
 Barness, B, 837(ab)
 Barnett, CA, 938(ab)
 Barnhart, CS, 951(ab)
 Barrett, HH, 851(ab), 879(ab), 891(ab), 1002(ab)
 Barrett, JS, 959(ab)
 Barrio, JR, 633, 1472
 Barron, BJ, 968(ab), 1047(ab)
 Bartelsmeier, A, 906(ab)
 Bartenstein, P, 915(ab)
 Barthelemy, E, 956(ab)
 Bartlett, B, 1024(ab)
 Bartolozzi, C, 954(ab)
 Barton, D, 846(ab)
 Barton, H, 2222
 Barzen, G, 902(ab), 971(ab), 997(ab), 1018(ab)
 Basile, F, 866(ab)
 Basmadjian, GP, 981(ab)
 Basoglu, T, 906(ab)
 Bassano, DA, 150, 901(ab)
 Bassingthwaigite, JB, 581
 Bataille, G, 832(ab)
 Batchelor, S, 1041(ab)
 Bateman, TM, 876(ab), 951(ab)
 Battisti, C, 1859
 Baudhuin, T, 825(ab), 837(ab), 875(ab)
 Baudoux, M, 1337
 Bauer, A, 865(ab), 993(ab)
 Baum, RP, 853(ab), 904(ab), 912(ab)
 Baxter, KG, 1039(ab), 1046(ab)
 Bayhan, H, 464(le), 866(ab)
 Bayouth, JE, 941(ab)
 Bazin, JP, 1011(ab)
 Beanlands, R, 684, 826(ab), 865(ab), 882(ab)
 Beatty, BG, 953(ab)
 Beauchamp, HT, 900(ab)
 Beaumier, P, 934(ab)
 Beaumier, PL, 394, 880(ab), 909(ab), 910(ab), 1028(ab)
 Bebin, M, 971(ab)
 Beck, P, 972(ab)
 Becker, DP, 867(ab)
 Becker, JA, 1005(ab), 1043(ab)
 Becker, W, 903(ab), 1428(le)
 Beckers, C, 73
 Bede, JJ, 1914(le)
 Beetz, R, 1021(ab)
 Behrenbeck, T, 2080
 Beierwaltes, WH, 2116
 Beilin, I, 886(ab)
 Bekdik, C, 319
 Belinka, BA Jr, 988(ab)
 Bellande, E, 989(ab), 1034(ab)
 Bellen, J, 1283
 Beller, GA, 668, 1732, 864(ab)
 Bellina, CR, 1020(ab)
 Bellingier, MF, 923(ab), 977(ab)
 Belliveau, JW, 867(ab)
 Bellon, EM, 1044(ab)
 Belzberg, AS, 1468
 Benard, JF, 1003(ab)
 Bender, H, 942(ab), 1002(ab)
 Bendriem, B, 2020, 843(ab), 882(ab), 883(ab), 888(ab), 943(ab)
 Ben-Haim, S, 1486
 Benhali, H, 1011(ab)
 Ben-Harush, M, 1699
 Benjamin, C, 855(ab), 866(ab)
 Benjamin, RS, 858(ab), 992(ab)
 Benkert, O, 887(ab)
 Bennett, DV, 849(ab)
 Bennett, LR, 827(ab), 1043(ab)
 Benoiel, J, 1846
 Bensek, K, 835(ab)
 Benvenuti, C, 471
 Berding, G, 972(ab)
 Berg, BO, 918(ab)
 Berger, HJ, 144
 Berger, KL, 1579, 858(ab), 1003(ab), 1007(ab), 1009(ab)
 Berger, MR, 1982, 966(ab), 1019(ab)
 Bergh, JR, 1039(ab)
 Bergmann, SR, 836(ab), 837(ab), 855(ab), 884(ab), 1426(le)
 Berk, MR, 1556
 Berkovic, SF, 930(ab)
 Berkovitz, DM, N25(10)
 Berkowitz, KA, 512
 Berlangieri, SU, 1047(ab)
 Berliin, JA, 858(ab), 873(ab)
 Berman, DS, 1509, 854(ab), 876(ab), 911(ab)
 Berná, L, 840(ab), 845(ab), 895(ab), 994(ab)
 Bernstein, HF, 955(ab)
 Bernstein, ID, 863(ab), 941(ab), 960(ab), 987(ab)
 Berrah, H, 843(ab), 888(ab)
 Berridge, MS, 885(ab), 984(ab)
 Berry, J, 2067
 Bertoni, JM, 1047(ab)
 Bertrand, A, 906(ab), 956(ab)
 Besnard, J-C, 981(ab)
 Besozzi, MC, 885(ab), 931(ab), 983(ab)
 Besser, GM, 1121, 914(ab)
 Bessières, M, 906(ab)
 Bettinardi, V, 973(ab)
 Beuscart, R, 947(ab)
 Bex, M, 832(ab)
 Bhadkamkar, VA, 858(ab), 1001(ab)
 Bhatia, K, 1994
 Bhargava, KK, 919(ab), 986(ab)
 Bhattacharva, S, 938(ab)
 Bianchi, R, 1020(ab)
 Bianco, JA, 1586(le)
 Biasio, Y, 854(ab)
 Bice, AN, 771, 864(ab), 872(ab), 889(ab), 1005(ab), 1251(le),

Bidaut

- 1429(le)
Bidaut, LM, 868(ab)
Biedler, JL, 1373
Biegel, J, 878(ab)
Biegon, A, 890(ab)
Biemer, E, 859(ab)
Bierman, R, 435
Biersack, H-J, 526, 839(ab),
844(ab), 914(ab), 972(ab),
995(ab), 1028(ab)
Bigard, M-A, 956(ab)
Biggs, T, 676
Bigner, DD, 1535, 881(ab),
934(ab)
Bihl, H, 839(ab)
Bilchik, T, 269
Billings, J, 870(ab), 890(ab),
963(ab), 989(ab)
Billingsley, JL, 2052
Biniakiewicz, D, 993(ab)
Binon, J-P, 1337
Birnbaum, BA, 960(ab)
Bischof Delaloye, A, 1756,
903(ab), 956(ab)
Bischoff, H, 828(ab),
1045(ab)
Bishop, HA, 1040(ab)
Bisson, G, 855(ab), 866(ab)
Bjorn, MJ, 1099
Bjornson, B, 1758
Black, HR, 2045, 906(ab)
Black, KL, 867(ab)
Black, PMcL, 844(ab),
1018(ab)
Bladin, PF, 930(ab)
Blaha, WH, 1017(ab)
Blahd, W, 967(ab)
Blair, DR, 1011(ab),
1018(ab)
Blanche, S, 976(ab)
Blanchot, C, 913(ab)
Blank, EW, 1530
Blankenship, D, 993(ab)
Blankespoor, SC, 1881,
901(ab)
Blanksma, PK, 870(ab)
Blaser, K, 231
Blatchford, G, 975(ab)
Bläuenstein, P, 231
Blaufox, MD, 175, 739,
1723, 907(ab)
Blend, MJ, 853(ab)
Blickman, JG, 2249
Blokland, JAK, 1406
Blomqvist, G, 908(ab)
Bloomfield, PM, 1669,
911(ab), 994(ab), 1008(ab)
Blower, PJ, 469(le)
Blum, R, 912(ab)
Blumenthal, RD, 958(ab),
1000(ab)
Blumhardt, R, 984(ab)
Böck, JC, 971(ab)
Bockisch, A, 887(ab),
1021(ab)
Boelrijk, A, 921(ab)
Boerman, OA, 958(ab)
Bohdiewicz, PJ, 898(ab)
Boisson, N, 1006(ab)
Bok, BD, 380, 835(ab),
1251(le)
Bol, A, 837(ab), 875(ab),
884(ab)
Boles, MA, 2214, 1041(ab)
Boles Ponto, LL, 1008(ab),
1027(ab)
Bolzati, C, 850(ab)
Bomanji, J, 1121, 904(ab),
914(ab), 924(ab)
Bond, HW, 885(ab)
Boni, G, 1020(ab)
Boniface, G, 853(ab)
Bonilla, JJ, 955(ab)
Bonino, C, 999(ab)
Bonnet, AM, 1481, 1019(ab)
Bonow, RO, 815, 1209,
2226, 2057(le), 881(ab),
938(ab)
Bonte, F, 992(ab)
Bonte, FJ, 826(ab)
Booker, FS, 850(ab)
Borbely, K, 1931
Borchert, R, 830(ab),
975(ab), 983(ab)
Bordlee, RP, 1857
Borer, JS, 2057(le), 845(ab)
Borges-Neto, S, 825(ab)
Borkon, AM, 951(ab)
Borm, JJJ, 917(ab)
Bormans, G, 937(ab)
Bormans, GM, 551
Borst, MM, 2138
Bosworth, M, 974(ab)
Bottino, B, 1028(ab)
Bottlaender, M, 883(ab),
973(ab)
Botvinick, EH, 1444,
896(ab), 910(ab), 935(ab),
994(ab)
Boucher, Y, 1801, 894(ab)
Boudreau, RJ, 873(ab)
Bouillon, R, 832(ab)
Boulahdour, H, 919(ab)
Bourekas, EC, 1553
Bourgeois, P, 1427(le)
Bourguignon, M, 696,
896(ab), 1019(ab)
Bourguignon, MH, 471,
1481, 843(ab), 888(ab),
896(ab), 947(ab)
Bourne, D, 981(ab)
Bove, E, 68
Boven, E, 2000
Bowen, WD, 981(ab)
Bowman, BM, 975(ab)
Bowsher, JE, 879(ab),
961(ab)
Boyd, SJ, 1029(ab)
Braat, S, 874(ab), 875(ab)
Braat, SH, 874(ab)
Bracken, RB, 937(ab)
Brady, LW, 942(ab)
Brady, T, 867(ab)
Braegelmann, F, 845(ab)
Brandau, W, 920(ab)
Brandt, J, 848(ab)
Branscheid, D, 828(ab)
Brass, LM, 878(ab)
Brasseur, P, 1337
Braun, A, 2103
Braun, J, 1001(ab)
Brechtel, MW, 842(ab),
1001(ab), 1031(ab)
Breeman, A, 1727
Breeman, WAP, 652,
955(ab)
Breen, S, 1005(ab)
Breen, SL, 1316
Breithardt, G, 915(ab)
Breitz, HB, 1099
Bremner, JD, 911(ab)
Brennan, KM, 884(ab)
Brenner, N, 900(ab)
Bresnahan, DR Jr, 951(ab)
Briele, B, 526, 839(ab),
844(ab), 914(ab), 995(ab)
Britell, C, 1035(ab)
Britton, KE, 1121, 904(ab),
914(ab), 924(ab)
Broadhurst, P, 938(ab)
Brodack, J, 1025(ab)
Brodack, JW, 850(ab),
937(ab), 980(ab)
Brodie, JD, 192, 287, 1720,
847(ab)
Broich, K, 870(ab), 898(ab),
972(ab)
Brooks, CE, 950(ab)
Brooks, KM, 921(ab)
Brooks, RA, 1931
Broquet, PE, 1766
Brotchi, J, 868(ab)
Brouillet, E, 973(ab)
Broussard, W, 985(ab)
Brown, DW, 1750
Brown, J, 848(ab)
Brown, JA, 985(ab)
Brown, JK, 1881, 901(ab)
Brown, MA, 884(ab)
Brown, MD, 885(ab)
Brown, ML, 1613, 923(ab)
Brown, MT, 966(ab)
Brown, RS, 841(ab), 893(ab),
1021(ab)
Brown, SJ, 2017, 835(ab),
1049(ab)
Brown, T, 949(ab)
Brownell, AL, 946(ab)
Brownell, GL, 946(ab)
Bruchelt, G, 859(ab)
Brun, A, 868(ab)
Brunetti, A, 834(ab)
Brunken, R, 882(ab)
Brunken, RC, 1628, 856(ab),
857(ab), 945(ab), 977(ab)
Bruno, C, 652
Bubeck, B, 629(le)
Buchbinder, B, 867(ab)
Buchbinder, SF, 842(ab),
926(ab)
Buchegger, F, 903(ab)
Buchsbau, DJ, 1029(ab)
Buchwald, AB, 845(ab)
Buckley, KR, 922(ab)
Buczala, S, 832(ab)
Budihna, NV, 587
Budinger, TF, 2133, 862(ab),
884(ab), 915(ab), 939(ab)
Buell, U, 102, 886(ab),
1001(ab)
Bugaj, JE, 979(ab)
Buijs, WCAM, 1113
Buist, MR, 2000
Bulteau, C, 977(ab)
Bunker, C, 1301
Bunko, H, 441, 1200,
875(ab)
Bunting, RW, 1028(ab)
Buonanno, FS, 908(ab)
Buonocore, E, 885(ab),
923(ab)
Burg, MM, 939(ab)
Burke, TS, 1390
Burkholder, D, 979(ab)
Bremner, JD, 911(ab)
Burns, HD, 900(ab)
Burrows, L, 949(ab)
Buscombe, JR, 903(ab)
Bushe, H, 958(ab)
Bushman, MJ, 989(ab),
1033(ab), 1024(ab)
Bushnell, DL, 2214
Busnardo, B, 1478
Bussiére-Lapalus, F, 1846
Butchko, G, 912(ab)
Butler, CS, 964(ab)
Butler, RE, 1014(ab)
Butler, SP, 1029(ab),
1252(le)
Buxton, DB, 865(ab),
945(ab), 1425(le)
Bylund, DB, 861(ab)
Byrne, CL, 843(ab)
Cabahug, C, 1015(ab),
1028(ab)
Cacheris, W, 974(ab)
Cacini, W, 2190
Cahill, N, 19N(le)
Caillaud-Vigneron, N, 913(ab)
Cain, JW, 838(ab)
Calay, R, 1337
Caldwell, JH, 102, 2144,
2202
Calenoff, E, 934(ab), 936(ab)
Çaliköglu, T, 319
Callahan, AP, 910(ab),
1023(ab), 1028(ab)
Callahan, RJ, 819, 845(ab),
925(ab), 1024(ab),
1028(ab)
Calne, DB, 964(ab)
Caluser, C, 867(ab)
Camargo, EE, 1216,
1004(ab)
Camera, L, 842(ab),
1001(ab)
Camici, PG, 1353
Cammilleri, S, 990(ab)
Campini, R, 846(ab)
Camrud, AR, 845(ab)
Cancro, R, 287
Caner, B, 319
Cann, CE, 1881, 901(ab)
Cantos, E, 1046(ab)
Cao, Q, 905(ab)
Cao, ZJ, 892(ab)
Capelli, L, 68
Caraceni, T, 1014(ab)
Caracò, C, 892(ab), 918(ab),
999(ab)
Caraher, J, 994(ab)
Caraher, JM, 1243, 881(ab)
Carey, D, 865(ab)
Carey, JE, 423
Caride, VJ, 1712, 913(ab)
Carlsen, J, 251
Carlson, KE, 558
Carpenter, RC, 873(ab)
Carpi, A, 954(ab)
Carrasquillo, JA, 842(ab),
986(ab), 1001(ab)
Carretta, R, 939(ab)
Carril, JM, 955(ab)
Carriò, I, 2249, 840(ab),
845(ab), 895(ab), 994(ab)
Carroll, RG, 498, 2249(le)
Carson, GC, 1047(ab)
Carson, RE, 2103, 881(ab),
945(ab), 1010(ab)
Carstens, MC, 992(ab)
Cartner, T, 874(ab)
Carton, EG, 239
Cartwright, PC, 873(ab)
Carvalho, PA, 181, 1516,
970(ab)
Casara, D, 1478
Casciari, JJ, 2202, 1010(ab)
Casey, ME, 861(ab), 1430(le)
Casey, MJ, 829(ab)
Cashman, P, 938(ab)
Casi, M, 863(ab)
Cassel, D, 916(ab), 952(ab)
Castaigne, A, 471, 896(ab)
Castaneda, AR, 838(ab),
930(ab)
Castelli, L, 892(ab), 918(ab),
999(ab)
Cattaruzzi, E, 895(ab)
Cavagnaro, CF, 956(ab)
Cave, V, 186, 2086, 854(ab),
866(ab), 952(ab)
Cerar, A, 587
Ceriani, R, 912(ab)
Ceriani, RL, 1530
Cerino, M, 951(ab)
Cerletty, JM, 869(ab)
Cerrequeira, MD, 202, 763,
1324, 1493, 1642, 866(ab),
939(ab)
Cerrito, M, 959(ab)
Cesaro, P, 858(ab)
Cestaro, V, 1046(ab)
Chabriet, H, 1481, 1019(ab)
Chabris, CF, 908(ab)
Chaiken, L, 829(ab)
Chaillout, JJ, 1003(ab)
Chaiwanarat, T, 924(ab)
Chalmers, N, 872(ab)
Chalon, S, 981(ab)
Chaly, T, 923(ab), 1027(ab)
Chamberlain, MJ, 516
Chamovitz, DL, 2055
Chan, A, 836(ab), 865(ab)
Chan, H-W, 14
Chan, K, 833(ab)
Chan, SY, 836(ab), 856(ab),
857(ab), 1009(ab)
Chan, YW, 920(ab)
Chandariapaty, SCK,
1045(ab)
Chang, CJ, 985(ab)
Chang, L, 839(ab), 977(ab)
Chang, PI, 993(ab)
Chang, SL, 1012(ab)
Chang, W, 852(ab)
Chao, BH, 981(ab)
Chaovapong, W, 2006,
880(ab)
Chapnick, J, 960(ab)
Chapuis, A, 1003(ab)
Charkes, ND, 1780
Charney, DS, 1964, 848(ab),
911(ab), 945(ab)
Charron, M, 923(ab),
977(ab), 996(ab), 997(ab)
Chartrand, R, 1550
Chatal, JF, 912(ab), 943(ab),
985(ab), 1030(ab)
Chatterjee, K, 896(ab)
Chatterjee, S, 830(ab)

- Chatzioannou, A, 861(ab)
 Chaudhuri, TK, 1035(ab)
 Chavali, RV, 839(ab), 1005(ab), 1018(ab), 1043(ab)
 Chen, BC, 613
 Chen, B-S, 282
 Chen, C, 848(ab), 964(ab)
 Chen, CL, 955(ab)
 Chen, C-T, 783, 947(ab), 949(ab), 962(ab), 1012(ab), 1019(ab)
 Chen, CY, 955(ab)
 Chen, DCP, 844(ab), 937(ab)
 Chen, EQ, 888(ab)
 Chen, F, 934(ab), 936(ab)
 Chen, GH, 997(ab)
 Chen, GTY, 1005(ab), 1043(ab)
 Chen, K, 944(ab)
 Chen, LS, 1132, 894(ab)
 Chen, MN, 986(ab)
 Chen, MT, 1034(ab)
 Chen, TT, 829(ab), 867(ab)
 Chen, WL, 1033(ab)
 Chen, YK, 922(ab), 1010(ab)
 Cheng, H, 871(ab)
 Cheres, A, 2017
 Cherqui, D, 919(ab)
 Cherrick, I, 914(ab)
 Cherrier, F, 906(ab)
 Cherry, SC, 1045(ab)
 Cherry, SR, 595, 862(ab), 879(ab), 922(ab), 1010(ab)
 Chetanneau, A, 912(ab)
 Cheung, N-KV, 2020
 Chevres, A, 2017, 835(ab), 1049(ab)
 Chi, SC, 977(ab)
 Chiang, J-H, 282
 Chiao, P, 933(ab)
 Chiariello, M, 505
 Chin, HW, 1047(ab)
 Chin, J, 988(ab)
 Chin, M, 994(ab)
 Chinen, LK, 937(ab), 980(ab)
 Chinol, M, 900(ab), 942(ab), 985(ab), 1030(ab)
 Chiotelis, E, 988(ab)
 Chiron, C, 696, 976(ab), 977(ab)
 Chiu, ML, 1516, 864(ab), 1033(ab)
 Cho, DS, 1146, 1613
 Cho, KS, 991(ab)
 Choi, BI, 2118
 Choi, CW, 877(ab)
 Choi, J, 1031(ab)
 Choi, Y, 339, 633, 828(ab), 829(ab), 865(ab), 881(ab), 882(ab), 944(ab), 945(ab)
 Chon, KS, 1010(ab)
 Chong, R, 900(ab), 1025(ab)
 Choong, KKL, 2094
 Chou, J-S, 1012(ab)
 Chou, KT, 1013(ab)
 Chow, WK, 997(ab)
 Christensen, M, 975(ab)
 Christian, BT, 850(ab), 931(ab)
 Christian, PE, 467(le), 833(ab), 878(ab), 892(ab), 901(ab), 1003(ab)
 Christian, TF, 2080
 Christman, DR, 192
 Chrumpradit, S, 890(ab)
 Chu, LS, 1012(ab)
 Chu, TS, 865(ab)
 Chua, T, 854(ab), 911(ab)
 Chun, SB, 986(ab)
 Chung, D-G, 55
 Chung, JK, 877(ab), 892(ab), 905(ab)
 Chung, Y-H, 919(ab)
 Ciarmiello, A, 68
 Cini, R, 900(ab)
 Cinotti, L, 953(ab), 1011(ab)
 Claessens, RAMJ, 388, 1113, 1330, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab)
 Clark, CM, 157
 Clarke, LP, 161, 889(ab)
 Clarke, SEM, 469(le)
 Clavo, A, 841(ab)
 Cleeland, R, 924(ab)
 Clerc, J, 2162
 Cleto, EM, Jr, 435
 Cleynhens, B, 1032(ab)
 Clinthorne, NH, 831(ab), 842(ab), 878(ab)
 Cload, P, 875(ab)
 Cloninger, K, 876(ab)
 Clorius, JH, 907(ab)
 Coade, G, 939(ab)
 Coakley, AJ, 313
 Cody, R, 1020(ab)
 Coenen, HH, 2138
 Cohen, AM, 904(ab)
 Cohen, C, 973(ab)
 Cohen, RC, 2094, 949(ab)
 Cohen, RM, 1383, 945(ab), 965(ab)
 Cohen, TJ, 910(ab)
 Cohen, WA, 1789
 Colan, SD, 930(ab)
 Colcher, D, 23, 1648
 Cole, WC, 974(ab)
 Coleman, PS, 905(ab)
 Coleman, RE, 532, 575, 922, 825(ab), 834(ab), 838(ab), 872(ab), 879(ab), 891(ab), 901(ab), 961(ab), 966(ab), 1047(ab)
 Collier, BD, 2110, 868(ab), 869(ab)
 Collier, TL, 890(ab), 1025(ab)
 Collins, REC, 313
 Colombo, F, 924(ab)
 Colsher, JG, 1430(le)
 Comazzi, V, 850(ab), 989(ab), 1034(ab)
 Combs, MJ, 833(ab)
 Comerota, AJ, 952(ab)
 Comet, M, 953(ab), 1034(ab)
 Conlin, CJ, 1042(ab)
 Connett, JM, 1685
 Conrad, G, 1046(ab)
 Conrady, A, 223
 Consigny, PM, 973(ab)
 Constantinescu, A, 974(ab), 990(ab), 1003(ab), 1010(ab)
 Conversano, A, 855(ab)
 Conway, JJ, 2047
 Conzo, G, 892(ab)
 Cook, SA, 1040(ab), 1041(ab), 1048(ab), 1586(le)
 Cooke, CD, 876(ab), 927(ab)
 Cooper, DL, 913(ab)
 Cooper, JA, 59, 1566, 932(ab)
 Cooper, M, 829(ab), 982(ab), 1011(ab), 1012(ab), 1018(ab), 1019(ab)
 Cooper, MD, 947(ab), 949(ab)
 Cooper, R, 868(ab)
 Cooper, S, 964(ab)
 Coote, D, 868(ab)
 Coppens, A, 875(ab)
 Coppola, N, 68
 Corbett, JR, 927(ab), 990(ab)
 Cordes, M, 922(ab), 964(ab), 971(ab), 1018(ab)
 Cordon Cardo, C, 1002(ab)
 Cordovilla, JJ, 955(ab)
 Corlija, M, 851(ab), 988(ab), 1032(ab), 1048(ab)
 Corne, RA, 2061
 Corona, JF, 287
 Correia, JA, 620, 924(ab)
 Corrigan, GE, 1042(ab)
 Corrigan, P, 1620, 948(ab)
 Corstens, FHM, 388, 1113, 1330, 1958, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab), N16(4)
 Cosgrove, R, 971(ab)
 Costa, DC, 1014(ab)
 Costello, J, 838(ab), 930(ab)
 Coubes, P, 970(ab)
 Coughlin, DJ, 988(ab)
 Coulange, C, 990(ab)
 Countryman, PH, 861(ab)
 Countryman, PJ, 862(ab)
 Coupal, JJ, 991(ab)
 Courtois, M, 836(ab)
 Cowan, MJ, 2202
 Cowie, AR, 2222
 Coxson, PG, 884(ab)
 Craddock, TD, 1005(ab), 1007(ab), 1043(ab)
 Crane, J, 992(ab)
 Crawford, D, 858(ab)
 Crowley, J, 448, 451
 Croft, BY, 833(ab)
 Cromwell, T, 883(ab)
 Cronin, V, 1000(ab)
 Crouzel, C, 883(ab), 896(ab)
 Crouzel, M, 888(ab)
 Csernay, L, 458
 Cullom, SJ, 161, 2232, 842(ab)
 Culver, CM, 1402
 Cumming, MC, 1044(ab)
 Cumming, P, 916(ab)
 Cummings, D, 1132, 894(ab)
 Cunningham, J, 941(ab)
 Cunningham, JR, 1001(ab)
 Cuocolo, A, 505, 1209, 833(ab), 905(ab), 915(ab), 938(ab)
 Curley, T, 859(ab)
 Curtet, C, 912(ab)
 Curtis, JJ, 924(ab)
 Curtis, RL, 1024(ab)
 Cutler, C, 899(ab)
 Cutler, PD, 595, 1045(ab)
 Cyr, J, 920(ab)
 Czernin, J, 856(ab)
 Czernin, I, 836(ab)
 Czernin, J, 1628, 856(ab), 857(ab), 865(ab), 1009(ab)
 DaCosta, M, 969(ab)
 DaCosta, MC, 969(ab)
 Dadparvar, S, 2017, 835(ab), 1049(ab)
 Dae, MW, 1444, 896(ab), 910(ab), 935(ab), 994(ab)
 Daemen, BJG, 373
 Daghighian, F, 2020
 Dahlberg, ST, 1783, 846(ab), 864(ab)
 Dahlbom, M, 633, 1191, 828(ab), 862(ab), 1045(ab)
 Dai, WL, 996(ab)
 Dalley, RW, 1789
 Dalrymple, G, 978(ab)
 Damasio, H, 1008(ab)
 Dambro, TJ, 1701
 Damjanov, A, 851(ab)
 Danchin, N, 906(ab)
 Dannals, RF, 847(ab), 848(ab), 860(ab), 883(ab), 885(ab), 929(ab), 964(ab), 968(ab)
 Danos, P, 972(ab)
 Dao, NH, 1039(ab)
 Darbee, J, 835(ab)
 Darcourt, J, 1846
 Darras, J-C, 409
 DaSilva, IN, 983(ab)
 DaSilva, JN, 861(ab), 870(ab)
 Datz, FL, 260, 467(le), 833(ab), 878(ab), 892(ab), 901(ab), 1003(ab)
 Daube-Witherspoon, ME, 1010(ab), 1430(le)
 Dave, K, 944(ab)
 Davidson, J, 900(ab)
 Davidson, M, 856(ab)
 Davies, H, 1935
 Davis, K, 312
 Davison, A, 558, 1357, 1949, 1033(ab)
 Dawood, FW, 978(ab)
 Day, DE, 1024(ab)
 Dean, CJ, 2154
 Dean, GW, 1875
 Dean, RT, 144, 845(ab)
 Deane, CP, 1468
 Debrand-Passard, A, 902(ab)
 Dec, GW, 477
 De Carle, D, 2059(le)
 De Chiro, G, 834(ab)
 deCosta, BR, 981(ab)
 Decoster, P, 905(ab)
 Decostre, P, 175
 DeDeyn, PP, 972(ab)
 De Fabritiis, A, 2040
 de Gaudio, C, 954(ab)
 De Geeter, F, 1914(le)
 DeGrado, TR, 865(ab), 870(ab), 994(ab)
 De Groof, M, 825(ab), 836(ab), 1009(ab)
 Degrossi, OJ, 999(ab)
 DeHaan, CE, 1012(ab)
 de Jong, M, 652, 955(ab), 1025(ab)
 de Kaski, MC, 756
 de Klerk, JMH, 646
 DeKock, M, 905(ab)
 Delaage, M, 912(ab), 1000(ab)
 de la Fourniere, L, 981(ab)
 DeLaney, ML, 969(ab)
 DeLaPaz, R, 867(ab)
 DeLaPena, R, 1014(ab)
 Delbeke, D, 826(ab)
 Delcourt, E, 1337
 deLearie, L, 974(ab)
 de Leon, F, 1043(ab)
 Delforge, J, 882(ab), 883(ab), 888(ab), 896(ab), 943(ab)
 Delgado-Escueta, AV, 1017(ab)
 Della Vittoria, G, 915(ab)
 Del Rio, P, 999(ab)
 del Rosario, RB, 860(ab)
 Del Vecchio, S, 1848
 De Marco, T, 1444, 896(ab)
 Demirel, D, 464(le)
 Demonceau, G, 480
 DeNardo, GL, 1030, 862(ab), 863(ab), 926(ab), 927(ab), 941(ab), 982(ab), 1031(ab)
 DeNardo, S, 912(ab)
 DeNardo, SJ, 862(ab), 863(ab), 927(ab), 941(ab), 982(ab), 1030(ab), 1031(ab)
 DeNardo, SL, 926(ab)
 Denays, R, 485
 Dence, CS, 724, 925(ab), 932(ab)
 Denis, M, 81
 Depas, G, 976(ab), 977(ab)
 de Paulis, T, 847(ab), 848(ab)
 DePuey, EG, 876(ab), 928(ab), 957(ab)
 Derebek, E, 1722
 Dereme, T, 875(ab), 905(ab)
 Dereniak, EL, 1002(ab)
 Derenzo, SE, 862(ab)
 de Ridder, LIF, 1167
 Derick, FHM, 990(ab)
 DeRogatis, AJ, 957(ab)
 De Roo, MJ, 551, 832(ab), 933(ab), 937(ab), 1032(ab)
 De Rosch, MA, 850(ab)
 Desai, HJ, 1943
 Desai, SP, 1704
 de Silva, R, 1669
 Detry, JM, 825(ab)
 Deussen, A, 2138
 Deutsch, E, 981, 2190, 850(ab), 899(ab), 900(ab), 924(ab), 937(ab), 980(ab), 988(ab), 1025(ab)
 Deutsch, EA, 993(ab)
 Deutsch, G, 826(ab)
 Deutsch, K, 2190, 900(ab), 981(ab), 1025(ab)
 Deutsch, KF, 850(ab), 937(ab), 980(ab)
 De Vernejoul, P, 409
 DeVito, RP, 889(ab), 932(ab)
 Devous, MD, Sr, 1888, 1919, 2030, 826(ab), 827(ab), 838(ab), 1018(ab)
 deVries, DJ, 1004(ab)
 Dewan, NA, 836(ab)

- Dewanjee, MK, 777, 921(ab), 956(ab), 980(ab)
 Dewey, SL, 521, 830(ab), 847(ab), 887(ab), 888(ab)
 Dewhurst, MW, 958(ab)
 DeWoody, K, 848(ab)
 Dey, HM, 1964, 878(ab), 886(ab), 896(ab), 906(ab)
 De Zwart, F, 1722
 Dhawan, V, 923(ab)
 D'Hondt, AM, 825(ab)
 Dhumeaux, D, 919(ab)
 Diamanti, CI, 2006, 931(ab)
 Diaz, C, 840(ab)
 Di Carli, M, 825(ab), 856(ab)
 Di Chiro, G, 1931
 Dick, R, 1020(ab)
 Diego, I, 992(ab)
 Dierckx, R, 972(ab), 1013(ab)
 Dieren, EV, 927(ab)
 Diethelm, AG, 1178, 924(ab)
 Digby, WM, 595
 Diggles, L, 835(ab), 846(ab), 876(ab)
 Dilizian, V, 1209
 Dilsizian, V, 815, 938(ab)
 Dimitrakopoulou, A, 1982, 1019(ab)
 Ding, XS, 1012(ab)
 Ding, Y-S, 830(ab)
 Di Palma, E, 999(ab)
 Di Paola, R, 1011(ab)
 Di Resta, G, 2020
 Diril, H, 942(ab), 1031(ab)
 DiRocco, RJ, 1152, 865(ab), 993(ab)
 Ditlow, C, 934(ab), 936(ab)
 Divgi, C, 1002(ab)
 Divgi, CR, 904(ab), 913(ab), 941(ab)
 DiZio, JP, 558
 Dobbela, A, 972(ab), 1013(ab), 1021(ab)
 Dobovskiy, EV, 948(ab)
 Dobrinsky, C, 928(ab)
 Docter, R, 955(ab)
 Dodd, T, 880(ab), 934(ab)
 Dodek, PM, 1468
 Dodge, RK, 1542
 Doerr, RJ, 14, 886(ab), 959(ab)
 Dohi, Y, 932(ab)
 Dohzono, H, 1033(ab)
 Doi, T, 1637
 Dökmeci, B, 866(ab)
 Doll, J, 1007(ab), 1045(ab)
 Donath, A, 1766
 Dondi, M, 2040
 Donna, GA, 877(ab)
 Donohoe, KJ, 947(ab), 1003(ab)
 Dörr, U, 839(ab)
 Dosio, F, 924(ab)
 Doty, R, 858(ab)
 Doucet, S, 875(ab)
 Doudet, DJ, 1383, 945(ab), 965(ab)
 Dougall, NJ, 1623
 Douglas, MA, 881(ab)
 Dove, P, 471
 Dowling, D, 989(ab)
 Downey, A, 912(ab)
 Drane, WE, 876(ab), 923(ab)
 Driedger, AA, 1722
 Drozda, SE, 860(ab)
 Drücke, T, 913(ab)
 Drum, DE, 643, 849(ab)
 Dua, G, 972(ab)
 Duara, R, 1459
 Duatti, A, 850(ab), 989(ab)
 Duboc, D, 471
 Dubois-Randé, J-L, 471, 896(ab)
 Dubovsky, EV, 1178, 924(ab)
 duCret, RP, 873(ab)
 Dujčić, Ž, 1917(le), 2056(le)
 Dulac, O, 696, 977(ab)
 Duncker, D, 840(ab), 845(ab), 895(ab), 994(ab)
 Dunigan, KA, 975(ab)
 Dunn, B, 938(ab)
 Dunn, EK, 117, 973(ab), 1035(ab)
 Dunn, J, 974(ab)
 Dunn, WL, 1039(ab)
 Dunning, AJ, 895(ab)
 du Plessis, AJ, 838(ab)
 Durack, LD, 771, 864(ab), 889(ab), 941(ab)
 Durakc, LD, 1005(ab)
 Durski, K, 872(ab), 922(ab)
 Duus, S, 251
 Duval, AM, 471
 Dworkin, HJ, 1402
 Dwyer, JP, 1594
 Dymond, DS, 2124
 Eary, JF, 748, 771, 863(ab), 864(ab), 889(ab), 941(ab), 960(ab), 987(ab)
 Eberl, S, 901(ab)
 Eberling, JL, 939(ab)
 Ebmire, KP, 1623
 Eccles, SA, 2154
 Eckard, DA, 826(ab)
 Edelbroek, M, 1283
 Edwards, B, 850(ab)
 Edwards, DS, 979(ab)
 Efange, SMN, 890(ab), 983(ab)
 Egbe, P, 1411, 1994
 Egeli, R, 1766
 Egli, DF, 1143, 1854, 947(ab)
 Ehrenkauf, RL, 829(ab), 985(ab)
 Ehrhardt, GJ, 558, 1024(ab)
 Eichstädt, H, 902(ab), 997(ab)
 Eidelberg, D, 923(ab)
 Eisenberg, B, 972(ab)
 Eisner, RL, 1571, 865(ab)
 Elander, N, 1026(ab)
 Elder, ST, 829(ab)
 Elgazzar, AH, 898(ab), 978(ab), 1047(ab), 1048(ab)
 Elias, AD, 1594
 Elkowitz, S, 914(ab)
 Ell, PJ, 1843, 903(ab), 1014(ab)
 Ellis, A, 1040(ab)
 Ellis, WG, 939(ab)
 Ellison, D, 1121, 904(ab)
 Elmaleh, D, 946(ab)
 Elmaleh, DR, 946(ab), 1026(ab)
 Elmendorf, SL, 59
 Elmqvist, D, 868(ab)
 Elsinga, PH, 373, 870(ab)
 Emrich, D, 223, 845(ab), 957(ab)
 Emrich, JG, 942(ab), 1002(ab)
 Enas, J, 890(ab)
 Enderle, A, 950(ab)
 Endo, K, 1181, 853(ab), 905(ab), 1001(ab)
 Engel, U, 251
 Englaro, EE, 351, 1132, 894(ab)
 Enomoto, K, 333
 Ensing, G, 1025(ab)
 Ensminger, WD, 735
 Epstein, A, 987(ab)
 Erbas, B, 854(ab), 859(ab)
 Erben, D, 319
 Ercan, MT, 1027(ab)
 Erdman, WA, 992(ab)
 Eriksson, L, 861(ab), 908(ab), 1011(ab)
 Ernest, D, 1468
 Errico, D, 855(ab)
 Erwin, WD, 927(ab), 932(ab), 938(ab), 941(ab)
 Eschima, D, 1029(ab)
 Eshbach, J, 851(ab)
 Eshima, D, 33, 1620, 921(ab), 990(ab), 1031(ab)
 Eskridge, JM, 1789
 Essamri, B, 837(ab)
 Esser, PD, 1411, 1042(ab)
 Essiambre, R, 1091, 855(ab)
 Esterbrooks, DJ, 837(ab)
 Esterhai, J, 902(ab)
 Estorch, M, 840(ab), 845(ab), 895(ab), 994(ab)
 Estrada, WN, 898(ab)
 Eterović, D, 1917(le), 2056(le)
 Evans, D, 902(ab)
 Evans, N, 959(ab), 1000(ab)
 Evans, NH, 14
 Evans-Blumer, M, 1024(ab)
 Even-Sapir, E, 950(ab)
 Evora, PH, 829(ab), 985(ab)
 Eybalin, C, 951(ab)
 Eybalin, MC, 951(ab)
 Ezekowitz, MD, 777
 Ezuddin, S, 839(ab), 1016(ab), 1035(ab)
 Ezzeddine, B, 975(ab)
 Faber, TL, 927(ab)
 Facchetti, L, 846(ab)
 Fagret, D, 953(ab), 1034(ab)
 Fahey, FH, 537, 1859, 833(ab), 899(ab)
 Faivre-Chauvet, A, 943(ab)
 Falcone, S, 1016(ab)
 Falconer, SJ, 1039(ab)
 Falk, P, 975(ab)
 Fallon, PS, 904(ab)
 Fan, KT, 974(ab)
 Fang, LST, 948(ab)
 Fang, Y-B, 982(ab)
 Fanti, S, 2040
 Farber, L, 913(ab)
 Farde, L, 860(ab), 931(ab), 1011(ab), 1016(ab)
 Farhangi, M, 1451
 Farlow, DC, 2094
 Farnsworth, RH, 1022(ab)
 Farrell, E, 14, 959(ab), 1000(ab)
 Fass, J, 1001(ab)
 Fawwaz, RA, 570, 988(ab)
 Fayad, PB, 878(ab)
 Fazio, F, 834(ab), 924(ab), 925(ab), 944(ab), 959(ab), 973(ab), 1014(ab)
 Fedio, VA, N15(3), N30(9), N14(12)
 Feine, U, 309, 956(ab)
 Feinendegen, LE, 2138
 Feld, T, 88
 Feldman, JM, 834(ab)
 Feldman, M, 883(ab)
 Feldstein, ML, 849(ab)
 Felix, R, 902(ab), 971(ab), 997(ab), 1018(ab)
 Feller, AM, 859(ab)
 Fer, MF, 1099
 Ferguson, DM, 239
 Fernandez, G, 854(ab)
 Fernandez-Ulloa, M, 1692, 898(ab), 978(ab), 1047(ab)
 Fernando, J, 1003(ab), 1010(ab)
 Ferremans, W, 1427(le)
 Ferrieri, RA, 847(ab)
 Fessler, JA, 831(ab), 878(ab), 882(ab)
 Fettich, JJ, 873(ab)
 Fiasse, R, 976(ab)
 Ficken, VJ, 927(ab), 1034(ab)
 Ficsman, AJ, 946(ab)
 Fig, LM, 1608, 834(ab)
 Fink, L, 978(ab)
 Fink, S, 1035(ab)
 Fink-Bennett, D, 1393, 876(ab), 898(ab), 1017(ab)
 Finlay, J, 867(ab)
 Finn, RD, 2020, 867(ab), 904(ab)
 Fioravanti, C, 900(ab), 979(ab)
 Fisch, I, 1766
 Fischer, S, 920(ab)
 Fischman, AJ, 996, 845(ab), 867(ab), 910(ab), 915(ab), 924(ab), 965(ab), 998(ab), 1024(ab), 1587(le)
 Fischman, SJ, 1378
 Fisher, DR, 1099, 863(ab), 941(ab)
 Fisher, KM, 359
 Fisher, RS, 832(ab), 929(ab)
 Fisher, SJ, 869(ab), 893(ab), 926(ab), 959(ab), 1021(ab)
 Fishman, AJ, 1026(ab)
 Fishman, EK, 1042(ab)
 Fissekis, JD, 1373
 Fitzpatrick, JM, 952(ab)
 Fleishman, MJ, 906(ab)
 Fleming, E, 1029(ab)
 Fleming, WK, 1915(le)
 Fletcher, JW, 1046(ab)
 Fliebert, E, 859(ab)
 Floyd, CE, Jr, 879(ab)
 Fogarasi, M, 925(ab)
 Foged, C, 931(ab)
 Fogelman, I, 1589
 Foisie, DC, 1099
 Foley, K, 859(ab)
 Folks, R, 1620, 948(ab)
 Folks, RD, 927(ab)
 Folli, S, 903(ab)
 Fonazzari, I, 970(ab)
 Ford, K, 874(ab)
 Ford, PV, 127
 Forman, D, 1000(ab)
 Formiconi, AR, 831(ab)
 Forrest, LJ, 1542
 Forster, AM, 850(ab)
 Forstrom, LA, 840(ab), 845(ab)
 Fossella, FV, 992(ab)
 Foster, ED, 59
 Foster, NL, 887(ab)
 Fournier, D, 973(ab)
 Fourné, C, 2162
 Fowler, JS, 192, 521, 1720, 830(ab), 847(ab), 853(ab), 870(ab), 887(ab), 888(ab), 946(ab)
 Fowler, PJ, 516
 Fox, J, 966(ab)
 Fox, KR, 1588(le)
 Fragu, P, 2162
 Fraiderik, R, 1006(ab)
 Franceschi, G, 863(ab)
 Francesconi, LC, 989(ab)
 Francis, IR, 1125
 Francken, G, 1040(ab)
 Frangin, Y, 981(ab)
 Frank, AR, 829(ab), 836(ab), 975(ab)
 Frankar, G, 884(ab)
 Franken, Ph, 1914(le)
 Franklin, T, 851(ab)
 Franks, W, 55
 Franzius, C, 906(ab)
 Freedman, N, 1209
 Freedman, NMT, 2226, 881(ab), 938(ab)
 Freemer, M, 1044(ab)
 Frenkel, A, 49, 1774
 Freudenberg, N, 1399
 Frey, D, 888(ab)
 Frey, EC, 2238
 Frey, KA, 423, 1836, 858(ab), 882(ab), 887(ab), 929(ab), 1003(ab)
 Frick, MP, 829(ab), 836(ab), 837(ab), 861(ab), 975(ab), 1026(ab)
 Friden, A, 1304
 Fried, M, 956(ab)
 Friedland, RP, 2184
 Friedlander-Klar, H, 859(ab)
 Friedman, J, 854(ab)
 Friedman, JD, 1509
 Frist, WH, 826(ab)
 Fritsch, HW, 906(ab)
 Fritz, B, 1810, 934(ab)
 Fritzbeg, AR, 394, 1099, 880(ab), 909(ab), 910(ab), 934(ab), 979(ab)
 Front, D, 1699, 1774
 Frost, J, 883(ab)
 Frost, JJ, 872(ab), 883(ab), 911(ab), 922(ab), 929(ab)
 Frost, MF, 1042(ab)
 Frouin, F, 1011(ab)
 Frouin, V, 882(ab)
 Frover-McKay, M, 1917
 Fryer, DG, 972(ab)

- Fucello, AJ, 1378
 Fujibayashi, Y, 545, 659, 891(ab), 1023(ab), 1026(ab)
 Fujii, R, 413, 466(le)
 Fujii, T, 893(ab), 933(ab), 969(ab), 972(ab), 1004(ab)
 Fujita, H, 135, 272, 1696, 827(ab), 909(ab)
 Fujita, T, 897(ab), 966(ab)
 Fukuchi, M, 834(ab)
 Fukuda, H, 911(ab)
 Fukui, H, 997(ab)
 Fukumura, T, 877(ab), 945(ab), 1015(ab)
 Fukuyama, H, 1637, 897(ab)
 Fulham, MJ, 1931, 834(ab)
 Fulmer, H, 876(ab)
 Fulton, RR, 901(ab)
 Funke, M, 950(ab)
 Furmanski, P, 912(ab)
 Fusamoto, H, 997(ab)
 Futami, S, 971(ab)
- Gabel, M, 993(ab)
 Gabor, FV, 1003(ab)
 Gad, MA, 431, 929(ab)
 Gaggi, R, 2040
 Gagne, GM, 1428(le), 901(ab), 961(ab)
 Gagnon, D, 875(ab)
 Gajardo, P, 998(ab)
 Gal, RA, 2124
 Galantowicz, P, 1040(ab)
 Galati, MG, 892(ab)
 Galen, K, 974(ab)
 Gallagher, KP, 1346
 Galle, P, 919(ab)
 Galli, M, 856(ab)
 Gallinger, S, 960(ab)
 Galloway, S, 897(ab), 898(ab), 954(ab)
 Galt, JR, 2232, 842(ab), 991(ab)
 Gambhir, SS, 613, 944(ab), 1045(ab)
 Gan, MP, 827(ab), 1043(ab)
 Gansow, OA, 842(ab), 1001(ab), 1031(ab)
 Ganz, WI, 1304, 921(ab), 1016(ab), 1022(ab), 1035(ab)
 Garada, BM, 1312, 839(ab), 887(ab), 970(ab), 1018(ab), 1043(ab), 1432(le)
 Garber, CE, 876(ab), 951(ab)
 Garcia, A, 403, 2060(le)
 Garcia, EV, 2232, 468(le), 842(ab), 876(ab), 927(ab), 948(ab)
 Garcia, F, 403, 2060(le)
 Garcia, FA, 1949
 Garcia del Rio, H, 999(ab)
 Gardin, D, 380
 Gardner, KA, 1045(ab)
 Garg, PK, 575, 934(ab)
 Garg, S, 934(ab)
 Garmestani, K, 842(ab), 1001(ab)
 Gascon, P, 904(ab)
 Gaskin, G, 491
 Gaston, RS, 924(ab)
 Gatley, SJ, 830(ab), 853(ab), 870(ab), 995(ab)
- Gaul, FE, 710
 Gautherot, E, 912(ab), 1000(ab)
 Gavin, PR, 1012(ab)
 Gazelle, S, 179
 Ge, YW, 1032(ab)
 Gearhart, JP, 924(ab)
 Geatti, O, 895(ab)
 Geckle, WJ, 968(ab)
 Gee, A, 1041(ab)
 Gelfand, MJ, 351, 1048(ab)
 Geltman, EM, 855(ab), 1426(le)
 Geltofsky, J, 1378
 Genç, C, 866(ab)
 Genna, S, 852(ab)
 Gennaro, O, 999(ab)
 Gentili, A, 1044(ab)
 Georgiou, M, 1035(ab)
 Gerada, B, 181, 1005(ab)
 Germano, G, 613, 1509, 854(ab), 911(ab)
 Germine, M, 1964
 Gerrity, JI, 988(ab)
 Gerson, MC, 993(ab)
 Gestin, JF, 943(ab)
 Geworski, L, 972(ab)
 Ghafouripour, AK, 921(ab), 980(ab)
 Ghali, A, 978(ab)
 Gianolli, L, 924(ab)
 Gianuzzi, P, 846(ab)
 Gibbons, R, 927(ab)
 Gibbons, RJ, 176, 2080
 Gibson, RE, 900(ab), 979(ab)
 Gibson, T, 1589
 Gifford, HC, 891(ab)
 Giganti, M, 850(ab)
 Gil, M, 998(ab)
 Gilardi, MC, 1014(ab)
 Gilbert, JC, 2133
 Gildersleeve, DL, 860(ab)
 Gill, HK, 850(ab)
 Gilland, DR, 451, 879(ab), 901(ab), 961(ab)
 Gilmore, MP, 846(ab), 864(ab)
 Gilroy, J, 1017(ab)
 Gindi, G, 963(ab)
 Gingold EL, 1881, 901(ab)
 Giorgi, MCP, 995(ab)
 Girelli, ME, 1478
 Girgensohn, S, 1021(ab)
 Gitler, MS, 883(ab)
 Giubbini, R, 846(ab)
 Gjedde, AH, 585, 847(ab), 848(ab), 879(ab), 909(ab), 916(ab)
 Gladish, GW, 1044(ab)
 Glantz, MJ, 532
 Glaspy, JA, 828(ab)
 Glass, J, 867(ab)
 Glenn, S, 912(ab), 980(ab)
 Glennon, P, 942(ab)
 Glick, SJ, 605, 843(ab)
 Glickman, SL, 910(ab)
 Glover, DK, 864(ab)
 Glowniak, JV, 431, 716, 935(ab)
 Glutowski, TD, 869(ab)
 Gmeiner, B, 1028(ab)
 Go, A, 827(ab)
 Go, RT, 928(ab), 970(ab), 1040(ab), 1041(ab), 1048(ab), 1586(le)
 Gobuty, AH, 982(ab)
 Goddard, A, 896(ab), 911(ab)
 Goddard, AW, 1964
 Goedemans, W, 1025(ab)
 Goffe, DK, 943(ab)
 Gøeugis, T, 319
 Goin, J, 849(ab)
 Goins, B, 984(ab), 1027(ab)
 Gold, RH, 1039(ab)
 Goldberg, IE, 867(ab)
 Goldenberg, DM, 803, 1110, 863(ab), 903(ab), 904(ab), 910(ab), 958(ab), 1000(ab), 1002(ab)
 Goldenberg, JA, 516
 Goldhaber, SZ, 849(ab)
 Golding, R, 858(ab), 927(ab)
 Goldman, S, 868(ab)
 Goldsmith, SJ, 1175, 949(ab), 969(ab), 995(ab), 999(ab), 1031(ab)
 Goldstein, I, 46
 Gomes, JA, 995(ab)
 Gomez-Mont, F, 287
 Gona, JM, 1040(ab)
 Gonin, R, 1594
 Goodman, MM, 885(ab), 890(ab), 931(ab), 983(ab), 1025(ab)
 Goodrich, JK, 631(le)
 Goodwin, DA, 1816, 2006, 880(ab), 931(ab)
 Goodwin, GM, 1623
 Goomer, NC, 990(ab), 1010(ab)
 Gordon, E, 992(ab)
 Gordon, I, 1935, 2090
 Gorenberg, M, 1699, 1774
 Goris, ML, 1578, 933(ab)
 Goris, RJA, 1330, 936(ab), 950(ab)
 Gorlin, R, 995(ab)
 Gorrie, GH, 974(ab)
 Gosfield, E III, 992(ab)
 Gottschalk, A, 1422
 Gotzens, V, 403, 2060(le)
 Gözükkara, I, 869(ab), 885(ab), 968(ab)
 Grady, C, 2103
 Grady, MS, 1789
 Grafrström, G, 953(ab)
 Grafton, SC, 1472
 Graham, MC, 2020, 941(ab)
 Graham, MM, 581, 2202, 944(ab), 1009(ab), 1010(ab), 1045(ab)
 Graham, W, 996(ab)
 Grandin, C, 837(ab)
 Granowska, M, 904(ab)
 Grant, A, 903(ab)
 Grassi, F, 973(ab), 1014(ab)
 Gratz, KF, 972(ab)
 Gray, BD, 921(ab)
 Gray, BG, 55
 Graziani, LJ, 1943
 Greco, A, 1014(ab)
 Green, AJ, 1020(ab)
 Green, JF, 931(ab)
 Green, JM, 989(ab)
 Green, MA, 837(ab), 931(ab), 1049(ab)
- Green, MV, 2057(le), 852(ab)
 Green, SL, 1010(ab)
 Greenberg, ID, 2061
 Greenberg, J, 985(ab), 1012(ab)
 Greene, R, 961(ab)
 Greene, RW, 964(ab)
 Greenough, R, 438, 828(ab), 858(ab)
 Greenspan, RG, 906(ab)
 Greer, KL, 901(ab)
 Gregoir, C, 1337
 Grégoire, J, 875(ab)
 Gregory, C, 947(ab)
 Grehl, O, 1001(ab)
 Greitemann, B, 840(ab)
 Grenier, RP, 2124, 846(ab)
 Greve, J, 1022(ab)
 Grierson, JR, 2202
 Griffin, T, 904(ab)
 Griffith, J, 1183
 Griffith, JL, 905(ab)
 Griffiths, GL, 1110, 910(ab)
 Grill, V, 908(ab)
 Grinspoon, SK, 906(ab)
 Gritters, LS, 975(ab)
 Groch, MW, 927(ab), 932(ab), 938(ab), 941(ab)
 Grochowski, EW, 157
 Grond, M, 940(ab)
 Grootoank, S, 861(ab)
 Gropler, RJ, 855(ab)
 Groshar, D, 49, 1699
 Grossman, A, 1121, 914(ab)
 Grossman, M, 857(ab), 1012(ab)
 Grossman, ZD, 150
 Grothaus-King, A, 1789
 Grotta, J, 968(ab)
 Grover-McKay, M, 1917(le)
 Growdon, JH, 704
 Gruaz-Guyon, A, 912(ab), 1000(ab)
 Gruber, M, 867(ab)
 Gruenewald, SM, 2094
 Gruenewald, F, 526, 844(ab)
 Grummon, GD, 850(ab), 1033(ab)
 Grünwald, F, 972(ab)
 Guerra, UP, 895(ab)
 Guerrero, TM, 1045(ab)
 Guibourg, HC, 999(ab)
 Guidry, GW, 995(ab)
 Guillevin, L, 913(ab)
 Guillon JM, 81
 Guilloteau, D, 981(ab)
 Gullberg, GT, 831(ab), 878(ab), 891(ab), 892(ab), 901(ab), 902(ab), 961(ab), 1003(ab)
 Gulyás, B, 908(ab)
 Günalp, B, 866(ab)
 Gunes, I, 868(ab)
 Guo, LW, 1685
 Guo, YZ, 870(ab), 871(ab), 982(ab), 989(ab)
 Gupta, NC, 829(ab), 836(ab), 837(ab), 975(ab)
 Gupta, SM, 919(ab), 1251(le)
 Gustavson, LM, 880(ab)
 Gutowski, TD, 926(ab)
 Gyobu, T, 967(ab)
- Haapanen, A, 1255
 Haaparanta, M, 1255
 Haberkorn, U, 1981, 1019(ab)
 Hademenos, GJ, 605, 962(ab)
 Hadian, D, 955(ab)
 Hagberg, C-E, 860(ab)
 Hahn, K, 887(ab), 1021(ab)
 Haire, W, 978(ab)
 Haka, MS, 1125
 Halama, JR, 1043(ab)
 Haldemann, A, 231
 Haldin, C, 1016(ab)
 Halkar, RK, 837(ab), 991(ab)
 Hall, H, 860(ab), 931(ab), 1011(ab)
 Hall, K, 878(ab)
 Hall, LC, 1692
 Halldin, C, 860(ab), 931(ab), 1011(ab)
 Hallgring, E, 1312, 887(ab)
 Halpern, S, 2162
 Halpern, SE, 2148
 Ham, H, 485
 Ham, HR, 174, 175
 Hamacher, K, 2138
 Hamamoto, K, 135, 893(ab), 909(ab), 912(ab), 919(ab), 933(ab), 969(ab), 972(ab), 1004(ab)
 Hamamoto, T, 976(ab)
 Hamblen, SM, 1047(ab)
 Hamilton, SE, 908(ab)
 Hamlin, DK, 943(ab)
 Hammell, TC, 1006(ab)
 Hampel, KE, 997(ab)
 Hamvas, A, 1661
 Han, MC, 2118
 Handa, N, 969(ab), 1014(ab), 1015(ab)
 Hanelin, LG, 972(ab)
 Hanna, MG, 1031(ab)
 Hanrahan, S, 890(ab)
 Hanrath, P, 886(ab)
 Hansen, CL, 1574, 952(ab)
 Hansen, HJ, 863(ab), 904(ab), 910(ab), 1002(ab)
 Hansen, L, 900(ab), 921(ab)
 Hanson, G, 1008(ab)
 Hanson, MW, 532, 838(ab), 966(ab)
 Hanson, S, 968(ab)
 Hantraye, P, 946(ab)
 Hanyu, H, 1019(ab)
 Hara, M, 988(ab), 1033(ab)
 Harada, K, 988(ab), 1029(ab), 1033(ab)
 Harapanhalli, RS, 2196
 Harcke, HT, 873(ab), 874(ab)
 Hardman, N, 903(ab)
 Hardoff, R, 845(ab)
 Harker, J, 827(ab)
 Harkness, BA, 1859, 833(ab)
 Härkönen, R, 1255
 Harp, GD, 763
 Harrell, CR, 963(ab), 1006(ab)
 Harris, CC, 922(ab)
 Harris, GC, 867(ab)
 Harris, JM, 826(ab)
 Harris, RE, 1048(ab)

- Harris, TD, 979(ab)
Harrison, K, 978(ab)
Harrison, R, 989(ab)
Hartiala, J, 1255
Hartman, JJ, 836(ab)
Hartman, NG, 1468
Hartoko, Th, 1013(ab)
Hartsough, NE, 1002(ab)
Harwood, SJ, 498, 2249(le)
Hasan, A, 980(ab)
Haspelik, Z, 1027(ab)
Hasegawa, BH, 1881, 901(ab)
Hasegawa, S, 988(ab)
Hasegawa, Y, 208
Haseman, MK, 1750
Hasfeld, M, 915(ab)
Hashikawa, K, 940(ab), 969(ab), 1014(ab), 1015(ab)
Hashimoto, S, 934(ab)
Hasizume, 958(ab)
Haspel, MV, 1031(ab)
Hasselquist, BE, 852(ab), 873(ab)
Hatano, K, 897(ab)
Hatazawa, J, 1696, 827(ab), 857(ab), 897(ab)
Hattner, RS, 115, 1444, 918(ab)
Hauptmann, St, 1001(ab)
Hauser, MF, 840(ab)
Hauser, MM, 710
Haustein, J, 971(ab)
Hawes, DR, 1486
Hawk, TC, 1472, 1047(ab)
Hawkins, HH, 1044(ab)
Hawkins, R, 856(ab)
Hawkins, RA, 339, 633, 1191, 828(ab), 829(ab), 867(ab), 881(ab), 944(ab), 945(ab), 1039(ab), 1045(ab)
Hawkins, WG, 1007(ab)
Hawman, PC, 852(ab)
Hayashi, H, 333, 1015(ab)
Hayashida, K, 365
Haynie, TP, 828(ab), 858(ab), 992(ab), 1001(ab)
Hayostek, RJ, 1613
Haywood, L, 1000(ab)
Haze, K, 853(ab)
He, XS, 981(ab)
He, Z-X, 1846
Heelan, R, 345
Hefti, F, 890(ab)
Heidner, GL, 1542
Heikkonen, JJ, 913(ab)
Heironimus, JD, 2052
Heiser, RC, 468(le)
Heiss, WD, 861(ab), 940(ab), 1013(ab)
Helfaer, MA, 1004(ab)
Heller, GV, 876(ab), 951(ab)
Helling, D, 1024(ab)
Hellman, RS, 868(ab), 939(ab)
Hellström, I, 2160, 862(ab)
Hellström, KE, 2160, 862(ab)
Helwig, A, 957(ab)
Hendel, RC, 1783
Heninger, GR, 1964
Henkes, H, 971(ab), 1018(ab)
Henkin, RE, 1041(ab)
Henkin, RI, 996(ab)
Henneman, G, 894(ab)
Hennessey, JG, 1042(ab)
Henrich, M, 2138
Henry, TR, 929(ab)
Heo, J, 186, 2086, 854(ab), 866(ab), 916(ab), 952(ab)
Herbst, CP, 888(ab)
Herholz, K, 940(ab)
Herman, SD, 951(ab)
Herman, Z, 992(ab)
Herrero, P, 837(ab), 884(ab)
Herrin, JT, 73
Herrold, EM, 845(ab)
Herscovitch, P, 2103, 1010(ab)
Hertel, A, 853(ab), 904(ab), 912(ab)
Hertzberg, VS, 1132, 894(ab)
Herzog, H, 2138
Herzog, KM, 2190
Hess, H, 853(ab)
Hesse, B, 2106
Heusser, CH, 903(ab)
Heya, T, 957(ab)
Heyman, S, 269, 873(ab)
Heyndrickx, GR, 884(ab)
Hichwa, RD, 1008(ab), 1027(ab), 1430(le)
Hickey, J, 954(ab)
Hickey, P, 838(ab)
Hicks, KW, 1011(ab)
Hierholzer, J, 902(ab), 971(ab), 1018(ab)
Hiesiger, E, 1720
Hiesiger, EM, 192
Higano, S, 911(ab), 963(ab)
Higashi, K, 841(ab)
Higashi, S, 967(ab), 998(ab)
Hildebrand, J, 868(ab)
Hill, TC, 965(ab)
Hilleman, D, 837(ab)
Hilson, AJW, 1020(ab)
Hilton, S, 1002(ab)
Hilton, TC, 847(ab), 876(ab)
Hindmarsh, T, 1016(ab)
Hinge, D, 875(ab)
Hinkin, C, 967(ab)
Hinnefeld, JD, 1132, 894(ab)
Hirano, M, 920(ab)
Hirano, T, 1181
Hirata, K, 886(ab)
Hirayama, K, 917(ab)
Hironaka, FH, 995(ab)
Hirose, Y, 1008(ab)
Hirth, W, 900(ab), 974(ab)
Hisada, K, 179, 441, 1200, 2024, 877(ab), 918(ab), 957(ab), 967(ab), 1020(ab)
Hitchens, RE, 1430(le)
Hitzemann, 521
Hitzemann, R, 887(ab), 888(ab), 1046(ab)
Hixson, DJ, 537
Hnatowich, DJ, 1810, 909(ab), 921(ab), 925(ab), 934(ab), 958(ab), 1030(ab)
Ho, PJ, 1608, 834(ab)
Ho, VB, 1039(ab)
Hobbs, KEF, 1020(ab)
Hoberman, A, 923(ab)
Hoch, DB, 2211
Hochberg, F, 867(ab)
Hodgson, HJ, 756
Hodson, EM, 2094
Hoekstra, OS, 858(ab), 927(ab)
Hoffer, P, 896(ab)
Hoffer, PB, 1964, 848(ab), 878(ab), 906(ab), 911(ab), 913(ab), 945(ab)
Höfken, H, 906(ab)
Hoffman, BJ, 935(ab)
Hoffman, EJ, 595, 613, 1191, 828(ab), 879(ab), 1010(ab), 1045(ab), 1430(le)
Hoffman, JM, 532, 1472, 838(ab), 922(ab), 966(ab), 1047(ab)
Hoffman, TJ, 435, 988(ab), 1032(ab), 1048(ab)
Höflich, G, 972(ab)
Hofstetter, J, 981(ab)
Högberg, T, 860(ab)
Hoh, CK, 339, 633, 1191, 828(ab), 829(ab), 867(ab), 945(ab), 1045(ab)
Højgaard, L, 2106
Holan, V, 949(ab), 969(ab)
Holdeman, K, 978(ab)
Holden, JE, 922(ab)
Holman, BL, 181, 704, 1312, 1357, 1516, 1888, 1949, 839(ab), 852(ab), 887(ab), 970(ab), 1005(ab), 1018(ab), 1033(ab), 1043(ab), 1432(le)
Holmes, DR, 845(ab)
Holmes, GL, 1018(ab)
Holmes, RA, 435, 1451, 851(ab), 988(ab), 1032(ab), 1048(ab)
Holoye, P, 992(ab)
Holsclaw, D, 835(ab)
Holt, SA, 1417
Holthoff, VA, 1013(ab)
Holweg, R, 931(ab)
Hommeyer, SH, 748
Honda, N, 969(ab)
Honeyman, J, 1043(ab)
Honeyman, JC, 1042(ab), 1043(ab)
Hong, CD, 991(ab)
Hong, J, 1035(ab)
Hong, MK, 892(ab)
Hong, SB, 877(ab)
Hong, WH, 962(ab)
Hoogeveen, EK, 990(ab)
Hör, G, 853(ab), 904(ab), 912(ab)
Horai, Y, 891(ab)
Horan, PK, 899(ab), 921(ab)
Hori, M, 952(ab)
Horibe, K, 246
Hörl, W, 859(ab)
Horn, L, 973(ab)
Hornu, CHG, 832(ab)
Horowitz, M, 2027
Horowitz, M, 1283
Horowski, R, 1018(ab)
Hörtnagl, H, 108
Hortobagyi, G, 828(ab)
Hosain, F, 1251(le)
Hoschl, R, 868(ab)
Hoshi, H, 916(ab), 971(ab)
Hosono, M, 853(ab), 893(ab), 1001(ab)
Hotchkiss, RS, 925(ab)
Hotson, G, 117
Hotze, AL, 526, 839(ab), 844(ab), 914(ab)
Houle, S, 960(ab)
Hoverath, H, 828(ab), 1007(ab), 1045(ab)
Hovsepian, D, 1042(ab)
Howell, RW, 277, 2196
Hradilek, P, 982(ab)
Hsieh, J, 852(ab)
Hsu, CY, 997(ab), 1013(ab)
Hsu, TH, 1034(ab)
Hua, T, 878(ab)
Huang, G, 852(ab)
Huang, H, 861(ab), 974(ab), 1026(ab)
Huang, SC, 339, 613, 633, 1235, 1472, 881(ab), 882(ab), 944(ab), 945(ab)
Huberty, JP, 1444
Hubner, KF, 885(ab), 923(ab), 983(ab)
Huck, S, 108
Hudson, HM, 960(ab)
Huesman, 884(ab), RH
Hughes, JA, 1048(ab)
Hughes, JMB, 836(ab), 1022(ab)
Hughey, BJ, 932(ab)
Huijgens, PC, 858(ab), 927(ab)
Hundeshagen, H, 972(ab)
Hung, GL, 844(ab)
Hung, JC, 176, 306, 1613
Hunink, MGM, 1432(le)
Hunter, DW, 1039(ab)
Hupp, T, 907(ab)
Hurwitz, RA, 918(ab)
Hutchins, B, 934(ab)
Hutchins, G, 882(ab), 1008(ab), 1020(ab)
Hutchins, GD, 684, 1243, 826(ab), 870(ab), 878(ab), 881(ab), 933(ab), 994(ab)
Hutchinson, RJ, 1735
Hutson, WR, 833(ab)
Hutton, BF, 901(ab), 960(ab)
Hvid-Jacobsen, K, 251
Hwang, D-R, 830(ab), 975(ab), 983(ab)
Hwang, YC, 830(ab)
Hynes, M, 974(ab)
Ibis, E, 2110
Ichihara, T, 1200, 918(ab)
Ichijo, K, 1851
Ichise, M, 55, 970(ab)
Ichiya, Y, 877(ab), 945(ab), 1015(ab)
Ide, M, 932(ab)
Ido, T, 413, 1972, 840(ab), 897(ab), 984(ab)
Iervasi, G, 1020(ab)
Ii, M, 967(ab)
Iida, H, 1669, 827(ab), 911(ab), 963(ab), 994(ab), 1008(ab)
Iida, Y, 897(ab), 1024(ab)
Iijima, N, 891(ab)
Iio, A, 933(ab)
Ikeda, M, 940(ab)
Ike Kubo, K, 659, 885(ab)
Ikeoka, N, 744
Iles, S, 950(ab)
Im, J-G, 2118
Imahori, Y, 413, 466(le)
Imai, K, 951(ab)
Imai, Y, 853(ab)
Imaizumi, M, 246
Imaseki, K, 324
Imbriaco, M, 915(ab)
Immerzeel, DJMJ, 936(ab)
Ingvar, M, 908(ab), 1011(ab)
Innis, RB, 1964, 848(ab), 896(ab), 911(ab), 945(ab), 961(ab)
Inoue, O, 917(ab)
Inoue, T, 1181, 909(ab), 912(ab), 969(ab), 972(ab), 1004(ab)
Inoue, Y, 857(ab), 968(ab), 969(ab)
Inugami, A, 1696
Iravani, A, 923(ab)
Isacson, O, 946(ab)
Isaka, Y, 246
Ishida, Y, 940(ab), 952(ab), 969(ab), 1014(ab), 1015(ab)
Ishii, I, 1020(ab)
Ishii, K, 1016(ab)
Ishii, S, 1016(ab)
Ishimaru, T, 1023(ab)
Ishimura, J, 834(ab)
Ishiwata, K, 1972, 840(ab), 841(ab), 897(ab), 984(ab), 1016(ab), 1025(ab)
Išak, E, 866(ab)
Isitman, AT, 2110
Iskandrian, AS, 186, 2086, 854(ab), 866(ab), 916(ab), 952(ab)
Iskandrian, B, 854(ab), 916(ab), 952(ab)
Iskandrian, BB, 186
Islan, S, 435
Isobe, M, 1000(ab)
Isono, K, 333
Israel, O, 1699, 1774
Itami, J, 324
Itami, M, 324
Itoh, H, 1696, 911(ab), 963(ab)
Itoh, M, 857(ab), 897(ab)
Itoh, T, 917(ab)
Itoi, Y, 246
Itti, R, 874(ab), 875(ab), 1011(ab)
Iuliucci, JD, 978(ab)
Ivanovic, M, 842(ab), 851(ab), 1012(ab), 1015(ab)
Iwasaki, Y, 897(ab), 966(ab)
Iwashita, S, 996(ab)
Iwata, R, 897(ab)
Izaki, M, 995(ab)
Izon, D, 904(ab)
Jabhour, BA, 829(ab)
Jabir, AM, 1044(ab), 1045(ab)
Jabir, R, 1044(ab), 1045(ab)
Jacobs, MP, 830(ab), 975(ab), 983(ab)
Jacobs, W, 1035(ab)
Jacobson, AF, 202, 1642,

- 849(ab), 866(ab), 1035(ab)
 Jaggi, J, 1012(ab)
 Jagust, WJ, 890(ab), 939(ab)
 Jahan, S, 978(ab)
 Jain, D, 874(ab), 938(ab),
 939(ab), 993(ab)
 Jain, SP, 981(ab)
 Jamar, F, 73, 976(ab)
 Jang, JJ, 892(ab)
 Janicsek, MJ, 1758, 970(ab)
 Janin, C, 1003(ab)
 Jansen, J, 957(ab)
 Jansons, D, 947(ab)
 Janssen, AGM, 917(ab),
 1016(ab)
 Jarrousse, B, 913(ab)
 Jarry, M, 855(ab)
 Jaszczak, RJ, 961(ab)
 Jaszczak, RJ, 451, 879(ab),
 891(ab), 901(ab), 922(ab)
 Jauch, M, 956(ab)
 Jay, M, 398, 1915(le)
 Jeffery, PJ, 883(ab)
 Jehan, A, 835(ab)
 Jensen, PF, 251
 Jeong, JM, 889(ab), 986(ab),
 1001(ab)
 Jerushalmi, J, 1774
 Jeusset, J, 2162
 Jewett, DM, 423, 982(ab)
 Jhingran, SG, 974(ab)
 Jia, MX, 927(ab)
 Jimenez, H, 1304, 987(ab)
 Jinnouchi, S, 971(ab)
 Jocheison, MS, 1594
 Joensuu, H, 691
 John, CS, 889(ab)
 John, E, 851(ab), 979(ab),
 987(ab)
 Johnson, DK, 904(ab)
 Johnson, JC, 623, 1916(le)
 Johnson, K, 1312
 Johnson, KA, 181, 704,
 887(ab), 1005(ab),
 1018(ab), 1043(ab),
 1432(le)
 Johnson, LL, 229, 1411,
 1994, 846(ab)
 Johnson, MC, 820
 Johnson, SH, 575
 Johnson, VE, 879(ab)
 Johnston, GS, 966(ab),
 970(ab)
 Johnston, RE, 842(ab)
 Jomura, I, 744
 Jones, AG, 1357, 1516,
 1949, 937(ab), 1033(ab)
 Jones, AL, 1002(ab)
 Jones, BE, 676
 Jones, FD-L, 827(ab)
 Jones, JJ, 1014(ab)
 Jones, M, 948(ab)
 Jones, RH, 825(ab)
 Jones, RML, 1766
 Jones, T, 1669
 Jones, WT, 41
 Jonker, N, 491
 Jonkhoff, AR, 927(ab)
 Jönsson, B-A, 1654, 1825,
 953(ab), 954(ab)
 Jørgensen, F, 2106
 Jorgenson, MA, 845(ab)
 Joseph, JL, 968(ab)
 Joseph, K, 906(ab)
 Joshua, AV, 841(ab)
 Jouve, B, 843(ab)
 Joyce, ME, 716
 Juillière, Y, 906(ab)
 Julian, BA, 924(ab)
 Juni, JE, 239, 1206,
 1017(ab)
 Juweid, M, 873(ab), 893(ab)
 Jyawook, S, 996(ab)
 Kabalka, GW, 890(ab),
 931(ab), 983(ab), 1025(ab)
 Kaieda, M, 1016(ab)
 Kairemo, KJA, 913(ab)
 Kaiser, HJ, 886(ab)
 Kalagian, H, 867(ab)
 Kalf, V, 1346, 2222
 Kalkowski, PJ, 881(ab)
 Kallergi, M, 889(ab)
 Kalloo, AN, 1216
 Kamada, M, 998(ab)
 Kamada, T, 940(ab),
 952(ab), 969(ab), 997(ab),
 1014(ab), 1015(ab)
 Kamano, T, 969(ab)
 Kamata, R, 951(ab)
 Kambara, H, 659, 856(ab),
 885(ab), 886(ab), 953(ab)
 Kaminski, MS, 893(ab)
 Kämmer, M, 1019(ab)
 Kammermeier, H, 102
 Kanada, H, 1001(ab)
 Kanaya, K, 958(ab),
 1004(ab), 1005(ab)
 Kanaya, S, 958(ab),
 1004(ab), 1005(ab)
 Kaneko, M, 6
 Kang, SB, 905(ab)
 Kanke, M, 144
 Kanmaz, B, 868(ab)
 Kanner, AM, 1014(ab)
 Kanno, I, 1696, 827(ab),
 857(ab), 911(ab), 1008(ab)
 Kanstrup, IL, 251
 Kanvinde, MH, 981(ab)
 Kao, CH, 254, 955(ab),
 977(ab), 986(ab), 997(ab),
 1013(ab)
 Kao, PF, 1022(ab)
 Kapadvanjwala, M, 956(ab),
 980(ab)
 Kaphan, G, 990(ab)
 Kaplan, JD, 1661
 Kaplan, WD, 1594
 Kappes, R, 1035(ab)
 Kapucu, O, 917(ab),
 1016(ab)
 Karalasingam, L, 1253(le)
 Karayalcin, G, 914(ab)
 Karcher, G, 906(ab)
 Kari, B, 852(ab)
 Karl, IE, 925(ab)
 Karlsson, P, 860(ab)
 Karp, JS, 861(ab), 862(ab),
 871(ab), 1430(le)
 Karrison, T, 853(ab)
 Kasahara, A, 997(ab)
 Kashikura, K, 1005(ab)
 Kashiwagi, T, 997(ab)
 Kasi, LP, 941(ab), 992(ab),
 1001(ab)
 Kasper, S, 972(ab)
 Kassir, AI, 384, 781
 Katafuchi, T, 272
 Katayama, S, 968(ab)
 Katial, R, 266
 Kato, H, 659, 885(ab)
 Kato, M, 1015(ab)
 Kato, N, 1017(ab)
 Katona, CE, 1014(ab)
 Katsetos, CD, 2017
 Katti, KK, 910(ab), 1032(ab)
 Katti, KV, 851(ab), 910(ab),
 979(ab), 987(ab),
 1032(ab), 1048(ab)
 Katz, RD, 1039(ab)
 Katzenellenbogen, JA, 558,
 724
 Kaufman, GE, 2214
 Kaul, S, 1732
 Kavanagh, P, 911(ab)
 Kawada, T, 844(ab)
 Kawai, C, 659
 Kawai, H, 6
 Kawai, K, 891(ab)
 Kawai, T, 1023(ab)
 Kawakami, K, 1004(ab)
 Kawamoto, M, 659, 856(ab),
 885(ab), 886(ab), 953(ab)
 Kawamura, M, 1516
 Kawarabayashi, C, 853(ab)
 Kawasaki, Y, 967(ab)
 Kawasui, M, 441
 Kearfott, KJ, 842(ab)
 Keeling, CA, 1750
 Keenan, A, 848(ab)
 Kegel, J, 186
 Keiser, HR, 833(ab)
 Keller, F, 1178
 Kelley, A, 956(ab)
 Kelley, MJ, 2222
 Kelly, JD, 850(ab)
 Kemler, S, 952(ab)
 Kemp, BJ, 1875
 Kempf, J, 2014
 Kenda, R, 873(ab)
 Kenemans, P, 1113, 1958,
 2000
 Kengen, RAM, 1251(le)
 Kennedy, DN, 867(ab)
 Kennedy, JW, 939(ab)
 Kennedy, RL, 127
 Kerr, JM, 1836
 Kershaw, G, 907(ab)
 Kessler, J, 940(ab), 1013(ab)
 Kessler, ML, 926(ab)
 Kessler, RM, 826(ab),
 847(ab), 848(ab)
 Ketring, AR, 623, 1916(le),
 851(ab), 910(ab), 979(ab),
 987(ab), 1032(ab),
 1048(ab)
 Kettle, AG, 313
 Keyes, JW, Jr, 1859
 Khalkhali, I, 835(ab)
 Khanna, S, 825(ab), 856(ab),
 867(ab), 944(ab), 1009(ab)
 Khaw, BA, 144, 1994,
 895(ab), 934(ab), 936(ab),
 943(ab), 959(ab)
 Khazaeli, MB, 23, 1648
 Khedkar, N, 258
 Khelifa, F, 990(ab)
 Khonsari, A, 967(ab)
 Kiat, H, 1509, 854(ab),
 876(ab), 911(ab)
 Kiba, A, 1935
 Kiefer, J, 912(ab)
 Kijewski, MF, 962(ab)
 Kikuchi, H, 893(ab)
 Kikuchi, T, 333
 Kilbourn, MR, 423, 861(ab),
 870(ab), 882(ab), 982(ab),
 983(ab)
 Kilts, CD, 922(ab)
 Kim, A, 836(ab)
 Kim, BT, 828(ab)
 Kim, CK, 902(ab), 919(ab),
 999(ab)
 Kim, C-W, 2118
 Kim, EE, 828(ab), 858(ab),
 985(ab), 992(ab), 1001(ab)
 Kim, H, 974(ab)
 Kim, H-L, 1225
 Kim, KY, 936(ab)
 Kim, SB, 991(ab)
 Kim, SE, 877(ab)
 Kim, SM, 961(ab)
 Kim, SY, 902(ab)
 Kimball, AW, 869(ab)
 Kimball, AW Jr, 883(ab)
 Kimura, J, 1637
 Kimura, Y, 893(ab), 909(ab),
 912(ab), 933(ab)
 Kinahan, PE, 871(ab)
 King, HF, 963(ab)
 King, MA, 161, 605,
 842(ab), 843(ab), 962(ab)
 King, PT, 847(ab)
 Kinoshita, M, 969(ab)
 Kinoshita, R, 988(ab),
 1029(ab), 1033(ab)
 Kinoshita, S, 932(ab)
 Kinsey, BM, 983(ab)
 Kinuya, K, 967(ab)
 Kinuya, S, 842(ab), 889(ab),
 957(ab), 986(ab), 1001(ab)
 Kippenhan, JS, 1459
 Kipper, SL, 902(ab)
 Kir, M, 464(le)
 Kirchner, PT, 1917(le)
 Kirsch, C-M, 832(ab),
 897(ab), 917(ab)
 Kirsh, C-M, 1291
 Kirsh, J, 960(ab)
 Kirsh, JC, 55, 970(ab)
 Kitamura, S, 1016(ab)
 Kitapci, M, 319
 Kiuru, AJ, 913(ab)
 Kjoller, E, 251
 Klauser, AG, 1291
 Klein, BE, 1701
 Klein, HA, 996(ab)
 Klein, HH, 223, 906(ab)
 Klemm, E, 972(ab)
 Klingensmith, WC, III, 1417
 Klinkowstein, RE, 932(ab)
 Klipper, R, 984(ab),
 1027(ab)
 Klosa, B, 1399
 Knapp, FF Jr, 910(ab),
 995(ab), 1023(ab),
 1024(ab), 1028(ab)
 Knecht, R, 912(ab)
 Kneeland, B, 992(ab)
 Knight, D, 756
 Knight, LC, 710, 467(le),
 832(ab), 964(ab)
 Knobloch, E, 1035(ab)
 Knopp, MV, 828(ab),
 1007(ab), 1045(ab)
 Knusel, B, 890(ab)
 Knuuti, MJ, 1255
 Kobayashi, A, 6
 Kobayashi, H, 853(ab),
 893(ab), 1001(ab)
 Kobayashi, K, 744
 Koch, KT, 895(ab)
 Koch, P, 959(ab)
 Koenders, EB, 1031(ab)
 Koeppel, RA, 423, 1008,
 858(ab), 870(ab), 878(ab),
 882(ab), 887(ab),
 1003(ab), 1007(ab),
 1009(ab)
 Koga, S, 1741, 965(ab)
 Koh, C-S, 2118, 877(ab),
 892(ab), 905(ab)
 Köhler, U, 995(ab)
 Kojima, A, 988(ab),
 1029(ab), 1033(ab)
 Kojima, H, 998(ab)
 Kolbe, H, 972(ab)
 Kollman, M, 710
 Kollmann, M, 832(ab)
 Kolodny, GM, 1699, 1774,
 947(ab), 1003(ab)
 Kolsky, KL, 900(ab),
 980(ab), 985(ab)
 Komai, S, 1741
 Kondo, S, 893(ab)
 Konings, AWT, 373
 Konishi, J, 545, 659, 897,
 1263, 1501, 1637, 853(ab),
 856(ab), 885(ab), 886(ab),
 891(ab), 893(ab), 953(ab),
 966(ab), 1001(ab),
 1023(ab), 1024(ab),
 1026(ab)
 Konstam, MA, 905(ab)
 Kooij, PPM, 652, 894(ab),
 914(ab)
 Kooji, PPM, 990(ab)
 Koon T'oh, S, 1312
 Koper, JW, 652
 Kopiccka, K, 910(ab),
 979(ab), 982(ab), 1032(ab)
 Korai, KF, 842(ab), 926(ab)
 Kosslyn, SM, 908(ab)
 Kostakoglu, L, 345, 1396,
 843(ab), 1002(ab)
 Köster, G, 950(ab)
 Kosuda, S, 844(ab), 966(ab)
 Kotlyarov, EV, 966(ab),
 970(ab)
 Kotts, C, 934(ab)
 Kousaka, T, 853(ab)
 Kovacs, FM, 403, 2060(le)
 Kozawa, SM, 581
 Kozell, LB, 581
 Kozuka, K, 952(ab),
 1015(ab)
 Kozuka, T, 365, 940(ab),
 969(ab), 997(ab), 1014(ab)
 Kramer, EL, 912(ab),
 966(ab), 960(ab)
 Krasnow, AZ, 868(ab)
 Krause, B, 885(ab)
 Krenning, EP, 652, 894(ab),
 903(ab), 914(ab), 955(ab),
 990(ab)
 Kretschko, J, 859(ab)
 Kreuzer, H, 845(ab)
 Krevsky, B, 467(le), 832(ab)
 Krishna, L, 2017
 Krishnamurthy, GT, 431,
 542

- Krishnamurthy, S, 542
 Krishnan, R, 910(ab), 994(ab)
 Krivokapich, J, 856(ab)
 Kroger, L, 912(ab)
 Kroger, LA, 862(ab)
 Krohn, KA, 581, 2202, 987(ab)
 Kroll, K, 2202
 Krom, RF, 239
 Kronauge, JF, 1357, 1516, 1949, 864(ab), 1033(ab)
 Kronrad, L, 982(ab)
 Kroon, D, 910(ab)
 Kroop, S, 898(ab)
 Kropp, J, 526, 844(ab), 995(ab), 1028(ab)
 Kruezer, H, 223
 Krumholz, A, 966(ab)
 Krumholz, H, 1003(ab)
 Kuang, L-R, 985(ab)
 Kuba, A, 458
 Kubo, A, 875(ab), 934(ab)
 Kubodera, A, 891(ab)
 Kubota, K, 1972, 840(ab), 841(ab), 984(ab)
 Kubota, R, 1972, 840(ab), 841(ab), 984(ab)
 Kuczynski, BL, 1152, 865(ab), 993(ab)
 Kuebler, WK, 1007(ab)
 Kuhar, MJ, 964(ab)
 Kuhl, DE, 423, 1125, 1836, 858(ab), 882(ab), 887(ab), 929(ab), 1003(ab), 1009(ab)
 Kuhle, W, 1628
 Kuhle, WG, 1235
 Kuhlmann, L, 920(ab), 1030(ab)
 Kuijper, AFM, 1727
 Kuiper, MA, 917(ab), 1016(ab)
 Kuji, I, 1020(ab)
 Kukis, DL, 942(ab), 1030(ab), 1031(ab)
 Kulkarni, PV, 974(ab), 990(ab), 1003(ab), 1010(ab)
 Kumar, A, 1548, 2103, 1013(ab)
 Kung, HF, 1964, 848(ab), 870(ab), 871(ab), 890(ab), 896(ab), 945(ab), 954(ab), 982(ab), 989(ab)
 Kung, MP, 871(ab), 890(ab), 982(ab), 989(ab)
 Kuni, CC, 873(ab)
 Kuniyasu, Y, 998(ab)
 Kupfer, S, 949(ab)
 Kurata, C, 6, 845(ab)
 Kurihara, K, 1005(ab)
 Kurkoki, T, 744
 Kursh, ED, 41
 Kurt, AM, 1766
 Kusakabe, K, 958(ab), 1004(ab), 1005(ab)
 Kuten, A, 1774
 Kutom, AH, 951(ab)
 Kuwabara, H, 879(ab), 909(ab), 916(ab)
 Kuwabara, Y, 877(ab), 945(ab), 1015(ab)
 Kuyama, J, 324
 Kvols, LJ, 1613
 Kwan, A, 844(ab)
 Kwekkeboom, DJ, 652, 914(ab)
 Labresh, KA, 951(ab)
 Ladd, W, 1269
 Laflamme, L, 696
 LaFrance, N, 878(ab)
 LaFrance, ND, 968(ab)
 Lahiri, A, 448, 874(ab), 875(ab), 938(ab)
 Lai, J, 987(ab)
 Laks, H, 977(ab)
 Lakshmanan, M, 1848
 Lalonde, D, 866(ab)
 Lalush, DS, 832(ab)
 Lam, C, 888(ab)
 Lam, WC, 1007(ab)
 Lambert, CR, 980(ab), 1023(ab), 1028(ab), 1029(ab)
 Lambert, R, 1091, 1801, 855(ab), 866(ab), 894(ab), 1034(ab)
 Lamberts, SWJ, 652, 894(ab), 903(ab), 914(ab), 955(ab)
 Lambrecht, RM, 2020
 Lamki, L, 968(ab)
 Lamki, LM, 1047(ab)
 Lammert, G, 1048(ab)
 Lammertsma, AA, 1669
 Landais, P, 1011(ab)
 Landoni, C, 944(ab)
 Lang, EV, 1797
 Lang, TF, 1881, 901(ab)
 Lange, RC, 304
 Langer, R, 971(ab)
 Langhammer, HR, 854(ab), 859(ab)
 Langhorst, SM, 623, 1916(le)
 Lanier, L, 1043(ab)
 Lanigan, JP, 1024(ab)
 Lanspa, S, 975(ab)
 Lantto, E, 1253(le)
 Lantto, T, 1253(le)
 Larar, GN, 2209
 Larar, JM, 844(ab)
 Larar, JN, 1186
 Larcos, G, 1588(le)
 Larkin, R, 960(ab)
 Laroock, MP, 874(ab)
 Larson, S, 867(ab)
 Larson, SM, 345, 803, 1373, 1396, 2020, 843(ab), 859(ab), 904(ab), 913(ab), 941(ab), 1002(ab)
 Larsson, BS, 1825
 Laruelle, M, 848(ab), 911(ab), 945(ab)
 Lasdun, A, 981(ab)
 Lasser, EC, 237
 Lastoria, S, 892(ab), 918(ab), 999(ab)
 Latham, TB, 355
 Latifc-Jasnic, D, 587
 Latino, FA, 990(ab)
 Lattimer, JC, 1024(ab)
 Lau, A, 2059(le)
 Lauer, U, 903(ab)
 Laurent, R, 868(ab)
 Laurie, AJ, 237
 Lavender, JP, 491, 756
 Lawson, AJ, 886(ab)
 Laxer, KD, 967(ab)
 Layer, G, 914(ab)
 Lazewatsky, J, 989(ab)
 Le, N, 889(ab), 957(ab)
 Lear, JL, 1819, 463(le), 908(ab), 947(ab)
 Le Bars, D, 953(ab), 1011(ab)
 LeBlanc, AD, 974(ab)
 LeBouthillier, G, 1550
 Lechevallier, E, 990(ab)
 Leclercq, B, 874(ab)
 Leddy, C, 934(ab)
 Le Doussal, JM, 912(ab), 1000(ab)
 Lee, C, 964(ab)
 Lee, DS, 877(ab)
 Lee, FA, 939(ab)
 Lee, HB, 739, 907(ab)
 Lee, HP, 905(ab)
 Lee, JD, 1183
 Lee, K, 684
 Lee, KS, 1579, 981(ab)
 Lee, M, 869(ab), 963(ab)
 Lee, MC, 877(ab), 892(ab), 905(ab)
 Lee, ME, 972(ab)
 Lee, MH, 919(ab), 936(ab), 991(ab)
 Lee, MK, 919(ab)
 Lee, RF, 972(ab)
 Lee, SF, 282
 Lee, SH, 936(ab)
 Lee, TW, 986(ab)
 Lee, VW, 463(le)
 Lee, YI, 2118
 Lees, AM, 845(ab)
 Lees, RS, 845(ab)
 Lefebvre, B, 1034(ab)
 Lefkowitz, D, 1047(ab)
 Léger, GC, 879(ab), 916(ab)
 Lehtikoinen, P, 691
 Leichner, PK, 1007(ab)
 Leighton, DM, 1022(ab)
 Leisure, GP, 885(ab)
 Leitha, T, 1028(ab)
 Lemlek, J, 2086, 866(ab), 916(ab)
 Lemmens, JAM, 1330, 950(ab)
 Lenners, N, 976(ab)
 Lennon, SE, 1797
 León, AS, 1949
 León, ET, 1949
 Leonard JC, 981(ab), 1034(ab)
 Leonidas, JC, 914(ab)
 Leppo, JA, 120, 1783, 468(le), 846(ab), 864(ab), 993(ab)
 Lerner, D, 1022(ab)
 Leroy, RF, 1018(ab)
 Lesch, MD, 994(ab)
 Leskinen-Kallio, S, 691
 Lesser, I, 838(ab)
 Lesser, RP, 929(ab)
 Lette, J, 938(ab), 951(ab)
 Leuven, KU, 832(ab)
 Levasseur, A, 951(ab)
 Levasseur, M, 1481, 1019(ab)
 Léveillé, J, 480, 1091, 1034(ab)
 Lever, SZ, 899(ab), 921(ab), 1032(ab)
 Levina, T, 1022(ab)
 Levine, MA, 869(ab)
 Levine, R, 1014(ab)
 Levivier, M, 868(ab)
 Levni, E, 932(ab)
 Levy, A, 1046(ab)
 Levy, AV, 287
 Levy, WC, 763, 1324, 1642
 Lewellen, TK, 771, 2202, 889(ab), 1430(le)
 Lewis, DH, 1789
 Lewis, ML, 512
 Leys, D, 1431(le)
 Li, J, 842(ab), 891(ab)
 Liang, AY, 946(ab)
 Liang, C-H, 282
 Liang, Z, 872(ab)
 Liao, S-C, 282
 Liao, SK, 926(ab)
 Liao, SQ, 997(ab), 1013(ab)
 Libby, D, 880(ab), 1028(ab)
 Licho, R, 907(ab)
 Lidgi, S, 49
 Lie, KI, 870(ab)
 Liebes, L, 912(ab)
 Liedtke, AJ, 1864
 Liew, SC, 1881
 Lightfoote, JB, 1039(ab)
 Lin, H, 974(ab)
 Lin, KN, 1012(ab)
 Lin, KP, 882(ab)
 Lin, MS, 997(ab)
 Lin, S, 1033(ab)
 Lin, W, 974(ab)
 Lin, WY, 977(ab), 986(ab), 997(ab), 1013(ab)
 Linder, KE, 1152, 865(ab), 920(ab)
 Lindsley, K, 867(ab)
 Line, BR, 1939, 848(ab)
 Lingen, AV, 858(ab), 927(ab)
 Linhart, NC, 380
 Link, JM, 581
 Links, JM, 968(ab), 1007(ab), 1430(le)
 Linsen, MCJG, 102
 Liow, J-S, 871(ab)
 Lisboa, R, 1223
 Liscic, E, 1024(ab)
 Lister-James, J, 845(ab)
 Little, JW, 1035(ab)
 Littlefield, JL, 1042(ab), 1046(ab)
 Litton, J-E, 860(ab), 1011(ab), 1016(ab)
 Liu, A, 724
 Liu, HC, 1012(ab)
 Liu, J, 962(ab)
 Liu, RS, 997(ab), 1034(ab)
 Liu, S, 1012(ab)
 Liu, T, 23, 1648
 Liu, XJ, 938(ab)
 Liu, Y, 852(ab), 924(ab)
 Livni, E, 924(ab)
 Ljungberg, M, 962(ab)
 Lloyd, T, 1143
 LoBuglio, AF, 23, 1648
 Loc'h, C, 1481, 883(ab), 1019(ab)
 Logan, J, 192, 521, 847(ab), 887(ab), 888(ab), 946(ab)
 Logan, KW, 1451
 Logemann, TN, 884(ab)
 Loisanche, D, 471, 896(ab)
 Loncaric, S, 842(ab), 851(ab)
 Longford, CPD, 890(ab), 931(ab), 1025(ab)
 Lopez, M, 914(ab)
 Lorenz, CH, 826(ab)
 Lorenz, WJ, 828(ab), 1007(ab), 1045(ab)
 Losinno, F, 2040
 Lötter, MG, 777, 888(ab)
 Lovins, K, 991(ab), 1046(ab)
 Low, J, 937(ab)
 Lowe, J, 860(ab)
 Lowe, JL, 1919, 2030, 827(ab)
 Löwenberg, B, 903(ab)
 Loyalka, SK, 623, 1916(le)
 Loyd, D, 1789
 Lucignani, G, 944(ab), 973(ab)
 Ludbrook, PA, 836(ab)
 Lueth, K, 853(ab)
 Luh, KE, 1011(ab), 1018(ab)
 Lui, D, 903(ab)
 Liebes, L, 912(ab)
 Luo, J, 926(ab)
 Lutterman, JA, 1330, 950(ab)
 Luxen, A, 1472, 868(ab)
 Lyle, LR, 2184
 Lyon, SG, 237
 Lyons, EA, 1044(ab)
 Lythgoe, MF, 1935, 2090
 Ma, GQ, 844(ab), 937(ab)
 Maas, K, 874(ab)
 Macalintal, S, 867(ab)
 Macapinlac, H, 867(ab)
 MacEwan, DW, 1044(ab)
 Macey, DJ, 926(ab), 927(ab), 941(ab)
 MacFall, JR, 922(ab)
 MacGregor, R, 521, 887(ab), 888(ab)
 MacGregor, RR, 192, 847(ab), 946(ab)
 Mach, JP, 1766, 903(ab)
 Mach, RH, 829(ab), 985(ab)
 Machac, J, 995(ab)
 Machecourt, J, 953(ab)
 Machida, K, 969(ab)
 MacIntyre, WJ, 866(ab), 928(ab), 970(ab), 1040(ab), 1048(ab), 1586(le)
 Maclean, JB, 972(ab)
 MacNabb, CJ, 870(ab)
 Macy, C, 912(ab)
 Madani, S, 458
 Madar, I, 883(ab)
 Maddahi, J, 1509, 825(ab), 828(ab), 829(ab), 854(ab), 856(ab), 867(ab), 876(ab), 1009(ab), 1045(ab)
 Maddax, A, 1283
 Maddock, EN, 863(ab)
 Maddock, SW, 862(ab), 863(ab)
 Maden, HA, 464(le)
 Madras, B, 946(ab)
 Madras, BK, 946(ab)
 Madsen, J, 844(ab)
 Madsen, MT, 1859, 1917(le)

- Maeda, H, 1741, 965(ab), 1023(ab)
 Maeda, Y, 967(ab)
 Maegdenberg, Vvd, 832(ab)
 Magata, Y, 856(ab), 886(ab), 897(ab), 953(ab), 966(ab), 1023(ab), 1024(ab)
 Magnani, P, 834(ab), 959(ab)
 Magné, J, 1846
 Magoun, S, 991(ab)
 Maguire, GQ Jr, 960(ab)
 Mahe, MA, 941(ab)
 Mahler, M, 967(ab)
 Mahmarian, JJ, 1600, 905(ab), 916(ab), 995(ab)
 Mahmood, A, 937(ab)
 Mahoney, DK, 1472, 1045(ab)
 Mahussain, SA, 978(ab)
 Maier-Borst, W, 1366
 Mailliard, JA, 975(ab)
 Maincent, P, 956(ab)
 Maisch, B, 906(ab)
 Maizels, M, 2047
 Majd, M, 976(ab)
 Majocha, RE, 2184
 Makay, Á, 458
 Maki, M, 958(ab)
 Makino, M, 958(ab), 1004(ab), 1005(ab)
 Mal, H, 835(ab)
 Malarme, M, 1427(le)
 Malik, AB, 1023(ab)
 Malison, RT, 848(ab), 945(ab), 961(ab)
 Maljkovic, V, 908(ab)
 Malkin, RD, 876(ab)
 Mallin, W, 993(ab)
 Malmud, LS, 24N(6), N31(3)
 Malveaux, G, 921(ab)
 Mamiya, T, 969(ab)
 Mand, FF, 167
 Mandelkern, M, 967(ab), 1017(ab)
 Mandell, GA, 873(ab), 874(ab)
 Maneval, DC, 934(ab)
 Manglos, SH, 150, 901(ab), 961(ab)
 Mangner, T, 684
 Mangner, TJ, 860(ab), 861(ab), 870(ab), 882(ab), 982(ab), 983(ab)
 Man in 't Veld, AJ, 990(ab)
 Mankovich, NJ, 827(ab), 1043(ab)
 Manning, RG, 847(ab)
 Manno, M, 929(ab)
 Mannting, F, 928(ab)
 Mantil, JC, 830(ab), 975(ab), 983(ab)
 Maquire, GQ Jr, 926(ab)
 Maraganore, J, 981(ab)
 Marboe, C, 1994
 Marciano, DM, 867(ab)
 Mardrossian, G, 909(ab), 921(ab), 934(ab), 1030(ab)
 Mardrossian, GC, 958(ab)
 Marengo, M, 2040
 Margouloff, D, 898(ab), 923(ab), 1027(ab)
 Mariani, G, 1020(ab)
 Mariani, M, 999(ab)
- Marie, PY, 906(ab)
 Mariën, P, 1013(ab)
 Marienhagen, J, 903(ab)
 Markham, J, 1661
 Markham, JA, 1045(ab)
 Markowitz, A, 852(ab)
 Marks, PH, 516
 Marmion, ME, 850(ab), 1033(ab)
 Marmor, A, 938(ab)
 Marotta, CA, 2184
 Marshall, RC, 938(ab)
 Marshall, CC, 850(ab), 884(ab), 931(ab)
 Martin, GV, 2144, 2202
 Martin, M, 912(ab), 1000(ab)
 Martin, P, 863(ab), 941(ab), 960(ab)
 Martin, SE, 865(ab)
 Martinez, C, 258
 Maruyama, Y, 920(ab)
 Marwick, T, 825(ab), 837(ab), 866(ab), 875(ab), 1040(ab), 1041(ab)
 Marzilli, LG, 900(ab), 921(ab)
 Marzullo, P, 1925
 Masaki, K, 744
 Mason, G, 835(ab)
 Mason, GR, 836(ab), 1022(ab)
 Mason, NS, 847(ab)
 Mason, RP, 974(ab)
 Mason, WH, 930(ab)
 Massuger, LFAG, 1113, 1958
 Masters, PR, 1048(ab)
 Mastin, ST, 923(ab)
 Mastrostamatis, S, 988(ab)
 Masuda, K, 877(ab), 945(ab), 998(ab), 1015(ab)
 Masure, M-C, 696
 Matacchieri, R, 1027(ab)
 Matarrese, M, 924(ab), 944(ab), 1014(ab)
 Máté, E, 458
 Matheja, P, 915(ab)
 Mather, S, 1121, 914(ab)
 Mather, SJ, 904(ab)
 Mathews, D, 826(ab)
 Mathias, CJ, 931(ab)
 Mathieu, D, 919(ab)
 Mathieu, JP, 1034(ab)
 Mathis, CA, 2133, 890(ab)
 Mathisen, G, 827(ab)
 Matoba, N, 966(ab)
 Matsouka, DT, 1642
 Matsuda, H, 877(ab), 967(ab)
 Matsudaira, M, 918(ab)
 Matsumori, A, 1501
 Matsumoto, K, 413, 545
 Matsumoto, M, 940(ab), 969(ab), 1014(ab), 1015(ab)
 Matsunaga, T, 1015(ab)
 Matsuoka, DT, 763
 Matsushita, R, 998(ab)
 Mattered, J, 855(ab), 927(ab)
 Mattered, JA, 874(ab)
 Matteucci, F, 1020(ab)
 Matthey, KK, 918(ab)
 Matthews, D, 863(ab), 941(ab), 960(ab)
 Matthews, KJ, 863(ab)
 Mattis, JA, 144
 Matzku, S, 1366
 Maurea, S, 833(ab), 905(ab), 915(ab), 918(ab)
 Maurelli, L, 918(ab)
 Maurer, A, 952(ab)
 Maurer, AH, 710, 467(le), 832(ab), 964(ab)
 Maurer, M, 880(ab)
 Mausner, LF, 305, 899(ab), 900(ab), 942(ab), 980(ab), 985(ab), 1030(ab)
 Maxon, HR, 1132, 894(ab), 898(ab), 937(ab), 978(ab), 1048(ab)
 Mayaud, Ch, 81
 Mayberg, HS, 18N(6)
 Mayeur, S, 832(ab)
 Maynard, C, 939(ab)
 Maziere, B, 696, 1481, 973(ab), 977(ab), 1019(ab)
 Mazière, M, 883(ab), 973(ab)
 Mazzeo, S, 954(ab)
 Mazziota, JC, 867(ab)
 Mazziotta, JC, 1472, 922(ab), 1010(ab)
 McAfee, JG, 889(ab), 1428(le)
 McAteer, E, 872(ab)
 McBride, BJ, 1836
 McCabe, R, 1031(ab)
 McCall, MJ, 2006, 880(ab), 1031(ab)
 McCallum, RW, 833(ab)
 McCandless, BK, 59, 1566, 1023(ab)
 McCarthy, G, 961(ab)
 McCartney, WH, 831(ab), 842(ab)
 McClanahan, TB, 1346
 McCord, ME, 1209, 2226
 McDermott, K, 904(ab)
 McDermott, MP, 1044(ab)
 McDevitt, GR, Jr, 2052
 McDevitt, MR, 851(ab), 986(ab)
 McDevitt, R, 898(ab), 978(ab)
 McDonald, KL, 1040(ab)
 McEntee, MC, 1542
 McEwan, AJ, 841(ab)
 McGee, S, 926(ab)
 McIlvain, HB, 899(ab)
 McIntyre, R, 1028(ab)
 McIntyre, WJ, 1041(ab)
 McKay, WJ, 877(ab), 930(ab)
 McKeever, PE, 735
 McKusick, KA, 915(ab), 1254(le)
 McLaughlin, AF, 438
 McLean, RG, 2059(le)
 McLellan, CA, 1383, 945(ab)
 McMahan, CA, 1496
 McMahan, M, 874(ab), 927(ab)
 McMillin, CH, 1046(ab)
 McMurry, TJ, 1031(ab)
 McNamara, D, 951(ab)
 McPartlin, M, 850(ab)
 McPherson, DW, 1023(ab), 1028(ab)
- McShan, DI, 735
 McSherry, B, 1783
 McTigue, M, 2006, 880(ab), 931(ab)
 Meares, CE, 2006
 Meares, CF, 1685, 880(ab), 942(ab), 1030(ab), 1031(ab)
 Mease, RC, 900(ab), 942(ab), 943(ab), 985(ab), 1030(ab)
 Medina, LS, 835(ab)
 Medrano, R, 905(ab), 916(ab)
 Meeder, JG, 870(ab)
 Meeuwisse, E, 955(ab)
 Megbow, A, 960(ab)
 Mehta, BM, 1373
 Mehta, VD, 974(ab)
 Meignan, M, 81, 919(ab)
 Meikle, S, 879(ab)
 Meikle, SR, 862(ab), 901(ab), 1045(ab)
 Meindl, J, 859(ab)
 Meindok, H, 1548
 Meinken, GE, 900(ab), 942(ab), 985(ab), 1028(ab), 1030(ab)
 Mekkawy, MA, 526
 Melega, WP, 1472
 Melero, M, 999(ab)
 Melin, J, 825(ab)
 Melin, JA, 837(ab), 875(ab), 884(ab), 905(ab)
 Melis, K, 1021(ab)
 Melman, A, 1723
 Melon, P, 826(ab)
 Melon, PG, 865(ab), 994(ab)
 Meltzer, L, 992(ab)
 Meltzer, PC, 946(ab)
 Mena, I, 835(ab), 838(ab), 839(ab), 846(ab), 876(ab)
 Mendelson, J, 1312, 887(ab)
 Meneguetti, JC, 995(ab)
 Merchant, EB, 14
 Meredith, RF, 23, 1648
 Merhige, ME, 1040(ab)
 Merino, MJ, 1848
 Merlet, P, 471, 896(ab)
 Merli, G, 999(ab)
 Merola, TF, 304
 Merrick, MV, 872(ab)
 Mertens, H, 102
 Mertens, WC, 1437
 Messa, C, 339, 945(ab)
 Messian, O, 835(ab)
 Messinger, DE, 876(ab), 951(ab)
 Mestais, C, 1003(ab)
 Mester, J, 458
 Metherall, JA, 905(ab)
 Metz, CE, 451
 Metz, JT, 1011(ab), 1018(ab), 1019(ab)
 Meuli, R, 956(ab)
 Meyer, E, 909(ab)
 Meyer, K, 851(ab), 1032(ab)
 Meyer, MA, 887(ab), 894(ab)
 Meyerrose, GE, 849(ab)
 Meyne, NG, 895(ab)
 Mezianne, MA, 1048(ab)
 Michel, C, 837(ab), 884(ab)
 Michelson, RH, 890(ab)
 Michigishi, T, 2024,
- 1020(ab)
 Mićinski, M, 587
 Middleton, ML, 985(ab)
 Mielke, R, 940(ab)
 Migneco, O, 1846, 839(ab)
 Miikata, A, 324
 Miki, H, 969(ab)
 Milan, E, 846(ab)
 Milius, R, 945(ab)
 Milko, D, 996(ab)
 Millard, RW, 993(ab)
 Miller, B, 838(ab), 839(ab)
 Miller, EG, 961(ab)
 Miller, FJ, Jr, 260
 Miller, J, 1016(ab)
 Miller, JH, 930(ab)
 Miller, K, 900(ab), 1025(ab)
 Miller, MI, 964(ab)
 Miller, RF, 903(ab)
 Miller, TR, 1678, 1710, 964(ab)
 Millet, P, 1011(ab)
 Mills, BJA, 398, 1556
 Mills, SL, 981(ab), 982(ab)
 Milot, A, 1034(ab)
 Min, YI, 919(ab)
 Minami, C, 835(ab)
 Minoshima, S, 1579, 858(ab), 929(ab), 1003(ab), 1007(ab), 1008(ab), 1009(ab)
 Mintun, MA, 684, 1579, 1007(ab), 1009(ab)
 Miraldi, F, 41
 Mirelli, M, 2040
 Mirick, GE, 941(ab)
 Miron, SD, 1044(ab)
 Mirzadeh, S, 1024(ab)
 Mita, A, 954(ab)
 Mitchell, DS, 973(ab)
 Miura, S, 827(ab), 1008(ab)
 Miyamae, T, 932(ab)
 Miyamoto, C, 1002(ab)
 Miyaoka, RS, 1429(le)
 Miyatake, S, 893(ab)
 Miyauchi, T, 967(ab)
 Miyazaki, S, 853(ab)
 Mizrachi, H, 912(ab)
 Mizukami, Y, 2024
 Møller, JT, 251
 Mochizuki, T, 1851, 919(ab), 976(ab), 997(ab)
 Modell, JG, 826(ab)
 Modorati, G, 959(ab)
 Mody, F, 856(ab)
 Moerlein, SM, 848(ab), 883(ab)
 Mohamed, FB, 973(ab)
 Molea, N, 845(ab), 1020(ab)
 Molina-Murphy, IL, 1558
 Molinoff, PB, 982(ab)
 Möller, H-J, 972(ab)
 Mollthoff, CF, 2000
 Momose, T, 827(ab), 857(ab), 968(ab), 969(ab), 1006(ab), 1009(ab)
 Mone, SM, 930(ab)
 Monetti, N, 2040
 Monsein, LH, 968(ab)
 Moon, DH, 919(ab), 936(ab), 991(ab)
 Moon, S, 869(ab), 926(ab)
 Moore, D, 974(ab)
 Moore, JA, 467(le)

- Moore, JG, 833(ab)
 Moore, M, 2059(le)
 Moore, RH, 948(ab), 998(ab)
 Moore, SC, 962(ab), 1004(ab)
 Moore, WH, 889(ab), 938(ab)
 Morabito, MD, 1002(ab)
 Morais, J, 1550
 Mordenti, J, 924(ab)
 Moresco, RM, 944(ab)
 Morgan, HT, 892(ab), 901(ab), 962(ab)
 Morgan, MG, 928(ab)
 Morgenthaler, JJ, 231
 Morguet, AJ, 223
 Moriarty, JM, 1758
 Morisco, C, 905(ab)
 Morishima, S, 1501
 Morita, R, 998(ab)
 Moriwaki, H, 940(ab), 969(ab), 1014(ab), 1015(ab)
 Morozumi, T, 952(ab), 963(ab)
 Morrell, NW, 676
 Morris, G, 904(ab)
 Morris, HH, 928(ab)
 Morris, JG, 438
 Morris, KDW, N30(9), N15(3), N14(12)
 Morrissey, MA, 2249(le)
 Morrison, D, 1012(ab)
 Morrison, SL, 985(ab)
 Morrissey, MA, 498
 Mortelmans, L, 933(ab), 937(ab)
 Mortensen, T, 992(ab)
 Morton, KA, 260, 833(ab), 1003(ab)
 Moscatelli, G, 863(ab), 915(ab)
 Moser, EA, 1399
 Moser, L, 937(ab)
 Moses, WW, 862(ab)
 Mossberg, KA, 1523
 Motomura, N, 1200
 Moulton, JS, 937(ab)
 Mountz, JM, 826(ab)
 Moyes, J, 1121
 Moyse, D, 471, 896(ab)
 Mozley, D, 870(ab), 871(ab), 897(ab), 898(ab)
 Mozley, PD, 954(ab)
 Muehlechner, G, 861(ab), 1430(le)
 Mueller, SP, 962(ab)
 Mueller-Lissner, SA, 1291, 832(ab)
 Mufaggi, N, 403, 2060(le)
 Mui, F, 1949
 Muirhead, KA, 899(ab), 921(ab)
 Mukherjee, J, 829(ab), 982(ab)
 Mulder, RU, 833(ab)
 Müller-Gärtner, HW, 929(ab)
 Mulholland, GK, 423, 882(ab), 982(ab), 984(ab)
 Mullan, BP, 840(ab)
 Muller, D, 826(ab)
 Müller, L, 931(ab)
 Müller, P, 836(ab), 856(ab), 865(ab)
 Müller-Gärtner, HW, 872(ab), 922(ab)
 Müller-Schauenburg, W, 956(ab)
 Mumper, RJ, 398
 Munaka, M, 911(ab), 963(ab)
 Munoz, L, 994(ab)
 Munson, PR, 988(ab)
 Munz, DL, 223, 845(ab), 950(ab), 957(ab)
 Murakami, M, 827(ab), 911(ab), 963(ab), 1008(ab)
 Muraki, A, 867(ab)
 Muramatsu, T, 932(ab)
 Muramori, A, 441
 Murase, K, 135, 909(ab), 912(ab), 919(ab), 969(ab), 972(ab), 976(ab), 1004(ab)
 Murphey, MM, 1039(ab)
 Murphy, B, 1040(ab)
 Murphy, PH, 889(ab), 938(ab), N38(9), N32(12)
 Murray, CL, 1623
 Murray, G, 1269
 Murray, JL, 941(ab), 1001(ab)
 Murthy, S, 863(ab), 904(ab)
 Mut, F, 1949
 Muzi, M, 944(ab)
 Muzic, RF, 885(ab)
 Muzik, O, 684, 826(ab), 865(ab), 882(ab)
 Muzinic, M, 969(ab)
 Myers, MJ, 173
 Na, HW, 936(ab)
 Naber, AHJ, 920(ab)
 Nadel, DM, 1013(ab)
 Nagamachi, S, 971(ab)
 Nagashima, J, 998(ab)
 Nagata, K, 1696
 Nagazumi, A, 1016(ab)
 Nagel, AA, 830(ab)
 Nagel, J, 1459, 998(ab)
 Nagel, JS, 704, 2209
 Nagle, KR, 850(ab)
 Någren, K, 691
 Nair, N, 914(ab)
 Nair, S, 2017
 Nakabeppu, Y, 996(ab)
 Nakagawa, I, 1033(ab)
 Nakagawa, T, 1741
 Nakagawara, J, 1017(ab)
 Nakahashi, H, 413
 Nakai, T, 853(ab), 893(ab), 1001(ab)
 Nakajima, K, 441, 1200, 918(ab)
 Nakajo, M, 996(ab)
 Nakaki, M, 935(ab), 936(ab)
 Nakamura, J, 1017(ab)
 Nakamura, K, 934(ab)
 Nakamura, M, 1851
 Nakamura, O, 844(ab), 966(ab)
 Nakamura, S, 893(ab), 933(ab), 972(ab)
 Nakane, K, 1741, 965(ab)
 Nakano, K, 958(ab)
 Nakano, S, 208
 Nakata, S, 972(ab)
 Nakata, Y, 1023(ab)
 Nakatani, N, 920(ab)
 Nakatsuka, I, 848(ab)
 Nakayama, M, 988(ab), 1029(ab), 1033(ab)
 Naldöken, S, 1027(ab)
 Namba, Y, 893(ab)
 Nanba, R, 1023(ab)
 Nappi, A, 905(ab), 915(ab)
 Narabayashi, I, 1023(ab)
 Narahara, K, 876(ab)
 Narahara, KA, 846(ab)
 Nariai, T, 413
 Narra, RK, 88, 1152, 865(ab), 993(ab)
 Narra, VR, 277, 2196
 Naruki, Y, 920(ab)
 Narula, J, 845(ab), 915(ab), 934(ab), 936(ab), 943(ab), 959(ab)
 Nash, R, 924(ab)
 Natale, A, 958(ab)
 Natale, D, 855(ab)
 Natarajan, TK, 968(ab)
 Nathan, M, 949(ab)
 Nathan, MA, 1011(ab), 1012(ab), 1018(ab)
 Nattel, S, 951(ab)
 Navia, B, 1312, 887(ab)
 Nawaz, K, 978(ab)
 Nebandahl, K, 223
 Nebeling, B, 1013(ab)
 Nebendahl, K, 845(ab)
 Nedelman, M, 978(ab)
 Nedelman, MA, 144
 Neer, RM, 170
 Negrin, JA, 898(ab)
 Neiman, J, 1016(ab)
 Nellis, SN, 1864
 Nelp, W, 941(ab), 960(ab)
 Nelp, WB, 863(ab), 864(ab), 924(ab), 987(ab), 1005(ab)
 Nelson, AD, 41, 885(ab)
 Nemetz, ST, 468(le)
 Netten, PM, 1330, 950(ab)
 Netto, ICV, 1035(ab)
 Neumann, DA, 1048(ab)
 Neumann, DR, 131, 952(ab), 1040(ab), 1041(ab)
 Neumann, PH, 1566, 1023(ab)
 Neumann, RD, 833(ab), 852(ab), 889(ab), 893(ab), 957(ab), 986(ab), 1001(ab)
 Neumeyer, JL, 945(ab), 964(ab)
 Newberg, A, 857(ab), 940(ab), 965(ab)
 Newell, DW, 1789
 Newman, JS, 256
 Newton, MR, 930(ab)
 Ney, DR, 1042(ab)
 Nguyen, BA, 263
 Nguyen, D, 1011(ab)
 Nguyen, N, 1346, 865(ab), 994(ab)
 Ngyen, A, 865(ab)
 Nichols, DC, N30(9), N14(12)
 Nichols, K, 928(ab)
 Nicholson, RL, 1875
 Nickerson, JP, 975(ab)
 Nickerson, R, 950(ab)
 Nickles, RJ, 850(ab), 884(ab), 931(ab), 1014(ab)
 Nicol, PD, 895(ab)
 Nicolai, E, 905(ab), 915(ab)
 Niedzwiecki, D, 345
 Nielsen, SL, 251
 Nieman, L, 834(ab)
 Niemeyer, MG, 1727
 Niesen, A, 904(ab), 912(ab)
 Niio, Y, 998(ab)
 Nijran, KS, 676
 Nikpoor, N, 643
 Nimmon, CC, 924(ab)
 Nishigori, H, 1025(ab)
 Nishihara, M, 1015(ab)
 Nishikawa, J, 857(ab), 875(ab), 968(ab), 1006(ab), 1009(ab)
 Nishimura, K, 932(ab)
 Nishimura, S, 1600
 Nishimura, T, 272, 365, 1014, 853(ab), 875(ab), 940(ab), 952(ab), 969(ab), 997(ab), 1015(ab)
 Nishiyama, H, 1047(ab)
 Nishizaki, Y, 963(ab)
 Nishizawa, S, 966(ab)
 Nisikawa, J, 827(ab)
 Nitzsche, EU, 1399, 828(ab), 865(ab)
 Noca, A, 1003(ab)
 Nodel, D, 858(ab)
 Noël, P, 485
 Noguchi, M, 2024
 Nohara, R, 659, 856(ab), 884(ab), 885(ab), 886(ab), 953(ab)
 Northover, JMA, 904(ab)
 Norton, JA, 1848
 Nosco, DL, 551, 850(ab), 1033(ab)
 Noska, MA, 1357, 958(ab)
 Nossiff, ND, 934(ab), 936(ab)
 Notghi, A, 872(ab)
 Noujaim, AA, 853(ab), 904(ab)
 Nourigat, C, 987(ab)
 Novak-Hofer, I, 231
 Novell, JR, 1020(ab)
 Novotney, AC, 1542
 Nowak, D, 831(ab)
 Nowak, PA, 829(ab), 985(ab)
 Nowotnik, DP, 920(ab)
 Noz, ME, 912(ab), 926(ab), 960(ab)
 Nozaki, T, 1025(ab)
 Nunn, AD, 88, 94, 1152, 850(ab), 865(ab), 920(ab), 993(ab)
 Nutin, C, 977(ab)
 Nuutila, P, 1255
 Nuyts, J, 933(ab), 937(ab)
 Oates, E, 256, 905(ab), 1041(ab)
 Oberdorfer, F, 1982, 828(ab), 1019(ab)
 O'Brien, CP, 898(ab)
 O'Brien, JP, 1396
 O'Carroll, RE, 1623
 Ochi, H, 744
 O'Connell, JW, 1444, 910(ab), 935(ab)
 O'Connor, MK, 239, 1146, 1613, 1006(ab)
 Oda, K, 1016(ab)
 Odana, I, 1015(ab)
 O'Dell, M, 859(ab)
 O'Doherty, MJ, 313
 O'Donnell, SM, 934(ab), 936(ab), 959(ab)
 Odze, R, 960(ab)
 Oei, HY, 652, 894(ab), 903(ab), 907(ab), 914(ab), 990(ab)
 Oertel, WH, 897(ab), 917(ab)
 Offord, RE, 1766
 Ogata, Y, 841(ab)
 Ogawa, K, 963(ab)
 Ogawa, M, 1637
 Ogawa, T, 1696
 Ogilby, D, 866(ab), 916(ab), 952(ab)
 Ogilby, JD, 2086
 O'Grady, LF, 862(ab)
 Ohashi, K, 1692
 Ohnishi, T, 971(ab)
 Ohno, T, 918(ab)
 Ohta, S, 969(ab)
 Ohta, Y, 958(ab)
 Ohtake, T, 875(ab), 1006(ab), 1009(ab)
 Ohtani, H, 1000(ab)
 Ohyama, M, 1016(ab)
 Ohyama, Y, 988(ab), 1033(ab)
 Oja, P, 1137
 Okada, J, 324
 Okarvi, S, 1032(ab)
 Okazaki, Y, 940(ab), 969(ab), 1014(ab), 1015(ab)
 Okazumi, S, 333
 O'Keefe, JH, 951(ab)
 Oku, N, 940(ab), 969(ab), 1014(ab), 1015(ab)
 Oku, S, 1006(ab), 1009(ab)
 Okudera, T, 1696
 Okumura, A, 969(ab), 972(ab)
 Old, LJ, 913(ab)
 Oldfield, E, 834(ab)
 Olea, E, 998(ab)
 Oliveira, MC, 1949
 Olivier, P, 906(ab)
 Olsen, L, 1016(ab)
 Ono, M, 1741
 Ono, S, 856(ab), 953(ab)
 Ono, Y, 994(ab)
 Onsal, I, 1027(ab)
 Oosterhuis, WP, 1727
 Oosterwijk, E, 913(ab)
 Oosterwijk, J, 913(ab)
 Opie, LH, 1353
 Oratz, R, 912(ab)
 Orellana, P, 998(ab)
 Oriuchi, N, 1181
 Orr, RA, 23
 Orringer, M, 828(ab)
 Orsolon, PG, 895(ab)
 Ortega, JC, 990(ab)
 Ortiz, M, 999(ab)
 Ortiz, V, 998(ab)
 Orton, M, 2090
 Osaka, G, 934(ab)
 Ossenkoppelle, GJ, 858(ab), 927(ab)
 Oster, ZH, 1028(ab)
 Ostertag, H, 828(ab)
 Ostertag, HJ, 1007(ab), 1045(ab)

- O'Sullivan, F, 944(ab), 1009(ab)
 Othmer, P, 1046(ab)
 Otsuka, M, 877(ab), 945(ab), 1015(ab)
 Otsuka, S, 920(ab)
 Ott, RJ, 2154
 Otto, CA, 423
 O'Tuama, LA, 1758, 2098, 838(ab), 844(ab), 930(ab)
 Ouchi, Y, 1637
 Overbeck, B, 526, 839(ab), 972(ab)
 Owens, ES, 852(ab)
 Owunwanne, A, 978(ab)
 Oyen, WJG, 388, 1330, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab)
 Ozaki, M, 333
 Ozawa, Y, 951(ab)
 Özgüven, M, 866(ab)
 Özkilic, H, 1722
 Öztürk, E, 866(ab)
 Paans, AMJ, 373, 870(ab)
 Pabst, HW, 854(ab), 859(ab)
 Pace, L, 68, 505, 905(ab), 915(ab)
 Padhy, AK, 904(ab), 924(ab)
 Padilla, ML, 1175
 Paganelli, G, 834(ab), 925(ab), 959(ab)
 Page, RL, 1542
 Pai, LH, 842(ab)
 Paik, CH, 842(ab), 889(ab), 957(ab), 986(ab), 1001(ab)
 Pak, KY, 144
 Palenker, J, 971(ab)
 Palestro, CJ, 1175, 2027, 969(ab), 999(ab), 1031(ab), 1039(ab)
 Palevsky, HI, 751, 2036, 849(ab)
 Palko, D, 1040(ab)
 Palmer, CK, 1042(ab), 1043(ab)
 Paltiel, HJ, 351, 1048(ab)
 Pan, X, 962(ab)
 Pandian, N, 905(ab)
 Pang, L, 865(ab)
 Pant, KD, 1530
 Papadopoulos, SM, 1836
 Papapoulos, SE, 1406
 Pappas, A, 978(ab)
 Parekh, JS, 971(ab)
 Parisi, MT, 115, 918(ab)
 Park, CH, 1183, 1943, 961(ab)
 Park, H, 956(ab)
 Park, JH, 2118
 Park, JS, 991(ab)
 Park, SK, 991(ab)
 Parker, A, 930(ab)
 Parker, GE, Jr, 1390
 Parker, JA, 849(ab), 947(ab), 1003(ab)
 Parkes, SL, 1029(ab)
 Parkey, RW, 990(ab), 1003(ab), 1010(ab)
 Parkinson, D, 848(ab), 883(ab)
 Parmentier, C, 1020(ab)
 Parodi, O, 1925
 Parrot, A, 81
 Parsons, JA, 1039(ab)
 Parsons, SM, 983(ab), 1011(ab)
 Pascal, S, 1459
 Pasqualini, R, 850(ab), 989(ab), 1034(ab)
 Passeri, A, 831(ab)
 Pastan, I, 842(ab)
 Patch, GG, 260
 Pate, BD, 964(ab)
 Patel, K, 923(ab)
 Patel, NH, 849(ab)
 Patel, RB, 914(ab)
 Patterson, RE, 865(ab)
 Pauli, S, 1011(ab)
 Pauwels, EKJ, 1406, 1727
 Pauwels, S, 976(ab)
 Pavoni, R, 959(ab)
 Pawlik, G, 1013(ab)
 Pawlowski, J, 852(ab)
 Payne, JK, 1919, 2030, 827(ab)
 Payne, SE, 990(ab)
 Pearson, G, 847(ab)
 Pelagi, M, 834(ab)
 Pèleggrin, A, 1766, 903(ab)
 Pelizzari, CA, 922(ab), 1005(ab), 1043(ab), 1047(ab)
 Pellegrino-Gensey, JL, 1378
 Peller, PH, 1039(ab)
 Peller, PJ, 968(ab)
 Pellevoisin, C, 981(ab)
 Pellikka, PA, 2080
 Peltier, P, 912(ab)
 Penney, BC, 161, 843(ab), 1004(ab)
 Pentlow, KS, 2020
 Pepping, M, 972(ab)
 Perani, D, 973(ab), 1014(ab)
 Perdikaris, N, 2059(le)
 Pereszlenyiova, E, 982(ab)
 Perez, JE, 855(ab), 884(ab)
 Periasamy, M, 974(ab)
 Periman, SB, 1014(ab)
 Perin, M, 1766
 Perlmutter, JS, 848(ab), 883(ab)
 Perrone-Filardi, P, 881(ab), 938(ab)
 Perry, BD, 829(ab)
 Perry, DL, 1002(ab)
 Perry, JR, 451, 2238, 831(ab), 842(ab), 961(ab)
 Pestika, B, 258
 Peters, AM, 65, 173, 491, 756, 836(ab), 1022(ab)
 Peters, CA, 2098
 Peterson, CD, 830(ab), 975(ab), 983(ab)
 Peterson, J, 912(ab)
 Peterson, LM, 1010(ab)
 Petiet, A, 380
 Petrella, G, 999(ab)
 Petrick, N, 842(ab)
 Petry, N, 684
 Petry, NA, 423, 1836, 2067, 865(ab)
 Pezzullo, L, 892(ab)
 Pfeiffer, N, 871(ab), 963(ab)
 Phalen, JJ, 975(ab)
 Pham, DH, 1548
 Pham, H, 846(ab)
 Pham, T, 965(ab)
 Phaneuf, DC, 1091, 855(ab)
 Phelps, M, 825(ab), 856(ab), 865(ab)
 Phelps, ME, 339, 595, 613, 633, 945, 1191, 1235, 1472, 1628, 828(ab), 829(ab), 836(ab), 856(ab), 881(ab), 882(ab), 944(ab), 1045(ab)
 Phillips, W, 819, 984(ab), 1027(ab)
 Phillips, WT, 1496
 Philpott, GW, 1685
 Picard, D, 1550
 Picard, M, 1550, 951(ab)
 Piccolo, M, 1478
 Pich, S, 223
 Piepenburg, R, 887(ab), 1021(ab)
 Piepsz, 175
 Piepsz, A, 174, 485
 Pierfitte, M, 1003(ab)
 Pieri, PL, 915(ab)
 Piers, DA, 1251(le)
 Pierson, R, 549
 Pieterman, H, 990(ab)
 Pietrzyk, U, 861(ab), 1013(ab)
 Piffanelli, A, 850(ab)
 Pike, M, 910(ab)
 Pilcher, G, 974(ab)
 Pileggi, F, 995(ab)
 Pinedo, HM, 2000
 Pinsky, CM, 863(ab), 904(ab), 1002(ab)
 Pipes, D, 1024(ab)
 Pippin, CG, 1031(ab)
 Piret, L, 73
 Pirro, JP, 1152, 865(ab), 993(ab)
 Pisani, T, 870(ab)
 Pisani, TL, 861(ab)
 Pivnic-Worms, D, 1516, 864(ab), 1033(ab)
 Plaizier, MABD, 1915(le)
 Platt, DA, 876(ab)
 Platts, S, 989(ab)
 Platts, SH, 979(ab)
 Pleus, RC, 861(ab), 1026(ab)
 Plott, G, 1648
 Plott, WE, 23
 Pochon, S, 1766
 Podoloff, D, 992(ab)
 Podoloff, DA, 828(ab), 858(ab), 992(ab), 1001(ab)
 Poels, LG, 1958
 Poewe, W, 1018(ab)
 Pohl, J, 981(ab)
 Pohost, GM, 915(ab)
 Pollard, KR, 771, 864(ab), 889(ab), 1005(ab)
 Pomier, G, 1550
 Ponto, J, 1027(ab)
 Poppe, G, 937(ab)
 Porenta, G, 1235, 1628, 836(ab), 856(ab), 857(ab), 1009(ab)
 Port, SC, 2124, 846(ab)
 Portenoy, R, 859(ab)
 Porter, AT, 1316, 1437
 Porter, B, 863(ab)
 Portlock, C, 345
 Posniakoff, TA, 1411
 Potchen, EJ, 1807
 Potts, MS, 998(ab)
 Potvin, C, 1801, 894(ab)
 Poublon, RML, 894(ab)
 Powe, JE, 1316, 1437
 Prados, MD, 2133
 Prandi, D, 403, 2060(le)
 Prat, L, 845(ab)
 Prato, FS, 355, 1875
 Pratt, JP, 947(ab)
 Preslar, J, 1917(le)
 Press, O, 941(ab)
 Press, OW, 863(ab), 960(ab)
 Preston, DF, 1039(ab), 1046(ab)
 Pretorius, PH, 888(ab)
 Price, DC, 967(ab), 974(ab)
 Price, JC, 883(ab), 911(ab)
 Prieto, I, 866(ab)
 Prigent, F, 1509
 Prince, JR, 927(ab)
 Prior, J, 1003(ab), 1010(ab)
 Prohovnik, I, 940(ab)
 Proto, G, 895(ab)
 Provenzale, J, 248
 Prummel, MF, 894(ab)
 Przedborski, S, 868(ab)
 Puma, J, 825(ab)
 Purdy, PD, 826(ab)
 Purnell, G, 978(ab)
 Pusey, CD, 491
 Puskás, C, 840(ab), 920(ab)
 Pütter, D, 1030(ab)
 Pyzalski, R, 1014(ab)
 Qian, J, 932(ab), 938(ab)
 Qian, W, 889(ab)
 Quadri, SF, 853(ab)
 Quadri, SM, 987(ab)
 Quaipe, RA, 927(ab)
 Queloz, J, 956(ab)
 Quesenberry, J, 1024(ab)
 Quick, C, 954(ab)
 Quinn, RJ, 1029(ab), 1252(le)
 Quinones, N, 967(ab), 1017(ab)
 Quint, L, 828(ab)
 Quintana, C, 998(ab)
 Quirce, JM, 955(ab)
 Rabito, CA, 948(ab)
 Rabushka, LS, 1042(ab)
 Rackover, M, 1002(ab)
 Radcliffe, R, 988(ab)
 Radensky, P, 19N(l)
 Raisys, V, 866(ab)
 Raja, S, 996(ab), 997(ab)
 Raju, N, 920(ab)
 Ram, S, 1029(ab)
 Ramalingam, K, 920(ab)
 Ramanathan, P, 914(ab)
 Ramanna, L, 843(ab), 869(ab)
 Ramos, J, 957(ab)
 Rampal, M, 990(ab)
 Ramsay, SC, 438
 Rangarajan, A, 963(ab)
 Rangarajan, V, 914(ab)
 Ransone, C, 2006, 880(ab), 931(ab)
 Rao, DV, 277, 2196
 Rasey, JS, 2202, 1010(ab)
 Rath, P, 859(ab)
 Rathe, R, 1043(ab)
 Ratib, O, 1628
 Ratliff, BA, 1099
 Rattner, Z, 878(ab), 911(ab)
 Rauh DA, 710
 Raval, U, 875(ab)
 Ravert, HT, 847(ab), 848(ab), 860(ab), 883(ab), 885(ab), 929(ab), 968(ab)
 Ray, S, 924(ab)
 Raylman, RR, 1243, 881(ab)
 Raynaud, C, 696, 1481, 976(ab), 977(ab), 1019(ab)
 Reba, RC, 1225, 883(ab), 889(ab), 996(ab)
 Reba, RS, 966(ab)
 Redepenning, L, 836(ab)
 Reece, C, 161
 Reed, BR, 939(ab)
 Reed, J, 1366
 Reed, NL, 1750
 Reekers, JA, 907(ab)
 Reese, L, 355, 1875
 Rege, S, 828(ab), 829(ab)
 Rehnrona, S, 868(ab)
 Reiche, W, 886(ab)
 Reid, R, 1437
 Reijts, AEM, 652
 Reilly, RM, 2248(le), 960(ab)
 Reilly, SM, 1881
 Reiman, RE, 834(ab)
 Reinartz, R, 1001(ab)
 Reinbold, F, 907(ab)
 Reinhardt, CP, 993(ab)
 Reinhardt, M, 1981, 1019(ab)
 Reiser, M, 914(ab)
 Reist, H, 884(ab)
 Reither, H, 108
 Reitz, R, 1032(ab)
 Reivich, M, 857(ab), 929(ab), 940(ab), 965(ab), 985(ab), 1012(ab), 1013(ab)
 Remy, Ph., 858(ab)
 Renn, O, 880(ab)
 Reno, JM, 2184, 880(ab), 1028(ab)
 Renstrom, B, 1864
 Reubi, JC, 652, 903(ab)
 Reuland, P, 309
 Reskin, J, 939(ab)
 Reyes, P, 961(ab)
 Reynolds, JC, 1848, 833(ab), 986(ab)
 Rhodes, BA, 1028(ab), 1029(ab), 1031(ab)
 Rhodes, CG, 1669
 Riambau, V, 845(ab)
 Ricard, M, 1006(ab), 1020(ab)
 Ricaurte, GA, 964(ab)
 Ricciardelli, B, 505
 Rice, KC, 981(ab)
 Richmond, JC, 1027(ab)
 Richmond, JCW, 1008(ab)
 Richter, W, 902(ab), 997(ab)
 Riddell, C, 843(ab), 888(ab)
 Rieker, O, 839(ab), 844(ab), 914(ab)
 Riesinger, U, 854(ab)
 Rifkin, CK, 896(ab)
 Rigo, P, 874(ab), 875(ab)
 Riley, R, 964(ab)
 Rios, L, 998(ab)
 Risler, LJ, 987(ab)
 Ritchie, JL, 939(ab)
 Riva, N, 863(ab)
 Riva, P, 863(ab)

- Rivera-Luna, H, 1004(ab)
 Rivitz, SM, 470, 1905
 Robbins, J, 1848
 Roberson, PL, 735, 1833
 Roberts, CM, 676
 Roberts, R, 1024(ab)
 Robertson, JS, 777, 1726
 Robeson, W, 923(ab)
 Robinson, RG, 1046(ab)
 Roca, M, 845(ab)
 Rocca, C, 953(ab)
 Rockett, J, 1269
 Rocque, PA, 1685
 Rodney, RA, 1411, 846(ab)
 Roessner, J, 841(ab)
 Rogers, GA, 1011(ab)
 Rogers, KD, 923(ab)
 Rogers, WL, 1836, 831(ab),
 842(ab), 878(ab), 933(ab)
 Rogulski, MM, 851(ab),
 1002(ab)
 Roh, JK, 877(ab)
 Rojas-Burke, J, 13N(6),
 17N(6), 24N(5), N19(9),
 N22(9), N24(9), N34(9),
 N9(2), N13(4), N13(7),
 N15(1), N15(7), N16(10),
 N18(1), N23(11), N25(1),
 N27(3), N28(8), N35(11),
 N25(12), N30(12),
 N31(12)
 Rokhsar, S, 856(ab)
 Roman, R, 2017, 1049(ab)
 Romano, J, 832(ab)
 Romano, G, 846(ab)
 Roodt, A, 899(ab)
 Rooholamini, SA, 1486
 Roos, JC, 1915(le)
 Ropchan, JR, 1017(ab)
 Roque, C, 1046(ab)
 Ros, P, 1043(ab)
 Rosa, E, 1373
 Rose, A, 1021(ab)
 Rose, EA, 1994
 Rose, K, 1766
 Rosebrough, SF, 880(ab)
 Rosen, BR, 867(ab)
 Rosen, G, 843(ab), 869(ab)
 Rosen, I, 868(ab)
 Rosen, T, 830(ab)
 Rosenblate, H, 258
 Rosenfeld, SS, 532
 Rosenkranz, K, 971(ab)
 Rosenpire, KC, 1125
 Rosenquist, G, 836(ab),
 1009(ab), 1045(ab)
 Rosenqvist, G, 1191, 856(ab)
 Rosenson, AS, 1022(ab)
 Rosenspire, KC, 94
 Rosenthal, L, 950(ab)
 Rossi, MA, 952(ab)
 Rossini, P, 846(ab)
 Rossleigh, MA, 1022(ab)
 Rössler, B, 839(ab)
 Rosso, J, 81
 Roszell, N, 993(ab)
 Roth, CA, 988(ab)
 Rothberg, ML, 836(ab)
 Rothpearl, A, 1042(ab)
 Rothstein, RD, 1707
 Rottenberg, DA, 200
 Roussel, P, 947(ab)
 Rowe, CC, 930(ab)
 Royal, HD, 330, 835(ab),
 849(ab)
 Rozanski, A, 2074, 928(ab)
 Rubello, D, 1478
 Rubin, RH, 1378, 910(ab),
 924(ab)
 Rubinstein, M, 1005(ab)
 Ruck, P, 309
 Ruhrmann, S, 972(ab)
 Ruiz, M, 864(ab)
 Rumsey, WL, 94, 1152
 Ruotsalainen, U, 691, 1255
 Rusckowski, 921(ab)
 Rusckowski, M, 1810,
 925(ab), 934(ab)
 Rush, AJ, 838(ab)
 Russell, C, 1648
 Russell, CD, 23, 1178,
 924(ab), 948(ab)
 Ruth, TJ, 922(ab), 964(ab)
 Ryan, JR, 898(ab), 978(ab)
 Ryan, PJ, 1589
 Ryo, UY, 398, 1915(le)
 Rysavy, J, 829(ab), 975(ab)
 Rysavy, JA, 861(ab),
 1026(ab)
 Ryser, JE, 1766
 Ryu, M, 333
 Sabbe, J, 827(ab)
 Sacker, D, 851(ab)
 Sacker, DF, 1028(ab)
 Sadato, N, 886(ab), 897(ab),
 966(ab)
 Sadato, N, 1637
 Saerens, J, 1013(ab)
 Saffer, JR, 879(ab)
 Saga, T, 853(ab), 889(ab),
 957(ab), 986(ab), 1001(ab)
 Sager, LH, 1001(ab)
 Saha, GB, 928(ab), 1040(ab),
 1041(ab)
 Sahajwalla, M, 996(ab)
 Saika, Y, 1023(ab)
 Sai-Maurel, C, 943(ab)
 Saing, H, 899(ab)
 Saini, S, 1344
 Saito, JM, 1042(ab)
 Saito, N, 967(ab)
 Saito, S, 951(ab)
 Saji, H, 848(ab), 891(ab),
 897(ab), 1023(ab), 1024(ab)
 Sakahara, H, 853(ab),
 893(ab), 905(ab), 1001(ab)
 Sakai, S, 1015(ab)
 Sakaki, S, 135, 909(ab),
 912(ab), 969(ab)
 Sakakibara, E, 1741, 965(ab)
 Sakowski, R, 878(ab)
 Sakurai, Y, 827(ab)
 Salako, QA, 982(ab),
 1030(ab)
 Saleh, MN, 23
 Salford, L, 868(ab)
 Sallan, SE, 844(ab)
 Salmon, Y, 175
 Saltzberg, MT, 993(ab)
 Salvatore, M, 68, 505,
 892(ab), 905(ab), 915(ab),
 918(ab), 999(ab)
 Samaratunga, R, 937(ab)
 Samaratunga, RC, 783
 Sambucetti, G, 1925
 Sampathkumaran, KS, 855(ab)
 Sampathkumaran, R, 912(ab)
 Samson, Y, 1481, 858(ab),
 1019(ab)
 Sanchez, J, 2014
 Sanchez, JA, 1994
 Sanchez-Urdazpal, L, 239
 Sander, B, 971(ab)
 Sanderson, JA, 880(ab)
 Sandler, ED, 115, 918(ab)
 Sandler, MP, 826(ab)
 Sandrock, D, 845(ab),
 950(ab), 957(ab)
 Sands, H, 29
 Sanger, J, 912(ab)
 Sanger, JJ, 926(ab), 960(ab)
 Sano, I, 968(ab)
 San Roman, F, 403
 Santini, L, 892(ab)
 Santos, O, 1530
 Santos-Ocampo, C, 951(ab)
 Sarangarajan, R, 2190
 Saraste, M, 1255
 Sarkar, S, 1035(ab)
 Sarkar, SD, 1551
 Sarkar, SS, 117
 Sasaki, H, 857(ab)
 Sasaki, M, 877(ab), 1015(ab)
 Sasaki, T, 1016(ab), 1017(ab),
 1025(ab)
 Sasaki, W, 945(ab)
 Sasaki, Y, 827(ab), 857(ab),
 875(ab), 968(ab), 1006(ab)
 Sasner, JJ, 998(ab)
 Sassaman, MB, 981(ab)
 Sastry, KSR, 2196
 Satake, R, 2024
 Satin, A, 181
 Satlin, A, 1432(le)
 Sato, J, 893(ab), 957(ab)
 Sato, K, 1017(ab)
 Sato, S, 958(ab)
 Sato, T, 841(ab)
 Satyamurthy, N, 633
 Sauter, MK, 970(ab)
 Savi, A, 924(ab)
 Sawamura, H, 988(ab)
 Sayman, HB, 629(le)
 Schaab, K, 899(ab)
 Schad, N, 1269
 Schäfers, M, 915(ab)
 Schaible, T, 848(ab)
 Schaible, TF, 978(ab)
 Schalekamp, MADH, 990(ab)
 Schapiro, M, 2103
 Scharf, S, 992(ab)
 Scharff, MD, 985(ab)
 Scheffel, U, 860(ab), 883(ab),
 885(ab), 964(ab)
 Scheinberg, DA, 941(ab)
 Scheipers, C, 1191
 Schelbert, H, 825(ab),
 856(ab), 865(ab), 882(ab),
 1009(ab)
 Schelbert, HR, 1235, 1263,
 1628, 836(ab), 856(ab),
 857(ab), 881(ab), 945(ab),
 977(ab)
 Schelosky, L, 1018(ab)
 Schelstaete, KHG, 1167
 Schembri, GP, 840(ab)
 Scher, H, 859(ab)
 Scherrer, M, 81
 Schiepers, C, 633, 827(ab),
 933(ab), 937(ab)
 Schiff, RG, 914(ab), 1042(ab)
 Schifter, T, 838(ab), 966(ab),
 1047(ab)
 Schlegel, S, 887(ab)
 Schleicher, W, 950(ab)
 Schlom, J, 23, 1648
 Schlumberger, M, 172
 Schlyer, D, 995(ab)
 Schmarkey, LS, 865(ab)
 Schmidt, DE, 847(ab)
 Schmidt, DH, 2124
 Schmidt, K, 944(ab)
 Schneider, J, 956(ab)
 Schneider, RF, 1428(le)
 Schnobrich, KE, 904(ab)
 Schnur, W, 1
 Schnyder, P, 956(ab)
 Schober, O, 840(ab), 915(ab),
 920(ab), 1428(le)
 Schochat, D, 23
 Schofer, O, 1021(ab)
 Schold, SC, 532, 966(ab)
 Schörner, W, 971(ab)
 Schrader, J, 2138
 Schroder, LE, 937(ab)
 Schroettle W, 1291
 Schroff, RW, 1099
 Schubiger, PA, 231
 Schuhmacher, J, 1366
 Schulmberger, M, 1020(ab)
 Schultz, B, 2027
 Schulzer, M, 964(ab)
 Schumpelick, V, 1001(ab)
 Schuster, DP, 1661
 Schuster, JM, 958(ab)
 Schwaiger, M, 684, 1125,
 1346, 2067, 826(ab),
 834(ab), 865(ab), 870(ab),
 882(ab), 933(ab), 994(ab),
 1008(ab)
 Schwartz, D, 910(ab)
 Schwartz, DA, 710
 Schwartz, JG, 1496
 Schwartz, RB, 839(ab),
 970(ab)
 Schwartz, RS, 845(ab)
 Schwarz, J, 897(ab), 917(ab)
 Schwarz, SW, 1685
 Schwarzer, A, 868(ab)
 Schweighardt, S, 14, 959(ab)
 Schwimmer, JJ, 926(ab)
 Schwizer, W, 956(ab)
 Schyler, D, 521
 Sciuic, J, 840(ab), 920(ab),
 1428(le)
 Sclafani, S, 117
 Scott, A, 867(ab)
 Scott, AM, 1396, 868(ab),
 904(ab)
 Scott, JA, 407, 470, 820, 1918,
 2061, 2249, 2250, 1254(le)
 Scott, JR, 841(ab)
 Scott, RM, 844(ab)
 Seabold, JE, 1486
 Sedvall, G, 860(ab), 1016(ab)
 Seed, WA, 676
 Seeger, LL, 1399, 1039(ab)
 Seftel, AD, 46
 Segall, GM, 1797, 629(le)
 Segers, MFG, 1958
 Sehgal, VJ, 895(ab)
 Seibyl, JP, 1964, 896(ab),
 911(ab)
 Seiler, CA, 1099
 Seki, C, 885(ab), 968(ab)
 Seldin, DW, 1411, 1994
 Selikson, MH, 954(ab)
 Selin, CE, 1045(ab)
 Sen, C, 969(ab)
 Senda, M, 1016(ab),
 1025(ab)
 Senekowitsch, R, 859(ab)
 Senneff, MJ, 836(ab),
 1426(le)
 Senoh, M, 1017(ab)
 Seo, S, 857(ab)
 Serafini, A, 1016(ab),
 1022(ab), 1035(ab)
 Serafini, AN, 1304, 921(ab),
 956(ab), 980(ab), 1045(ab)
 Serra, R, 994(ab)
 Serrano, J, 955(ab)
 Setaro, JF, 906(ab)
 Setoain, J, 403
 Seymour, J, 1043(ab)
 Sfakianakis, G, 1022(ab)
 Sfakianakis, GN, 1304,
 921(ab), 956(ab), 980(ab),
 1016(ab), 1035(ab), 1045(ab)
 Sgouros, G, 2167, 941(ab)
 Shah, A, 977(ab)
 Shalaby, K, 934(ab)
 Shani, J, 1031(ab)
 Shanker, R, 977(ab)
 Shao, L, 870(ab), 963(ab),
 985(ab)
 Shapiro, B, 1125, 1608, 1735,
 834(ab), 895(ab)
 Sharkey, RM, 863(ab),
 904(ab), 958(ab), 1000(ab),
 1002(ab)
 Shattuc, S, 866(ab)
 Shaw, R, 161
 Shaw, SM, 1049(ab)
 Shaya, E, 847(ab), 848(ab)
 Shaya, EK, 964(ab)
 Shea, C, 830(ab), 853(ab)
 Shea, NL, 905(ab)
 Sheehan, FH, 763, 1642
 Shefer, RE, 932(ab)
 Shelton, ME, 836(ab)
 Shen, LH, 986(ab)
 Shen, S, 926(ab)
 Shepard, HM, 934(ab)
 Sheperd, JH, 904(ab)
 Sherman, P, 870(ab)
 Sherman, PS, 423, 861(ab)
 Sherman, T, 856(ab)
 Sherwood, DF, 359
 Shi, QX, 993(ab)
 Shibasaki, H, 897(ab)
 Shibata, N, 208
 Shidara, N, 844(ab), 966(ab)
 Shieh, CB, 1022(ab)
 Shields, AF, 581, 1009(ab)
 Shields, AT, 115, 967(ab)
 Shields, S, 847(ab), 876(ab)
 Shigesawa, T, 919(ab),
 976(ab)
 Shigetani, A, 958(ab)
 Shih, W-J, 1556, 991(ab),
 1046(ab)
 Shimizu, M, 1023(ab)
 Shimozawa, E, 1696, 827(ab)
 Shinotoh, H, 917(ab)
 Shiomi, S, 744
 Shirato, M, 853(ab), 893(ab)
 Shiue, CY, 861(ab), 975(ab),
 1026(ab)
 Shiue, GG, 861(ab), 1026(ab)

- Shochat, D, 1648
 Shoemaker, RL, 851(ab)
 Shortkroff, S, 937(ab)
 Shoup, TM, 946(ab), 1026(ab)
 Shreve, PD, 860(ab)
 Shuke, N, 1200, 2024, 877(ab), 957(ab), 1020(ab)
 Shulkin, BL, 1125, 1735
 Siccardi, AG, 834(ab)
 Siegel, A, 269
 Siegel, BA, 855(ab)
 Siegel, J, 904(ab)
 Siegel, JA, 1574
 Siegel, ME, 844(ab), 937(ab)
 Sievanen, H, 1137
 Silagan, GT, 1509, 854(ab), 876(ab)
 Silberstein, EB, I, 2190, 1025(ab)
 Silberzweig, J, 973(ab)
 Silbiger, M, 161
 Siles, S, 990(ab)
 Silveira, ST, 826(ab)
 Silverman, C, 1780
 Silverman, CL, 964(ab)
 Silverstein, EA, 946(ab)
 Silzofski, WJ, 2017
 Simanis, JP, 864(ab)
 Simmons, G, 1046(ab)
 Simons, ME, 1548
 Simpson, N, 938(ab)
 Sinclair, I, 924(ab)
 Singer, H, 848(ab)
 Singh, A, 435, 1451
 Singh, J, 469(le)
 Singh, M, 974(ab)
 Singh, PR, 851(ab), 910(ab), 9387(ab), 1032(ab), 1048(ab)
 Singletary, S, 828(ab)
 Sinusas, A, 874(ab), 927(ab)
 Sinusas, AJ, 855(ab), 993(ab)
 Sisson, JC, 1125, 894(ab), 1021(ab)
 Sitbon, R, 973(ab)
 Sitomer, J, 1008(ab)
 Sjöholm, H, 868(ab)
 Skagen, K, 251
 Skamel, HJ, 906(ab)
 Skaug, I, 912(ab)
 Sketch, M, 825(ab)
 Sledge, CB, 937(ab)
 Sleiman, C, 835(ab)
 Slichter, SJ, 924(ab)
 Slinkin, MA, 943(ab)
 Slizofski, WJ, 2017, 835(ab), 1049(ab)
 Slowikowski, J, 928(ab)
 Smart, RC, 2059(le)
 Smekal, AV, 914(ab)
 Smekal, AV, 995(ab)
 Smith, AM, 878(ab)
 Smith, AP, 852(ab)
 Smith, CA, 1049(ab)
 Smith, E, 896(ab)
 Smith, EO, 1964, 848(ab), 911(ab), 945(ab)
 Smith, G, 847(ab)
 Smith, GT, 172, 885(ab), 923(ab), 983(ab)
 Smith, H, 1132, 894(ab)
 Smith, RH, 1042(ab)
 Smith, RJ, 861(ab), 862(ab), 1013(ab)
 Smith, RL, 512
 Smith, WH, 668, 864(ab)
 Snelling, LK, 1004(ab)
 Snider, RM, 860(ab)
 Snitkowski, R, 995(ab)
 Snook, D, 1022(ab)
 Snow, BJ, 922(ab), 964(ab)
 Snyder, DL, 964(ab)
 Soares, J Jr, 995(ab)
 Sobel, BE, 836(ab), 855(ab)
 Sobus, KS, 873(ab)
 Sokoloff, L, 944(ab)
 Solanki, K, 924(ab)
 Som, P, 1028(ab)
 Song, JH, 991(ab)
 Song, S-K, 925(ab)
 Songini, C, 834(ab), 959(ab)
 Soobramoney, S, 904(ab)
 Sood, VK, 986(ab)
 Sorandes, T, 966(ab), 970(ab)
 Soroa, VE, 999(ab)
 Sorrentino, S, 68
 Sossi, V, 922(ab)
 Sostre, S, 1216, 869(ab), 924(ab), 968(ab), 1004(ab)
 Soto, R, 1035(ab)
 Souder, E, 857(ab), 858(ab), 940(ab), 965(ab)
 Soufer, R, 886(ab)
 Southee, AE, 1594
 Southern, JF, 1558
 Spaulding, MB, 14
 Specker, B, 898(ab), 978(ab)
 Speelman, JD, 917(ab), 1016(ab)
 Spence, A, 944(ab)
 Spence, AM, 581
 Spencer, RP, 1701, 999(ab), 1251(le)
 Sperling, M, 930(ab)
 Sperling, RA, 704
 Spetsieris, P, 923(ab)
 Speyer, J, 912(ab)
 Spicer, K, 888(ab)
 Spiegelhoff, D, 839(ab)
 Spiegler, EJ, 1216
 Spies, SM, 946(ab)
 Spies, WG, 946(ab)
 Spinelli, A, 915(ab)
 Spitzer, AR, 1943
 Sridhara, BS, 875(ab), 938(ab)
 Srinivasan, A, 880(ab)
 Srivastava, PC, 980(ab)
 Srivastava, SC, 305, 307, 989, 899(ab), 900(ab), 942(ab), 943(ab), 980(ab), 985(ab), 1030(ab)
 Staab, EV, 1042(ab), 1043(ab)
 Stabin, M, 33
 Stabin, MG, 783
 Stack, R, 825(ab)
 Stafford, KA, 2067
 Stanus, E, 868(ab)
 Starren, JB, 1042(ab)
 Staudenherz, A, 1028(ab)
 Stecker, MM, 929(ab)
 Steelhammer, LC, 1001(ab)
 Steinert, H, 887(ab)
 Steinling, M, 1431(le)
 Stella, A, 2040
 Stephens, TS, 923(ab)
 Steplewski, Z, 900(ab), 942(ab), 985(ab), 1002(ab), 1030(ab)
 Stepniak-Biniakiewicz, D, 924(ab), 988(ab)
 Stern, H, 960(ab)
 Stern, R, 898(ab)
 Stern, S, 2061
 Stern, Y, 940(ab)
 Stevick, CD, 1797
 Stewart, CA, 844(ab)
 St. Gibson, W, 2080
 Stöcklin, G, 2138, 1013(ab)
 Stocks, G, 865(ab)
 Stoffer, SS, 1393
 Stone, CK, 850(ab), 884(ab), 931(ab)
 Stone-Elander, S, 908(ab), 1011(ab)
 Stone-Elander, SA, 1026(ab)
 Storb, R, 924(ab)
 Storey, AE, 850(ab)
 Stoub, EW, 1430(le)
 Stowers, SA, 847(ab), 876(ab)
 Strand, S-E, 1654, 1825, 953(ab), 954(ab), 962(ab)
 Strashun, A, 117, 215, 973(ab), 1021(ab), 1035(ab)
 Stratton, JR, 763, 1324, 1642
 Straub, R, 900(ab)
 Straub, RF, 307, 900(ab), 989(ab)
 Strauss, DJ, 1396
 Strauss, HE, 3A(7)
 Strauss, HW, 3A, 144, 935, 1378, 2246, 3A(5), 3A(6), 3A(1), 3A(2), 845(ab), 910(ab), 915(ab), 924(ab), 934(ab), 936(ab), 946(ab), 959(ab), 996(ab), 998(ab), 1000(ab), 1026(ab), 1028(ab), 1587(le)
 Strauss, LG, 1981, 1019(ab)
 Stray, JE, 943(ab)
 Strelkov, AB, 841(ab)
 Striano, G, 973(ab), 1014(ab)
 Stritzke, P, 969(ab)
 Stritzke, PH, 949(ab)
 Ström, P, 860(ab)
 Strother, SC, 871(ab)
 Stubgaard, M, 2106
 Studer, M, 880(ab), 942(ab)
 Stuttle, AWJ, 756
 Styles, JM, 2154
 Su, F-M, 880(ab), 909(ab), 910(ab), 934(ab), 979(ab)
 Subramanian, G, 1428(le)
 Subramanian, R, 1031(ab)
 Sucharski, LA, 2067
 Sudati, F, 959(ab)
 Suehiro, M, 860(ab)
 Suematsu, K, 1017(ab)
 Suess, E, 108
 Suey, C, 912(ab)
 Sueyoshi, K, 1023(ab)
 Sufka, B, 970(ab)
 Sugawara, T, 972(ab)
 Sugawara, Y, 909(ab), 912(ab), 969(ab), 1004(ab)
 Sugii, A, 988(ab), 1029(ab), 1033(ab)
 Suhara, T, 917(ab)
 Sulavic, SB, 999(ab)
 Sultzter, D, 967(ab)
 Sumida, R, 865(ab)
 Sumiya, H, 877(ab), 967(ab)
 Summers, B, 1035(ab)
 Sumrani, N, 1035(ab)
 Sun, B, 957(ab)
 Sun, K, 865(ab)
 Sunderland, J, 829(ab), 975(ab)
 Sung, KB, 919(ab)
 Susaki, Y, 1009(ab)
 Susskind, H, 1717, 1012(ab)
 Sutor, R, 826(ab)
 Suzuki, K, 844(ab), 917(ab), 966(ab)
 Suzuki, S, 932(ab), 998(ab)
 Suzuki, T, 932(ab), 998(ab), 1019(ab)
 Swartz, BE, 1017(ab)
 Sweeney, DC, 996(ab)
 Swenson, ER, 581
 Swyer, AF, 1175
 Swyer, AJ, 2027, 999(ab)
 Sybirska, EH, 848(ab), 945(ab)
 Syrota, A, 471, 696, 976, 1481, 843(ab), 858(ab), 882(ab), 883(ab), 888(ab), 896(ab), 943(ab), 977(ab), 1019(ab)
 Szabo, Z, 869(ab), 885(ab), 968(ab), 1004(ab)
 Szlachzky, LA, 990(ab)
 Tabuchi, K, 1023(ab)
 Taegtmeier, H, 1523
 Taguchi, T, 6
 Taillefer, R, 668, 1091, 1801, 855(ab), 866(ab), 894(ab), 1034(ab)
 Tainturier, C, 991(ab)
 Takahashi, 885(ab)
 Takahashi, A, 994(ab)
 Takahashi, M, 930(ab), 1029(ab), 1033(ab), 988(ab), 017(ab)
 Takahashi, N, 659, 856(ab), 886(ab), 953(ab), 1015(ab)
 Takahashi, T, 897(ab), 969(ab)
 Takamori, M, 1020(ab)
 Takano, M, 920(ab)
 Takasaki, M, 1019(ab)
 Takashima, Y, 744
 Takasiro, K, 857(ab)
 Takechi, T, 919(ab), 976(ab)
 Takeda, R, 1017(ab)
 Takeda, T, 1023(ab)
 Takehara, Y, 1851
 Takemoto, K, 854(ab)
 Takemura, Y, 545
 Takeshita, G, 1741, 965(ab)
 Takeuchi, A, 1741, 965(ab)
 Taki, J, 441, 1200, 918(ab), 1020(ab)
 Taki, S, 1020(ab)
 Takikawa, H, 998(ab)
 Takikawa, S, 923(ab)
 Takizawa, K, 998(ab)
 Tamahashi, N, 1972
 Tamaki, N, 659, 1263, 1501, 1637, 856(ab), 875(ab), 885(ab), 886(ab), 897(ab), 953(ab), 966(ab), 1026(ab)
 Tamburro, F, 992(ab)
 Tamura, Y, 994(ab)
 Tan, J, 935(ab)
 Tan, P, 901(ab)
 Tanabe, H, 940(ab)
 Tanada, S, 135, 893(ab), 909(ab), 912(ab), 969(ab), 972(ab), 1004(ab)
 Tanaka, K, 1008(ab)
 Tange, S, 1004(ab), 1005(ab)
 Taniuchi, H, 1026(ab)
 Tansey, W, 985(ab)
 Tararine, M, 1003(ab)
 Tarbell, NJ, 844(ab)
 Tarburton, JP, 2148
 Tardieu, M, 976(ab)
 Tarry, CT, 2059(le)
 Tateno, M, 1181
 Tateno, Y, 917(ab)
 Tatsch, K, 1291, 832(ab), 897(ab), 917(ab)
 Tatum, WO, 929(ab)
 Tauxe, N, 997(ab)
 Tawarahara, K, 6
 Taylor, A, Jr, 33, 296, 1620, 2055(le), 900(ab), 921(ab), 948(ab), 991(ab)
 Taylor, LP, 972(ab)
 Taylor, S, 890(ab)
 Taylor, SF, 1836, 1007(ab), 1008(ab)
 Teates, CD, 833(ab), 971(ab)
 Tedder, TE, 852(ab)
 Teixeira, JP, III, 59
 Tenenbaum, F, 1020(ab)
 ten Haken, RK, 735
 Teoh, SK, 887(ab)
 Ter, S-E, 999(ab)
 Terada, K, 966(ab)
 Teräs, M, 691, 1255
 Terashi, A, 1016(ab)
 Tercilla, OF, 2059(le)
 Ter-Pogossian, MM, 1214
 Terry, JA, 961(ab)
 Terry, JD, 829(ab)
 Testa, D, 1014(ab)
 Teule, GJJ, 1915(le), 858(ab), 927(ab)
 Tewson, TJ, 983(ab)
 Thakur, ML, 851(ab), 973(ab), 979(ab), 986(ab), 987(ab)
 Thaler, H, 859(ab)
 Thedrez, Ph, 943(ab)
 Thérour, P, 875(ab)
 Thie, JA, 923(ab)
 Thierens, HMA, 1167
 Thies, P, 997(ab)
 Thiessen, JJ, 2248(le)
 Thoams, SR, 937(ab)
 Thomas, CMG, 1958
 Thomas, FD, 150, 961(ab)
 Thomas, JR, 890(ab)
 Thomas, SR, 783, 1132, 1717, 894(ab)
 Thompson, NW, 1125
 Thompson, RB, 2059(le)
 Thompson, RC, 847(ab), 876(ab)
 Thompson, S, 41
 Thompson, W, 908(ab)
 Thoolen, MJ, 989(ab)
 Thorson, A, 975(ab)
 Thorson, LL, 1006(ab)
 Thouvenot, P, 956(ab)
 Thrall, DE, 1542
 Tiel-van Buul, MMC, 907(ab)
 Tien, R, 1047(ab)
 Tikofsky, RS, 939(ab)
 Tilbury, R, 985(ab), 992(ab)

- Tilbury, RS, 828(ab)
 Ting, G, 986(ab)
 Tison, V, 863(ab)
 Tisselli, A, 915(ab)
 Tobin, M, 1073(ab)
 Todde, S, 973(ab)
 Todd-Pokropek, A, 1007(ab)
 Tomiguchi, S, 988(ab),
 1029(ab), 1033(ab)
 Tomita, J, 998(ab)
 Tomiyoshi, K, 1181
 Tonami, N, 441, 2024,
 877(ab), 957(ab), 967(ab),
 1020(ab)
 Tondeur, M, 485
 Toney, MO, 2052
 Toni, MG, 954(ab)
 Toorongian, SA, 870(ab),
 982(ab), 983(ab), 994(ab)
 Topchik, S, 1304
 Torchilin, VP, 943(ab),
 959(ab)
 Torelli, J, 866(ab)
 Torizuka, T, 886(ab)
 Torres, G, 840(ab), 845(ab),
 895(ab), 994(ab)
 Toth-Abonyi, M, 1935
 Tournier, E, 1003(ab)
 Tow, DE, 964(ab)
 Toyama, H, 1741, 965(ab),
 970(ab), 1016(ab)
 Tran, H, 968(ab)
 Tran, HD, 1047(ab)
 Tranel, D, 1008(ab)
 Travagli, JP, 1020(ab)
 Travin, MI, 876(ab)
 Treffert, JD, 932(ab), 947(ab),
 949(ab)
 Trehan, J, 825(ab)
 Treves, ST, 1758, 2098,
 838(ab), 844(ab), 930(ab),
 1018(ab)
 Trimarco, B, 505, 905(ab),
 915(ab)
 Trivedi, MH, 838(ab)
 Tromholt, N, 2106
 Troutner, DE, 899(ab), 921(ab)
 Trubetskoy, V, 959(ab)
 Trubetskoy, VS, 943(ab)
 Trulock, EP, 835(ab)
 Tsang, BW, 931(ab)
 Tse, N, 828(ab)
 Tselentakis, M, 886(ab)
 Tselfes, J, 1003(ab)
 Tsuchida, T, 897(ab), 966(ab)
 Tsuda, T, 912(ab), 1004(ab)
 Tsui, BMW, 451, 2238,
 831(ab), 832(ab), 842(ab),
 892(ab), 961(ab)
 Tsuji, S, 877(ab), 967(ab)
 Tsutsumi, K, 969(ab)
 Tuama, LAO, 1018(ab)
 Tulchinsky, M, 1854, 947(ab)
 Tuli, M, 978(ab)
 Tumeh, SS, 1186
 Tunc, L, 847(ab)
 Tung, C-H, 901(ab), 902(ab)
 Tupler, RH, 1553
 Turbiner, EH, 1553
 Turkheimer, F, 944(ab)
 Turkington, TG, 901(ab),
 922(ab), 1047(ab)
 Turner, FE, 716, 935(ab)
 Turner, M, 1045(ab)
 Turpin, S, 1034(ab)
 Twiford, TW, 1047(ab)
 Tzen, KY, 1022(ab)
 Ucar, N, 859(ab)
 Uccelli, L, 850(ab)
 Udelson, JE, 905(ab)
 Uebis, R, 886(ab)
 Ueda, S, 413, 466(le)
 Ueda, T, 744, 971(ab)
 Uehara, T, 272, 365
 Uemura, K, 1696, 827(ab),
 857(ab), 911(ab), 963(ab),
 1008(ab)
 Ueno, A, 1023(ab)
 Underwood, D, 866(ab)
 Unlü, M, 319
 Uno, K, 324
 Unsworth, C, 982(ab)
 Untereker, WJ, 2086,
 866(ab)
 Ur, E, 1121, 914(ab)
 Urbain, JL, 832(ab)
 Urion, DK, 1758
 Urita, Y, 920(ab)
 Utsunomiya, H, 575
 Uyan, C, 866(ab)
 Uygur, G, 868(ab), 869(ab)
 Uzum, F, 868(ab)
 Vaalburg, W, 373, 870(ab)
 Vaccarino, RA, 1411, 1994,
 846(ab)
 Vaghaiwalla-Mody, F, 856(ab),
 857(ab)
 Vaghi, M, 924(ab)
 Vahjen, GA, 304
 Vaidyanathan, G, 1535,
 881(ab)
 Valette, H, 471, 843(ab),
 888(ab), 896(ab)
 Valk, PE, 2133
 Valkow, ND, 287
 Vallabhajosula, S, 969(ab),
 995(ab), 1031(ab)
 van Aswegen, A, 888(ab)
 Van Cauteren, J, 832(ab)
 van den Mieracker, AH,
 990(ab)
 Vanderheyden, J-L, 1099,
 900(ab), 934(ab), 979(ab),
 981(ab), 1025(ab)
 van der Meer, JWM, 388,
 1330, 903(ab), 920(ab),
 936(ab), 950(ab), 1031(ab)
 van der Pluijm, M, 955(ab)
 van der Vliet, JA, 1330,
 950(ab)
 Vandervoot, PM, 1558
 van der Vusse, GJ, 102
 van der Wall, EE, 1727
 Vander Zwagg, R, 1269
 Vandevivere, J, 972(ab),
 1013(ab), 1021(ab)
 Van de Wiele, C, 1167
 Vandewoude, M, 1013(ab)
 van Dieren, EB, 1915(le)
 van Dijk, A, 646
 van Dongen, A, 907(ab)
 Van Frank, R, 1427(le)
 Van Haelst, JP, 1167
 van Hagen, PM, 652
 Vanhagen, PM, 903(ab)
 Van Haight, C, 2184
 Vanhaverbeek, M, 1337
 van Heerden, BB, 883(ab)
 Van Heertum, R, 939(ab)
 Van Heertum, RL, 906(ab),
 988(ab)
 van het Schip, AD, 646
 van Kaick, G, 1982, 828(ab),
 907(ab), 1019(ab), 1045(ab)
 van Lingen, A, 1915(le)
 van Montfrans, GA, 907(ab)
 Van Nerom, C, 1032(ab)
 Van Nerom, CG, 551
 Vanoverschelde, JL, 837(ab),
 884(ab)
 van Rensburg, AA, 888(ab)
 van Rijk, PP, 646
 van Royen, EA, 894(ab),
 895(ab), 907(ab), 917(ab),
 1016(ab)
 Van Train, K, 854(ab),
 876(ab)
 Van Train, KF, 1509
 van Vlies, B, 895(ab)
 van Waarde, A, 870(ab)
 Varastet, M, 883(ab), 973(ab)
 Vardi, Y, 49
 Vargas, K, 885(ab)
 Varma, VM, 996(ab)
 Varney, DM, 748
 Vavouraki, H, 988(ab)
 Veilleux, M, 951(ab)
 Veith R, 1324
 Vekemans, MC, 832(ab)
 Velasquez-Rocha, S, 935(ab)
 Vellet, AD, 516
 Vemon, P, 831(ab)
 Vemuru, RP, 919(ab)
 Venkatesan, P, 979(ab)
 Venkatesan, PP, 987(ab)
 Vera, DR, 1160
 Verani, M, 927(ab)
 Verani, MS, 1600, 905(ab),
 916(ab), 995(ab)
 Verbruggen, A, 1032(ab)
 Verbruggen, AM, 551
 Verdera, ES, 1949
 Verdy, M, 894(ab)
 Vergara, E, 892(ab), 918(ab),
 999(ab)
 Vergnes, R, 947(ab)
 Verheggen, R, 957(ab)
 Verheij, LF, 1406
 Verheijin, RHM, 1958
 Verhoeff, NPLG, 916(ab),
 917(ab), 1016(ab)
 Verma, RC, 827(ab), 1043(ab)
 Vernick, J, 1183
 Vervae, A, 1013(ab)
 Verzijlbergen, FJ, 1727
 Vespie, A, 937(ab)
 Vessella, RL, 943(ab)
 Vetter, RJ, 1613
 Vetterlein, D, 934(ab)
 Vezina, WC, 516
 Vidaihet, M, 1019(ab)
 Vidailhet, M, 1481
 Vieregge, P, 1013(ab)
 Vijayakumar, S, 853(ab)
 Vijayakumar, V, 853(ab)
 Villanueva-Meyer, J, 838(ab),
 839(ab), 846(ab), 876(ab)
 Villela, MA, 942(ab), 1030(ab)
 Vining, DJ, 1044(ab)
 Vinitski, S, 973(ab)
 Vinson, EL, 668
 Virzi, F, 921(ab), 925(ab),
 934(ab)
 Visser, G, 858(ab)
 Visser, GM, 870(ab)
 Visser, TJ, 652, 955(ab)
 Vitols, PJ, 993(ab)
 Vleugels, S, 937(ab)
 Voderholzer, A, 1291
 Voderholzer, W, 832(ab)
 Vogel, JM, 127
 Voipio-Pulki, L-M, 1255
 Volkert, EW, 1024(ab)
 Volkert, WA, 623, 1451,
 1916(le), 851(ab),
 910(ab), 979(ab),
 987(ab), 988(ab),
 1032(ab), 1048(ab)
 Volkow, N, 995(ab)
 Volkow, ND, 521, 1720,
 2020, 830(ab), 847(ab),
 887(ab), 888(ab),
 946(ab), 1046(ab)
 vom Dahl, J, 886(ab)
 von Smekal, A, 536
 Vorne, M, 1253(le)
 Votaw, JR, 826(ab), 847(ab)
 Vral, AM, 1167
 Vuori, I, 1137
 Wackers, FJTh, 855(ab),
 874(ab), 886(ab), 927(ab),
 938(ab), 939(ab), 993(ab)
 Wada, A, 208
 Wada, K, 545, 1026(ab)
 Wada, M, 1029(ab)
 Wadas, MA, 2214
 Wagner, HN, Jr, 1216,
 847(ab), 848(ab), 860(ab),
 869(ab), 885(ab), 929(ab),
 964(ab), 968(ab), 1004(ab),
 N10(8)
 Wagner, R, 1013(ab)
 Wagner, RH, 1041(ab)
 Wahl, RL, 975, 828(ab),
 841(ab), 869(ab), 893(ab),
 894(ab), 926(ab), 959(ab),
 1020(ab), 1021(ab)
 Wahner, HW, 1039(ab)
 Waite, SD, 1006(ab)
 Wakasugi, S, 208, 935(ab),
 936(ab)
 Wakisaka, S, 971(ab)
 Wakita, K, 413
 Walker, B, 992(ab)
 Walker, BS, 826(ab)
 Walker, WJ, Jr, 20N(6)
 Wallace, R, 974(ab)
 Wallace, S, 985(ab)
 Wallich, R, 1982, 1019(ab)
 Wallis, JW, 1678, 1710, 964(ab)
 Walovitch, RC, 480, 878(ab),
 968(ab)
 Walsh, C, 912(ab)
 Walsh, J, 438
 Walsh, RA, 993(ab)
 Waltman, AC, 948(ab)
 Wanet, P, 1005(ab)
 Wang, AK, 1039(ab)
 Wang, F, 854(ab)
 Wang, FP, 1509
 Wang, GJ, 521, 2020, 887(ab),
 888(ab), 946(ab), 1028(ab),
 1046(ab)
 Wang, H, 891(ab)
 Wang, KY, 955(ab)
 Wang, MF, 1044(ab)
 Wang, PY, 1013(ab)
 Wang, R, 991(ab)
 Wang, S, 868(ab)
 Wang, S-J, 254, 955(ab),
 977(ab), 986(ab), 997(ab),
 1012(ab), 1013(ab)
 Wang, TST, 570, 1994,
 988(ab)
 Wang, X, 842(ab)
 Ward, R, 898(ab)
 Ware, RW, 1857
 Warhoe, KA, 862(ab)
 Wartski, M, 843(ab), 888(ab),
 947(ab)
 Washburn, LC, 937(ab),
 993(ab), 1048(ab)
 Wassink, HA, 838(ab)
 Wasserman, L, 1411
 Watabe, K, 897(ab)
 Watanabe, E, 857(ab)
 Watanabe, K, 971(ab)
 Watanabe, N, 1181
 Watanabe, R, 1033(ab)
 Watanabe, T, 1001(ab),
 1006(ab), 1009(ab), 827(ab),
 68(ab)
 Watanabe, Y, 919(ab),
 976(ab), 1020(ab)
 Watanuki, S, 857(ab)
 Waters, D, 951(ab)
 Watkins, GL, 1008(ab),
 1027(ab)
 Watson, DD, 668, 864(ab)
 Watson, E, 777
 Watson, EE, 819
 Wauters, E, 1427(le)
 Waxman, AD, 843(ab),
 869(ab)
 Webb, D, 925(ab)
 Webber, D, 1041(ab)
 Weber, DA, 1717, 842(ab),
 851(ab), 1012(ab), 1015(ab)
 Weber, W, 859(ab)
 Webster, WB, 498, 2249(le)
 Wegelius, U, 1255
 Weiden, PL, 1099
 Weiland, DM, 1125
 Weinberger, DR, 981(ab)
 Weindling, SN, 930(ab)
 Weiner, RE, 1701
 Weinheimer, CJ, 884(ab)
 Weinreich, R, 884(ab)
 Weinstein, H, 1783, 993(ab)
 Weinstein, J, 957(ab),
 1022(ab)
 Weinstein, JN, 893(ab)
 Weise, SB, 908(ab)
 Weisman, H, 848(ab)
 Weisman, HF, 978(ab)
 Weiss, A, 843(ab)
 Weiss, MJ, 1291
 Welch, MJ, 558, 724, 1685,
 837(ab), 925(ab), 932(ab)
 Welcke, U, 906(ab)
 Wellman, H, 918(ab)
 Wells, P, 313
 Welt, S, 913(ab)
 Wernovsky, G, 930(ab)
 Wernz, J, 912(ab)
 Wese, F-X, 73
 Wessel, D, 838(ab)
 Wetzell, H, 887(ab)
 Wetzell, LH, 1039(ab)

- Wheeler, RH, 23, 1648
 White, D, 974(ab)
 White, DL, 974(ab)
 Whiting, JH, Jr, 260
 Widen, L, 908(ab), 1011(ab)
 Widman, J, 2116
 Wiebe, LI, 841(ab)
 Wiegand, V, 845(ab)
 Wieland, DM, 860(ab), 870(ab)
 Wielopolski, L, 1278
 Wienhard, K, 861(ab), 1013(ab)
 Wieringa, AR, 373
 Wiersinga, WM, 894(ab)
 Wiesner, RF, 239
 Wiesniewski, G, 911(ab)
 Wijngaarde, R, 894(ab)
 Wijns, W, 825(ab), 837(ab), 875(ab), 884(ab), 905(ab)
 Wikander, R, 832(ab)
 Wilbur, DS, 465(le), 943(ab)
 Wilder, S, 851(ab), 979(ab), 987(ab)
 Wilkinson, G, 872(ab)
 Wilkinson, R, 936(ab), 996(ab)
 Wilkinson, RA, 845(ab), 1024(ab)
 Wilkinson, RW, 1028(ab)
 Willemart, B, 825(ab), 875(ab), 905(ab)
 Williams, CC, 1048(ab)
 Williams, HJ, 847(ab), 876(ab)
 Williams, JR, 987(ab)
 Williams, KA, 359
 Williams, LE, 953(ab)
 Williams, RG, 977(ab)
 Wilson, A, 834(ab)
 Wilson, AA, 847(ab), 848(ab), 883(ab), 929(ab)
 Wilson, CR, 2110, 869(ab)
 Wilson, IK, 830(ab)
 Wilson, LA, 953(ab)
 Wilson, ME, 306
 Wilson, RA, 716
 Wilson, SD, 869(ab)
- Winn, HR, 1789
 Winnard, P, 909(ab)
 Wironen, J, 993(ab)
 Wiseman, JC, 868(ab)
 Wisenberg, S, 355
 Wisniewski, G, 848(ab), 945(ab)
 Wittry, MD, 1046(ab)
 Woda, A, 897(ab)
 Wolber, G, 828(ab)
 Wolf, A, 995(ab)
 Wolf, AP, 192, 521, 1720, 830(ab), 847(ab), 853(ab), 870(ab), 887(ab), 888(ab), 946(ab)
 Wolf, F, 903(ab)
 Wolf, JE, 953(ab)
 Wolf, SB, 1099
 Wolf, W, 830(ab)
 Wolfangel, R, 1024(ab)
 Wolfangel, RG, 308, 989(ab), 1033(ab)
 Wolfe, E, 882(ab)
 Wolfe, ER, 1008(ab)
 Wolk, AP, 2020
 Wolters, EC, 917(ab)
 Wolters, ECMJ, 1016(ab)
 Wong, A, 1045(ab)
 Wong, C, 851(ab)
 Wong, CTC, 1012(ab), 1015(ab), 1028(ab)
 Wong, DF, 847(ab), 848(ab), 964(ab), 968(ab)
 Wong, GY, 904(ab)
 Wong, S, 945(ab)
 Wong, WH, 828(ab), 985(ab), 992(ab), 1011(ab), 1430(le)
 Woodin, M, 878(ab)
 Woodle, DR, 880(ab)
 Woods, RP, 922(ab), 1010(ab)
 Woods, S, 896(ab)
 Woods, SW, 1964
 Woolfenden, JM, 851(ab), 879(ab), 1002(ab)
 Wooter, W, 33
 Worth, J, 1312, 887(ab)
- Worthy, M, 865(ab)
 Wszolek, Z, 964(ab)
 Wu, AM, 953(ab)
 Wu, C, 1030(ab), 1031(ab)
 Wu, KH, 977(ab)
 Wyatt, RJ, 1383, 965(ab)
 Wysor, W, 2067
- Xu, X-L, 871(ab)
- Yaghmai, I, 827(ab), 1043(ab)
 Yamada, J, 1024(ab)
 Yamada, S, 1972, 840(ab), 841(ab), 984(ab)
 Yamada, T, 1501
 Yamagami, H, 952(ab)
 Yamaguchi, N, 967(ab)
 Yamaguchi, S, 1637
 Yamamoto, H, 333
 Yamamoto, I, 998(ab)
 Yamamoto, Y, 1008(ab)
 Yamanaka, M, 998(ab)
 Yamasaki, T, 917(ab)
 Yamashita, J, 967(ab)
 Yamashita, S, 932(ab)
 Yamauchi, H, 1637
 Yamazaki, N, 6
 Yang, D, 985(ab)
 Yang, DJ, 828(ab), 992(ab)
 Yang, KTA, 282
 Yang, SH, 1008(ab)
 Yang, SK, 919(ab)
 Yang, S-O, 2118
 Yang, WJ, 924(ab)
 Yang, Y, 989(ab)
 Yang, Z-Y, 829(ab), 982(ab)
 Yao, T-J, 345
 Yap, JT, 947(ab), 949(ab)
 Yarmush, ML, 1378
 Yasuda, T, 1558, 1905
 Yasugi, T, 951(ab)
 Ye, J, 842(ab)
 Yeh, S, 867(ab)
 Yeh, SDJ, 345, 2020, 843(ab), 859(ab)
 Yeh, SH, 955(ab), 977(ab), 997(ab), 1012(ab), 1013(ab), 1034(ab)
- Yeo, E, 937(ab)
 Yeung, DW, 899(ab), 954(ab)
 Yokoi, T, 911(ab)
 Yokota, A, 1025(ab)
 Yokoyama, A, 545, 891(ab), 897(ab), 1023(ab), 1024(ab), 1026(ab)
 Yokoyama, K, 957(ab), 1020(ab)
 Yonekura, R, 996(ab)
 Yonekura, Y, 545, 659, 1023, 1263, 1637, 856(ab), 885(ab), 886(ab), 891(ab), 897(ab), 953(ab), 966(ab), 1024(ab), 1026(ab)
 Yoon, B-W, 877(ab)
 Yoshida, A, 1501
 Yoshikawa, K, 324
 Yoss, RG, 2110
 Yost, RW, 1046(ab)
 You, DL, 1022(ab)
 Young, ET, 1002(ab)
 Young, P, 1789
 Yu, CC, 964(ab)
 Yu, DC, 1045(ab)
 Yu, L, 868(ab)
 Yu, S, 926(ab)
 Yu, SL, 997(ab)
 Yuen-Green, MS, 1444
 Yuille, D, 839(ab)
 Yuille, DL, 1704
 Yung, B, 847(ab), 964(ab)
 Yung, BCK, 924(ab)
- Zaidel, M, 947(ab)
 Zaino, EC, 1278
 Zalutsky, MR, 575, 1535, 881(ab), 934(ab), 958(ab)
 Zambuto, G, 989(ab)
 Zamora, PO, 1029(ab), 1031(ab)
 Zang, Y, 1010(ab)
 Zanzi, I, 898(ab), 923(ab)
 Zanzonico, P, 2180, 845(ab)
 Zaret, B, 927(ab)
 Zaret, BL, 855(ab), 874(ab), 886(ab), 938(ab), 939(ab), 993(ab)
- Zasadny, K, 1020(ab)
 Zasadny, KR, 926(ab)
 Zca-Ponce, Y, 1964, 848(ab), 896(ab), 911(ab), 945(ab)
 Zeeberg, BR, 883(ab)
 Zeeburg, BR, 1225
 Zeiter, PC, 863(ab)
 Zeng, GL, 831(ab), 891(ab), 892(ab), 901(ab)
 Zhang, JJ, 1943, 961(ab)
 Zhang, XX, 989(ab)
 Zhang, Y, 831(ab)
 Zhao, XD, 831(ab)
 Zheng, J, 984(ab)
 Zhu, X, 954(ab)
 Ziegler, SI, 1007(ab)
 Zierz, St, 995(ab)
 Ziessman, HA, 266, 537, 833(ab), 899(ab)
 Ziffer, J, 876(ab)
 Ziffer, JA, 927(ab)
 Zilbovicius, M, 696, 1481, 858(ab), 1019(ab)
 Zilleruelo, GE, 956(ab)
 Zimmer, AM, 946(ab)
 Zimmerman, RE, 839(ab), 852(ab), 1005(ab), 1018(ab), 1043(ab)
 Zingraff, J, 913(ab)
 Zinn, KR, 1685
 Zito, F, 959(ab)
 Zito, V, 1859
 Zloty, M, 886(ab), 913(ab)
 Zoccarato, O, 846(ab)
 Zoghbi, SS, 1964, 848(ab), 896(ab), 911(ab), 945(ab)
 Zöller, M, 1366
 Zonnenberg, BA, 646
 Zupal, G, 1964, 906(ab)
 Zupal, IG, 1712, 963(ab), 1006(ab)
 Zubieta, JA, 882(ab)
 Zuccala, A, 2040
 Zuckier, LS, 1723, 985(ab)
 Zuñiga, EH, 1047(ab)
 Zwas, ST, 859(ab)
 Zwinderman, AH, 1406, 1727

A

- Abdomen**
diffuse uptake of Tc-99m MDP, continuous ambulatory dialysis, bone scintigraphy, 2052
fast diagnosis of infections, Tc-99m HMPAO lymphocytes, 1253(le)
- Abscess**
focal infection, radiolabeled proteins, biodistribution and kinetics, 388
intracranial, differential diagnosis, Tc-99m antigranulocyte antibody, 957(ab)
odontogenic, spread of infectious complications, Tc-99m HMPAO white blood cells, 254
- Absorptiometry**
dual energy X-ray
bone mineral and body composition, fan-beam design, 1063(ab)
bone mineral density, skeletal sites, 1137
dual photon absorptiometry
single-photon, utility of, 170
- Acetate**, cellulose-, hemodialyzer, comparative thrombogenicity, 956(ab)
- Acetazolamide**
cerebrovascular response, Tc-99m DTPA-HSA, new method for monitoring, 969(ab)
effect on vascular response, diasthesis, Tc-99m HMPAO SPECT, 967(ab)
Tc-99m HMPAO SPECT, PET and, cerebrovascular disease, 877(ab)
- Acetylcholine**, release and endogenous dopamine, GABAergic modulation, PET, 847(ab)
- Achalasis**, esophageal scintigraphy, 590
- Acquired immunodeficiency syndrome (AIDS)**
cerebral perfusion imaging, 827(ab)
dementia complex, cocaine abuse, brain perfusion SPECT, 887(ab), 1312
differentiation of infectious from malignant CNS lesions, FDG-PET, 838(ab)
gastric uptake of Ga-67, 643
infectious diseases and, Annual Meeting highlights, 24N(8)
noninvasive monitoring of drug targeting, 3'-fluoro-3'-deoxythymidine, 830(ab)
Pneumocystis pneumonia, pulmonary disposition, Ga-67, 512
- Acromegaly**
active, rest and exercise radionuclide ventriculography, 834(ab)
bone mineral density, axial skeleton, 1608
- Actomyosin**, contraction/relaxation, T2 relaxation behavior, 974(ab)
- Acupuncture**
anatomic divisions, 407
message transmission, nuclear medicine, 409
- ADAC Laboratories**, lawsuit filed by Trionix, gamma camera technology, 18N(2)
- Adenocarcinoma**, CEA concentration measurement, quantitative autoradiography, 892(ab)
- Adenoma**
parathyroid
hyperparathyroidism, Tc-99m sestamibi, 1801
Tc-99m sestamibi double-phase study, primary hyperparathyroidism, 894(ab)
parathyroid imaging, 1807
- Adenosine**
choice of stress for diagnostic perfusion, wall motion imaging, MIBI-SPECT and stress echocardiography, 825(ab)
detection of total ischemic myocardium at jeopardy, combination of flow reserve with metabolic assessment, 837(ab)
extent and location of CAD, patients without prior myocardial infarction, 2067
-induced coronary hyperemia, early thallium imaging after PTCA, 2086
infusion, myocardial ischemia, hemodynamic-scintigraphic study, 952(ab)
myocardial perfusion imaging, serum caffeine levels, 24-hour abstention, 866(ab)
regional cardiac, noninvasive assessment, PET, 2138
stress N-13 ammonia myocardial perfusion PET, coronary artery disease, 825(ab)
teboroxime myocardial perfusion imaging, accuracy, optimal imaging time, 854(ab)
thallium scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
Tl-201 compared to Tc-99m teboroxime, coronary stenosis, 864(ab)
Tl-201 scintigraphy, lung thallium uptake, 1600
- S-Adenosyl-L-homocysteine hydrolase**, potential inhibitor, synthesis and metabolism, I-125 iodocycloadenosin-4'-ene, 980(ab)
- Adhesion molecules**, intercellular, lung neutrophil sequestration, endotoxemia, 1023(ab)
- Adrenal gland**
adrenocortical scintigraphy, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)
C-11 cocaine, distribution and kinetics, 521
C-11 HED PET, localization, pheochromocytoma, 1125
SPECT, without dexamethasone suppression, primary aldosteronism, 834(ab)
- Adrenoceptors**
alpha-2, ligands, C-11 MK-912 and C-11 WY 26703, 861(ab)
beta, use of CGP-12177 and CGP-26505, 870(ab)
- Adriamycin**
acute cardiotoxicity, Tc-99m sestamibi, chick heart cells, 864(ab)
cardiomyopathy
abnormal cardiac adrenergic neuron activity, I-125 MIBG, 208
disturbed neuronal energy metabolism, 935(ab)
myocardial damage, In-111 antimyosin antibody, 936(ab)
prediction of congestive heart failure, I-125 MIBG, 935(ab)
congestive cardiomyopathy, I-125 MIBG, 215
risk of congestive heart failure, In-111 antimyosin studies, 895(ab)
- Agings**
central dopamine D2 receptors, specific and non-specific binding, C-11 YM-09151-2, 897(ab)
decline of L-6-[F-18]fluorodopa rate constant K_1 , 964(ab)
declining myocardial flow reserve, higher cardiac work at rest, 836(ab)
dopamine receptors, SPECT and IBZM, 897(ab)
older adults, blunted response of myocardial perfusion, dipyridamole, 1425(le)
- Air pollution**, exposed persons, burning oil wells in Kuwait, lung imaging studies, 978(ab)
- Alcohol**
acute and chronic, antral processing, solid meal, 832(ab)
- dependent men, C-11 flumazenil binding, benzodiazepine receptors, 1016(ab)
diffuse liver disease, emission tomography, 1337
intoxication, cocaine distribution and kinetics, human brain and heart, 946(ab)
young alcoholics, brain deficits, PET and MRI, 1070(ab)
- Aldosteronism**, primary, adrenal SPECT, without dexamethasone suppression, 834(ab)
- Algorithms**
accelerated reconstruction, ordered subsets, 960(ab)
cone beam reconstruction, displaced center-of-rotation, 891(ab)
estimation of slope in PATLAK analysis, dynamic PET data, 944(ab)
fan beam convolution reconstruction, variable focal length collimators, 891(ab)
FFT interpolation, 1007(ab)
generalized Gibbs prior, maximum *a posteriori*-EM SPECT reconstruction, 832(ab)
image reconstruction, brain phantom design, computer simulation studies, 1012(ab)
improved signal-to-noise, 3D ML-EM reconstruction, 961(ab)
issues in quantitation, reoriented cardiac PET images, 1235
iterative linear, filtered back-projection, image reconstruction, 871(ab)
iterative reconstruction, SPECT grey matter imaging, 1225
knowledge-based boundary detector, clinical verification, 938(ab)
least squares, region-of-interest evaluation, emission tomography, 831(ab)
linearization, cerebral blood flow, Tc-99m HMPAO SPECT, 912(ab)
lung scan interpretation, 1417, 1422
mathematical modeling and dosimetry, plasmapheresis, radioimmunotherapy of micrometastases, 941(ab)
multi-energy maximum-likelihood reconstruction, SPECT and PET, 831(ab)
reconstruction
fast interactive method, functional regions, 831(ab)
singular value decomposition, attenuation in SPECT, 831(ab)
restoration and correction, improved quantitation of small objects, PET, 872(ab)
subtraction, parathyroid scintigraphy, 996(ab)
three-dimensional functional brain images, automated method, rotational correction, 1579
- Alkylamine**, conjugation chemistry for labeling antibodies, 986(ab)
- Allied health**, Title VII appropriations, 26N(3)
- Allograft**, cardiac, rejection detection, I-123 anti-ICAM-1 imaging, 1000(ab)
- Alzheimer's disease**
absolute whole brain glucose metabolism, sensitive marker, 940(ab)
atypical dementia and comparison, FDG PET and MRI data, 965(ab)
cerebral perfusion abnormalities, SPECT, 973(ab)
cognitive and pharmacological challenges, brain disease detection, 1019(ab)
cortical perfusion deficit, demographic and cognitive variables, 940(ab)
delayed SPECT and regional cerebral blood

- flow, I-123 IMP, 1015(ab)
 diagnostic accuracy of SPECT, 1019(ab)
 differential diagnosis of dementia, cerebral blood flow, SPECT and MRI, 1014(ab)
 evaluation of neural-network classifier, PET scans, 1459
 functional brain SPECT, powerful clinical method, 1888
 hippocampal blood flow, SPECT, 940(ab)
 hypometabolic parietal cortex, unaltered benzodiazepine receptors, 887(ab)
 monoclonal antibody specific for β /A4 amyloid, angiopathy, brain, 2184
 patterns of dementia, 1431(le)
 scintigraphic appearance, Tc-99m HMPAO SPECT, 181, 312
- American College of Cardiology (ACC),**
 standardization, cardiac tomographic imaging, 1434
- American College of Nuclear Medicine (ACNM),**
 petition would ease strictures, outpatient nuclear medicine therapy, 13N(7)
- American College of Nuclear Physicians (ACNP)**
 budget testimony, 13N(6)
 government relations update, 30N(9)
 licensing decision, California radioactive waste site, 40N(9)
 SNM and, Medicare fee schedule, 18N(1)
- American Heart Association (AHA),**
 standardization, cardiac tomographic imaging, 1434
- American Medical Association (AMA),** revisions to RVU update, 36N(9)
- γ -Aminobutyric acid,** modulation of endogenous dopamine, acetylcholine release, PET, 847(ab)
- 1-Aminocyclobutane[C-11]carboxylic acid,** dynamic PET, 2-compartment model, brain tumors, 922(ab)
- Amino-dextran,** poly-lysine and, In-111 labeled MAB, 988(ab)
- Amygdala,** quantitation in PET, two-dimensional restoration filter, 921(ab)
- Amyloid**
 angiopathy, monoclonal antibody specific for β /A4 amyloid, Alzheimer's disease, 2184
 P-component, radiolabeling, kinetic and scintigraphic studies, 913(ab)
- Anatomy**
 cross-sectional, Macintosh tutorial, 1063(ab)
 radiologic, 1067(ab)
- Aneurysm**
 bleeding mycotic iliac, Tc-99m renal scan, 1548
 inflammatory abdominal aortic, In-111 imaging, 1553
 mycotic, diagnosis, leukocyte scintigraphy, 1486
- Angina**
 -like chest pain, abnormal esophageal motility, gastroesophageal reflux, 955(ab)
 unstable, In-111 antimyosin uptake, acute and remote myocardial infarction, 587
- Angiography**
 comparative study of Tl-201, CT/MRI, bone and soft tissue sarcoma, 843(ab)
 first-pass radionuclide
 exercise-induced myocardial ischemia, upright bicycle ergometry, 359
 ordinary gamma camera, computer program, 1064(ab)
 moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
 planar myocardial perfusion imaging, Tc-99m tebo, 1783
 pulmonary, intermediate probability/
 indeterminate lung scans, 849(ab)
 Tc-99m HMPAO, quantitative approach, brain, 877(ab)
- Angiography, radionuclide**
 first-pass, count-based ratio method, left ventricular volume, 2124
 left ventricular diastolic function, systemic sclerosis, 68
 SPECT myocardial perfusion and, Tc-99m MIBI, dipyridamole, 846(ab)
 Tc-99m in thrombosis detection, left atrial appendage, 365
- Angioplasty, cerebral,** delayed ischemia due to vasospasm, brain SPECT, 1789
- Angioplasty, percutaneous transluminal coronary**
 early thallium imaging, 866(ab)
 utility of Tc-99m SPECT, spontaneous chest pain, prediction of clinical improvement, 875(ab)
- Angiotensin converting enzyme,** renal functional response, captopril, diuretic therapy, 739
- Angiotensin II, receptor ligand,** distribution, imaging potential, 900(ab)
- Animal research**
 campaign against animal activists, engaging physicians, 24N(5)
 design feature and performance, PET system, 595
 thwarting attacks, 19N(2)
- Animals, small**
 scintillating fiber detector module, Cu-64 radiopharmaceuticals, PET, 1010(ab)
 SPECT imaging, 852(ab)
- Anti-antibody,** prospects and problems, radioimmunotherapy, 958(ab)
- Antibodies,** radioimmunoassay and cancer identification, 803
- Anticoagulants**
 platelet/fibrin deposition, coronary stents, minipig model, 845(ab)
 UltraTag RBC kit, 989(ab)
- Antimycin**
 cardiac transplantation rejection, primates, 1994
 imaging to detect tumor invasion, muscle layer, 841(ab)
 negatively charged-polymer-modified, infarct imaging, different cross-linkers, 959(ab)
- Antisense oligonucleotide,** In-111, direct method of cell-labeling, whole blood, 980(ab)
- Anti-thyroglobulin antibodies,** circulating, clinical meaning, differentiated thyroid neoplasms, 1478
- Aorta**
 abdominal, arterial input function determination, hepatic and renal PET studies, 613
 injured tissue, radioiodinated endothelin-1, cholesterol-fed rabbits, 845(ab)
- Aphasia**
 acute, Tc-99m HMPAO brain perfusion SPECT, 970(ab)
 childhood, regional cerebral perfusion, Landau-Kleffner syndrome, 1758
 progressive
 pathophysiological evaluation, PET, 1016(ab)
 PET and MRI, 857(ab)
- Arteriography,** contrast, peripheral vascular disease, 1797
- Arteriovenous malformations,** hepatic, embolization, hereditary hemorrhagic telangiectasia, 260
- Artery**
 carotid
 stenosis, cerebrovascular reserve capacity, 971(ab)
 Tc-99m HMPAO injection, recurrent glioma, 966(ab)
- carotid, external-to-internal, SPECT/MRI/angiography, moyamoya disease, 1692
 carotid, internal, occlusion, Tc-99m HMPAO evaluation of cerebral perfusion, 969(ab)
 cerebral, unilateral occlusive disorders, crossed cerebellar hypoperfusion, 1637
 changing the level of partial pressure, photic stimulation, carbon dioxide, 827(ab)
 coronary
 acute onset, cardiogenic shock, 1558
 bypass graft, C-VEST, 1914(le)
 bypass grafting, continuous ventricular function monitor with miniature cadmium telluride detector, 441
 cardiac perfusion abnormalities, Kawasaki syndrome, 929(ab)
 fibrin deposition following injury, I-125 fibrinogen, 845(ab)
 myocardial viability, status of collateral flow, 856(ab)
 occlusion, myocardial perfusion and ventricular function, 825(ab)
 coronary LAD
 imaging regional hypoxia, Tc-99m 2-nitroimidazole, 865(ab)
 misonidazole retention after occlusion, myocardial metabolism and blood flow, 993(ab)
 experimental wall injury, uptake, In-111 polyclonal IgG and I-125 LDL, 845(ab)
 iliac, stenosis, renal transplant hypertension, 1178
 patency, serial tomographic imaging, Tc-99m sestamibi, 2080
- renal
 segmental branch stenosis, captopril renography, 266
 stenosis, captopril renal scintigraphy, 2045
 stenosis, captopril-stimulated PRA, 907(ab)
 stenosis, cortical residual activity on captopril renography, 906(ab)
 stenosis, en-bloc pediatric renal transplant, 263
 stenosis, renal kinetics in transplants, 923(ab)
 stenosis, Tc-99m MAG₃ scintigraphy with captopril, 990(ab)
- Artifacts**
 nuclear medicine, 1068(ab)
 PET image reconstruction, 1069(ab)
- Ascites,** bile extravasation, hepatic transplantation, scintigraphy, 115
- Asphyxia,** perinatal, cerebral palsy, Tc-99m HMPAO SPECT, 977(ab)
- Assays,** robotic solid phase extraction, C-11 raclopride, plasma, 853(ab)
- Astrocytoma,** low grade and anaplastic, FDG PET brain imaging, 966(ab)
- Atelectasis,** infrequent chest X-ray finding, pulmonary embolism, 849(ab)
- Atherosclerosis**
 imaging lesions with monoclonal antibody Z2D3, antibody-avidin-biotin interactions, 934(ab)
 imaging with I-123 SP4, 845(ab)
 localization of lesions, class-switched monoclonal antibody Z2D3, 936(ab)
- Athletes,** myocyte damage, pathologic cardiac hypertrophy, In-111 antimyosin antibody, 994(ab)
- Atomic Energy of Canada, Ltd. (AECL),**
 threatened reactor worker strike, 19N(9)

Atrophy

Atrophy, multi-system, I-123 IBZM SPECT, 1018(ab)

Attenuation correction

accuracy of, PET, transmission processing, 862(ab)

breast tissue, myocardial imaging, 961(ab)
cardiac PET, three-dimensional registration, 881(ab)

comparison of left anterior oblique, geometric mean method, gastric emptying, 833(ab)
Cramer-Rao bound analysis of effects, feature size and activity estimation, SPECT, 962(ab)

effect on brain SPECT, 961(ab)
factors, Bremsstrahlung imaging, gamma camera, 161

non-uniform, emission and transmission noise propagation, cardiac SPECT, 902(ab)
of theoretical derivations, empirical evidence, 1578

scanning line source, simultaneous emission/transmission SPECT, 901(ab)
scatter and depth-dependent resolution, 180° myocardial SPECT, 842(ab)

scatter correction and, SPECT quantification, cardiac imaging, 2232

simultaneous transmission and emission, three-detector SPECT, 901(ab)

SPECT

dual-energy X-ray CT, 901(ab)

iterative methods, 962(ab)

use of map, simple method, 843(ab)

Tc-99m HMPAO SPECT brain imaging, 1875
Tl-201 SPECT, differential attenuation, thallium photons, 1574

volume imaging PET scanner, 862(ab)
whole body PET, 862(ab)

Autopsy, -diagnosed dementia, SPECT perfusion imaging, 939(ab)

Autoradiography

dual-isotope

computed radiography, 1005(ab)

Tc-99m sestamibi and Tl-201, uptake in rabbits, 993(ab)

electron microscopic, intracellular distribution of I-125 MIBG, neuroblastoma xenografts, 1021(ab)

heterogeneous activity distribution, In-111 radiopharmaceuticals, rat tissues, 1825
quantitative

CEA concentration measurement,

adenocarcinoma, 892(ab)

radiopharmaceutical uptake, dose heterogeneity, 1833

Avidin

-biotin, localization of infection, 1816

-biotin immunoscintigraphy, pharmacokinetics, biotin-chelate conjugates, 880(ab)

imaging atherosclerotic lesions, monoclonal antibody Z2D3, 934(ab)

kidney uptake, isoelectric point, 986(ab)

B

4-BACE, 4-ICE and, chelating agents, 985(ab)

Back

low pain

180° SPECT of the spine, 950(ab)

SPECT vs. planar bone scintigraphy, 868(ab)

zygopophyseal joint injection, SPECT and planar bone scintigraphy, 868(ab)

Barre-Liou syndrome, Tc-99m HMPAO SPECT, cervical manipulation, 972(ab)

Basal ganglia

quantification, reiterative reconstruction,

878(ab)

uptake, quantitation with SPECT, monkey brain phantom, 963(ab)

B-cells, anti-pan B-cell antibodies, I-131 radioimmunotherapy, B-cell lymphoma, 863(ab)

Behavior, obsessive-compulsive disorder, cerebral blood flow, defects demonstrated by three-dimensional SPECT, 838(ab)

Benperidol analogs, D-2 receptor-specific PET tracers, 848(ab)

Benzamides, substituted, superior PET ligand, cerebral dopamine D2 receptors, 847(ab)

Benzodiazepine

central type receptors in baboons, triazolam, PET, 973(ab)

medication, benzodiazepine receptor occupancy, SPECT, 887(ab)

Berson-Yalow Award, FDG uptake in tumors, 15N(7)

Bicycle ergometry, first-pass radionuclide angiography, exercise-induced myocardial ischemia, 359

Bile

extravasation in presence of ascites, hepatic transplantation, scintigraphy, 115

lakes in liver transplant infarcts, hepatobiliary scintigraphy, 997(ab)

Bile duct, clearance measured by radionuclide injection, endoscopic nasobiliary drainage tube, gallbladder stone, 997(ab)

Biliary atresia, diagnostic criteria, neonatal jaundice, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)

Biopsy, -confirmed residual Hodgkin's disease, mediastinum, Ga-67 SPECT, 345

Biotin

-avidin, localization of infection, 1816

-chelate conjugates, pharmacokinetics, pretargeted avidin-biotin

immunoscintigraphy, 880(ab)

conjugates, anti-pan-carcinoma NR-LU-10 monoclonal antibody, radioimmunotherapy, 880(ab)

conjugation of human immunoglobulin, dendrimers as linker molecules, inflammation detection, 986(ab)

-deferoxamine derivatives, plasma stability, pharmacokinetics, 880(ab)

derivatives, evaluation, Tc-99m, 920(ab)

imaging atherosclerotic lesions, monoclonal antibody Z2D3, 934(ab)

radiolabeled, imaging infection/inflammation, streptavidin, 924(ab)

streptavidin

localization of infection, 1810

and tumor localization, substitute for antibody, 934(ab)

Bis(dithiocarbamate)nitrido Tc(V), subcellular distribution, myocardium cells, male rats, 850(ab)

Blood

clot imaging, preparation and evaluation, I-123 hirulog, 981(ab)

continuous withdrawal and counting systems, factors affecting dispersion correction, 1010(ab)

myocardial extraction of teboroxime, 94

reinfusion, infection-control problems, nuclear medicine departments, 13N(4)

whole, direct method of cell-labeling, In-111 antisense oligonucleotide, 980(ab)

Blood-brain barrier

regional transport, glucose and

fluoro-deoxyglucose, 1819

transport of glucose and fluoro-deoxyglucose, regional variations, 908(ab)

Blood flow

bone, influx rate, F-18 PET, 937(ab)

brain

high-resolution I-125 imaging, plastic scintillation detectors, 1003(ab)

interventional neuroradiology, SPECT, 826(ab)

cerebral

brain maturation, children and adolescents, 696

brain perfusion Tc-99m ECD SPECT, PET comparison, 966(ab)

brain tumors and strokes, HMPAO-SPECT and MRI technique, 971(ab)

brain tumors and strokes, Tc-99m HMPAO SPECT, 971(ab)

dementia, differential diagnosis, 1014(ab)
dementia, Parkinson's disease, 1012(ab)

Down's syndrome, Tc-99m HMPAO brain SPECT, 1013(ab)

glucose metabolism, patient surviving after CO intoxication, 1696

hyperventilation, temporal lobe epilepsy, 968(ab)

I-123 IMP SPECT, no arterial sampling, 969(ab)

impairment in myotonic dystrophy, 839(ab)
improvement with treatment, chronic cocaine

polydrug users, 887(ab)

infantile spasms, 1018(ab)

linearization algorithm, Tc-99m HMPAO SPECT, 912(ab)

mapping of, 1843

mean transit time, index of organ perfusion, 1004(ab)

N-isopropyl-[I-123]IMP SPECT, 1741

N-isopropyl-(I-123) p-iodoamphetamine, SPECT, 965(ab)

obsessive-compulsive disorder, defects demonstrated by three-dimensional SPECT, 838(ab)

partition coefficient, I-123 IMP SPECT and O-15 water PET, 911(ab)

partition coefficient, I-123 IMP SPECT, 911(ab)

photic stimulation study, arterial partial pressure of carbon dioxide, 827(ab)

predetermined ROIs, Xe-133 SPECT in children, 977(ab)

regional variation in statistical maps, 1008(ab)
rotating gamma camera, I-123 IMP, 963(ab)

simultaneous SPECT acquisitions, glucose metabolism, 965(ab)

Tc-99m HMPAO and I-123 IMP, SPECT and MRI, 1012(ab)

Tc-99m HMPAO brain SPECT, choreo-athetoid syndrome, 838(ab)

Tc-99m HMPAO brain SPECT, variability, 826(ab)

Tc-99m HMPAO SPECT, chronic subdural hematoma, 246

Tc-99m HMPAO SPECT, Wisconsin card sorting test, 967(ab)

coronary, uptake of tetrofosmin, rabbit heart, 846(ab)

flow reserve measurements and, viable and non-viable myocardium, 856(ab)

global cerebral, Tc-99m ECD and planar imaging, Rhesus monkeys, 979(ab)

hepatic arterial-to-portal venous, ratio, radionuclide techniques in an animal

- model, 239
- hippocampal, diagnosis of Alzheimer's disease, SPECT, 940(ab)
- MIBG heart and lung extraction fraction, first-pass analysis, 716
- myocardial
- co-injection technique, 1152
 - deoxyglucose uptake, myocyte viability in ischemia, 1353
 - expected variability, anesthetized canine, 884(ab)
 - glucose uptake in ischemic myocardium, F-18 deoxyglucose, 1346
 - methods for quantification, N-13 ammonia PET, 881(ab)
 - misonidazole retention, occlusion of LAD coronary artery, 993(ab)
 - perfusion, Tc-99m tetrofosmin, 993(ab)
 - polar map displays, cardiac PET, 1628
 - quantification, 172(le)
 - Tc-99m Q12 activity, canine heart, 993(ab)
- penile, tumescence, dual-radioisotopic technique, 41
- portal venous, pulsed Doppler and per-jejunum scintigraphy, liver cirrhosis, 997(ab)
- pulmonary, protein flux measurements, PET, 1661
- regional cerebral, 14N(8)
- renal, convection-diffusion model, 949(ab)
- stroke, clinical prognosis, SPECT, 878(ab)
- tumor, breast cancer, before and after treatment, 1020(ab)
- unilateral major cerebral artery occlusive disorders, crossed cerebellar hypoperfusion, 1637
- variations, N-13 ammonia, lack of correlation with other methods, 837(ab)
- Blood pool imaging, spillover, method for correction, dynamic cardiac FDG PET, 882(ab)**
- Blue Cross/Blue Shield, approval of neurological indications for PET, 40N(11)**
- Bone**
- benign and malignant lesions, Tc-99m MIBI uptake, Tc-99m MDP, 319
 - blood flow and influx rate, F-18 PET, 937(ab)
 - diagnosis of femoral head avascular necrosis, triple-head high-resolution SPECT, 936(ab)
 - dual bone and WBC scan imaging, osteomyelitis and cellulitis, planar and SPECT imaging, 839(ab)
 - extraosseous Tc-MDP uptake, pathophysiologic approach, 1063(ab)
 - formation, radiotherapy and, 1780
 - fracture, accumulation of F-18 FDG, Tc-99m MDP, 869(ab)
 - joint inflammation
 - Tc-99m HIG, 839(ab)
 - Tc-99m HIG, rheumatoid arthritis, 840(ab)
 - lesions, Tl-201 uptake pattern, 869(ab)
 - mass, optimization, follow-up measurements, 1406
 - metabolism, local and systemic effects of radiation, quantitative SPECT, 1774
 - metastases, pharmacokinetics, Re-186 after Re-186-HEDP, 646
 - metastases of prostate carcinoma, strontium-89, low-dose infusion cisplatin, 1437
 - metastatic cancer, escalating dose schedule, Sm-153 EDTMP, 1451
 - metastatic disease, multidose Sm-153 EDTMP, pain palliation, 992(ab)
 - mineral and body composition, dual energy X-ray absorptiometry, fan-beam design, 1063(ab)
 - mineral assessment, forearm, 1251(le)
 - mineral content and density, healthy twelve-year-old white females, 1143
 - mineral density
 - axial skeleton, acromegaly, 1608
 - dual-energy X-ray absorptiometry, skeletal sites, 1137
 - influence of parathyroidectomy, 869(ab)
 - predictor for osteoporosis, risk factor assessment, 869(ab)
 - mineral density and spine fracture, cyclic oral phosphate, etidronate, 1
 - pain, prostate carcinoma, Re-186 HEDP, 859(ab)
 - pain from metastases, different therapeutic doses, Sr-89, 937(ab)
 - planar scintigraphy and SPECT, zygapophyseal joint injection, chronic low back pain, 868(ab)
 - radionuclide scan
 - MRI imaging, detection of spinal metastases, 992(ab)
 - osteoid osteoma, 269
 - scan
 - chest X-rays and I-131 scans, well-differentiated thyroid cancer, 894(ab)
 - skeletal nonvisualization, intravenous etidronate therapy, 748
 - scintigraphy
 - intravenous pamidronate, Paget's disease, 1589
 - SPECT, low back pain, 868(ab)
 - Tc-99m MDP abdominal uptake, continuous ambulatory dialysis, 2052
 - scintigraphy and I-131 MIBG, detection of neuroblastoma, 1735
 - scintigraphy in preschool children, lower extremity pain of unknown origin, 351
 - seeking agents, comparison, mechanistic implications, 899(ab)
 - skeletal kinetics, F-18 fluoride ion PET, 633
 - soft tissue sarcoma and, Tl-201 scan patterns, 843(ab)
 - 180° SPECT of the spine, patients with LBP, 950(ab)
 - stress fractures, osteosarcoma, lower limb, 1699
 - subchondral infarctions, acute ligamentous knee injuries, scintigraphy and MRI, 516
 - suspected infections, Tc-99m anti-granulocyte antibodies, 526
 - to-marrow interface
 - calculation of radiation dose, 1915(le)
 - radiation dose calculation, Monte Carlo modeling, 623
- Bone marrow**
- body and blood clearance, I-131 Lym-1, B-cell malignancies, 941(ab)
 - hypermetabolic, Tl-201-chloride uptake, granulocyte stimulating factor, 2014
 - macro- and microscopic biodistribution, In-111, rats, 954(ab)
 - MRI and scintigraphy, staging, breast cancer, 914(ab)
 - radiation absorbed dose estimation, I-131 radioimmunotherapy, leukemia, 941(ab)
 - scintigraphic changes, hormonal changes, 1427(le)
 - suppression induced by I-131 monoclonal antibody therapy, recombinant G-CSF, 933(ab)
 - toxicity of I-131 monoclonal antibody fragments, 941(ab)
 - value of scanning, possible orthopedic infections, 840(ab)
- Book reviews**
- Biochemistry of Ionizing Radiation*, 1725
 - Computed Tomography and Magnetic Resonance of the Thorax*, 470
 - Future of Human Radiation Research. The, 821*
 - Guidelines for the Evaluation of Radiologic Technologies, BIR Working Party Report*, 819
 - Handbook of Nuclear Medicine: Volume 2: Heart*, 1918
 - ICRP Publication 60, 1990 Recommendations of the International Commission on Radiological Protection*, 821
 - Imaging of the Thyroid and Parathyroid Glands*, 820
 - Interventional Computed Tomography*, 179
 - Medical Radiation Protection Practice Within the EEC*, 820
 - Musculoskeletal Imaging: MRI, CT, Nuclear Medicine and Ultrasound in Clinical Practice*, 1254
 - NCRP REPORT No. 110, Some Aspects of Strontium Radiobiology*, 819
 - Nuclear Hepatology*, 1254
 - Nuclear Medicine: A Teaching File*, 1918
 - Nuclear Medicine in Gastroenterology*, 470
 - Radiation and Thyroid*, 179
 - Safe Use of Diagnostic Ultrasound. The, 820*
 - Selected Atlases of Gastrointestinal Scintigraphy*, 1254
 - Textbook of Radiopharmacy: Theory and Practice*, 819
- Brain**
- accuracy of perfusion SPECT, differential diagnosis, dementia, 1017(ab)
 - adult mouse, activity-related plasticity, benzodiazepine receptors, 883(ab)
 - alcohol intoxication, cocaine distribution and kinetics, 946(ab)
 - altered tritiated nicotine accumulation, senescence accelerated mouse, 1023(ab)
 - arrival delay of O-15 tracers, intravascular radioactivity, 909(ab)
 - auditory cognitive task, event-related potentials, O-15 water PET, 1016(ab)
 - benzodiazepine receptors, C-11 flumazenil PET, 1011(ab)
 - biodistribution and monkey PET imaging, C-11 tetrabenazine, monoaminergic neurons, 870(ab)
 - blood flow, interventional neuroradiology, SPECT, 826(ab)
 - blood flow and high-resolution I-125 imaging, plastic scintillation detectors, position-sensitive photomultipliers, 1003(ab)
 - C-11 cocaine, distribution and kinetics, 521
 - cerebral blood flow, glucose metabolism, patient surviving after CO intoxication, 1696
 - cerebral cortical activity, Tc-99m HMPAO, scintigraphy, 117
 - cerebral dopamine D2 receptors, superior PET ligand, 847(ab)
 - cerebral glucose uptake, hyperglycemia, 1-(C-11) D-glucose, 908(ab)
 - cerebral language area, O-15 water PET, 2D brain surface map, 857(ab)
 - cerebral metabolism
 - epilepsy and disease duration, PET, 1018(ab)
 - standardized approach, controlled behavioral conditions, 1011(ab)
 - cerebral perfusion
 - abnormalities, SPECT and Alzheimer's disease, 973(ab)

- imaging in AIDS, 827(ab)
 progressive supranuclear palsy, 704
 Tc-99m HMPAO, internal carotid artery occlusion, 969(ab)
- cerebrovascular reserve capacity, stenosis of carotid artery, thrombendarterectomy, 971(ab)
- cerebrovascular response to acetazolamide, Tc-99m DTPA-HSA, new method for monitoring, 969(ab)
- cerebrum and cerebellum, carbon dioxide reactivity, Tc-99m HMPAO SPECT, 1014(ab)
- chronic subdural hematoma, cerebral blood flow, Tc-99m HMPAO SPECT, 246
- clinical neurological PET, interactive computer-based atlas, 1071(ab)
- cortical areas, visual imagery of reading, PET study with O-15 butanol, 908(ab)
- crossed cerebellar diaschisis, cerebral infarction, 877(ab)
- crossed cerebellar hypoperfusion, unilateral major cerebral artery occlusive disorders, 1637
- cylindrical SPECT system, McSPECT prototype, 852(ab)
- death
 assessment, Tc-99m CEROTEC scan, 970(ab)
 comparative study, TcGH and TcHMPAO, 1016(ab)
 diagnostic dilemma, 2211
 timely declaration, Tc-99m HMPAO cerebral perfusion scintigraphy, 2209
- decreased binding of C-11 cocaine, cocaine addicts, 888(ab)
- decreased glucose metabolism, Cushing disease, FDG PET, 834(ab)
- developmental cognitive disorders, F-18 FDG PET, 973(ab)
- disease detection, cognitive and pharmacological challenges, 1019(ab)
- dopamine changes in cocaine abusers, 887(ab)
- dual-isotope brain SPECT, Tc-99m and I-123, 2030
- dual-isotope imaging in normal volunteers, Tc-99m HMPAO, I-123 IMP, 827(ab)
- dual-isotope SPECT, headtome set 031, phantom study, 1017(ab)
- examination of visual mental imagery with PET, 908(ab)
- F-18 DOPA uptake, delayed L-phenylalanine infusion, 1383
- F-18 FDG PET and MRI anatomy, registered atlas, 1071(ab)
- F-18 4-fluoro-4-deoxy-D-glucose imaging agent, 983(ab)
- feasibility of cortical activation study, sequential Tc-99m HMPAO SPECT, subtraction method, 1015(ab)
- functional, SPECT, powerful clinical method, 1888
- functional and structural deficits, young alcoholics, PET and MRI, 1070(ab)
- functional scans, evidence in criminal court, 18N(6)
- glucose metabolic rates, 30- and 45-minute acquisitions, 2103
- glucose metabolism, sensitive marker, Alzheimer's disease, 940(ab)
- grammatical and semantic components, sentence comprehension, PET activation study, 1012(ab)
- hippocampal blood flow, diagnosis of Alzheimer's disease, SPECT, 940(ab)
- hypometabolic parietal cortex, unaltered benzodiazepine receptors, Alzheimer's disease, 887(ab)
- imaging of subdural hematoma, current role of SPECT, 248
- I-131 MIBG approval, 33N(9)
- immature third ventricle teratoma, radiographic and neuro-SPECT imaging, 435
- improved SPECT, maximum-likelihood reconstruction, 964(ab)
- independent aura/ictal/interictal cerebral perfusion, 438
- interictal cerebral glucose metabolism, spontaneously epileptic rat, 1024(ab)
- intracranial abscess, differential diagnosis, Tc-99m antigranulocyte antibody, 957(ab)
- kinetic behavior, Tc-99m HMPAO SPECT, 135
- left premotor cortex specialization, finger movements, FDG PET, 857(ab)
- living human; C-11 WIN 35,428; dopamine transporter site, 964(ab)
- low grade and anaplastic astrocytomas, FDG PET, 966(ab)
- maturation in children and adolescents, changes, regional cerebral blood flow, 696
- model-based quantitation, knowledge-based factor analysis, 947(ab)
- monoclonal antibody specific for β /A4 amyloid, Alzheimer's disease, angiopathy, 2184
- neoplasms, *see* Brain neoplasms
- neural crest tumors, I-123 MIBG, 1072(ab)
- neuroma, PET-fluorodeoxyglucose, 1931
- nigrostriatal function in FDOPA PET studies, ratio method and graphical analyses, 945(ab)
- non-human primate, monoamine transporter sites, I-123 CIT SPECT, 945(ab)
- perfusion pattern in late life depression, 838(ab)
- perfusion SPECT, cocaine abuse, AIDS dementia complex, 887(ab), 1312
- perfusion SPECT with Tc-99m ECD, regional cerebral blood flow, PET comparison, 966(ab)
- PET
 automated stereotactic transformation, 1007(ab)
 MR images and, accuracy of surface fit registration, 921(ab)
 use of linear programming, glucose utilization, 944(ab)
- phantom design for computer simulation, image reconstruction algorithms, physiologic models, 1012(ab)
- quantification of human basal ganglia, iterative reconstruction, 878(ab)
- quantitation of basal ganglia uptake, SPECT, monkey brain phantom, 963(ab)
- rapid registration and review, MR, CT and SPECT, 1067(ab)
- regional cerebral perfusion
 Landau-Kleffner syndrome, related childhood aphasia, 1758
 preclinical studies, Tc-99m T691, 1836
- regional cerebral uptake, Tc-99m exametazine, unilateral voluntary hand movement, 1623
- retention of Tc-99m bicisate, effect of radiolabeled impurities, dosimetry, 989(ab)
- same living human, dopamine receptor density, C-11 raclopride and NMSP, 847(ab)
- somatosensory stimulation in thalamic lesions, O-15 water PET, 858(ab)
- SPECT
 attenuation effect, 961(ab)
 cerebral angioplasty, delayed ischemia due to vasospasm, 1789
- D-2 dopamine receptors, 2'-iodospiperone, 897(ab)
- dual radionuclide data acquisition, Tc-99m and I-123, 972(ab)
- extracorporeal membrane oxygenation, neonates, 1943
- multimedia multimodality interactive computer tutorial, 1071(ab)
- relative error-estimation, regional analysis, 969(ab)
- transcranial Doppler, acute ischemic stroke therapy, 968(ab)
- SPECT grey matter imaging, iterative reconstruction algorithm, 1225
- stereotactic biopsy, PET-defined targets, 868(ab)
- stereotactic metabolic atlas, functional brain imaging, 858(ab)
- stimulated auditory cortex, proton NMR spectroscopy, 974(ab)
- striatal FDOPA uptake, cerebral glucose metabolism, patients with chorea, 1015(ab)
- surgery and irradiation, TI-201 imaging, quantification using an animal model, 964(ab)
- synthesis, isomers of Tc-99m ECD, monkeys, 979(ab)
- Tc-99m, elimination of chiral centers, coordination sphere, 920(ab)
- Tc-99m HMPAO
 angiography, quantitative approach, 877(ab)
 high-resolution SPECT, neurofocal imaging, 1070(ab)
- Tc-99m HMPAO SPECT
 bilateral and symmetrical anomalies, 485
 cerebral blood flow, choreo-athetoid syndrome, 838(ab)
 rCBF variability, 826(ab)
 regional cerebral blood flow, Down's syndrome, 1013(ab)
- temporal lobe metabolism, refractory epilepsy, asymmetry in FDG PET scans, 928(ab)
- three-dimensional functional images, automated method, rotational correction, 1579
- three-dimensional images, automated method, anatomical standardization, 1003(ab)
- TI-201 SPECT, re-evaluation for brain tumor, 844(ab)
- traumatic injury
 remote history of, Tc-99m HMPAO SPECT, 52
 skeletal screening, children, 873(ab)
 tumor marker, [^{11}C]putrescine, 192, 200
 uptake of 6-[F-18] FDOPA, 916(ab)
- Brain neoplasms**
 childhood, Tc-99m MIBI/TI-201 SPECT, 844(ab)
 comparison of kinetics, Tc-99m ECD and Tc-99m HMPAO, SPECT and compartment model, 969(ab)
 dynamic PET, 1-aminocyclobutane[C-11] carboxylic acid, 2-compartment model, 922(ab)
 FDG studies, PET resolution, visual interpretation, 872(ab)
 primary, MRI and PET studies, 867(ab)
 recurrence
 TI-201 and Tc-99m MIBI MRI, 867(ab)
 TI-201 SPECT studies, 867(ab)
 recurrent primary, TI-201 SPECT, 1071(ab)
 recurrent supratentorial and infratentorial, TI-201 SPECT and F-18 FDG PET, MRI, 867(ab)
 strokes and, cerebral blood flow, HMPAO-

- SPECT and MRI technique, 971(ab)
therapy, F-18 FDG PET, 1071(ab)
- Breast**, tissue attenuation, myocardial imaging, 961(ab)
- Breast neoplasms**
autogenous reconstruction, transverse rectus abdominus myocutaneous flap, Tc-99m dextran lymphoscintigraphy, 859(ab)
before and after treatment, tumor blood flow, 1020(ab)
c-erbB2 protein overexpression, I-124 monoclonal antibodies, PET, 2154
labeled BC-2 monoclonal antibody, 999(ab)
locoregionally advanced, preoperative chemotherapy, F-18 FDG-PET, 828(ab)
metastatic
clinical value, CA 15-3 plasma levels, 854(ab)
radioimmunotherapy, 862(ab)
prognosis, internal mammary lymphoscintigraphy, 859(ab)
quantitative dynamic and whole body FDG PET, 828(ab)
radioimmunolocalization, In-111 BrE-3 antibody, Phase I study, 912(ab)
radiolabeled antibodies, oncogene-encoded molecules, tumor imaging and therapy, 2160
staging, MRI and scintigraphy, bone marrow, 914(ab)
- Bremsstrahlung**, imaging using gamma camera, factors affecting attenuation, 161
- Bronchoalveolar lavage**, pulmonary disposition of Ga-67, *Pneumocystis* pneumonia, 512
- Budd-Chiari syndrome**
hepatic necrosis, Tc-99m medronate, 1390
monitoring by I-123 iodoamphetamine scintigraphy, *per os* and *per rectum*, 744
- C
- CA 15-3, clinical value of plasma levels, follow-up, metastatic breast cancer, 854(ab)
- CA 125
human/mouse chimeric monoclonal antibody, ovarian cancer radioimmunotherapy, 1001(ab)
Tc-99m monoclonal antibody, early detection, ovarian cancer recurrences, 904(ab)
- Caffeine**, serum levels following 24-hr abstinence, myocardial perfusion, dipyrindamole or adenosine, 866(ab)
- Calcium carbonate**, cyclic oral phosphate and etidronate, bone mineral density, spine fracture, 1
- California**, radioactive waste site, licensing decision, 40N(9)
- Camera**: *see also* Gamma camera
-based method, calculation, Tc-99m MAG₃ clearance, 948(ab)
major changes in nuclear cardiovascular codes, 19N(1)
multicrystal scintillation, single radiopharmaceutical, left ventricular perfusion and performance, 1411
- Cancer**
CEA-producing, radioimmunodetection, 1750
clinical applications of PET, 330
imaging with two diastereomers, octreoscan-111, 900(ab)
methods and performance characteristics, whole-body PET, 1191
radioimmunotherapy, 1110
therapy, absorbed dose calculations, rapidly growing tumors, 277
- Captopril**
diuretic therapy, renal functional response, 739
-enhanced scintigraphy, renal artery stenosis, en-bloc pediatric renal transplant, 263
-mediated hemodynamic changes, renal ischemia, 907(ab)
renal scintigraphy
distinguishing functional from anatomic renal artery stenosis, 2045
prognostic value, renovascular hypertension, 2040
unexpected pressor responses, 906(ab)
vs. captopril test, renovascular hypertension, 907(ab)
renography
cortical residual activity, renal artery stenosis, 906(ab)
segmental branch renal artery stenosis, 266
-stimulated PRA, bilateral renal artery stenosis, 907(ab)
Tc-99m MAG₃ scintigraphy, renal artery stenosis, 990(ab)
- CARBIDOPA**
FDOPA PET studies, nigrostriatal function, ratio method and graphical analyses, 945(ab)
6-[¹⁸F]fluoro-L-dopa kinetics, PET, 1472
- Carbohydrate**, modification, localization of human polyclonal IgG, sites of bacterial infection, 1378
- Carbon-11**
alkylations, radiochemistry, microwave fields, 1026(ab)
contribution to PET imaging, labeled carbon dioxide, 581
incorrectly labeled reagent, 465(le)
- Carbon-11 1,2-diaclyglycerols**, membrane trapping, phosphatidylinositol turnover, neurotransmission process, 413
- Carbon-11 acetate**
accelerated clearance, PET ischemic segments, 856(ab)
PET
compared with F-18 FDG, recovery after revascularization, 855(ab)
oxidative metabolism, infarcted and periinfarcted myocardium, 953(ab)
- Carbon-11 carazolol**, PET, evaluation in pigs, 885(ab)
- Carbon-11 carfentanil**, PET, effect of nitrous oxide, endogenous opiate system, 883(ab)
- Carbon-11 CFT**, dopamine fiber loss in Parkinsonism, 946(ab)
- Carbon-11 CGP 12177**, PET, mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
- Carbon-11 cocaine**
decreased binding in brain, cocaine addicts, 888(ab)
distribution and kinetics, PET, human body, 521
- Carbon-11 doxepin**, C-11 pyrilamine and, imaging of H1 histamine receptors, heart, 885(ab)
- Carbon-11 FLB 457**, preparation of, 860(ab)
- Carbon-11 flumazenil**
binding to benzodiazepine receptors, chronic alcohol-dependent men, PET and MRI, 1016(ab)
PET, benzodiazepine receptors, human brain homogenates, 1011(ab)
- Carbon-11 forskolin**, potentiality for imaging, cAMP-related second messenger system, 1025(ab)
- Carbon-11 D-glucose**, cerebral glucose uptake, hyperglycemia, 908(ab)
- Carbon-11 HED**
kinetics in rat heart, 870(ab)
PET, localization of pheochromocytoma, 1125
- trans-Carbon-11 McN-5652**, PET, serotonin uptake sites, 860(ab)
- Carbon-11 methionine**, PET, effective method, imaging of head and neck cancer, 691
- Carbon-11 methylaltanserin**, C-11 methylketanserin and, mapping serotonin receptors, 1026(ab)
- 2-Carbon-11 methyl-amino-2-methyl-3-phenyl-1-propanol**, PET, serotonin uptake sites, 861(ab)
- Carbon-11 MK-912**, compared to C-11 WY 26703, *alpha-2* adrenoceptor ligands, 861(ab)
- Carbon-11 monoxide**, ECG gated PET, "background" question, planar Tc-99m gated blood-pool imaging, 938(ab)
- Carbon-11 NMPB**, tracer kinetic analysis, binding, muscarinic cholinergic receptors, 882(ab)
- Carbon-11 NMSP**, PET, D-2 dopamine receptor densities, 848(ab)
- Carbon-11 NNC 722**, potential radioligand, dopamine uptake system, 931(ab)
- Carbon-11 putrescine**
brain tumor, 200
usefulness as brain tumor marker, 192
- Carbon-11 pyrilamine**
C-11 doxepin and, imaging of H1 histamine receptors, heart, 885(ab)
distribution, H1 receptor blocking drugs, 968(ab)
- Carbon-11 raclopride**
NMSP and, dopamine receptor density, same living human brain, 847(ab)
plasma, robotic solid phase extraction assay, 853(ab)
- Carbon-11 RO 15-4513**, visualization of benzodiazepine receptor binding, 860(ab)
- Carbon-11 SAH**
PET
myocardial energy balance, 2144
regional cardiac adenosine, 2138
- Carbon-11 tetrabenazine**
PET
brain biodistribution, monoaminergic neurons, 870(ab)
monoamine terminals, 983(ab)
synthesis, PET imaging, monoamine terminals, 983(ab)
- Carbon-11 thymidine**, PET, kinetic modeling, DNA synthesis, 1009(ab)
- Carbon-11 2 α -tropanyl benzilate**, synthesis and biodistribution, muscarinic receptor imaging agent, 423
- Carbon-11 tyrosine**, PET, radiation-induced inhibition, tumor growth, 373
- Carbon-11 WIN 35,428**, imaging of dopamine transporter site, living human brain, 964(ab)
- Carbon-11 YM-09151-2**, specific and non-specific binding, age dependency, dopamine D-2 receptors, 897(ab)
- Carbon dioxide**
arterial partial pressure, photic stimulation study, 827(ab)
labeled
contribution to PET imaging, C-11 labeled compounds, 581
transient metabolite, 585
reactivity in cerebrum and cerebellum, Tc-99m HMPAO SPECT, 1014(ab)

Carbon monoxide

Carbon monoxide, intoxication, cerebral blood flow and glucose metabolism, 1696

2 β -Carboxymethoxy-3 β -(4-chlorophenyl)-8-(3E- and 3Z-iodopropen-2-yl)nortropans, radioiodinated, cocaine receptor site mapping, SPECT, 890(ab)

Carcinoembryonic antigen

clinical value of CA 15-3 plasma levels, metastatic breast cancer, 854(ab)
concentration measurement, adenocarcinoma, quantitative autoradiography, 892(ab)
content, role in gastrointestinal tumor targeting, Tc-99m F023C5 anti-CEA IgG1, 892(ab)
In-111 anti-CEA-F(ab')₂ fragments, radiation dosimetry, tissue distribution in rats, 1654
monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, colon carcinoma immunoscintigraphy, 1766
-producing cancer, radioimmunodetection, 1750
second generation high-affinity anti-CEA monoclonal antibody, 904(ab)

Carcinoid neoplasms

metastatic, scintigraphic comparison, I-123 MIBG and I-123 TOCT, 1121
somatostatin analog, 914(ab)

Carcinoid syndrome, I-131 MIBG therapy, 834(ab)

Carcinoma, breast, radioimmunodetection, 803

Carcinoma, colonic, immunoscintigraphy, monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, 1766

Carcinoma, colorectal

efficacy and safety, In-111 IVP ZCE 025 monoclonal antibody, 959(ab)
immunoscintigraphy, Loch Ness monster and, 1756
improved demarcation of tumors, dual isotope SPECT immunoscintigraphy, 1000(ab)
metastases detection, In-111 C110 anti-CEA monoclonal antibody, CT, 904(ab)
metastatic, Phase I trial, I-131 chimeric B72.3, 23
pharmacokinetics of In-111 B72.3 monoclonal antibody, 498
pre-operative staging, F-18 FDG PET, 975(ab)
radioimmunodetection, 803
safety and role, In-111 anti-CEA monoclonal antibody ZCE 025, 14

Carcinoma, epidermoid, xenografts, biodistribution, In-111 B3 monoclonal antibody, 842(ab)

Carcinoma, hepatocellular, high-dose targeted irradiation, I-131 lipiodol, 1020(ab)

Carcinoma, ovarian

immunoscintigraphy, I-131 labeled 145-9 monoclonal antibody, 905(ab)
radioimmunodetection, 803

Carcinoma, papillary, thyroidectomy, pelvic radioiodine uptake, rectal wall teratoma, 1848

Carcinoma, prostatic

marrow scintigraphic changes, hormonal therapy, 1427(le)
metastatic
preoperative identification, In-111 CYT-356, 1001(ab)
Sr-89 radiotherapy, 1316
metastatic to bone, strontium-89, low-dose infusion cisplatin, 1437
Re-186 HEDP, bone pain treatment, 859(ab)

Carcinoma, renal cell, radioimmunoscintigraphy, I-131 monoclonal antibody, 913(ab)

Carcinoma, squamous cell, head and neck, radiation-induced response, FDG PET, 829(ab)

Carcinoma, thyroid

autonomously functioning, euthyroid Graves' disease, 2024
detection of metastases, Tc-99m TBI scintigraphy, 914(ab)
differentiated
contribution of Tl-201 scan, 955(ab)
follow-up, Tc-99m MIBI and Tl-201 chloride, 844(ab)
I-123, scintigraphic follow-up, 1020(ab)
Hurthle cell, Tc-99m sestamibi uptake, 1393
I-131 therapy, complications, sequela and dosimetry, 2214
I-131 whole-body scan, replacement with thyroglobulin measurement, 172(le)
two-step immunoscintigraphy, anti-CEA/anti-DTPA bispecific monoclonal antibody, In-111 DTPA dimers, 912(ab)

Carcinoma, thyroid medullary, facile synthesis of Re-188-labeled R_c(V)-DMSA, triphenylphosphine reduction, perrhenate at room temperature, 1024(ab)

Cardiolite, vials and microwave boiling procedure, 468(le)

Cardiology

nuclear probes, 448
second Sino-American nuclear medicine conference, 16N(4)

Cardiomyopathy

Adriamycin
disturbed neuronal energy metabolism, 935(ab)
myocardial damage, In-111 antimyosin antibody, 936(ab)
prediction of congestive heart failure, I-125 MIBG, 935(ab)
Adriamycin-induced, abnormal cardiac adrenergic neuron activity, I-125 MIBG, 208
congestive, Adriamycin, I-125 MIBG, 215
hypertrophic
BMIPP, 1914(le)
myocardial emission computed tomography, 6
idiopathic, mechanisms of down-regulation, C-11 CGP 12177 PET and MIBG imaging, 896(ab)

Cardiotoxicity, Adriamycin, Tc-99m sestamibi, chick heart cells, 864(ab)

Cardiovascular system, major changes in CPT code, 19N(1)

Carditis, rheumatic fever, importance, scintigraphic diagnosis, 995(ab)

Catecholamines

C-11 cocaine, distribution and kinetics, human body, 521
serial measurements of cardiac volumes, count-based methods, 1324

Cations, organic, labeling with Tc-99m, synthesis and renal excretion, 2190

Cellulitis, osteomyelitis and, dual bone and WBC scan imaging, planar and SPECT imaging, 839(ab)

Cellulose, -acetate hemodialyzer, comparative thrombogenicity, 956(ab)

Central nervous system

infectious or malignant lesions, differentiation with FDG PET, AIDS, 838(ab)
primary, lymphoma, F-18 fluorodeoxyglucose PET, 532

Cerebellum, dissociated postnatal rat, uptake mechanisms, Tc-99m d.L-HMPAO, 108

Cerebral palsy, children, quantitative perfusion-defect indexes, Tc-99m HMPAO SPECT,

977(ab)

Cerebrovascular disease, acetazolamide Tc-99m HMPAO SPECT study with PET, 877(ab)

Cesium-137, myth-making at Hanford, 19N(7)
CGP-12177, CGP-26505 and, characterization, β -adrenergic receptors, 870(ab)

Chelating agents

alkylamine conjugation chemistry, labeling of antibodies, 986(ab)
bifunctional, copper-67, 942(ab)
-biotin conjugates, pharmacokinetics, pretargeted avidin-biotin immunoscintigraphy, 880(ab)
comparison of Tc-99m direct vs. N2S2 chelate, labeled NR-LU-10 Fab', tumored nude mice, 909(ab)
4-ICE and 4-BACE, 985(ab)
In-111 BAD-Lym-1, radiochemistry and pharmacokinetics, 1030(ab)
In-111 cyclohexyl EDTA, anti-CEA F(ab')₂ monoclonal antibody, human tumor xenografted nude mice, 943(ab)
methylene bridged phosphineoxide-phosphine, Re-188, 979(ab)
Pd-109, bioconjugates and, 987(ab)
phosphorus hydrazide, bifunctional frameworks, Tc-99m and Re-188, 910(ab)
radiolabeling, antibody-macrocytic chelate conjugates, 1031(ab)
Re-186 direct vs. chelate labeled NR-LU-10 mAb, tumored nude mice, 910(ab)
rigidity and denticity, biodistribution, Y-88 and Pb-203 labeled immunoconjugates, 1030(ab)
structure, In-111 labeled Ab-chelator, liver, 1001(ab)

Chemistry, targeted proteins for diagnostic imaging, 394

Chemotactic peptides, Tc-99m hydrazino nicotinamide, imaging focal sites of infection, 910(ab)

Chemotherapy

early detection of impact, F-18 FDG scintigraphy, malignant lymphoma, 858(ab)
enhanced fluorodeoxyglucose uptake, metabolic design, combination therapy, 1981
-induced kidney disorder, antimyosin antibody uptake, 309(le)
intrarterial carotid artery injection, Tc-99m HMPAO, recurrent glioma, 966(ab)
preoperative, F-18 FDG PET evaluation, locoregionally advanced breast cancer, 828(ab)

Chernobyl, surprise findings of thyroid cancer, 23N(11)

Chest, FDG PET imaging, 975(ab)

Chest pain

acute, myocardial reperfusion imaging, Tc-99m sestamibi, 876(ab)
angina-like, abnormal esophageal motility, gastroesophageal reflux, 955(ab)
spontaneous, coronary intervention, Tc-99m sestamibi SPECT, 875(ab)

Chimera, radiolabeled monoclonal antibodies, 29

Chloramine-T, TCB radioiodinated monomeric antibody P-67, improved tumor retention, 987(ab)

Cholecystectomy, laparoscopic, utility of cholescintigraphy, 898(ab)

Cholecystitis

acute, significance, duodenogastric reflux, 898(ab)
chronic acalculous, specificity, gallbladder ejection fraction, 899(ab)

- grading of hyperperfusion and rim sign, biliary scintigraphy, 898(ab)
- Cholecystokinin**, calculation of gallbladder ejection fraction, continuous sinicalde infusion, 3-min infusion method, 537
- Cholescintigraphy**
morphine-augmented
false-negative, subacute gallbladder perforation, 256
potential pitfalls, 898(ab)
Tc-99m IDA, differentiation, congenital gallbladder abnormality, 431
- Cholestasis**, intrahepatic vs. extrahepatic, hepatobiliary scintigraphy, 1186
- Cholesterol**, -fed rabbits, radioiodinated endothelin-1, injured aortic tissue, 845(ab)
- Chorea**, cerebral glucose metabolism, striatal F-DOPA uptake, PET, 1015(ab)
- Choreo-athetoid syndrome**, cerebral blood flow, brain Tc-99m HMPAO SPECT, 838(ab)
- Chromaffin cells**
C-11 cocaine, distribution and kinetics, human body, 521
MIBG heart and lung extraction fraction, first-pass analysis, 716
- Chromatofocusing**, monoclonal Fab', 2148
- Cintichem Corporation**, government molybdenum-99 plan, 11N(2)
- Cirrhosis**, liver, portal venous blood flow, pulsed Doppler and per-jejunum scintigraphy, 997(ab)
- Cisplatin**, low-dose infusion and strontium-89, hormone refractory prostate carcinoma metastatic to bone, 1437
- Citrate dextrose**, heparin and, preparation, Tc-99m red blood cells with UltraTag RBC kit, 306(le)
- Clean Air Act**, amendments, 29N(10)
- Cocaine**
abuse and AIDS dementia complex, brain perfusion SPECT, 1312, 887(ab)
abusers
brain dopamine changes, 887(ab)
decreased binding, C-11 cocaine, 888(ab)
distribution and kinetics, alcohol intoxication, human brain and heart, 946(ab)
intravenous injection, myocardial sympathetic neuronal function, dogs, 994(ab)
no-carrier added radioiodinated analogs, ligand binding, animal biodistribution, 981(ab)
polydrug users, regional cerebral blood flow, improvement with treatment, 887(ab)
radiolabeled analogs, receptor imaging agent, PET, 1025(ab)
receptors, PET imaging probes, non-human primate model, 946(ab)
receptor site mapping, radioligands, SPECT, 890(ab)
Tc-99m D,L-HMPAO, uptake and respiration, rat brain slices, 964(ab)
- Cole, Donald W., Jr.**, *In memoriam*, 1726
- Collimator**
cardiofocal, cardiac SPECT, 852(ab)
collimatorless coincidence imaging, computer simulations, 879(ab)
detector interactions and, In-111 imaging, 1004(ab)
distance-dependent blur in SPECT, restoration filter approach, 843(ab)
fan-beam, myocardial SPECT, newborn period and early infancy, 930(ab)
multi-head SPECT camera, sensitivity, resolution and image quality, 1859
penetration, camera-induced scatter, I-131 imaging, 889(ab)
rotating slit, planar scintigraphy, SPECT, 1005(ab)
SPECT collimation, spatially variant focusing, 891(ab)
structure, 1006(ab)
ultra high resolution, unitary construction, cylindrical gamma camera, 852(ab)
variable focal length, fan beam reconstruction algorithms, 891(ab)
- Colon**, improved transit procedure, easily prepared marker, SPECT, 833(ab)
- Colonic neoplasms**, metastatic, dose fractionation, radiolabeled antibodies, 1648
- Colony-stimulating factor**
granulocyte, bone marrow suppression, I-131 monoclonal antibody therapy, 933(ab)
granulocyte-macrophage, thrombocytopenia, hepatic sequestration of In-111 platelets, 923(ab)
- Colorectal neoplasms**
advanced, radioimmunotherapy I-131 CC49 SPECT, CT, 1002(ab)
Cu-64 antibodies for PET imaging, 1685
imaging considerations, I-131 labeled CC49 monoclonal antibody, 1001(ab)
management with Tc-99m monoclonal antibodies, 904(ab)
two-step targeting of iodinated bivalent haptens, dosimetry, nude mice hosts, 1000(ab)
- Commentary**
Lines from the President, 31N(3)
radiation safety for beginners, 167
utility of single-photon absorptiometry, dual-energy X-ray absorptiometry, 170
value of "the putrescine experience", 1720
- Computed tomography (CT)**
brain images, rapid registration, 1005(ab)
comparative study of Tl-201, MRI/angiography, bone and soft tissue sarcoma, 843(ab)
cone beam, image truncation, SPECT gamma camera, 901(ab)
cone beam transmission, imaging of human torso, gamma camera, 150
dual-energy X-ray, attenuation correction, SPECT images, 901(ab)
emission-transmission, prototype imaging system, 1881
fusion with SPECT images, radiolabeled monoclonal antibodies, 960(ab)
Ga-67 scan and, extrapulmonary tuberculosis, 2118
In-111 C110 anti-CEA monoclonal antibody, metastases detection, colorectal carcinoma, 904(ab)
I-131 QSPECT, manual alignment-error compensation, 925(ab)
osteoid osteoma, 269
radioimmunotherapy I-131 CC49 SPECT and, advanced colorectal cancer, 1002(ab)
rapid registration and review, brain, 1073(ab)
standardization, cardiac tomographic imaging, 1434
Tc-99m HMPAO SPECT, remote history, traumatic brain injury, 52
Tc-99m HMPAO SPECT and MR, diagnosis of dementia, 972(ab)
Tc-99m MIBI and Tl-201 scintigraphy, localization, parathyroid enlargement, 895(ab)
- Computer and Instrumentation Council**, sponsor of first Young Investigators Symposium, 32N(10)
- Computers**
-aided instruction
nuclear medicine, 1073(ab)
slide presentations, image acquisition, 1066(ab)
system for radiology, 1066(ab)
-assisted diagnosis
artificial neural network, coronary artery disease, 272
pulmonary embolism, ventilation-perfusion lung scanning, 1003(ab)
-based atlas, clinical neurologic PET, 1071(ab)
-based radiology teaching files, 1066(ab)
-based renal nuclear medicine teaching file, 1073(ab)
clinical validation of program, ordinary gamma camera first pass radionuclide angiography, 1064(ab)
-directed coregistration, multislice functional and anatomic images, external fiducials, 961(ab)
graphics for radiologic images, 1068(ab)
high-resolution plain-paper laser printers, hardcopy, nuclear medicine images, 947(ab)
instrumentation and, SNM Mid-Winter Meeting, 23N(1)
interfile file format, transfer of nuclear medicine images, 1007(ab)
Macintosh programs for PET, 1069(ab)
Macintosh tutorial, cross-sectional anatomy, 1063(ab)
major changes in nuclear cardiovascular codes, 19N(1)
model-based quantitation, knowledge-based factor analysis, 947(ab)
multifunctional image-containing database, 947(ab)
multimedia multimodality interactive tutorial, brain SPECT, 1071(ab)
nuclear medicine
efficient management, imaging and non-imaging information, 1006(ab)
multi-media workstation, 947(ab)
workstation, all digital department, 947(ab)
radiologic anatomy, 1067(ab)
simulations
brain phantom design, image reconstruction algorithms, 1012(ab)
collimatorless coincidence imaging, 879(ab)
teaching file for nuclear medicine, 1066(ab)
use of Internet, communications to world community, nuclear medicine, 1067(ab)
use of linear programming, glucose utilization and receptor binding, PET studies of heart and brain, 944(ab)
use of local area networks, intradepartmental distribution, nuclear medicine imaging data, 946(ab)
- Congress**
government will respond to those who seek influence, 25N(10)
report of disturbing findings, Secretary of Energy, 22N(10)
subcommittee, U.S. radioisotope supply crisis, 16N(10)
support of National Biomedical Tracer Facility, 35N(11)
- Contamination**
management of exposed or contaminated patient, 1065(ab)
prevention of, I.V. administration, radiopharmaceuticals, 1027(ab)
- Contrast material**, iodides, potential effects, radioactive thyroid uptake, 237

Copper-61 pyruvaldehyde thiosemicarbazone, quantification of regional canine myocardial perfusion, 884(ab)

Copper-62 PTSM
kinetics in the non-human heart, 684
regional myocardial perfusion, 837(ab)

Copper-64, PET, scintillating fiber detector module, small animals, 1010(ab)

Copper-64 antibodies, PET imaging, 1685

Copper-67
bifunctional chelating agents, 942(ab)
Sm-153 immunoconjugates, tumor therapy, 942(ab)

Copper-PTSM, retention of, complete ischemia-reperfusion, 1026(ab)

Coronary artery disease (CAD)
adenosine stress, N-13 ammonia myocardial perfusion PET, 825(ab)
adenosine thallium scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
areas of reverse redistribution, planar thallium imaging, viability with PET, 886(ab)
chronic
identification of viable myocardium, 505
rest-redistribution TI-201, relation to Tc-99m MIBI, 905(ab)
clinical validation of computer program, ordinary gamma camera, first pass radionuclide angiography, 1064(ab)
comparison of rest-redistribution TI-201 uptake, resting sestamibi uptake, 905(ab)
computer-aided diagnosis, artificial neural network, 272
continuous SPECT imaging protocol, Tc-99m tebo and TI-201, 1304
detection of total ischemic myocardium at jeopardy, combination of flow reserve with metabolic assessment, 837(ab)
dobutamine and exercise, Tc-99m sestamibi, 951(ab)
dobutamine Tc-99m sestamibi SPECT, 866(ab)
early and delayed myocardial Tc-99m sestamibi SPECT, 855(ab)
echocardiography, 866(ab)
effect of patient motion, tomographic perfusion imaging, 1566
exercise-induced myocardial ischemia, first-pass radionuclide angiography, bicycle ergometry, 359
extent and location, TI-201 tomography with pharmacologic stress, 2067
incremental diagnostic value and impact, patient treatment, thallium scintigraphy, 1727
incremental value of diagnostic test, cost consciousness, 1732
integration of wall kinetic and perfusion data, tomographic myocardial perfusion scintigraphy, 933(ab)
lung thallium uptake, adenosine TI-201 scintigraphy, 1600
metabolic cardiac imaging, I-123 IPPA, multicrystal gamma camera, 1269
myocardial imaging, Tc-99m tetrofosmin, 875(ab)
myocardial ischemia, hemodynamic-scintigraphic study, adenosine infusion, 952(ab)
myocardial viability, TI-201 SPECT vs. F-18 FDG PET, 886(ab)
nuclear probes in cardiology, 448
planar gated imaging, 866(ab)
planar myocardial perfusion imaging, TI-201,

Tc-99m sestamibi and Tc-99m teboroxime, 1091
predictive value of dipyridamole thallium imaging, myocardial bridging, 1905
regional glucose metabolism, relation to perfusion, 856(ab)
regional perfusion reserve, noninvasive determination, N-13 ammonia PET, 826(ab)
retrospective post therapy evaluation, cardiac function, PET, 885(ab)
Tc-99m sestamibi myocardial SPECT imaging, comparison, short and standard data acquisition, 855(ab)
Tc-99m sestamibi perfusion, left ventricular ejection fraction, 847(ab)
teboroxime resting washout, stress thallium SPECT, 876(ab)

Coronary stents, platelet/fibrin deposition, anticoagulation, minipig model, 845(ab)

Corticotropin-releasing factor, radioiodinated, potential tracer, CRF-receptor imaging, 996(ab)

Cortisol, adrenocortical scintigraphy, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)

Court system, criminal, functional brain scans, 18N(6)

Crossed cerebellar diaschisis, hypoperfusion, unilateral major cerebral artery occlusive disorders, 1637

Curshmann-Steinert, myocardial involvement, I-123 IPPA SPECT, 995(ab)

Cushing's disease, decreased cerebral glucose metabolism, FDG-PET, 834(ab)

Cyclic AMP, -related second messenger system, potentiality, C-11 forskolin, 1025(ab)

Cyclotron, industry split over approval, PET tracers, 24N(9)

Cyst, epidermoid inclusion, TI-201 accumulation, 1857

Cystic fibrosis, effectiveness of PEP mask, Tc-99m DTPA aerosol ventilation, 835(ab)

Cystography
cyclic voiding, vesicoureteral, asymptomatic siblings, 873(ab)
radionuclide, vesicoureteral reflux, children and adolescents, 1022(ab)

Cytomegalovirus, accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)

D

Deferoxamine, -biotin derivatives, plasma stability, pharmacokinetics, 880(ab)

Dementia
accuracy in diagnosis, PET imaging, 967(ab)
atypical, comparison, FDG PET and MRI data, 965(ab)
autopsy-diagnosed, SPECT perfusion imaging, 939(ab)
delayed SPECT and regional cerebral blood flow, I-123 IMP, 1015(ab)
differential diagnosis
brain perfusion SPECT accuracy, 1017(ab)
rCBF/SPECT and MRI, 1014(ab)
Tc-99m HMPAO, 939(ab)
functional brain SPECT, powerful clinical method, 1888
HIV, qualitative approach, SPECT, 1018(ab)
multiinfarct and degenerative, impairment of cognitive functions, extent of disturbance, 940(ab)
patterns of, Alzheimer's disease, 1431(le)

sensitivity and specificity, Tc-99m HMPAO SPECT, 1013(ab)

Deoxyglucose, hexadecylphosphocholine and, design of combination therapy, FDG uptake measurements, 1019(ab)

Department of Energy (DOE)
competition for research dollars, 15N(2)
GAO probe of U.S. isotope troubles, 22N(9)
government molybdenum-99 plan, slow advancement, 11N(2)
government relations update, 16N(3)
isotope problems, 34N(10)
myth-making at Hanford, 19N(7)
National Biomedical Tracer Facility, 33N(9)
panel to reconsider advanced neutron source, 32N(10)
questions about future, isotope production and research, 13N(6)
research appropriations, 30N(12)

Depression
late life
brain perfusion pattern, 838(ab)
F-18 FDG PET, 1013(ab)
schizophrenia and, Tc-99m HMPAO SPECT, 972(ab)

Dexamethasone, lack of suppression, adrenal SPECT, primary aldosteronism, 834(ab)

Diabetes
gastric motility disturbances, scintigraphy, 832(ab)
gastroparesis, gastric emptying rate, variable oral erythromycin, 833(ab)
infectious foot complications, In-111 human nonspecific IgG, 950(ab), 1330
insulin-dependent, secondary gastroparesis, 1707
type 2 patients, oral glucose solution, rapid gastric emptying, 1496

Dialysis, continuous ambulatory, diffuse abdominal uptake of Tc-99m MDP, bone scintigraphy, 2052

Diaminedithiol, ligand system, labeling with Re-186, 1032(ab)

Diaschisis
cross cerebellar, neurologic imaging, stroke, 968(ab)
vascular response to acetazolamide, Tc-99m HMPAO SPECT, 967(ab)

Digoxin
possible imaging agent, 549
radioiodinated derivative, myocardial accumulation, possible Na,K-ATPase imaging agent, 545

α -Dihydrotetrabenazine, C-11 tetrabenazine and C-11 methoxy derivative, PET, monoamine terminals, 983(ab)

Dipyridamole
blunted response of myocardial perfusion, older adults, 1425(le)
effects on renal function, Tc-99m DTPA, 355-induced left ventricular cavity dilatation, exercise, thallium imaging, 951(ab)
lack of thallium redistribution, postoperative and long-term outcome, 951(ab)
myocardial perfusion imaging, serum caffeine levels, 24-hour abstinence, 866(ab)
stress, metabolic evidence of ischemia, 866(ab)
Tc-99m MIBI radionuclide angiography, SPECT myocardial perfusion, 846(ab)
TI-201 imaging
dose comparisons, coronary artery disease, 866(ab)
improvement of image quality, walking exercise, 2061

- predictive value, myocardial bridging, 1905
- Diuresis**
 captopril, renal functional response, 739
 renogram, functional assessment, pre- and post-pyeloplasty, 977(ab)
 renography, gravity-assisted drainage view, 1022(ab)
 Tc-99m DTPA renography, ureteral status in children, kidney washout, 73
- DNA**, synthesis, kinetic modeling, C-11 thymidine PET, 1009(ab)
- Dobutamine**
 choice of stress for diagnostic perfusion, wall motion imaging, MIBI-SPECT and stress echocardiography, 825(ab)
 exercise and, Tc-99m sestamibi, coronary artery disease, 951(ab)
 stress thallium scintigraphy, usefulness and safety, 951(ab)
 Tc-99m sestamibi SPECT, detection, coronary artery disease, 866(ab)
- Dopamine**
 acetylcholine release and, GABAergic modulation, PET, 847(ab)
 changes in brain, cocaine abusers, 887(ab)
 D1 ligand, synthesis and *in vivo* evaluation, F-18 BT-SCH PET, 829(ab)
 D2 receptors, chemical family of ligands, 981(ab)
 fiber loss in Parkinsonism, C-11 CFT, 946(ab)
 "internalization" of F-18 N-methyl-spiroperidol, 870(ab)
 striatal F-DOPA uptake, cerebral glucose metabolism, patients with chorea, 1015(ab)
 transporter site; C-11 WIN 35,428; living human brain, 964(ab)
 uptake system, C-11 NNC 722, 931(ab)
- Doppler**: see Ultrasonography
- Dosimetry**
 absorbed dose and contamination risk, In-111 oxine, 953(ab)
 absorbed dose calculations, rapidly growing tumors, 277
 cellular level of Kupffer cells, Tc-99m sulphur colloid injection, 380
 C-11 2 α -tropanyl benzilate, synthesis, biodistribution, 423
 effect of radiolabeled impurities, brain retention, Tc-99m bicisate in monkeys, 989(ab)
 immunoscintigraphy, In-111 monoclonal antibody fragments, ovarian cancer, 1113
 I-131 QSPECT of phantom, transfer of CT vols, manual alignment, 925(ab)
 I-123 somatostatin analog, neuroendocrine tumors, 1613
 I-131 therapy for thyroid carcinoma, complications, sequela, 2214
 I-123 TISCH, 954(ab)
 management of exposed or contaminated patient, 1065(ab)
 mathematical modeling, plasmapheresis, radioimmunotherapy of micrometastases, 941(ab)
 MIRD dose estimate Report No. 16, 1717
 MIRDose software protocol, monoclonal antibody radioimmunotherapy, 926(ab)
 modeling, anti-CD33 monoclonal antibody M195, acute myelogenous leukemia, 941(ab)
 nuclear quantitation of tumor size and I-131 amount, planar imaging, 925(ab)
 plasmapheresis in radioimmunotherapy, micrometastases, 2167
 quantitative approach, I-131 therapy, thyroid cancer, 894(ab)
 radioimmunotherapy in a child with neuroblastoma, I-124 3F9 PET, 2020
 regional dose distribution to hands, staff formulating/dispersing/administering radiopharmaceuticals, 1065(ab)
 Sr-89 radiotherapy, metastatic prostatic carcinoma, 1316
 Tc-99m MAG₃, Tc-99m DTPA and I-131 OIH, human biodistribution studies, 33
 Tc-99m mapping of leukocytes, secondary ion mass spectrometry microscopy, 2162
 three-dimensional tumor, hepatic Y-90 microsphere therapy, 735
 two-step targeting of iodinated bivalent haptens, colorectal tumors hosted in nude mice, 1000(ab)
- Down's syndrome**
 nondemented old patients, I-123 IMP SPECT, 967(ab)
 regional cerebral blood flow, Tc-99m HMPAO brain SPECT, 1013(ab)
- Drug abuse**, comparative uptake, Tc-99m HMPAO, I-123 IMP rCBF, 1015(ab)
- Dual-photopeak window**, method for scatter correction, 605
- Dysphagia**, esophageal disorders and scintigraphy, 1301
- Dystonia**, I-123 IBZM SPECT, 1018(ab)
- E**
- Ebstein's deformity**, radionuclide evaluation, symptomatic infants and children, 930(ab)
- Echocardiography**
 detection of coronary artery disease, 866(ab)
 stress and MIBI SPECT, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
- Editorials**
 Adriamycin and congestive cardiomyopathy, I-125 MIBG, 215
 anatomic divisions, 407
 bloody future for clinical PET, 620
 brain death, diagnostic dilemma, 2211
 captopril renal scintigraphy, distinguishing functional from anatomic renal artery stenosis, 2045
 carbon-11 putrescine, 200
 clinical applications of PET in cancer, 330
 C-11 SAH PET, myocardial energy balance, 2144
 current role of SPECT, imaging of subdural hematoma, 248
 detection of cardiovascular infections, radiolabeled leukocytes, 1493
 diagnostic imaging of liver, 1344
 esophageal disorders and scintigraphy, 1301
 euglycemic hyperinsulinemic clamp, myocardial glucose utilization, PET, 1263
 gallbladder ejection fraction, decade of progress, future promise, 542
 go with the flow—but how far?, 1939
 hepatic clearance of Tc-99m HIDA derivatives, hyperbilirubinemic states, 1551
 how magic is the bullet, what will it do?, 549
 imaging inflammation, current role, labeled autologous leukocytes, 65
 immunoscintigraphy of colorectal carcinoma, Loch Ness monster and, 1756
 incremental value of diagnostic test, cost consciousness, 1732
 labeled carbon dioxide, transient metabolite, 585
 lung scan interpretation, 1422
 mapping cerebral blood flow, 1843
 MIRD approach and limitations, 781
 misalignment between PET transmission and emission scans, myocardial imaging, 1214
 myocardial blood flow, deoxyglucose uptake, myocyte viability in ischemia, 1353
 myocardial FDG PET studies, oral glucose loading or insulin clamp methods, 1263
 natural history of infantile hydronephrosis, diuretic renography, 2098
 new methods for localizing infection, avidin-biotin, 1816
 nonuniformity of dose, implications, radiation protection, 384
 nuclear medicine, acupuncture message transmission, 409
 nuclear probes in cardiology, 448
 of theoretical derivations, empirical evidence, 1578
 parathyroid imaging, 1807
 prognosis in congestive heart failure, 477
 quantitating tumor glucose metabolism, FDG and PET, 339
 quantitative autoradiography, radiopharmaceutical uptake, dose heterogeneity, 1833
 radioimmunotherapy of cancer, 1110
 continuing evolution, 2180
 radiolabeled antibodies, oncogene-encoded molecules, tumor imaging and therapy, 2160
 radiolabeled monoclonal antibodies, cancer therapy and diagnosis, chimera, 29
 radiotherapy and regional bone formation, 1780
 referral bias, efficacy, radionuclide stress tests, 2074
 risk to others, I-131-treated patients, 2116
 scintigraphic appearance, Alzheimer's disease, Tc-99m HMPAO SPECT, 312
 scintigraphic evaluation, Sphincter of Oddi dysfunction, 1223
 sensitivity of SPECT Tl-201 myocardial perfusion, patient motion, 1571
 SPECT, rapidly cleared tracers, 1206
 targeted proteins for diagnostic imaging, does chemistry make a difference, 394
 Tl-201 and Tc-99m sestamibi, viable myocardium, 815
 transmural uptake of perfusion tracers, infarct-specific tracers, 229
 ureteral function, assessment of hydronephrosis, 78
 vascular testing for impotence, 46
- Ejection fraction**
 gallbladder, specificity, chronic acalculous cholecystitis, 899(ab)
 left ventricular
 correlation with lung uptake, Tc-99m sestamibi, 846(ab)
 gated blood-pool studies, 932(ab)
 gated Tc-99m sestamibi SPECT, 927(ab)
 Tc-99m sestamibi perfusion, coronary artery disease, 847(ab)
 radionuclide evaluation of Ebstein's deformity, symptomatic infants and children, 930(ab)
 reduced exercise capacity, Starling effect, cardiac transplantation, 939(ab)
- Electric Power Research Institute (EPRI)**, vote on epidemiology study, 26N(1)
- Electrocardiography**
 response and perfusion images, thallium stress test, 1723(le)
 thallium scan, court litigation, 120
- Electron microscopy**, autoradiography,

Emission tomography

- intracellular distribution of I-125 MIBG, neuroblastoma xenografts, 1021(ab)
- Emission tomography**
diffuse alcoholic liver disease, 1337
I-123 beta-methyl-branched fatty acid, hypertrophic cardiomyopathy, 6
iodinated branched fatty acid analog, regional metabolic abnormality, relation to perfusion and wall motion, 659
region-of-interest evaluation, least squares algorithm, 831(ab)
- Encephalopathy**, opsoclonus-myoclonus, location of neuroblastoma, MIBG usage, 930(ab)
- Endocrine neoplasms**, gastro-entero-pancreatic, In-111 pentatreotide scintigraphy, 976(ab)
- Endocrinology**, second Sino-American nuclear medicine conference, 16N(4)
- Endoprostheses**, septic loosening, WBC scintigraphy with monoclonal antibodies, 840(ab)
- Endothelial cells**, uptake kinetics, Tc-99m sestamibi, Tl-201, 102
- Endothelin-1**, radioiodinated, injured aortic tissue, cholesterol-fed rabbits, 845(ab)
- Endotoxemia**, lung neutrophil sequestration, intercellular adhesion molecules, 1023(ab)
- Environmental Protection Agency (EPA)**
costs of dual regulation, 29N(10)
mixed waste petition, 33N(9)
national emission standards, 33N(9)
National Emission Standards for Hazardous Air Pollutants, 24N(3)
- Epigastric impedancemetry**, gastric emptying of liquids, 956(ab)
- Epilepsy**
Annual Meeting highlights, 22N(8)
cerebral metabolism, effect of disease duration, PET, 1018(ab)
functional brain SPECT, powerful clinical method, 1888
interictal localization of foci, Tc-99m CEROTEC SPECT, 966(ab)
intractable temporal lobe, 3-D semiquantitative method, F-18 FDG PET and Tc-99m HMPAO SPECT, 970(ab)
parietal lobe, F-18 FDG PET, 1017(ab)
presurgical localization of zones, F-18 FDG PET, 928(ab)
refractory, temporal lobe metabolism, asymmetry in FDG PET scans, 928(ab)
simple and partial complex seizures, foci localization, Tc-99m HMPAO SPECT, 971(ab)
spontaneously epileptic rat, interictal cerebral glucose metabolism, 1024(ab)
status epilepticus, Tc-99m HMPAO SPECT, 928(ab)
temporal lobe
decreased binding of I-123 IDEX, muscarinic cholinergic receptors, 928(ab)
hyperventilation, cerebral blood flow, 968(ab)
mesial temporal origin, PET scan findings, 1014(ab)
presurgical evaluation, ictal Tc-99m HMPAO SPECT, 929(ab)
surgical outcome, Xe-133 SPECT, 1018(ab)
temporal lobe surgery, prognostic implications, FDG PET, 929(ab)
- Erythrocytes**, modification of Tc-99m labeling method, effectiveness, 2222
- Erythromycin**, oral, gastric emptying rate, diabetic gastroparesis, 833(ab)
- Esophagus**
abnormal motility, gastroesophageal reflux, angina-like chest pain, 955(ab)
bolus transport and contraction parameters, multiple-swallow investigations, 1291
disorders and scintigraphy, 1301
motility after reconstructive operation, 955(ab)
scintigraphy
achalasia and achalasia-like disorders, 590
reproducibility, normal ranges, 2106
ROC-analysis, 832(ab)
- Estradiol**, -stimulated rat liver, binding of Tc-99m LDL and I-125 LDL, 1028(ab)
- Estrogen**, receptor imaging and PET, F-18 fluoro analog, tamoxifen, 985(ab)
- Ethanol**, percutaneous injection, autonomous thyroid nodule, 954(ab)
- Ethics**, knowing what is right, 296
(S)-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(3-[18F] fluoropropyl)2,3-dimethoxy-6-hydroxybenzamide, superior PET ligand, cerebral dopamine D2 receptors, 847(ab)
- Etidronate**
cyclic oral phosphate and, bone mineral density, spine fracture, 1
intravenous, skeletal nonvisualization, bone scan, 748
- Exercise**
dipyridamole-induced left ventricular cavity dilation, thallium imaging, 951(ab)
dobutamine and, Tc-99m sestamibi, coronary artery disease, 951(ab)
-induced perfusion defects, delay of image acquisition, Tc-99m TEBO SPECT, 952(ab)
left ventricular function, coronary jeopardy score, 938(ab)
reduced capacity, cardiac transplantation, Starling effect, 939(ab)
serial measurements of cardiac volumes, count-based methods, 1324
walking, improvement, dipyridamole Tl-201 image quality, 2061
- Extracellular fluid**, volume measurements, reproducibility, critically ill patients, 1468
- Extracorporeal membrane oxygenation**, brain SPECT, neonates, 1943
- Extremity**
lower
bone scintigraphy, preschool children, 351
site of fracture or surgery, chronic osteomyelitis, 902(ab)
- F**
- Fab fragments**
cross-linking, synthesis and radioiodination, ETAC reagent, 943(ab)
linker-conjugated, monoclonal antiferritin antibody, nude mouse model, 987(ab)
monoclonal antibody F(ab')₂ uptake in tumor, hyperthermia, 958(ab)
negatively charged-polymer-modified antimyosin, infarct imaging, 959(ab)
NR-LU-10, CH2 domain deletion mutant, radioimmunotherapy potential, 1028(ab)
transferrin and IgG, preparation, characterization, 986(ab)
- Fast Flux Test Facility**, halt of activities, 16N(6)
- Fatty acid analog**, iodinated branched, regional metabolic abnormality, relation to perfusion and wall motion, 659
- Fatty acids**
iodo-labeled methyl fatty acid, myocardial viability, FDG PET, 953(ab)
kinetics in aerobic myocardium, 1864
- FDOPA**
OMFD and, combined modeling analysis, non-human primates, 945(ab)
PET, nigrostriatal function, ratio method and graphical analyses, 945(ab)
- Fe-PDGF**, potential new hepatobiliary MR contrast agent, 974(ab)
- Ferrum**, evaluation as MR contrast agent, 973(ab)
- Fever**, unknown origin, Tc-99m antigranulocyte monoclonal antibody, 902(ab)
- Fibrin**
deposition following coronary artery injury, I-125 fibrinogen, porcine restenosis model, 845(ab)
deposition on coronary stents, anticoagulation, minipig model, 845(ab)
D-dimer plasma concentration, suspected pulmonary embolus, 978(ab)
- Fibroblast**, -like cells and uptake kinetics, Tc-99m sestamibi, Tl-201, 102
- Filters**
gamma camera images, beta-emitters, neural network restoration, 889(ab)
restoration
defect detection, cardiac SPECT, 842(ab)
distance-dependent collimator blur, SPECT, 843(ab)
two-dimensional restoration, quantitation of amygdala, PET, 921(ab)
- Flumazenil**, ligand, quantification of benzodiazepine receptors, PET, 883(ab)
- Fluorine-18**
acyclic analogues of vesamicol, potential cholinergic neuron markers, 983(ab)
labeling of monoclonal antibodies, N-succinimidyl 4-[F-18]fluorobenzoate, 881(ab)
PET
bone blood flow and influx rate, 937(ab)
derivatives of SCH 38548, dopamine D1 receptors, 829(ab)
ligands, benzodiazepine receptor studies, 883(ab)
production of, cryogenic O-18 water target, 932(ab)
- Fluorine-18 androgens**, potential imaging agents, prostatic cancer, 724
- Fluorine-18 antimyosin monoclonal antibody fragments**, preliminary investigations, canine myocardial infarct model, 575
- Fluorine-18 biotin**, tumor localization with PET, 1026(ab)
- Fluorine-18 BMY 14802**, synthesis and resolution, PET studies, baboons, 830(ab)
- Fluorine-18 BT-SCH**, synthesis and *in vivo* evaluation, dopamine D1 ligand, PET, 829(ab)
- Fluorine-18 2-deoxy-2-fluoro-D-glucose**, time course of skeletal muscle glucose uptake, euglycemic hyperinsulinemia, 1523
- Fluorine-18 deoxyglucose**
myocardial blood flow, glucose uptake, ischemic canine myocardium, 1346
PET, mediastinal lymph node mapping, 828(ab)
- Fluorine-18 DOPA**, uptake in brain, delayed L-phenylalanine infusion, 1383
- 6-Fluorine-18 DOPA**, parametric Dopa-decarboxylase imaging, 879(ab)
- Fluorine-18 FDG**
accumulation in bone fracture, correlation, Tc-99m MDP, 869(ab)
infection and reactive lymph nodes, 925(ab)
method for comparing different procedures, regional glucose metabolism, 157
microautoradiography, granulation tissues and

- phagocytes, mouse tumor tissue, 840(ab)
- PET**
- accuracy, dementia diagnosis, 967(ab)
- brain, registered atlas, 1071(ab)
- brain tumor therapy, 1071(ab)
- compared with C-11 acetate, recovery after revascularization, 855(ab)
- developmental cognitive disorders, 973(ab)
- 3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
- evaluation of liver tumors, 333
- glucose loading or insulin clamp methods, myocardium, 1263
- hibernating myocardium, irreversible perfusion defects, 105(ab)
- insulin clamp, myocardial glucose utilization, 1255, 1263
- late-life depression, 1013(ab)
- lymphoma, 532
- malignant lymphoma, proliferative activity, 325
- malignant melanoma, 975(ab)
- multiple systemic atrophy, selective metabolic involvement, 1014(ab)
- myocardial viability, coronary artery disease, 886(ab)
- parietal lobe epilepsy, 1017(ab)
- preoperative chemotherapy, locoregionally advanced breast cancer, 828(ab)
- pre-operative staging, colorectal carcinoma, 975(ab)
- presurgical localization, epileptogenic zones, 928(ab)
- quantitation, tumor glucose metabolism, 339
- radiation-induced inhibition, tumor growth, 373
- recurrent brain tumors, 867(ab)
- residual or recurrent musculoskeletal sarcoma, 992(ab)
- SPECT and, myocardial viability, 1064(ab)
- treatment planning and monitoring, lung tumors, 975(ab)
- scintigraphy, chemotherapeutic impact, malignant lymphoma, 858(ab)
- synthesis, simple procedural change, recovery of O-18 enriched water, 1027(ab)
- Tc-99m sestamibi SPECT and, malignancy, 858(ab)
- thermally stable ion exchange, heterogeneous nucleophilic radiofluorination, 984(ab)
- 2-Fluorine-18 FDOPA**, high accumulation in non-S phase melanocytes, B16 melanoma, microautoradiography, 984(ab)
- 6-Fluorine-18 FDOPA**
- decline of rate constant K_1 vs. age, 964(ab)
- loss of metabolites in striatum, 916(ab)
- OMFD and, combined modeling analysis, non-human primates, 945(ab)
- uptake in human brain, 916(ab)
- Fluorine-18 feroxacin**, PET, pharmacokinetics, rabbits, 924(ab)
- Fluorine-18 fluconazole**, PET, pharmacokinetics, humans, 924(ab)
- Fluorine-18 fluoride ion**, PET, evaluation, skeletal kinetics, 633
- Fluorine-18 fluorocarazolol**
- β -adrenergic radiotracer for PET, 984(ab)
- synthesis, ligand for β -adrenergic receptors, 983(ab)
- Fluorine-18 fluorodeoxyglucose**, PET, cranial and spinal neuromas, 1931
- Fluorine-18 4-fluoro-4-deoxy-D-glucose**, potential brain/heart/tumor imaging agent, 983(ab)
- 6-Fluorine-18 fluoro-L-dopa**, kinetics, carbidopa administration, PET, 1472
- 3-O-methyl-6-Fluorine-18 fluoro-L-dopa, FDOPA** and, combined modeling analysis, non-human primates, 945(ab)
- Fluorine-18 fluoromisonidazole**
- cellular hypoxia in sepsis, 924(ab)
- PET, hypoxia in human gliomas, 2133
- 4-(4-[Fluorine-18]fluorophenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole**, synthesis and biodistribution, imaging 5-HT₃ receptors, 830(ab)
- Fluorine-18 FMISO**
- PET
- noninvasive detection, hypoxic myocardium, 2202
- quantification, tumor oxygenation status, 1010(ab)
- Fluorine-18 MABN, F-18 MBP and F-18 NMSP**
- PET, comparative imaging studies, 985(ab)
- Fluorine-18 monoclonal antibody fragments**
- combination of radioimmunoscintigraphy and PET, 1535
- PET, 934(ab)
- Fluorine-18 NCQ 616**, preparation of, 860(ab)
- Fluorine-18 N-methyl-spiroperidol**, "internalization", 870(ab)
- Fluorine-18 NMSP**
- PET
- benzamide analogs and, 985(ab)
- F-18 MABN and F-18 MBP, comparative imaging studies, 985(ab)
- Fluorine-18 N-(2-(pyrrolidinyl)-1-phenylethyl)acetamide analog**, synthesis, κ opiate receptor, 830(ab)
- Fluorodeoxyglucose**
- areas of reverse redistribution, planar thallium imaging, viability with PET, 886(ab)
- blood-brain transport, regional variations, 908(ab)
- brain tumor studies, PET resolution, visual interpretation, 872(ab)
- enhanced uptake caused by chemotherapy, metabolic design, combination therapy, 1981
- glucose and, regional blood-brain transport, 1819
- increased uptake as prognostic indicator, myocardial infarction, 886(ab)
- PET
- Bayesian regression, metabolic rate of glucose utilization, 944(ab)
- decreased cerebral glucose metabolism, Cushing's disease, 834(ab)
- differential diagnosis, solitary pulmonary nodule, 836(ab)
- differentiation of infectious from malignant CNS lesions, AIDS, 838(ab)
- fully quantitative neurological studies, without arterial blood sampling, 922(ab)
- HIV-1-infected children, seropositive mothers, 976(ab)
- investigation of olfactory system, 858(ab)
- left premotor cortex specialization, finger movements, 857(ab)
- low grade and anaplastic astrocytomas, brain imaging, 966(ab)
- mediastinum, lung cancer, 828(ab)
- method for correcting myocardium to blood pool spillover, 882(ab)
- MIHA, myocardial viability, 953(ab)
- MRI data and, atypical dementia and Alzheimer's disease, 965(ab)
- post-treatment evaluation, genitourinary malignancies, 829(ab)
- prognostic implications, temporal lobe surgery, 929(ab)
- quantitative dynamic and whole body, breast cancer, 828(ab)
- radiation-induced response, head and neck carcinoma, 829(ab)
- temporal lobe metabolism, refractory epilepsy, 928(ab)
- TSH stimulation of thyroid cancer, T4 replacement therapy, 894(ab)
- PET imaging of the chest, 975(ab)
- purification of used O-18 target water, photochemical combustion, 982(ab)
- uptake in tumors, Berson-Yalow Award winners, 15N(7)
- uptake into human cancer cells, hypoxia, 841(ab)
- uptake kinetics in liver, impact of glucose ingestion, dynamic PET, 945(ab)
- uptake measurements, design of combination therapy, hexadecylphosphocholine and deoxyglucose, 1019(ab)
- 3'-Fluoro-3'-deoxythymidine**, noninvasive monitoring of targeting of drugs, AIDS, 830(ab)
- Food and Drug Administration (FDA)**
- approval of drug master file, PET, 33N(9)
- government relations update, 15N(3)
- PET tracers, industry split over approval, 24N(9)
- Foot**
- diabetic complications, In-111 human nonspecific IgG, 950(ab)
- infectious diabetic complications, In-111 human nonspecific immunoglobulin G, 1330
- Forearm**, bone mineral assessment, 1251(le)
- Fourier**
- amplitude and phase, three-dimensional presentation, gated cardiac blood-pool SPECT, 458
- approach to gastric motility, 956(ab)
- Fracture**
- bone, accumulation of F-18 FDG, Tc-99m MDP, 869(ab)
- stress, osteosarcoma, lower limb, 1699
- G**
- Gadolinium-DTPA**, MRI, recurrent brain tumors, 867(ab)
- Gadolinium (III) DTPA-bisamide complexes**, nonionic, MRI contrast agents, 974(ab)
- Gallbladder**
- biliary scintigraphy, grading of hyperperfusion, rim sign, 898(ab)
- calculation of ejection fraction, continuous sinclide infusion, 3-minute infusion method, 537
- differentiation of congenital abnormality, quantitative Tc-99m IDA cholescintigraphy, 431
- ejection fraction
- decade of progress, future promise, 542
- specificity, chronic acalculous cholecystitis, 899(ab)
- hepatobiliary scintigraphy, intrahepatic vs. extrahepatic cholestasis, 1186
- perforation, false-negative, morphine-augmented cholescintigraphy, 256
- stone, common bile duct clearance, radionuclide injection, 997(ab)
- Gallium**, octahedral gallium chelate, monoclonal antibodies, immunoscintigraphy with PET, 1366
- Gallium-67**

- accuracy of early imaging, pulmonary infection, immunocompromised patients, 957(ab)
- aminoxyacetyldeferoxamine, monoclonal anti-CEA antibody, colon carcinoma immunoscintigraphy, 1766
- chest X-ray patterns in HIV-positive patients, 999(ab)
- clinical experience with Tc-99m nanocolloid, 999(ab)
- computed tomography and, extrapulmonary tuberculosis, 2118
- distribution in man, decrease in both transferrin and hepatic Ga-67 concentration, 1701
- gastric uptake, AIDS, 643
- In-111 leukocyte and, acute sarcoidosis, 2027
- kinetics and therapeutic potential, malignant lymphoma, 926(ab)
- limitations in usefulness, prediction of recurrences, Hodgkin's disease, 913(ab)
- metastatic and recurrent soft-tissue sarcoma, 1594
- pulmonary disposition, *Pneumocystis pneumonia*, 512
- role in staging lymphoma, 1588(le)
- scanning and MRI, effect of therapy, Hodgkin's lymphoma, 914(ab)
- scintiscan, primary splenic non-Hodgkin's lymphoma, treatment of Hodgkin's disease, 1183
- Tc-99m DTPA aerosol, pulmonary complications, HIV infection, 81
- Tc-99m MDP and, scintigraphic differentiation, osteogenic and Ewing's sarcoma, 1063(ab)
- Gallium-67 citrate**
- disease activity in sarcoidosis, 751
- scanning in patients with sarcoid uveitis, 1851
- SPECT, biopsy-confirmed residual Hodgkin's disease, mediastinum, 345
- Gallium-68**, radiopharmaceuticals that are retained in myocardium, 931(ab)
- Gallium-68 DF-NGA**, regional measurement, hepatic receptor biochemistry, 1160
- Gallium-68 platelets**, PET imaging, 931(ab)
- Gallium-67 polyclonal IgG**, In-111 leukocytes and, acute focal inflammatory lesions, 1428(le)
- Gamma camera**
- Bremsstrahlung imaging, factors affecting attenuation, 161
- clinical, imaging therapeutic doses, I-131, 771
- collimator structure, 1006(ab)
- cone-beam transmission CT, imaging, human torso, 150
- cylindrical, unitary construction, ultra high resolution collimator, 852(ab)
- event loss estimation, radioimmunotherapy, 1005(ab)
- experimental myocardial infarction in rabbits, antimyosin Fab conjugation, N-terminal modified DTPA-succinylated polylysine, 943(ab)
- first pass radionuclide angiography, clinical validation, computer program, 1064(ab)
- gamma-ray
- miniature CsI photodiode detectors, 1004(ab)
- multiplexer and semiconductor detectors, 1002(ab)
- gamma variate fit, camera-based method, Tc-99m MAG_3 clearance, 991(ab)
- high-resolution plain-paper laser printers, hardcopy, nuclear medicine images, 947(ab)
- images of *beta*-emitters, neural network restoration, 889(ab)
- induced Compton scatter, collimator penetration, I-131 imaging, 889(ab)
- multicrystal, metabolic cardiac imaging, severe coronary disease, 1269
- piled-up events, digital processing, signal deconvolution, 1003(ab)
- rotating, cerebral blood flow, I-123 IMP, 963(ab)
- sensitivity per unit area, true characteristic, 1068(ab)
- single-headed, rapid radiotracer washout from the heart, SPECT, 1146
- SPECT, image truncation, cone beam CT, 901(ab)
- technology, lawsuit filed by Trionix against ADAC Laboratories, 18N(2)
- three-head rotating, Tc-99m DMSA SPECT, renal scan, 1021(ab)
- Gastric emptying**
- attenuation correction, left anterior oblique, geometric mean method, 833(ab)
- determination of time, different views, 127
- gastric motility disturbances, diabetes, scintigraphy, 832(ab)
- intragastric distribution and, oil, presence of liquid or solid meal, 1283
- measurement of liquids, 956(ab)
- normal and pathological, magnetic resonance imaging, nuclear medicine techniques, 956(ab)
- oral glucose solution, type 2 diabetic patients, 1496
- radionuclide, correlation, anterior-only and geometric mean method, 956(ab)
- rate, variable oral erythromycin, diabetic gastroparesis, 833(ab)
- secondary gastroparesis, insulin-dependent diabetes mellitus, 1707
- solid foods, proper definitions, lag phase, 466(le)
- Gastroenterology, nuclear**, Annual Meeting highlights, 26N(8)
- Gastro-entero-pancreatic neoplasms**, In-111 pentatrotide scintigraphy, 976(ab)
- Gastrointestinal neoplasms**, metastatic, radioimmunotherapy, 863(ab)
- Gastrointestinal tract**
- advanced ulcer avid agent, new procedure, Tc-99 phytate sucralfate, 1033(ab)
- bleeding studies, Tc-99m red blood cells, early negative images, 202
- gastric bleed studies, applications of amplitude images, 1006(ab)
- tumor targeting with Tc-99m F023C5 anti-CEA IgG1, role of CEA content, 892(ab)
- Gastroparesis**, secondary to insulin-dependent diabetes mellitus, 1707
- Gated blood-pool imaging**
- cardiac scintigraphy, Tc-99m liposomes, 984(ab)
- clinical verification, knowledge-based boundary detector, 938(ab)
- heart, three-dimensional presentation, Fourier amplitude and phase, 458
- knowledge-based LV detection, automatic EF calculation, 932(ab)
- left ventricular regions of interest, simulated annealing, 932(ab)
- SPECT
- parametric display, 3-D biventricular function, 952(ab)
- potential added clinical value, 910(ab)
- Tc-99m, ECG gated PET C-11 monoxide, "background" question, 938(ab)
- Gene**, models of mental disease, 22N(8)
- General Accounting Office (GAO)**
- probe details U.S. isotope troubles, 22N(9)
- scrutiny of federal isotope supply effort, 16N(2)
- Genitourinary system**, malignancy, post-treatment evaluation, FDG PET, 829(ab)
- Glioma**
- biodistribution of I-125 monoclonal antibody, hand-held NaI-crystal detector, 1002(ab)
- distinction of high-grade from low-grade, Tl-201 SPECT, 868(ab)
- human, hypoxia, F-18 fluoromisonidazole PET, 2133
- microdosimetry estimations, I-125 labeled monoclonal antibody 425, 942(ab)
- recurrent, intraarterial carotid artery injection, Tc-99m HMPAO, 966(ab)
- Glomerular filtration rate (GFR)**
- measurement in children, adequacy of one blood sample, 873(ab)
- quantitative analysis, dynamic renal studies, factor analysis, 949(ab)
- renal plasma flow and, spinal cord injury, 1035(ab)
- single plasma, children, 173(le)
- Tc-99m DTPA renal uptake, plasma volume product, 1712
- Glucose**
- absolute whole brain, sensitive marker, Alzheimer's disease, 940(ab)
- blood-brain transport, regional variations, 908(ab)
- cerebral metabolism in patients with chorea, striatal F-DOPA uptake, PET, 1015(ab)
- deoxyglucose uptake and myocardial blood flow, ischemia, myocyte viability, 1353
- fluorodeoxyglucose and, regional blood-brain transport, 1819
- ingestion, hepatic FDG uptake kinetics, dynamic PET, 945(ab)
- interictal cerebral metabolism, spontaneously epileptic rat, 1024(ab)
- metabolic rates, 30- and 45-minute acquisitions, cerebrum, 2103
- metabolism
- method for comparing different procedures, F-18 FDG, 157
- MPTP-primate model, Parkinson's disease, 965(ab)
- metabolism and cerebral blood flow, patient surviving after CO intoxication, 1696
- metabolism and rCBF, simultaneous SPECT acquisitions, 965(ab)
- metabolism in tumor, quantitation, FDG and PET, 339
- myocardial utilization, insulin clamp, F-18 FDG PET, 1255, 1263
- oral solution, rapid gastric emptying, type 2 diabetic patients, 1496
- regional metabolism in relation to perfusion, coronary artery disease, fasting and loading states, 856(ab)
- time course of uptake in skeletal muscle, euglycemic hyperinsulinemia, F-18 2-deoxy-2-fluoro-D-glucose study, 1523
- uptake and myocardial blood flow, ischemic myocardium, F-18 deoxyglucose, 1346
- utilization, Bayesian regression, estimation of metabolic rate, 944(ab)
- utilization and receptor binding, use of linear programming, PET studies of heart and brain, 944(ab)
- Glutathione**, -mediated decomposition, propylene amine oxime derivatives, ligand structure, 988(ab)
- Gold-199**, no-carrier-added, production of, 980(ab)

- Granulation tissue**, microautoradiographic study of F-18 FDG, mouse tumor tissue, 840(ab)
- Granulocytes**, radiolabeled, kinetics, systemic vasculitis, 491
- Granulocyte stimulating factor**, hypermetabolic bone marrow, Tl-201-chloride uptake, 2014
- Graves' disease**
euthyroid, autonomously functioning thyroid carcinoma, 2024
thyroid and orbital radiolabeled somatostatin accumulation, 894(ab)
- Gravity**, -assisted drainage view, diuresis renography, 1022(ab)
- H**
- Haloperidol**, SPECT imaging of dopamine D2 receptors, I-123 IBZM SPECT, 898(ab)
- Hand**
reflex sympathetic dystrophy, excessive inflammatory response, 936(ab)
regional dose distribution, staff formulating/dispensing/administering radiopharmaceuticals, 1065(ab)
unilateral voluntary movement, regional cerebral uptake, Tc-99m exametazine, 1623
- Hapten**, valency, pretargeted immunoscintigraphy, murine tumor uptake, 2006
- Head**, trauma, remote history of, Tc-99m HMPAO SPECT, 52
- Head and neck cancer**
C-11 methionine PET, 691
staging, Tc-99m monoclonal antibody 174H.64 SPECT, 912(ab)
- Health and Human Services (HHS)**
CLIA-88, 24N(3)
Medicare reimbursement, 19N(3)
new physicians, 19N(3)
nuclear medicine comments on RVUs and interim values, 19N(3)
outpatient hospital reimbursement, 23N(3)
rebundling of CPT-4 codes, 23N(3)
relative value unit update committee, 19N(3)
SPECT reimbursement, 19N(3)
- Heart**
abnormal adrenergic neuron activity, Adriamycin-induced cardiomyopathy, I-125 MIBG, 208
acute Adriamycin cardiotoxicity, Tc-99m sestamibi, chick heart cells, 864(ab)
acute onset of cardiogenic shock, normal coronary arteries, 1558
alcohol intoxication, cocaine distribution and kinetics, 946(ab)
allograft rejection, detection with I-123 anti-ICAM-1 imaging, rats, 1000(ab)
Annual Meeting highlights, 24N(8)
blood-pool scintigraphy, Tc-99m liposomes, 984(ab)
cardiac peak power, severely impaired left ventricular ejection fraction, good effort tolerance, 938(ab)
cardiovascular training requirements, 23N(4)
C-11 cocaine, distribution and kinetics, 521
C-11 HED kinetics, 870(ab)
complete ischemia-reperfusion, retention of Cu-PTSM, 1026(ab)
congestive heart failure prediction
Adriamycin cardiomyopathy, I-125 MIBG, 935(ab)
Adriamycin therapy, In-111 antimyosin studies, 895(ab)
congestive heart failure, prognosis, 477
coronary blood flow, tetrofosmin uptake, 846(ab)
deep hypothermic cardiac surgery, choreo-athetoid syndrome, brain Tc-99m HMPAO SPECT, 838(ab)
detection of cardiovascular infections, radiolabeled leukocytes, 1493
F-18 4-fluoro-4-deoxy-D-glucose imaging agent, 983(ab)
functional recovery after revascularization, C-11 acetate compared to F-18 FDG, PET, 855(ab)
function in neonates and children, arterial switch operation, PET, 977(ab)
globally denervated human and canine, scintigraphic assessment, MIBG uptake, 1444
high cardiac risk, patients referred for vascular surgery, adenosine thallium scintigraphy, 952(ab)
high count rate PET, spatially dependent deadtime losses, 2226
imaging of H1 histamine receptors, C-11 pyrilamine and C-11 doxepin, 885(ab)
immune mechanisms in disease, Mallinckrodt Fellow, 17N(6)
incomplete right bundle branch block, normal coronary angiogram, reversible Tl-201 perfusion defects, 1556
intracoronary Doppler probes and PET, concordant quantification, flow reserve, 836(ab)
iron, noninvasive in-vivo measurement, 1278
isolated perfused rat, subcellular distribution, Tc-99m MIBI, 1516
left ventricular mass and infarct size, N-13 ammonia PET, explanted human hearts for validation, 826(ab)
major upward creep, exercise Tl-201 myocardial SPECT, chronic obstructive pulmonary disease, 1846
measurement of receptor concentration, instrumental errors, PET, 882(ab)
metabolic imaging in severe coronary disease, I-123 IPPA, multicrystal gamma camera, 1269
MIBG extraction fraction, first-pass analysis, 716
MIBG imaging
patients with heart failure, 471
prognostic guide, heart failure, 896(ab)
MIBG uptake at 1-year post-cardiac transplant, partial reinnervation in man, 896(ab)
PET
reorientation, issues in quantitation, 1235
use of linear programming, glucose utilization, 944(ab)
postoperative and long-term outcome, lack of thallium redistribution, dipyridamole imaging, 951(ab)
radionuclide cardiac volumes, correction for Compton scatter, buildup factor, 1642
rapid radiotracer washout, single-headed gamma camera SPECT system, 1146
retrospective post-therapy evaluation, coronary artery disease patients, PET, 885(ab)
serial measurements of volumes, count-based methods, 1324
simultaneous estimation, myocardial perfusion, chamber volume, 933(ab)
SPECT
attenuation scans, three-dimensional registration, 881(ab)
cardiofocal collimator, 852(ab)-
defect detection, cone beam geometry, 961(ab)
defect detection, restoration filters, 842(ab)
emission and transmission noise propagation, non-uniform attenuation correction, 902(ab)
reconstructions, truncated projections, 831(ab)
three-detector, simultaneous transmission and emission, 901(ab)
standardization of cardiac tomographic imaging, 1434
standardized imaging, actions of the Board of Trustees, SNM, 23N(4)
static PET studies, automated three-dimensional analysis, 1008(ab)
Tl-201 SPECT, Tc-99m transmission source, simultaneous acquisition of emission/transmission data, 2238
transplantation, coronary arteriopathy, SPECT Tl-201 vs. sestamibi, 951(ab)
transplantation rejection in primates, antimyosin agents, 1994
uncomplicated valvular replacement, significance, In-111 antimyosin scintigraphy, 895
volumes, delineation of myocardium, PET and SPECT, 933(ab)
- Hemangioma**, hepatic, diagnosis, triple-head high-resolution SPECT, 918(ab)
- Hematoma**
chronic subdural, cerebral blood flow, Tc-99m HMPAO SPECT, 246
subdural, current role of SPECT, 248
- Hematopoietic neoplasia**, soft-shell clam, 998(ab)
- Hemiplegia**, alternating, childhood, Tc-99m HMPAO SPECT, 1021(ab)
- Hemodialyzer**, cellulose-acetate, comparative thrombogenicity, 956(ab)
- Hemodynamics**, captopril-mediated changes, renal ischemia, 907(ab)
- Heparin**
anticoagulant citrate dextrose and, preparation, Tc-99m red blood cells with UltraTag RBC kit, 306(le)
anticoagulation, Tc-99m antifibrin Fab' localization, acute venous thrombosis, 978(ab)
In-111 DTPA-heparin, radiolabeling, protamine, 1028(ab)
- Hepatobiliary tract**
excretion of Tc-99m MAG₃, 990(ab)
Fe-PDGF as MR contrast agent, 974(ab)
scintigraphy
bile lakes, liver transplant infarcts, 997(ab)
hepatic transport function, 998(ab)
- Hepatocytes**
evaluation of local reduced mass, Tc-99m NGA, chronic liver diseases, 998(ab)
In-111, distribution of transplanted cells, 918(ab)
primary rat culture model, inhibition of hepatic uptake, radiolabeled monoclonal antibodies, 893(ab)
- Hevesy Nuclear Medicine Pioneer Award**, Michael J. Welch, 16N(7)
- Hexadecylphosphocholine**, deoxyglucose and, design of combination therapy, FDG uptake measurements, 1019(ab)
- Hip**
prosthesis loosening, combined roentgenological contrast/radionuclide arthrography, 950(ab)
S-ROM prosthesis, perioperative uptake of MDP, 950(ab)
- Hippocampus**
blood flow, diagnosis of Alzheimer's disease,

Hippuric acid

SPECT, 940(ab)
temporal lobe epilepsy, decreased binding of I-123 IDEX, muscarinic cholinergic receptors, 928(ab)

Hippuric acid, ligands, Tc-99m renal function agents, 988(ab)

Hirulog, I-123, preparation and evaluation, blood clot imaging, 981(ab)

Histidine, second Tc-99m binding site in IgG, 1029(ab)

HIV-1: *see also* Human immunodeficiency virus-infected children, seropositive mothers, FDG PET, 976(ab)

Hodgkin's disease
biopsy-confirmed residual, Ga-67 SPECT, 345
effect of therapy on Hodgkin's lymphoma, Ga-67 scans and MRI, 914(ab)
limitations in usefulness, gallium imaging, prediction of recurrences, 913(ab)
primary splenic non-Hodgkin's lymphoma, Ga-67 scintiscan, 1183

Holmium-166, neuron-activated, polymeric microspheres, radionuclide synovectomy, 398

Holmium-166 hydroxyapatite, radiation synovectomy, 937(ab)

HPLC, Tc-99m monoclonal antibody, recovery and calibration, 1030(ab)

Human anti-mouse antibody
novel HAMA radioimmunoassay, ovarian cancer patients, 852(ab)
patient response, ImmuRAID-CEA, 1002(ab)
response after immunoscintigraphy, chimeric anti-CEA monoclonal antibodies, 903(ab)

Human immunodeficiency virus (HIV): *see also* HIV-1
dementia, qualitative approach, SPECT, 1018(ab)
noninvasive monitoring of targeting of drugs, 3'-fluoro-3'-deoxythymidine, AIDS, 830(ab)
-positive patients
acute infection detection, In-111 human immunoglobulin, 903(ab)
Ga-67 chest X-ray patterns, 999(ab)
pulmonary complications, Tc-99m DTPA aerosol, Ga-67 scanning, 81
-related incidents, infection-control problems, nuclear medicine departments, 13N(4)

Hunter, Oscar B. Jr., *In Memoriam*, 631

Huntington's disease, subjects with and at risk for, I-123 IBZM and Tc-99m HMPAO SPECT, 970(ab)

Hydronephrosis
antenatal, surgery vs. conservative management, impaired renal function, 873(ab)
assessment, ureteral function, 78
infantile, natural history of, diuretic renography, 2098
suspected uretero-pelvic junction obstruction, postnatal assessment, volume expanded diuretic renography, 2094
ureteral status in children, kidney washout, Tc-99m DTPA diuresis renography, 73
"well tempered" diuretic renogram, asymptomatic neonate, 2047

Hydrourteronephrosis, "well tempered" diuretic renogram, asymptomatic neonate, 2047

Hydroxyapatite, radiolabeling of particles, use, radiation synovectomy agents, 980(ab)

Hyperemia, adenosine-induced coronary, early thallium imaging after PTCA, 2086

Hyperglycemia, cerebral glucose uptake, I-(C-11) D-glucose, 908(ab)

Hyperinsulinemia, time course of skeletal muscle glucose uptake, F-18 2-deoxy-2-fluoro-D-glucose study, 1523

Hyperparathyroidism
localization of parathyroid adenoma, Tc-99m sestamibi, 1801
parathyroid imaging, 1807
parathyroid scintigraphy, subtraction algorithm, 996(ab)
primary, localization of adenomas, Tc-99m sestamibi dual-phase study, 894(ab)

Hyperplasia, focal nodular, hot spots, TBIDA liver scan, 918(ab)

Hypertension
localization of pheochromocytoma, C-11 HED PET, 1125
non-Goldblatt renovascular, distinctive pathophysiology, 907(ab)
renal functional response, captopril, diuretic therapy, 739
renovascular
captopril renal scintigraphy vs. captopril test, 907(ab)
prognostic value, captopril renal scintigraphy, 2040
triple radiopharmaceutical renal study, DTPA renogram, 1034(ab)

Hyperthermia, monoclonal antibody F(ab')₂ uptake in tumor, 958(ab)

Hyperthyroidism, lithium carbonate therapy, psychiatric disorders, 996(ab)

Hyperventilation, cerebral blood flow, temporal lobe epilepsy, 968(ab)

Hypoxia
cellular, sepsis, marker F-18 fluoromisonidazole, 924(ab)
chemistry of Tc-PnAO-nitroimidazole complex, 919(ab)
2-fluoro-2-deoxy-D-glucose uptake, human cancer cells, 841(ab)
human gliomas, F-18 fluoromisonidazole PET, 2133
myocardium, detection using F-18 FMISO PET, 2202
quantification of tumor oxygenation status, F-18 FMISO PET, 1010(ab)
Tc-labeled imaging agent, occlusion of LAD coronary artery, rabbit myocardium, 865(ab)
viable tissue, radioiodinated 2-nitroimidazole derivatives, SPECT, 891(ab)

Hysterosalpingography, radionuclide, Tc-99m pertechnetate, radiation dose to ovaries, 282

I

4-ICE, 4-BACE and, chelating agents, 985(ab)

Immunoconjugates
Cu-67 and Sm-157, tumor therapy, 942(ab)
In-111 cyclohexyl EDTA, anti-CEA F(ab')₂ monoclonal antibody, human tumor xenografted nude mice, 943(ab)
Re-186, effective stabilization, 979(ab)
simple synthesis and activation, 1,4,7,10-tetraazacyclododecane, 942(ab)

Immunoglobulin G
localization of infection, streptavidin and biotin, 1810
polyclonal, detection of inflammation, 1031(ab)
second Tc-99m binding site, relation to histidine groups, 1029(ab)
transferrin and F(ab')₂ conjugates, preparation, characterization, 986(ab)
vs. IgM antibodies, infection imaging, In-111

immunoglobulins, 1031(ab)

Immunoglobulin G4, I-131 chimeric B72.3, Phase I trial, metastatic colorectal cancer, 23

Immunoglobulins
conjugation with biotin, dendrimers as linker molecules, inflammation detection, 986(ab)
humanized, use of SCID mice for *in vivo* testing, 985(ab)
Tc-99m labeling, dendrimers as linker molecules, 986(ab)

Immunophoresis, efficacy, reduction of myelosuppression, radioimmunotherapy, 863(ab)

Immunoscintigraphy
avidin-biotin, pharmacokinetics, biotin-chelate conjugates, 880(ab)
colon carcinoma, monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, 1766
colorectal carcinoma, Loch Ness monster and, 1756
dosimetric evaluation, In-111 monoclonal antibody fragments, ovarian cancer, 1113
dual isotope SPECT, improved demarcation of tumors, occult colorectal carcinoma, 1000(ab)
gamma imaging, experimental myocardial infarction, rabbits, 943(ab)
human anti-mouse response, chimeric anti-CEA monoclonal antibodies, 903(ab)
immune mechanisms in heart disease, Mallinckrodt Fellow, 17N(6)
octahedral gallium chelate, monoclonal antibodies, PET, 1366
ovarian carcinoma, I-131 labeled 145-9 monoclonal antibody, 905(ab)
pretargeted, hapten valency, murine tumor uptake, 2006
technical limitations, Tc-99m anti-CEA antibodies, 1001(ab)
two-step, medullary carcinoma of thyroid, anti-CEA/anti-DTPA bispecific mAb and In-111 DTPA dimers, 912(ab)

Impotence
paraplegics, treatment choice, nuclear penogram, 1035(ab)
penile blood flow, tumescence, dual-radioisotopic technique, 41
quantitative dynamic parameters, 1723(le)
vascular testing, 46

Indium, radioindium-labeled autologous platelets, MIRD dose estimate No. 15, 777

Indium-111
antisense oligonucleotide, direct method of cell-labeling, whole blood, 980(ab)
attachment to antibody via popular chelators, liver homogenates, 1030(ab)
collimator and detector interactions, 1004(ab)
hepatocytes, distribution of transplanted cells, 918(ab)
human immunoglobulin, acute infection detection, HIV-positive patients, 903(ab)
imaging of inflammatory abdominal aortic aneurysm, 1553
labeled Ab-chelator, chelator structure, liver, 1001(ab)
labeled human nonspecific IgG, evaluation, inflammatory bowel disease, 919(ab)
labeled radiopharmaceuticals, quantitative autoradiographic study, heterogeneous activity distribution, 1825
macro- and microscopic biodistribution, bone marrow and testes, rats, 954(ab)
octreoscan-111, two diastereomers, cancer imaging, 900(ab)

- targeted proteins, diagnostic imaging, 394
whole-body retention, inflammatory bowel disease, 756
- Indium-111 anti-carcinoembryonic antigen, monoclonal antibody ZCE 025, safety and role, colorectal carcinoma, 14**
- Indium-111 anti-CEA-F(ab')₂ fragments, radiation dosimetry, tissue distribution, rats, 1654**
- Indium-111 antimyosin**
detection of tumor invasion of muscle layer, 841(ab)
myocardial damage in Adriamycin cardiomyopathy, 936(ab)
pathologic cardiac hypertrophy, myocyte damage, athletes, 994(ab)
risk of congestive heart failure, Adriamycin therapy, 895(ab)
scintigraphy, significance, uncomplicated valvular replacement, 895(ab)
uptake, chemotherapy-induced kidney disorder, 309(le)
uptake in acute and remote myocardial infarction, comparison with pathologic findings, 587
- Indium-111 antimyosin Fab, myocardial distribution, nontransmural infarction, 223**
- Indium-111 antimyosin monoclonal antibody, scintigraphy, time course, myocardial infarction, 1501**
- Indium-111 BAD-Lym-1, radiochemistry and pharmacokinetics, 1030(ab)**
- Indium-111 B3 monoclonal antibody, biodistribution in athymic nude mice, human epidermoid carcinoma xenografts, 842(ab)**
- Indium-111 B72.3 monoclonal antibody, pharmacokinetics in colorectal cancer, 498**
- Indium-111 BrE-3 antibody, radioimmunolocalization of breast cancer, Phase I study, 912(ab)**
- Indium-111 C110 anti-CEA monoclonal antibody, CT and, metastases detection, colorectal carcinoma, 904(ab)**
- Indium-111 cyclohexyl EDTA, anti-CEA F(ab')₂ monoclonal antibody and, human tumor xenografted nude mice, 943(ab)**
- Indium-111 CYT-356, preoperative identification, metastatic prostate carcinoma, 1001(ab)**
- Indium-111 DOCT, I-123 TOCT somatostatin analogues and, somatostatin receptor-positive neoplasms, 914(ab)**
- Indium-111 DTPA-D-Phe-1-octreotide handling by isolated perfused rat liver, 955(ab) somatostatin receptor scintigraphy, 652**
- Indium-111 DTPA-heparin, radiolabeling and pharmacokinetics, protamine, biodistribution, 1028(ab)**
- Indium-111 IgG**
infectious diabetic foot complications, 950(ab), 1330
reflex sympathetic dystrophy of the hand, excessive inflammatory response, 936(ab)
- Indium-111 immunoglobulins, infection imaging, IgM vs. IgG antibodies, 1031(ab)**
- Indium-111 leukocytes**
diffuse pulmonary uptake, drug-induced pneumonitis, 1175
Ga-67 and, acute sarcoidosis, 2027
Ga-67 polyclonal IgG and, acute focal inflammatory lesions, 1428(le)
infection mishaps, 27N(4)
- Indium-111 monoclonal antibody**
chimeric cT84.66, radiation dose estimates, 953(ab)
enhanced tumor targeting, metabolizable chemical spacer, 957(ab)
IVP ZCE 025, efficacy and safety, colorectal carcinoma, 959(ab)
preparation of high specific activity, amino-dextran and poly-lysine, 988(ab)
- Indium-111 monoclonal antibody fragments, dosimetric evaluation, immunoscintigraphy, ovarian cancer, 1113**
- Indium-111 monoclonal antimyosin Fab, cardiac transplantation rejection, primates, 1994**
- Indium-111 octreoscan, kit development for cancer detection, 1025(ab)**
- Indium-111 oxine**
absorbed dose and contamination risk, 953(ab)
Tc-99m HMPAO leukocytes, Tc-99m antigranulocyte Fab' fragments, infectious diseases, 903(ab)
Tc-99m leukocyte imaging and, simultaneous imaging, community hospital, 902(ab)
- Indium-111 pentatreotide, scintigraphy, gastroentero-pancreatic endocrine tumors, 976(ab)**
- Indium-111 platelets, thrombocytopenia and hepatic sequestration, GM-CSF, 923(ab)**
- Indium-111 polyclonal IgG**
carbohydrate modification, sites of bacterial infection, 1378
I-125 LDL and, uptake, experimental arterial wall injury, 845(ab)
single radiopharmaceutical kit, 1024(ab)
- Indium-111 somatostatin analogue**
scintigraphy, visualization, malignant lymphoma, 903(ab)
Tc-99m somatostatin analogue and, preparation, preliminary evaluation, 851(ab)
- Indium-111 transferrin, quantitation of intestinal protein loss, inflammatory bowel disease, 919(ab)**
- Indium-111 white blood cells**
chronic osteomyelitis, site of fracture or surgery, lower extremity, 902(ab)
necrotizing tracheobronchitis, 1704
- Infants: see also Pediatric patients**
Tc-99m MAG₃ clearance, preliminary "normal" values, 1021(ab)
- Infection**
acute, In-111 human immunoglobulin, HIV-positive patients, 903(ab)
AIDS and infectious disease, Annual Meeting highlights, 24N(8)
assessment of infectious conditions, musculoskeletal system, Tc-99m HIG, 839(ab)
bacterial, effects of carbohydrate modification, polyclonal IgG, 1378
bone, Tc-99m anti-granulocyte antibodies, 526
detection in rats, Tc-99m liposome labeling procedure, 1027(ab)
diagnosis of mycotic aneurysm, leukocyte scintigraphy, 1486
differentiation from malignant CNS lesions, FDG PET, AIDS, 838(ab)
F-18 FDG, 925(ab)
focal, radiolabeled proteins, biodistribution and kinetics, 388
imaging focal sites, Tc-99m hydrazino nicotinamide conjugated chemotactic peptides, 910(ab)
imaging in patients with streptavidin, radiolabeled biotin, 924(ab)
localization, role for avidin-biotin, 1816
orthopedic, value of bone marrow scanning, 840(ab)
- second Sino-American nuclear medicine conference, 16N(4)
sternal wound, diagnosis, Tc-99m leukocyte imaging, 59
targeted proteins, diagnostic imaging, 394
Tc-99m antigranulocyte Fab' fragments, scintigraphy, In-111 oxine/Tc-99m HMPAO leukocytes, 903(ab)
- Inflammation**
abdominal aortic aneurysm, In-111 imaging, 1553
accumulation in inflammatory focus, Tc-99m anti-fibrin monoclonal antibody, 1181
acute focal lesions, In-111 leukocytes, Ga-67 polyclonal IgG, 1428(le)
antimyosin imaging, detection of tumor invasion of muscle layer, 841(ab)
conjugation of human immunoglobulin, dendrimers as linker molecules, 986(ab)
imaging
current role, labeled autologous leukocytes, 65
Tc-99m dexamethasone phosphate, 1027(ab)
radiolabeled polyclonal IgG, 1031(ab)
reflex sympathetic dystrophy of the hand, excessive inflammatory response, 936(ab)
tumor and, one-step labeling kit, Tc-99m HIG, 1028(ab)
- Inflammatory bowel disease**
In-111 labeled human nonspecific immunoglobulin G, 919(ab)
In-111 whole-body retention, 756
quantitation of intestinal protein loss, In-111 transferrin, 919(ab)
Tc-99m glucoheptonate white blood cells, 998(ab)
- In memoriam**
Donald W. Cole, Jr., 1726
Oscar B. Hunter, Jr., 631
- Insulin**
clamp, myocardial glucose utilization, F-18 FDG PET, 1255, 1263
-dependent diabetes mellitus, secondary gastroparesis, 1707
- Interleukin 2, tumor uptake of monoclonal antibody, 934(ab)**
- Intestine, quantitation of protein loss, In-111 transferrin, inflammatory bowel disease, 919(ab)**
- Iodides, contrast material, potential effects, radioactive thyroid uptake, 237**
- Iodine-123**
I-125 and I-131 labeled compounds, radiotoxicity, mouse testes, 2196
myocardial viability after infarction, exercise-redistribution SPECT TI-201, 906(ab)
scintigraphic follow-up, differentiated thyroid carcinoma, 1020(ab)
Tc-99m and
dual radionuclide data acquisition, quantitative brain SPECT, 972(ab)
SPECT, brain, 2030
- Iodine-123 BMIPP**
hypertrophic cardiomyopathy, 1914(le)
TL-201 and, assessment, ischemic but viable myocardium, 885(ab)
- Iodine-123 CIT, SPECT, monoamine transporter sites, non-human primate brain, 945(ab)**
- Iodine-123 ERC 9, potential new pancreatic imaging agent, 841(ab)**
- Iodine-123 β -methyl-branched fatty acid, myocardial emission computed tomography, hypertrophic cardiomyopathy,**

- Iodine-123 HIDPM**, portal systemic shunt fraction quantification, liver diseases, 997(ab)
- Iodine-123 hirulog**, preparation and evaluation, blood clot imaging, 981(ab)
- Iodine-123 IBF**, SPECT, preclinical study, D2 dopamine receptor, 870(ab)
- Iodine-123 IBZM**
dopamine D2 receptors, dynamic SPECT and whole body imaging, 896(ab)
quantitation in human plasma, 871(ab)
SPECT
differential diagnosis of Parkinsonism, 917(ab)
dopamine D2 receptors, 1964
dopamine D2 receptors, effects of age, 897(ab)
dopamine D2 receptors, haloperidol, 898(ab)
dopamine D2 receptors, Parkinson's disease, 917(ab)
dopamine D2 receptors, Parkinson syndromes, 917(ab)
dopamine D2 receptors, unilateral Parkinson's disease, 1016(ab)
dopamine D2 receptors, Wilson's disease, 897(ab)
Parkinson's disease, multi-system atrophy and dystonia, 1018(ab)
semiquantification, scatter correction, 972(ab)
subjects with and at risk for Huntington's disease, 970(ab)
- Iodine-123 IDEX**, decreased binding to muscarinic cholinergic receptors, hippocampus, temporal lobe epilepsy, 928(ab)
- Iodine-123 ILIS**, SPECT, dopamine D2 receptors, supranuclear palsy, 1019(ab)
- Iodine-123 IMP**
cerebral blood flow
rotating gamma camera, 963(ab)
Tc-99m HMPAO and, uptake in drug abuse, 1015(ab)
SPECT
cerebral blood flow, no arterial sampling, 969(ab)
cerebral perfusion, progressive supranuclear palsy, 704
dementia, 1015(ab)
nondemented older patients, Down's syndrome, 967(ab)
partition coefficient, regional cerebral blood flow, 911(ab)
Tc-99m HMPAO and
dual-isotope brain imaging, normal volunteers, 827(ab)
regional cerebral blood flow, SPECT and MRI, 1012(ab)
- N-isopropyl-Iodine-123 IMP**, SPECT, regional cerebral blood flow, 965(ab), 1741
- Iodine-123 iodoamphetamine**, scintigraphy, Budd-Chiari syndrome, 744
- Iodine-123 IPPA**
metabolic cardiac imaging, multicrystal gamma camera, severe coronary disease, 1269
SPECT, myocardial involvement, systemic myopathies, 995(ab)
- Iodine-123 2'-ISP**, SPECT, D2 dopamine receptors, 897(ab)
- Iodine-123 LSD**, improved preparation, 982(ab)
- Iodine-123 MIBG**
cardiac imaging
prognostic guide, heart failure, 896(ab)
prognostic value, heart failure, 471
increased lung uptake, ischemic heart disease, 955(ab)
mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
neural crest tumors, 1072(ab)
prognosis in congestive heart failure, 477
scintigraphy, metastatic carcinoid tumors, 1121
uptake at 1-year post-cardiac transplant, partial reinnervation in man, 896(ab)
- Iodine-123 MIHA**, myocardial viability, FDG PET, 953(ab)
- Iodine-123 somatostatin analog**, dosimetry and biodistribution, neuroendocrine tumors, 1613
- Iodine-123 SP4**, imaging atherosclerosis, 845(ab)
- Iodine-123 TISCH**, dosimetry, 954(ab)
- Iodine-123 TOCT**
In-111 DOCT somatostatin analogues and, somatostatin receptor-positive neoplasms, 914(ab)
scintigraphy, metastatic carcinoid tumors, 1121
- Iodine-123 Tyr-3-octreotide**, compared to In-111 DTPA-D-Phe-1-octreotide, somatostatin receptor scintigraphy, 652
- Iodine-124 3F9**, PET, tumor dosimetry, radioimmunotherapy in a child with neuroblastoma, 2020
- Iodine-124 monoclonal antibodies**, PET, *c-erbB-2* protein overexpression, breast cancer, 2154
- Iodine-125**
anti-P185HER2 monoclonal antibody, animal tumor model, 934(ab)
I-123 and I-131 labeled compounds, radiotoxicity, mouse testes, 2196
rat brain blood flow, plastic scintillation detectors, position-sensitive photomultipliers, 1003(ab)
- Iodine-125 altanserine**, synthesis, potential ligand, SPECT and serotonin S₂ receptors, 1023(ab)
- Iodine-125 antimyosin**, interference of myosin heavy chain fragments, myocardial infarction, 895(ab)
- Iodine-125 digoxin**, high myocardial accumulation, 545
- Iodine-125 epidepride**, I-125 ioxipride and, alternate syntheses, 982(ab)
- Iodine-125 epidermal growth factor**, handling by isolated perfused rat liver, 955(ab)
- Iodine-125 fibrinogen**, fibrin deposition, coronary artery injury, 845(ab)
- Iodine-125 iodoacyclicloadenosin-4'-ene**, synthesis and metabolism, potential inhibitor, S-adenosyl-L-homocysteine hydrolase, 980(ab)
- Iodine-125 5-iodo-6-nitroquipazine**, synthesis and evaluation, presynaptic serotonin ligand, 890(ab)
- Iodine-125 ioxipride**, I-125 epidepride and, alternate syntheses, 982(ab)
- Iodine-125 LDL**
binding to parenchymal and non-parenchymal cells, normal and estradiol-stimulated rat liver, 1028(ab)
In-111 polyclonal IgG and, uptake, experimental arterial wall injury, 845(ab)
- Iodine-125 LSD**, improved preparation, 982(ab)
- Iodine-125 MIBG**
abnormal cardiac adrenergic neuron activity, Adriamycin-induced cardiomyopathy, 208
Adriamycin and congestive cardiomyopathy, 215
intracellular distribution, electron microscopic autoradiography, neuroblastoma
xenografts, 1021(ab)
intraoperative detection, pheochromocytoma, 1020(ab)
uptake by serotonin transporter, 935(ab)
- Iodine-125 monoclonal antibody**
biodistribution, hand-held NaI-crystal detector, 1002(ab)
microdosimetry estimations, internalization, human glioma cells, 942(ab)
- Iodine-125 PAB**, preparation and characterization, potential malignant melanoma imaging radiopharmaceutical, 889(ab)
- Iodine-125 QNB**, muscarinic receptor binding, pharmacokinetic sensitivity, rat brain, 883(ab)
- Iodine-125 Tyr-3-octreotide**, handling by isolated perfused rat liver, 955(ab)
- Iodine-131**
amount and tumor size, Alderson phantom, planar imaging, 925(ab)
anti-pan B-cell antibodies, radioimmunotherapy, B-cell lymphoma, 863(ab)
B1 and BC8 antibodies, trace and therapeutic amounts, 864(ab)
camera-induced scatter, collimator penetration, 889(ab)
contamination, thyroid cancer patients, 2110
I-123 and I-125 labeled compounds, radiotoxicity, mouse testes, 2196
imaging therapeutic doses, clinical gamma camera, 771
outpatient nuclear medicine therapy, petition would ease strictures, 13N(7)
pan-B-cell monoclonal antibody, B-cell lymphoma, radioimmunotherapy, 893(ab)
post-thyroid cancer therapy, radiation safety considerations, 1402
QSPECT of phantom, transfer of CT coils, manual alignment, 925(ab)
radioimmunotherapy of leukemia, bone marrow radiation absorbed dose estimation, 941(ab)
taste dysfunction, thyroid cancer, 996(ab)
therapeutic amounts, iodination of monoclonal antibodies, 982(ab)
therapy for thyroid cancer, quantitative dosimetric approach, 894(ab)
therapy for thyroid carcinoma, complications, sequela and dosimetry, 2214
-treated patients, risk to others, 2116
utility in well-differentiated thyroid cancer, chest X-rays, bone scans, 894(ab)
whole-body scan, replacement with thyroglobulin measurement, 172(le)
- Iodine-131 chimeric B72.3**, Phase I trial, metastatic colorectal cancer, 23
- Iodine-131 hippurate**, Tc-99m MAG₃ or, functional and anatomic evaluation, renal transplants, 1035(ab)
- Iodine-131 lipiodol**, high-dose targeted irradiation, liver tumors, 1020(ab)
- Iodine-131 LL2 monoclonal antibody**, repeated low-dose radioimmunotherapy, lymphoma, 863(ab)
- Iodine-131 Lym-1**, body and blood clearance and marrow radiation dose, B-cell malignancies, 941(ab)
- Iodine-131 MIBG**
bone scintigraphy and, detection of neuroblastoma, 1735
brain imaging, 33N(9)
diagnosis of pheochromocytoma, 833(ab)
scintigraphic assessment of uptake, globally denervated human and canine hearts, 1444

- scintigraphy
 diagnostic value, kindred with MEN-II, 1065(ab)
 pitfalls, diagnosis of neuroblastoma, 930(ab)
 therapy for carcinoid syndrome, 834(ab)
- Iodine-131 monoclonal antibody**
 bone marrow suppression, recombinant G-CSF, 933(ab)
- CC49
 imaging considerations, 1001(ab)
 radioimmunotherapy SPECT images, CT and advanced colorectal cancer, 1002(ab)
 immunoscintigraphy of ovarian carcinoma, 905(ab)
 radioimmunoscintigraphy, renal cell carcinoma, 913(ab)
- Iodine-131 monoclonal antibody fragments**, bone marrow toxicity, 941(ab)
- Iodine-131 Mu-9 IgG**, Re-188 and, therapeutic potential, single and fractionated doses, 1000(ab)
- Iodine-131 octreotide**, dosimetry and biodistribution, I-123 somatostatin analog, neuroendocrine tumors, 1613
- Iodine-131 OIH**
 radiation dosimetry, human biodistribution studies, 33
 single-injection multi-sample renal clearance methods
 comparison, 948(ab)
 optimum sample times, 948(ab)
- Iodine-131 1,2-Pal-3-IPPA**, site specific/stable radiodination, pancreatic lipase, urine analysis, 1028(ab)
- Iodocholesterol**, radiation injury after interstitial injection, 1722(le)
- 5-Iododeoxyuridine**, efficacy of radioimmunotherapy, human tumors growing in nude mice, 1530
- 3-Iodophenylisothiocyanate**, radiodinated, coupling to monoclonal antibodies, 1029(ab)
- Iomazenil**, binding to human benzodiazepine receptor, dynamic SPECT, 911(ab)
- Ion mass spectrometry microscopy**, secondary, Tc-99m mapping, leukocytes, 2162
- Iron**
 hepatic and cardiac, noninvasive *in vivo* measurement, 1278
 transferrin and hepatic Ga-67 concentration, Ga-67 distribution, 1701
- Irradiation**
 high-dose targeted, primary liver tumors, I-131 lipiodol, 1020(ab)
 total body, toxicity, non-Hodgkin's lymphoma, 960(ab)
- Ischemia**
 delayed, cerebral angioplasty and vasospasm, brain SPECT, 1789
 renal, captopril-mediated hemodynamic changes, 907(ab)
- Isoelectric focusing**, chromatofocusing studies, monoclonal Fab', 2148
- Isotec, Inc.**, rejection of petition, 14N(6)
- Isotopes**
 DOE's problems, 34N(10)
 medical use of, Nuclear Regulatory Commission, 30N(9)
 trouble in U.S., GAO probe, 22N(9)
- J**
- Jaundice**, neonatal, diagnostic criteria for biliary atresia, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)
- Joint**
 inflammation
 Tc-99m HIG, 839(ab)
 Tc-99m HIG and bone scans, rheumatoid arthritis, 840(ab)
- Journal of Nuclear Medicine (JNM)**, seeking new editor, 20N(7)
- K**
- Kanji-Kana reading process**, analysis by PET, 827(ab)
- Kawasaki syndrome**, cardiac perfusion abnormalities, long-term follow-up, 929(ab)
- Kidney**
 blood flow, convection-diffusion model, 949(ab)
 cancer, pre-operative sterilization, intra-arterial Sm-153 microspheres, 1024(ab)
 cationic renal tubular agent, Tc-99m DACH, normal human volunteers, 923(ab)
 chemotherapy-induced disorder, antimyosin antibody uptake, 309(le)
 clearance, single-injection multisample methods, 948(ab)
 comparison of Tc-99m direct vs. N2S2 chelate, labeled NR-LU-10 Fab', tumored nude mice, 909(ab)
 computer-based nuclear medicine teaching file, 1073(ab)
 -depth correction in renal uptake rate, Tc-99m DMSA, compartment modeling, 1004(ab)
 direct and indirect Tc-99m labeled antibody, comparison in mice, 909(ab)
 diuretic MAG₃ renal scintigraphy, routine protocol, congenital and acquired renal disorders, 1035(ab)
 DMSA renal scans, variability, standardized rating scale, 922(ab)
 dynamic studies, quantitative analysis, factor analysis, 949(ab)
 effects of dipyridamole on function, Tc-99m DTPA, 355
 excretion of Tc-99m-labeled organic cations, 2190
 functional clearance, captopril, diuretic therapy, 739
 imaging with Tc-99m 2GAM, 923(ab)
 impaired renal function, antenatal hydronephrosis, surgery vs. conservative management, 873(ab)
 model-based quantitation, knowledge-based factor analysis, 947(ab)
 normalized diuretic renogram parameters, diagnosis, obstructive uropathy, 923(ab)
 parenchymal renal lesion after ESWL, Tc-99m DMSA, 990(ab)
 PET studies, use of abdominal aorta, arterial input function determination, 613
 plasma flow and glomerular filtration rate, spinal cord injury, 1035(ab)
 post-transplanted patients, radioangiostigraphy, 991(ab)
 potential imaging agents, Tc-99m MAG₃, 919(ab)
 potential of camera-based method, MAG₃ clearance, gamma variate fit, 991(ab)
 pre- and post-pyeloplasty, functional assessment, diuretic renogram, 977(ab)
 procedures of choice in renal nuclear medicine, 175(le)
 prospective validation, single sample technique, Tc-99m MAG₃ clearance, 1620
 rapid tubular transport, structural requirements, Re and Tc-99m complexes, 900(ab)
 real time monitoring, risk of radiocontrast-
- induced acute renal failure, 948(ab)
 renal artery stenosis, cortical residual activity, captopril renography, 906(ab)
 renal tubular transport, Tc-99m complexes, 920(ab)
 suspected uretero-pelvic junction obstruction, postnatal assessment, volume expanded diuretic renography, 2094
 Tc-99m, ligands related to MAG₃ and hippuric acid, 988(ab)
 Tc-99m DMSA high-resolution SPECT, three-head rotating gamma camera, 1021(ab)
 Tc-99m DTPA uptake-plasma volume product, glomerular filtration rate, 1712
 Tc-99m L,L-EC imaging agent, 551
 Tc-99m MAG₃
 hepatic activity, 992(ab)
 simplified ERPF determination, 1034(ab)
 Tc-99m scan, diagnosis, bleeding mycotic iliac aneurysm, 1548
 transplantation
 functional and anatomic evaluation, Tc-99m MAG₃ vs. I-131 hippurate, 1035(ab)
 kinetics and chronic rejection, renal artery stenosis, 923(ab)
 renal artery stenosis, captopril-enhanced scintigraphy, 263
 Tc-99m mertiatide, atlas, 1073(ab)
 transplant hypertension, iliac artery stenosis, 1178
 triple radiopharmaceutical renal study, standard DTPA renogram, renovascular hypertension, 1034(ab)
 unexpected pressor responses, captopril renal scintigraphy, 906(ab)
 uptake of avidin, isoelectric point, 986(ab)
 washout during Tc-99m DTPA diuresis renography, ureteral status, children, 73
- Knee**, acute ligamentous injuries, subchondral bone infarctions, scintigraphy and MRI, 516
- Krypton-81m**
 anatomy of radioisotope lung scanning, 676
 go with the flow—but how far?, 1939
 multiple-gated imaging, right ventricular volume determination, 932(ab)
 separation of regional ventilation and volume, 1935
- Kupffer cells**, dosimetry at cellular level, Tc-99m sulphur colloid injection, 380
- Kuwait**, burning oil wells and air pollution, lung imaging studies, 978(ab)
- L**
- Laminin**, platelet-binding, direct Tc-99m labeling, 1031(ab)
- Landau-Kleffner syndrome**, regional cerebral perfusion, related childhood aphasias, 1758
- Language**, analysis of Kanji-Kana reading process by PET, 827(ab)
- Lead-203 immunoconjugates**, biodistribution, chelate rigidity and denticity, 1030(ab)
- Leukemia**, bone marrow radiation absorbed dose estimation, I-131 radioimmunotherapy, 941(ab)
- Leukemia, myelogenous**, acute, modeling and dosimetry, anti-CD33 monoclonal antibody M195, 941(ab)
- Leukocytes**
 labeled autologous, current role, imaging inflammation, 65
 radiolabeled, detection, cardiovascular infections, 1493
 scintigraphy, diagnosis of mycotic aneurysm,

Ligands

- 1486
Tc-99m mapping, secondary ion mass spectrometry microscopy, 2162
- Ligands**
angiotensin II, distribution, imaging potential, 900(ab)
binding and animal biodistribution, no-carrier-added radioiodinated cocaine analogs, 981(ab)
chemical family of, dopamine D2 receptors, 981(ab)
diaminedithiol, labeling with Re-186, 1932(ab)
flumazenil, quantification of benzodiazepine receptors, PET, 883(ab)
macrocyclic, bifunctional DTPA and, serum stability studies with Y-88, 1031(ab)
PET, cerebral dopamine D2 receptors, 847(ab)
phosphorus-nitrogen backbone, formulation, new radiopharmaceuticals, 1072(ab)
radioiodinated high-affinity dopamine D2 receptor, *in vivo* comparison, 848(ab)
-receptor modeling, PET, multi-injection approach, 943(ab)
relation to MAG₃ and hippuric acid, Tc-99m renal function agents, 988(ab)
structure, glutathione-mediated decomposition, propylene amine oxime derivatives, 988(ab)
synthesis of I-125 altanserine, SPECT, serotonin S₂ receptors, 1023(ab)
Tc and Re complexes, unsymmetrical BAT ligand, 989(ab)
- Light**, photic stimulation study, arterial partial pressure, carbon dioxide, 827(ab)
- Liposomes**, Tc-99m, new labeling procedure, infection detection in rats, 1027(ab)
- Lithium carbonate**, therapy for psychiatric disorders, hyperthyroidism, 996(ab)
- Lithotripsy**, extracorporeal shockwave, parenchymal renal lesion, Tc-99m DMSA, 990(ab)
- Liver**
activity in Tc-99m MAG₃ renal scans, 992(ab)
arteriovenous malformations, embolization, hereditary hemorrhagic telangiectasia, 260
chelator structure, In-111 labeled Ab-chelator, 1001(ab)
chronic disease, evaluation of local reduced mass, Tc-99m NGA, 998(ab)
cirrhosis, portal venous blood flow, pulsed Doppler and per-jejunum scintigraphy, 997(ab)
clearance of Tc-99m HIDA derivatives, hyperbilirubinemic states, 1551
diagnosis of hepatic hemangioma, triple-head high-resolution SPECT, 918(ab)
diagnostic imaging, 1344
enhanced tumor targeting, metabolizable chemical spacer, In-111 monoclonal antibody, 957(ab)
FDG uptake kinetics, impact of glucose ingestion, dynamic PET, 945(ab)
hepatic arterial-to-portal venous blood flow, validation, radionuclide techniques in an animal model, 239
hepatic sequestration of In-111 platelets, thrombocytopenia, GM-CSF, 923(ab)
hepatobiliary scintigraphy, intrahepatic vs. extrahepatic cholestasis, 1186
homogenates of In-111 and Y-90, attachment to antibody via popular chelators, 1030(ab)
inhibition of hepatic uptake, radiolabeled monoclonal antibody, primary rat hepatocyte culture model, 893(ab)
iron, noninvasive *in vivo* measurement, 1278
isolated perfused, I-125 Tyr-3-octreotide, In-111 DTPA-D-Phe-1-octreotide and I-125 epidermal growth factor, 955(ab)
lesions, Tc-99m monoclonal antibodies and Tc-99m colloid, image subtraction analysis, 913(ab)
model-based quantitation, knowledge-based factor analysis, 947(ab)
necrosis, Tc-99m medronate, Budd-Chiari syndrome, 1390
normal and estradiol-stimulated, binding of Tc-99m LDL and I-125 LDL, 1028(ab)
PET studies, use of abdominal aorta, arterial input function determination, 613
portal systemic shunt fraction quantification, I-123 HIDPM, 997(ab)
reduced accumulation, radiolabeled monoclonal antibodies, In-111 thioether-poly-L-lysine-DTPA monoclonal antibody-TP41.2F(ab')₂, 570
-spleen scan, fatty liver, masquerade as neoplasm, 258
TBIDA scan hot spots, focal nodular hyperplasia, 918(ab)
transplantation, bile extravasation, scintigraphy, 115
transplant infarcts, bile lakes, hepatobiliary scintigraphy, 997(ab)
transport function, hepatobiliary scintigraphy, 998(ab)
volume measurement with SPECT, autopsy and NMR imaging, 1066(ab)
Y-90 microsphere therapy, three-dimensional tumor dosimetry, 735
- Liver disease**, diffuse alcoholic, emission tomography, 1337
- Liver neoplasms**
dual energy acquisition, Tl-201 and Tc-99m phytate, high-resolution three head SPECT, 976(ab)
evaluation with F-18 FDG PET, 333
high-dose targeted irradiation, I-131 lipiodol, 1020(ab)
imaging by Tl-201 and Tc-99m phytate, high-resolution three-head SPECT, 918(ab)
- Low-level radioactive waste (LLRW)**
California radioactive waste site, licensing decision, 40N(9)
disposal of, 30N(10)
federal deadline, activists and politicians, 15N(1)
federal policy, challenged, 25N(12)
gauging the effect of court ruling, 28N(8)
repository closures, 34N(9)
shouldering burden of, 20N(6)
waste network, 34N(9)
- Low-Level Radioactive Waste Policy Amendments Act (LLRWPA)**
shouldering burden, 20N(6)
Supreme Court to hear case, 33N(3)
- Lung**
blood flow, protein flux measurements, PET, 1661
chronic obstructive pulmonary disease, major upward creep of heart, exercise Tl-201 myocardial SPECT, 1846
complications of HIV infection, Tc-99m DTPA aerosol, Ga-67 scanning, 81
diffuse pulmonary uptake, In-111 leukocytes, drug-induced pneumonitis, 1175
diseases, V/Q ratio frequency distribution, 1023(a)
disposition of gallium-67, *Pneumocystis pneumonia*, 512
enhanced V/Q mismatch sign, pulmonary embolism, 1072(ab)
imaging studies of persons exposed to air pollution, burning oil wells in Kuwait, 978(ab)
increased uptake of I-123 MIBG, ischemic heart disease, 995(ab)
indeterminate probability scan, decision analysis, 1251(le)
infection, accuracy of early gallium imaging, immunocompromised patients, 957(ab)
intermediate probability/indeterminate scans, pulmonary angiography, 849(ab)
mean transit times of technetium, compared to Tc-99m pertechnetate, 846(ab)
metastases, microdistribution, monoclonal antibodies, 957(ab)
MIBG extraction fraction, first-pass analysis, 716
model-based quantitation, knowledge-based factor analysis, 947(ab)
neutrophil sequestration, intercellular adhesion molecules, endotoxemia, 1023(ab)
perfusion and ventilation scans, severe diffuse obstructive airway disease, 1072(ab)
radioaerosol clearance, effect of molecular size, 1022(ab)
radioisotope scanning, anatomy of, 676
radiolabeled granulocyte kinetics, systemic vasculitis, 491
radiopulmonary clearance, appropriate background subtraction, 836(ab)
scan and pulmonary arteriogram improvement, urokinase, 849(ab)
scan interpretation, 1417, 1422
interobserver variation, 978(ab)
scintigraphy, follow-up, transplantation, 835(ab)
single transplant, quantitative exercise-rest ventilation-perfusion imaging, 835(ab)
solitary pulmonary nodule, differential diagnosis, FDG PET, 836(ab)
thallium uptake, adenosine Tl-201 scintigraphy, 1600
uptake of Tc-99m sestamibi, correlation with LV ejection fraction, 846(ab)
ventilation, Tc-99m DTPA and Tc-99m desferoxamine aerosols, SPECT, 835(ab)
ventilation-perfusion scans
computer-assisted diagnosis, pulmonary embolism, 1003(ab)
number of segmental mismatches, likelihood of pulmonary embolism, 849(ab)
- Lung neoplasms**
mediastinum, FDG PET staging, 828(ab)
radioimmunodetection, human monoclonal antibody, 958(ab)
treatment planning and monitoring, F-18 FDG PET, 975(ab)
- Lymphedema**
lymphoscintigraphy, 999(ab)
multiscintigraphic imaging approach, 874(ab)
- Lymph nodes**
mediastinal, mapping, F-18 deoxyglucose PET, 828(ab)
reactive, infection and, F-18 FDG, 925(ab)
- Lymphocytes**, Tc-99m HMPAO, radiotoxicity study, micronucleus assay, 1167
- Lymphoma**
F-18 FDG PET, 532
Hodgkin's, effect of therapy, Ga-67 scans and MRI, 914(ab)
malignant
F-18 FDG scintigraphy, chemotherapeutic impact, 858(ab)

In-111 somatostatin analogue scintigraphy, 903(ab)
 kinetics and therapeutic potential, Ga-67, 926(ab)
 proliferative activity, PET F-18 FDG, 325
 non-Hodgkin's
 Ga-67 scintiscan, 1183
 toxicity, total body irradiation, 960(ab)
 optimal imaging time for thallium, tumor agent, 844(ab)
 repeated low-dose radioimmunotherapy, I-131 LL2 monoclonal antibody, 863(ab)
 staging, role of gallium scanning, 1588(le)
 thyroid, uptake, Tc-99m MIBI and Tl-201 chloride, 1396
Lymphoma, B-cell, I-131 anti-pan B-cell antibodies, radioimmunotherapy, 863(ab), 893(ab)
Lymphoscintigraphy
 diagnosis of lymphedema, 999(ab)
 internal mammary, breast cancer prognosis, 859(ab)
 Tc-99m dextran, transverse rectus abdominus myocutaneous flap, autogenous breast reconstruction, 859(ab)

M

Magnetic resonance spectroscopy, fluorinated polymeric molecular probes, non-invasive assessment, pH, 974(ab)
Malignancies, intracranial arteriovenous, sequential high resolution SPECT, Tc-99m RBC and Tc-99m HMPAO, 839(ab)
Malignancy
 bone lesions, Tl-201 uptake pattern, 869(ab)
 genitourinary, post-treatment evaluation, FDG PET, 829(ab)
 Tc-99m sestamibi SPECT, F-18 FDG glucose, 858(ab)
Malignancy, B-cell, body and blood clearance, marrow radiation dose, I-131 Lym-1, 941(ab)
Manometry, esophageal disorders and scintigraphy, 1301
Manpower Survey, 1992, 51N(11)
MDP, perioperative uptake, S-ROM hip prosthesis, 950(ab)
Mediastinum
 biopsy-confirmed residual Hodgkin's disease, Ga-67 SPECT, 345
 FDG PET staging, lung cancer, 828(ab)
 lymph node mapping, F-18 deoxyglucose PET, 828(ab)
Medical Internal Radiation Dose (MIRD), radiopharmaceutical uptake, dose heterogeneity, quantitative autoradiography, 1833
Medicare
 fee schedule, 34N(9)
 SNM and ACNP response, 18N(1)
 Office of Payment Policy, 36N(9)
 reform, charting the impact, 18N(2)
 statement by physician payment review commission, 24N(3)
 volume performance standard, 24N(3)
Melanoma
 malignant
 F-18 FDG PET, 975(ab)
 preparation of I-125 PAB, 889(ab)
 uveal, radioimmunoscintigraphy, 3-step monoclonal antibody pretargeting technique, 959(ab)
Melanoma, B16, non-S phase melanocytes, accumulation of 2-[F-18]FDOPA,

microautoradiography, 984(ab)
MEN-II, kindred with, diagnostic value, I-131 MIBG scintigraphy, 1065(ab)
Meningioma, prediction of histological type, Tl-201 SPECT, 971(ab)
Mental disease, genetic models, 22N(8)
Metaiodobenzylguanidine, heart and lung extraction fraction, first-pass analysis, 716
Metastasis
 bone, pharmacokinetics, Re-186 after Re-186-HEDP, 646
 bone cancer, escalating dose schedule, Sm-153 EDTMP, 1451
 bone disease, multidose Sm-153 EDTMP, pain palliation, 992(ab)
 bone pain, different therapeutic doses, Sr-89, 937(ab)
 breast cancer
 clinical value, CA 15-3 plasma levels, 854(ab)
 radioimmunotherapy, 862(ab)
 carcinoid tumors, scintigraphic comparison, I-123 MIBG and I-123 TOCT, 1121
 colon cancer, dose fractionation, radiolabeled antibodies, 1648
 detection in colorectal carcinoma, In-111 C110 anti-CEA monoclonal antibody, CT, 904(ab)
 gastro-entero-pancreatic endocrine tumors, In-111 pentatreotide scintigraphy, 976(ab)
 gastrointestinal cancer, radioimmunotherapy, 863(ab)
 lung, microdistribution, monoclonal antibodies, 957(ab)
 prostate carcinoma, preoperative identification, In-111 CYT-356, 1001(ab)
 prostate carcinoma to bone, strontium-89, low-dose infusion cisplatin, 1437
 quantitative tumor scintigraphy, dogs with osteosarcoma, 1542
 recurrent soft-tissue sarcoma and, gallium imaging, 1594
 spinal, radionuclide bone scan, MRI imaging, 992(ab)
 thyroid carcinoma, Tc-99m TBI scintigraphy, 914(ab)
Methionine, thymidine or, location in cell, radiation-induced alterations, 841(ab)
Methylene, bridged phosphineoxide-phosphine, versatile chelating agent, Re-188, 979(ab)
MIBI, -SPECT and stress echocardiography, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
Microautoradiography
 F-18 FDG, granulation tissues and phagocytes, mouse tumor tissue, 840(ab)
 high accumulation of 2-[F-18]FDOPA, non-S phase melanocytes, B16 melanoma, 984(ab)
Microdosimetry, estimations of I-125 monoclonal antibody 425, internalization, human glioma cells, 942(ab)
Micrometastases
 continuing evolution, 2180
 neuroblastoma, radioiodinated MIBG, multicellular tumor spheroids, 859(ab)
 plasmapheresis in radioimmunotherapy, mathematical model, dosimetry, 2167
Micronucleus assay, lymphocyte labeling, Tc-99m HMPAO, radiotoxicity, 1167
Microspheres
 intra-arterial Sm-153, pre-operative sterilization, kidney cancer, 1024(ab)
 polymeric, radionuclide synovectomy, neuron-activated holmium-166, 398

Y-90 therapy, three-dimensional tumor dosimetry, 735
Microwave
 boiling procedure for Cardiolite vials, 468(le)
 breakage of Tc-99m sestamibi vial, 176(le)
MIRD dose
 approach and limitations, 781
 estimate No. 15, radioindium-labeled autologous platelets, 777
 pamphlet No. 14, urinary bladder model, radiation dose calculations, 783
Misonidazole, retention after occlusion of LAD coronary artery, regional myocardial metabolism, blood flow, 993(ab)
Mitral valve disease, Tc-99m radionuclide angiography, thrombosis detection, left atrial appendage, 365
Molybdenum-99
 DOE actions, 14N(6)
 doubts about U.S. production, 21N(10)
 government plan, slow advancement, 11N(2)
 threatened reactor worker strike, 19N(9)
Monoamine, transporter sites, I-123 CIT SPECT, non-human primate brain, 945(ab)
Monoclonal antibodies
 A11, diagnosis, neuroendocrine tumors, 834(ab)
 β /A4 amyloid, Alzheimer's disease, angiopathy, 2184
 Annual Meeting highlights, 13N(8)
 anti-CEA/anti-DTPA bispecific, two-step immunoscintigraphy, medullary carcinoma of thyroid, 912(ab)
 antiferritin, linker-conjugated F(ab')₂ fragments, 987(ab)
 anti-fibrin, Tc-99m labeling, accumulation in inflammatory focus, 1181
 anti-pan-carcinoma NR-LU-10, biotin conjugates, radioimmunotherapy, 880(ab)
 attachment of monofunctional DTPA analogs, 988(ab)
 BC-2, detection of breast tumors, 999(ab)
 B72.3/CC49/CC83, radioiodination, pharmacokinetics, 960(ab)
 CEA-producing cancer, radioimmunodetection, 1750
 chimeric antibody chCE7, radioimmunolocalization, neuroblastoma xenografts, 231
 chimeric anti-CEA, HAMA response after immunoscintigraphy, 903(ab)
 chimeric cT84.66, In-111 labeling, radiation dose estimates, 953(ab)
 chimeric MOv18, reactive with ovarian cancer-associated antigen, 2000
 coupling, radioiodinated 3-iodophenylisocyanate, 1029(ab)
 Cu-64-labeled, PET imaging, 1685
 direct and indirect Tc-99m labeled antibody, comparison in mice, 909(ab)
 dose fractionation of radiolabeled antibodies, metastatic colon cancer, 1648
 ethics, 296
 F(ab')₂ fragments, c-kit protooncogene overexpression, scintigraphic detection, 893(ab)
 F(ab')₂ tumor uptake, hyperthermia, 958(ab)
 F-18 antimyosin monoclonal antibody fragments, preliminary investigations, canine myocardial infarct model, 575
 human/mouse chimeric, recognition of CA125, ovarian cancer radioimmunoinaging, 1001(ab)
 I-131 chimeric B72.3, Phase I trial, metastatic colorectal cancer, 23

- In-111 B72.3, pharmacokinetics, colorectal carcinoma, 498
- In-111 labeled IVP ZCE 025, efficacy and safety, colorectal carcinoma, 959(ab)
- In-111 thioether-poly-L-lysine-DTPA monoclonal antibody-TP41.2F(ab')₂, reduced hepatic accumulation, 570
- iodination, therapeutic amounts of I-131, 982(ab)
- labeling of white blood cells, 34N(5)
- labeling with F-18, *N*-succinimidyl 4-[F-18] fluorobenzoate, 881(ab)
- M195, modeling and dosimetry, acute myelogenous leukemia, 941(ab)
- microdistribution, experimental lung metastases, 957(ab)
- monoclonal Fab', chromatofocusing studies, 2148
- NR-LU-10
- CH2 domain deletion mutant, radioimmunotherapy potential, 1028(ab)
- Re-186 direct vs. chelate labeling, tumored nude mice, 910(ab)
- octahedral gallium chelate, immunoscintigraphy, PET, 1366
- optimizing intraperitoneal radioimmunotherapy, 959(ab)
- radioimmunodetection of lung cancer, 958(ab)
- radioimmunotherapy, MIRDose dosimetry software protocol, 926(ab)
- radiolabeled
- antibody-macrocytic chelate conjugates, 1031(ab)
 - chimeras, 29
 - fusion of SPECT images with CT/MRI images, 960(ab)
 - heterogeneous distribution, binding site barrier, 893(ab)
 - inhibition of hepatic uptake, primary rat hepatocyte culture model, 893(ab)
 - oncogene-encoded molecules, tumor imaging and therapy, 2160
 - radiation absorbed dose, planar scintigraphic views, 925(ab)
- second generation high-affinity anti-CEA, 904(ab)
- 3-step pretargeting technique, radioimmunoscintigraphy, uveal melanoma, 959(ab)
- TNT-1 and TNT-1-F(ab')₂, Re-186, radioimmunotherapy, 987(ab)
- tumor-associated antigens, similarity and co-expression, 853(ab)
- tumor uptake, effect of interleukin 2, 934(ab)
- ZCE 025, In-111 anti-CEA, colorectal carcinoma, 14
- Z2D3
- imaging atherosclerotic lesions, antibody-avidin-biotin interactions, 934(ab)
 - localization, atherosclerotic lesions, 936(ab)
- Monte Carlo**, modeling techniques, radiation dose calculation, bone-to-marrow interface, 623
- Morphine**
- augmented cholescintigraphy
 - false-negative, subacute gallbladder perforation, 256
 - potential pitfalls, 898(ab)
- Moyamoya disease**, SPECT/MRI/angiography, before and after external-to-internal carotid artery bypass, 1692
- Multidrug resistance**, tumor, *in vivo* identification, tritium-3-colchicine, 1373
- Multiple systemic atrophy**, selective metabolic involvement, 1014(ab)
- Muscle, skeletal**, time course of glucose uptake, euglycemic hyperinsulinemia, F-18 2-deoxy-2-fluoro-D-glucose study, 1523
- Muscular dystrophy**, myocardial involvement, I-123 IPPA SPECT, 995(ab)
- Musculoskeletal system**, assessment of infectious conditions, Tc-99m HIG, 839(ab)
- Myasthenia gravis**, Tl-201 SPECT, 1020(ab)
- Mycobacterium avium-intracellulare**, accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)
- Myelosuppression**, reduction of, efficacy of immunophoresis, radioimmunotherapy, 863(ab)
- Myocardial infarction**
- acute, Tc-99m glucarate and Tl-201, rats, 1988
 - acute and remote, In-111 antimyosin uptake, pathologic findings, 587
 - artifact or, gated Tc-99m sestamibi SPECT, 927(ab)
 - canine model, preliminary investigations, F-18 antimyosin monoclonal antibody fragments, 575
 - consequences of ventricular tachycardia, scintigraphic phase analysis, 994(ab)
 - experimental, gamma imaging, rabbits, 943(ab)
 - increase in FDG uptake, prognostic indicator, 886(ab)
 - infarct-specific tracers, transmural uptake, perfusion tracers, 229
 - inferior, right ventricular ischemia, low-level exercise Tc-99m sestamibi SPECT, 876(ab)
 - instant kit method, labeling antimyosin Fab', Tc-99m, 144
 - interference in antimyosin imaging, circulating myosin heavy chain fragments, 895(ab)
 - interval between reinjection and imaging, Tl-201 image, 915(ab)
 - late infarct size and ejection fraction, thrombolytic therapy, 939(ab)
 - left ventricular mass and, N-13 ammonia PET, explanted human hearts for validation, 826(ab)
 - necessity of thallium reinjection, 916(ab)
 - negatively charged-polymer-modified antimyosin, 959(ab)
 - patients without, pharmacologic stress, extent and location of CAD, 2067
 - regional metabolic abnormality, relation to perfusion, wall motion, 659
 - related arterial patency, serial tomographic imaging, Tc-99m sestamibi, 2080
 - size determination, cardiac myosin heavy chain, 853(ab)
 - time course, In-111 antimyosin monoclonal antibody scintigraphy, 1501
 - Tl-201 compared to Tc-99m sestamibi, 865(ab)
 - viability, iodo-labeled methyl fatty acid, FDG PET, 953(ab)
- Myocardial ischemia**
- adenosine infusion, hemodynamic-scintigraphic study, 952(ab)
 - assessment of viable myocardium, combined imaging, I-123 BMIPP and Tl-201, 885(ab)
 - blood flow and deoxyglucose uptake, myocyte viability, 1353
 - blood flow and glucose uptake, F-18 deoxyglucose, 1346
 - detection by combining flow reserve with metabolic assessment, coronary artery disease, 837(ab)
 - early or delayed reperfusion, myocardial oxidative metabolism, mechanical function, 884(ab)
- ECG response and perfusion images, thallium stress test, 1723(le)
- enhanced detection after thallium reinjection, quantitative reversibility maps, visual analysis, 916(ab)
- exercise-induced, first-pass radionuclide angiography, upright bicycle ergometry, 359
- extent and severity, PET, predictor of prognosis following thrombolytic therapy, 837(ab)
- general thallium redistribution model, 915(ab)
- increased lung uptake in I-123 MIBG, 955(ab)
- metabolic evidence, dipyridamole stress, 866(ab)
- myocardial energy balance, C-11 SAH PET, 2144
- PET ischemic segments, accelerated clearance, C-11 acetate, 856(ab)
- regional cardiac adenosine, PET, 2138
- reperfusion, retention of Cu-PTSM, Langendorff perfused rat heart, 1026(ab)
- right ventricular, inferior myocardial infarction, low-level exercise Tc-99m sestamibi SPECT, 876(ab)
- Tl-201 defect reversibility and severity, quantitative vs. visual analysis, 905(ab)
- Myocarditis**, immune mechanisms in heart disease, Mallinckrodt Fellow, 17N(6)
- Myocardium**
- accumulation of radioiodinated digoxin derivative, possible Na,K-ATPase imaging agent, 545
 - aerobic, fatty acid kinetics, 1864
 - biokinetics of Tc-99m tetrofosmin, one-day imaging, 874(ab)
 - blood flow
 - co-injection technique, 1152
 - expected variability, anesthetized canine, 884(ab)
 - methods for quantification, N-13 ammonia PET, 881(ab)
 - polar map displays, cardiac PET images, 1628
 - Tc-99m Q12 activity, dogs, 993(ab) - blood flow and glucose uptake, ischemia, F-18 deoxyglucose, 1346
 - blood pool spillover, method for correction, dynamic cardiac FDG PET, 882(ab)
 - bridging, predictive value, dipyridamole thallium imaging, 1905
 - characteristics of Tc-99m tetrofosmin, coronary heart disease, 875(ab)
 - clinical efficacy of tetrofosmin, 874(ab)
 - comparison of defect size, Tc-99m tetrofosmin, peak exercise, 874(ab)
 - computer-aided diagnosis, coronary artery disease, artificial neural network, 272
 - continuous monitoring, left ventricular function during exercise, coronary jeopardy score, 938(ab)
 - damage in Adriamycin cardiomyopathy, In-111 antimyosin antibody, 936(ab)
 - defect size and severity, correlation, Tc-99m sestamibi and N-13 ammonia PET, 875(ab)
 - delineation of, heart volumes, PET and SPECT, 933(ab)
 - diffuse necrosis, acute onset, cardiogenic shock, 1558
 - distribution of In-111 antimyosin Fab, Tc-99m sestamibi and, nontransmural infarction, 223
 - emission computed tomography, I-123 beta-methyl-branched fatty acid, hypertrophic cardiomyopathy, 6
 - extraction of teboroxime, interaction with

- blood, 94
- FDG PET studies, oral glucose loading or insulin clamp methods, 1263
- flow reserve decline with age, higher cardiac work at rest, 836(ab)
- glucose utilization, insulin clamp, F-18 FDG PET, 1255, 1263
- hibernating, irreversible perfusion defects, Rb-82 and F-18 FDG PET, 1065(ab)
- human pharmacokinetics and radiopharmacological studies, Tc-99m CPI, 1949
- hypoxic, detection using F-18 FMISO PET, 2202
- imaging, breast tissue attenuation, 961(ab)
- imaging regional hypoxia, Tc-99m 2-nitroimidazole, occlusion of LAD coronary artery, 865(ab)
- infarcted and perinfarcted, oxidative metabolism, C-11 acetate PET, 953(ab)
- iodo-labeled methyl fatty acid, viability, FDG PET, 953(ab)
- kinetics of Cu-62 PTSM, non-human heart, 684
- left ventricular time-activity curve, O-15 water PET, 1669
- MIBG heart and lung extraction fraction, first-pass analysis, 716
- misalignment between PET transmission and emission scans, 1209, 1214
- N-13 ammonia stress perfusion imaging in PET, objective computerized quantitative method, 1009(ab)
- oxidative metabolism, early or delayed reperfusion, mechanical function, 884(ab)
- perfusion
adenosine stress, N-13 ammonia PET, 825(ab)
blood flow and, Tc-99m tetrofosmin, 993(ab)
blunted response to dipyridamole, older adults, 1425(le)
long-term follow-up, Kawasaki syndrome, 929(ab)
quantification, O-15 water and Rb-82 PET, 884(ab)
quantitative evaluation, gated or non-gated Cardiolite SPECT, 927(ab)
radial slices, SPECT, 1070(ab)
Tc-99m MIBI radionuclide angiography and SPECT, dipyridamole, 846(ab)
thallium uptake after reinjection, 915(ab)
tissue viability, hypoperfused regions, 857(ab)
TI-201 SPECT vs. Rb-82 PET, 1064(ab)
wall thickness, simultaneous estimation, 933(ab)
- perfusion and ventricular function, simultaneous assessment, total coronary artery occlusion, 825(ab)
- perfusion and viability, 3-D SPECT, Tc-99m sestamibi stress perfusion, 926(ab)
- perfusion at fatal infarction, location and size, scintigraphic defects, 251
- perfusion imaging with dipyridamole or adenosine, serum caffeine levels, 24-hour abstinence, 866(ab)
- perfusion scintigraphy, integration of wall kinetic and perfusion data, 933(ab)
- perfusion studies, blinded evaluation, planar Tc-99m sestamibi, 668
- perfusion with PET correction for patient motion, automated region definition, 882(ab)
- PET, region-of-interest strategy, 1243
- planar perfusion imaging, Tc-99m tebo, TI-201 and coronary angiography, 1783
- quantification of blood flow, 172(le)
- rapid synthesis of no-carrier-added N-13 dopamine, 931(ab)
- regional metabolism and blood flow, misonidazole retention, occlusion of LAD coronary artery, 993(ab)
- regional perfusion
Cu-62 PTSM, 837(ab)
Cu-61 pyruvaldehyde thiosemicarbazone, 884(ab)
- reinjection studies, TI-201 SPECT, collateralization, 915(ab)
- reperfusion imaging with Tc-99m sestamibi, acute chest pain, non-diagnostic EKG, 876(ab)
- resting and exercise imaging in children, Tc-99m MIBI SPECT, 929(ab)
- retained Ga-68 radiopharmaceuticals, 931(ab)
- retention characteristics, TI-201, Tc-99m sestamibi and Tc-99m teboroxime, 865(ab)
- simultaneous rest TI-201/stress Tc-99m sestamibi, perfusion SPECT, 854(ab)
- 180° SPECT, scatter, attenuation and depth-dependent resolution, 842(ab)
- SPECT study with fan-beam collimators, newborn period and early infancy, 930(ab)
- structural characterization, Tc-99m tetrofosmin, 850(ab)
- subcellular distribution, bis(dithiocarbamate)nitrido Tc(V), male rats, 850(ab)
- sympathetic nerves, postnatal maturation, high-resolution scintigraphy, 935(ab)
- sympathetic neuronal function, intravenous cocaine injection, dogs, 994(ab)
- systemic myopathies, I-123 IPPA SPECT, 995(ab)
- Tc-99m imaging agent, kit development, Technecard, 850(ab)
- Tc-99m nitrido dithiocarbamate, improved synthesis, 989(ab)
- Tc-99m perfusion agents, 22N(1)
- Tc-99m PPN.1011 SPECT, clinical evaluation, 875(ab)
- Tc-99m sestamibi, comparison, same-day protocols, 186
- Tc-99m sestamibi SPECT
comparison, short and standard data acquisition, 855(ab)
early and delayed imaging, coronary artery disease, 855(ab)
same day, 876(ab)
- Tc-99m tebo SPECT, delay of image acquisition, 952(ab)
- teboroxime, adenosine, accuracy and optimal imaging time, 854(ab)
- thickening and phase analysis, Tc-99m sestamibi multiple gated SPECT, 926(ab)
- tissue fraction, rapid imaging technique, 994(ab)
- tissue uptake, cationic technetium complexes, 1033(ab)
- tomographic perfusion imaging, effect of patient motion, 1566
- uptake in dogs, side chain modifications, bis(dithiocarbamate) nitrido technetium(V), 1034(ab)
- viability
chronic coronary artery disease, TI-201 SPECT vs. F-18 DG PET, 886(ab)
delayed post-reinjection TI-201 imaging, 1064(ab)
F-18 FDG, PET and SPECT, 1064(ab)
radioisotopic assessment, sestamibi scintigraphy, 1925
- status of collateral flow, 856(ab)
- Tc-99m MIBI scintigraphy, thallous chloride injection, 906(ab)
- Tc-99m sestamibi SPECT vs. F-18 FDG PET, 886(ab)
- TI-201 and Tc-99m sestamibi SPECT, 905(ab)
- viability after infarction, exercise-redistribution SPECT TI-201, 906(ab)
- viable
chronic coronary artery disease, 505
TI-201 and Tc-99m sestamibi, 815
- viable and non-viable, blood flow and flow reserve measurements, 856(ab)
- Myocytes**
damage in pathologic cardiac hypertrophy, athletes, In-111 antimyosin antibody studies, 994(ab)
endothelial and fibroblast-like cells, Tc-99m sestamibi, TI-201, 102
- Myopathy, systemic, myocardial involvement, I-123 IPPA SPECT, 995(ab)**
- Myosin**
antimyosin imaging, detection of tumor invasion of muscle layer, 841(ab)
heavy chain, determination of infarct size, 853(ab)
heavy chain fragments, interference in antimyosin imaging, myocardial infarction, 895(ab)
- Myotonic dystrophy, regional cerebral blood flow impairment, 839(ab)**
- N**
- Na,K-ATPase, possible imaging agent, myocardial accumulation, radioiodinated digoxin derivative, 545**
- National Biomedical Tracer Facility**
Congressional subcommittee, U.S. radioisotope supply crisis, 16N(10)
Congressional support, 35N(11)
government relations update, 16N(3)
- National Emission Standards for Hazardous Air Pollutants (NESHAP), Environmental Protection Agency, 24N(3)**
- National Institutes of Health (NIH), educating lawmakers, 30N(10)**
- Neonates: see also Pediatric patients**
asymptomatic, hydronephrosis or hydroureteronephrosis, "well tempered" diuretic renogram, 2047
brain SPECT, extracorporeal membrane oxygenation, 1943
cardiac function, arterial switch operation, PET, 977(ab)
jaundice, diagnostic criteria for biliary atresia, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)
- Neoplasms: see also specific type**
somatostatin receptor-positive, I-123 TOCT and In-111 DOCT somatostatin analogues, 914(ab)
- Nerve, central cholinergic terminals, PET studies, 1011(ab)**
- Neural crest neoplasms, I-123 MIBG, 1072(ab)**
- Neural-network, classifier, PET scans, normal and Alzheimer's disease subjects, 1459**
- Neuroblastoma**
I-131 MIBG and bone scintigraphy, 1735
I-131 MIBG approval, 33N(9)
location of, opsoclonus-myoclonus, MIBG usage, 930(ab)
micrometastases, radioiodinated MIBG, multicellular tumor spheroids, 859(ab)

Neuroendocrine neoplasms

- pitfalls in diagnosis, I-131 MIBG scintigraphy, 930(ab)
- radioimmunotherapy in a child, tumor dosimetry, I-124 3F9 PET, 2020
- xenografts
- distribution of I-125 MIBG, electron microscopic autoradiography, 1021(ab)
 - radioimmunolocalization, chimeric antibody chCE7, 231
- Neuroendocrine neoplasms**
- diagnosis with A11 monoclonal antibody, 834(ab)
 - dosimetry and biodistribution, I-123 somatostatin analog, 1613
- Neurollite**
- aid in diagnosis and localization of stroke, 878(ab)
 - imaging of cross cerebellar diaschisis in stroke, 968(ab)
- Neurology**, second Sino-American nuclear medicine conference, 16N(4)
- Neuroma**, cranial and spinal, PET-fluorodeoxyglucose, 1931
- Neurons**
- activated holmium-166, polymeric microspheres, radionuclide synovectomy, 398
 - cholinergic, F-18 labeled acyclic analogues, vesamicol, 983(ab)
 - monoaminergic, C-11 tetrabenazine PET, brain biodistribution, 870(ab)
 - myocardial sympathetic neuronal function, intravenous cocaine injection, dogs, 994(ab)
- Neuropsychological test**, cerebral blood flow, Tc-99m HMPAO SPECT, chronic subdural hematoma, 246
- Neuroradiology**, interventional, brain blood flow, SPECT, 826(ab)
- Neurotransmission**, membrane trapping of C-11 1, 2-diacetylgllycerols, phosphatidylinositol turnover, 413
- Neutron**, source, Department of Energy, 32N(10)
- Neutrophils**, sequestration in lung, intercellular adhesion molecules, endotoxemia, 1023(ab)
- Newsline**
- Commentary
 - functional brain scans, evidence in criminal court, 18N(6)
 - government will respond to those who seek influence, 25N(10)
 - Lines from the President, 24N(6), 38N(9), 32N(12)
 - second Sino-American nuclear medicine conference, 16N(4)
 - shouldering burden of low-level radioactive waste, 20N(6) - Forum: The Future of Nuclear Medicine, 15N(5)
- Newspapers**, citations in medical journals, 27N(1)
- Nicotine**, tritiated, altered accumulation in brain, senescence accelerated mouse, 1023(ab)
- Nitrogen-13 ammonia**
- logistics, flow-through trapping, 931(ab)
 - myocardial perfusion PET images, adenosine stress, coronary artery disease, 825(ab)
- PET**
- defect size and severity, 875(ab)
 - left ventricular mass and infarct size, explanted human hearts for validation, 826(ab)
 - methods for quantification, myocardial blood flow, 881(ab)
 - regional perfusion reserve, coronary artery disease, 826(ab)
 - regional uptake and blood flow variations, lack of correlation with other methods, 837(ab)
 - stress perfusion imaging in PET, objective computerized quantitative method, heart, 1009(ab)
- Nitrogen-13 dopamine**, no-carrier-added, rapid synthesis, myocardial imaging, 931(ab)
- 2-Nitroimidazole**, radioiodinated derivatives, viable hypoxic tissue, SPECT, 891(ab)
- Nitroimidazoles**, chemistry of Tc-PnAO-nitroimidazole complex, localization in hypoxic tissue, 919(ab)
- Nitrous oxide**, endogenous opiate system, C-11 carfentanil PET, 883(ab)
- Nordion**, privatization, 19N(2)
- Norepinephrine**, disturbed neuronal energy metabolism, Adriamycin cardiomyopathy, 935(ab)
- Nuclear energy**
- history 16N(12)
- Nuclear magnetic resonance**
- anatomy-oriented 3-D ROI definition system, 1006(ab)
 - brain functional and structural deficits, young alcoholics, 1070(ab)
 - brain images, rapid registration, 1005(ab)
 - cerebral blood flow and SPECT, differential diagnosis, dementia, 1014(ab)
 - C-11 flumazenil, benzodiazepine receptor binding, alcohol-dependent men, 1016(ab)
 - chronic osteomyelitis, site of fracture or surgery, lower extremity, 902(ab)
 - comparative study of Tl-201, CT/angiography, bone and soft tissue sarcoma, 843(ab)
 - 3D PET and, image registration, simple device, 1008(ab)
 - FDG PET and, atypical dementia, Alzheimer's disease, 965(ab)
 - Fe-PDGF as hepatobiliary contrast agent, 974(ab)
 - ferrum as a contrast agent, 973(ab)
 - fusion with SPECT images, radiolabeled monoclonal antibodies, 960(ab)
 - Ga-67 scans and, effect of therapy, Hodgkin's lymphoma, 914(ab)
 - moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
 - MRI contrast agents, nonionic gadolinium (III) DTPA-bisamide complexes, 974(ab)
 - normal and pathological gastric emptying, 956(ab)
- PET and**
- accuracy of surface fit registration, brain, 921(ab)
 - fully automated and robust coordinate matching system, 1009(ab)
 - primary brain tumors, 867(ab)
 - primary progressive aphasia, 857(ab)
 - radionuclide bone scan and, detection of spinal metastases, 992(ab)
 - radionuclide studies and, osteomyelitis, 992(ab)
 - rapid registration and review, brain, 1067(ab)
 - scintigraphy and, bone marrow, staging of breast cancer, 914(ab)
 - SPECT liver volume measurement, 1066(ab)
 - standardization, cardiac tomographic imaging, 1434
 - subchondral bone infarctions, acute ligamentous knee injuries, 516
 - Tc-99m HMPAO and I-123 IMP, cerebral blood flow, SPECT, 1012(ab)
 - Tc-99m HMPAO SPECT and CT, diagnosis of dementia, 972(ab)
 - Tl-201 compared to Tc-99m MIBI, recurrent brain tumors, 867(ab)
 - Tl-201 SPECT and F-18 FDG PET, recurrent brain tumors, 867(ab)
- Nuclear magnetic resonance spectroscopy**, proton, stimulated auditory cortex, 974(ab)
- Nuclear medicine**
- accuracy of Neuronet diagnosis, thyroid nodule, backpropagation simulator, 954(ab)
 - acupuncture message transmission, 409
 - Annual Meeting highlights, 12N(8)
 - artifacts in, 1068(ab)
 - certificate program, nuclear pharmacy training, 1073(ab)
 - computer-aided instruction, 1067(ab)
 - computer-based radiology teaching files, 1066(ab)
 - computer-based renal teaching file, 1073(ab)
 - computerized teaching file, 1066(ab)
 - computer system, efficient management, imaging and non-imaging information, 1006(ab)
 - departments, infection-control problems, blood reinfusion, 13N(4)
 - forum, 15N(5)
 - hardcopy images, high-resolution plain-paper laser printers, 947(ab)
 - imaging data, use of local area networks, intradepartmental distribution, 946(ab)
 - misadministration spurs statewide inspection, California nuclear medicine departments, 32N(3)
 - multifunctional image-containing database, 947(ab)
 - multi-media workstation, 947(ab)
 - one day in the routine, 463(le)
 - outpatient therapy, petition would ease strictures, 13N(7)
 - practice of, 14N(8)
 - regional dose distribution to hands, staff formulating/dispensing/administering radiopharmaceuticals, 1065(ab)
 - role in systematic imaging evaluation, suspected osteomyelitis, 1063(ab)
 - therapeutic applications, 31N(3)
 - threatened reactor worker strike, 19N(9)
 - transfer of images, interfile file format, 1007(ab)
 - use of Internet, computer communications to world community, 1067(ab)
 - workstation for all digital department, 947(ab)
- Nuclear probes**
- cardiology, 448
 - miniature cadmium telluride detector, ventricular function, coronary artery bypass grafting, 441
- Nuclear Regulatory Commission (NRC)**
- "below regulatory commission" consensus failure, 25N(1)
 - below regulatory concern, 18N(3)
 - compatibility, agreement states still chafing, 27N(3)
 - costs of dual regulation, 29N(10)
 - licensing fees, 30N(9)
 - medical quality management rule, 18N(3)
 - medical use of isotopes, 30N(9)
 - new commissioner, 18N(3)
 - nuclear physician's case against QM rule, 37N(5)
 - override of OMB disapproval, quality management rule, 32N(10)
 - probe of Medical Uses staff, 30N(9)
 - quality management rule, 23N(4), 34N(9)
 - radiation protection, 33N(9)
 - sending teams to study risk, medical misadministration, 26N(4)
 - user fees, 18N(3)
 - withdrawal of training criteria, 33N(12)
- O
- Oak Ridge National Laboratory**, calutrons, 15N(6)
- Occupational Safety and Health Administration**

- (OSHA), blood-borne pathogens, 26N(3)
- Octreoscan**, In-111 labeled somatostatin analog, kit development, cancer detection, 1025(ab)
- Octreoscan-111**, two diastereomers, cancer imaging, 900(ab)
- Olfactory system**, investigation with FDG-PET, 858(ab)
- Oncogene**, -encoded molecules, radiolabeled antibodies, tumor imaging and therapy, 2160
- Oncology**, Annual Meeting highlights, 11N(8)
- Opiates**, effect of nitrous oxide, C-11 carfentanil PET, 883(ab)
- Orphan drug**, coalition, 33N(9)
- Osteoma**, osteoid, radionuclide imaging, radiography and computed tomography, 269
- Osteomyelitis**
cellulitis and, dual bone and WBC scan imaging, planar and SPECT imaging, 839(ab)
chronic, site of fracture or surgery, lower extremity, 902(ab)
comparison of MRI and radionuclide studies, 992(ab)
infectious diabetic foot complications, In-111 human nonspecific immunoglobulin G, 1330
suspected, role of nuclear medicine, systematic imaging evaluation, 1063(ab)
- Osteoporosis**
better prediction, risk factor assessment, multiple regression analysis, 869(ab)
bone mineral content and density, healthy twelve-year-old white females, 1143
bone mineral density and spine fracture, cyclic oral phosphate, etidronate, 1
optimization of follow-up measurements, bone mass, 1406
- Osteosarcoma**
lower limb, stress fractures, 1699
primary, thyroid, 1399
quantitative tumor scintigraphy, time to metastasis, 1542
- Ovarian neoplasms**
-associated antigen, characteristics, chimeric monoclonal antibody MOv18, 2000
dosimetric evaluation of immunoscintigraphy, In-111 monoclonal antibody fragments, 1113
early detection of recurrences, Tc-99m monoclonal antibody, CA 125, 904(ab)
management with Tc-99m monoclonal antibodies, 904(ab)
novel HAMA radioimmunoassay, 852(ab)
radioimmunoimaging, recognition of CA125, human/mouse chimeric monoclonal antibody, 1001(ab)
- Ovary**, radiation dose, radionuclide hysterosalpingography, Tc-99m pertechnetate, 282
- Oxygen-15**
arrival delay of tracers, intravascular radioactivity, brain, 909(ab)
PET, intrasubject and intersubject averaging, 1009(ab)
- Oxygen-15 butanol**, PET, cortical areas in brain, visual imagery in reading, 908(ab)
- Oxygen-15 water**
bolus, signal-to-noise improvements, 3D PET, 1010(ab)
myocardial tissue fraction, rapid imaging technique, 994(ab)
PET
cerebral language area, 2D brain surface map, 857(ab)
event-related potentials, auditory cognitive task, 1016(ab)
left ventricular time-activity curve, 1669
partition coefficient, regional cerebral blood flow, 911(ab)
somatosensory stimulation, thalamic lesions, 858(ab)
Rb-82 and, myocardial perfusion, PET, 884(ab)
- Oxygen-18 water**
purification, photochemical combustion, 982(ab)
simple procedural change, F-18 FDG synthesis, 1027(ab)
target for production of F-18, 932(ab)
- P**
- Paget's disease**, bone scintigraphy, intravenous pamidronate, 1589
- Pain**
bone
metastases, therapeutic doses of Sr-89, 937(ab)
Re-186 HEDP treatment, 859(ab)
low back
180° SPECT of the spine, 950(ab)
zygapophyseal joint injection, SPECT and planar bone scintigraphy, 868(ab)
lower extremity, bone scintigraphy, preschool children, 351
palliation, multidose Sm-153 EDTMP, metastatic bone disease, 992(ab)
- Palladium-109**, chelates and their bioconjugates, 987(ab)
- Palsy**
progressive supranuclear, cerebral perfusion, 704
supranuclear, dopamine D2 receptors, I-123 ILIS SPECT, 1019(ab)
- Pamidronate**, intravenous, bone scintigraphy, Paget's disease, 1589
- Pancreas**, new imaging agent I-123 ERC 9, 841(ab)
- Pancreatic lipase**, site specific/stable radioiodination, I-131 1,2-Pal-3-IPPA, urine analysis, 1028(ab)
- Paraplegia**, impotence, treatment choice, nuclear penogram, 1035(ab)
- Parathyroid**
imaging, 1807
imaging with Tc-99m sestamibi, 313
localization of enlargement, Tc-99m MIBI and Tl-201 scintigraphy, ultrasound and CT, 895(ab)
pathology, simultaneous dual-isotope SPECT, 131
scintigraphy, subtraction algorithm, 996(ab)
- Parathyroidectomy**, influence on bone mineral content, 869(ab)
- Parkinson's disease**
delayed SPECT and regional cerebral blood flow, I-123 IMP, 1015(ab)
dementia and laterality of disease onset, regional cerebral blood flow, 1012(ab)
differential diagnosis by I-123 IBZM SPECT, 917(ab)
differentiation of syndromes, dopamine D2 receptor imaging, I-123 IBZM SPECT, 917(ab)
discordant twins, PET, 1013(ab)
dopamine D2 receptor imaging, I-123 IBZM SPECT, 917(ab)
dopamine fiber loss, C-11 CFT, 946(ab)
I-123 IBZM SPECT, 1018(ab)
loss of 6-[F-18]fluoro-L-dihydroxyphenylalanine metabolites, striatum, 916(ab)
MPTP-primate model, glucose metabolism, 965(ab)
multiple systemic atrophy, selective metabolic involvement, 1014(ab)
striato-nigral degeneration, dopamine D1 and D2 receptor imaging, PET, 917(ab)
- Pathogens**, blood-borne, 26N(3)
- Paul Aebbersold Award**, Mathew Thakur, 34N(5)
- Pediatric patients**: see also Infants, Neonates
alternating hemiplegia, Tc-99m HMPAO SPECT, 1021(ab)
asymptomatic siblings, vesicoureteral reflux, cyclic voiding cystography, 873(ab)
brain tumors, Tc-99m MIBI/Tl-201 SPECT, 844(ab)
cardiac function in neonates and children, arterial switch operation, PET, 977(ab)
cerebral blood flow and predetermined ROIs, Xe-133 SPECT, 977(ab)
cerebral palsy, quantitative perfusion-defect indexes, Tc-99m HMPAO SPECT, 977(ab)
changes in regional cerebral blood flow, brain maturation, 696
children and adolescents, radionuclide cystography, vesicoureteral reflux, 1022(ab)
developmental cognitive disorders, F-18 FDG PET, 973(ab)
febrile urinary tract infections, Tc-99m DMSA scanning, 976(ab)
first nuclear medicine symposium, 40N(9)
glomerular filtration rate measurement, adequacy of one blood sample, 873(ab)
HIV-1-infected, seropositive mothers, FDG PET, 976(ab)
newborn period and early infancy, myocardial SPECT, fan-beam collimators, 930(ab)
obstructive uropathy diagnosis, normalized diuretic renogram parameters, 923(ab)
opsoclonus-myoclonus, location of neuroblastoma, MIBG usage, 930(ab)
preschool children, bone scintigraphy, lower extremity pain of unknown origin, 351
radioimmunotherapy for neuroblastoma, tumor dosimetry, I-124 3F9 PET, 2020
single plasma GFR, 173(le)
skeletal screening, traumatic brain injury, 873(ab)
symptomatic infants and children, radionuclide evaluation, Ebstein's deformity, 930(ab)
ureteral status, kidney washout, Tc-99m DTPA diuresis renography, 73
urinary tract infection, 872(ab)
- Pelvis**, radioiodine uptake, rectal wall teratoma, thyroidectomy for papillary carcinoma, 1848
- Penis**
blood flow, tumescence, dual-radioisotopic technique, 41
corporal venous leak, Tc-99m red blood cells, 49
nuclear penogram, treatment choice, impotent paraplegics, 1035(ab)
- Peptides**
attachment of monofunctional DTPA analogs, 988(ab)
imaging and therapy of tumors, 35N(5)
molecules with messages, annual meeting highlights, 10N(8)
- Percutaneous transluminal coronary angioplasty (PTCA)**, early thallium imaging, tomographic evaluation, adenosine-induced coronary hyperemia, 2086
- Perfusion**, index of, mean transit time, 1004(ab)
- Perfusion tracers**, transmural uptake, infarct-specific tracers, 229
- Peripheral vascular disease**, functional imaging, 1797
- pH**, non-invasive assessment, fluorinated polymeric molecular probes, magnetic resonance spectroscopy, 974(ab)
- Phagocytes**, microautoradiographic study of F-18 FDG, mouse tumor tissue, 840(ab)

Phantom

- Phantom**, influence of perfusion defect size, TI-201 activity, tomographic defect severity, 995(ab)
- L-Phenylalanine**, delayed infusion, F-18 DOPA uptake in brain, 1383
- Pheochromocytoma**
C-11 HED PET, 1125
I-131 MIBG approval, 33N(9)
I-131 MIBG imaging, 833(ab)
intraoperative detection, I-125 MIBG, 1020(ab)
- Phosphate**, cyclic oral, etidronate and, bone mineral density, 1
- Phosphatidylinositol**, turnover, membrane trapping, C-11 1,2-diacylglycerols, 413
- Phosphines**, methylene bridged phosphineoxide-phosphine, versatile chelating agent, Re-188, 979(ab)
- Phosphinimines**, functionalized, small molecule neutral-lipophilic Tc-99m agents, 851(ab)
- Phosphorus**, -nitrogen backbone ligands, formulation, new radiopharmaceuticals, 1072(ab)
- Phosphorus hydrazides**
chelating agents, bifunctional frameworks, Tc-99m and Re-188, 910(ab)
multifunctional, new Tc-99m radiopharmaceuticals, 1032(ab)
- Photodiodes**, room temperature, high-rate/high-resolution PET module, crystal identification, 862(ab)
- Physician Payment Review Commission (PPRC)**
access to care, 24N(3)
Medicare volume performance standard, 24N(3)
report to Congress, 36N(9)
statement on Medicare, 24N(3)
- Planar imaging**
Alderson phantom, nuclear quantitation, tumor size and I-131 amount, 925(ab)
bone scintigraphy and SPECT, zygapophyseal joint injection, chronic low back pain, 868(ab)
dual bone and WBC scan imaging, osteomyelitis, cellulitis, 839(ab)
gated, detection, coronary artery disease, 866(ab)
myocardial perfusion, Tc-99m, TI-201 and coronary angiography, 1783
scintigraphic views of monoclonal antibodies, biodistribution, radiation absorbed dose, 925(ab)
scintigraphy and SPECT, rotating slit collimator, 1005(ab)
Tc-99m ECD, global cerebral blood flow, Rhesus monkeys, 979(ab)
thallium, areas of reverse redistribution, viability with PET, 886(ab)
vs. SPECT, low back pain, 868(ab)
- Plasma**
algorithm for estimating slope, PATLAK analysis, dynamic PET data, 944(ab)
concentrations, body dimensions, single-sample clearance determinants, 629(1e)
D-dimer concentration, suspected pulmonary embolus, 978(ab)
extracellular fluid volume measurements and, reproducibility, critically ill patients, 1468
human, quantitation, I-123 IBZM, 871(ab)
- Plasmapheresis**, radioimmunotherapy of micrometastases, mathematical modeling, dosimetry, 2167, 941(ab)
- Plasminogen activator**, tissue, Tc-99m inhibition, thrombosis scintigraphy, 1029(ab)
- Platelet**
-binding laminin peptide, direct Tc-99m labeling, 1031(ab)
-fibrin deposition on coronary stents, anticoagulation, minipig model, 845(ab)
- radioindium-labeled autologous, MIRD dose estimate No. 15, 777
- Pneumocystis**, pneumonia, pulmonary disposition, gallium-67, 512
- Pneumocystis carinii**
accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)
Tc-99m DTPA aerosol and Ga-67 scanning, 81
- Pneumonitis**, drug-induced, diffuse pulmonary uptake, In-111 leukocytes, 1175
- Poland**, radionuclide production threatened, 20N(7)
- Polylysine**, amino-dextran and, In-111 labeled monoclonal antibody, 988(ab)
- Polyvinyl alcohol sponge**, embolization of hepatic arteriovenous malformations, hereditary hemorrhagic telangiectasia, 260
- Positive expiratory pressure**, effectiveness of PEP mask, Tc-99m DTPA aerosol ventilation, cystic fibrosis, 835(ab)
- Positron emission tomography**
F-18 FMISO, noninvasive detection, hypoxic myocardium, 2202
myocardial blood flow, deoxyglucose uptake, myocyte viability, 1353
regional cardiac adenosine, 2138
- Positron emission tomography (PET)**
acetazolamide Tc-99m HMPAO SPECT and, cerebrovascular disease, 877(ab)
analysis of Kanji-Kana reading process, 827(ab)
anatomy-oriented 3-D ROI definition system, 1006(ab)
approval of drug master file, 33N(9)
arterial input function determination, hepatic and renal studies, use of abdominal aorta, 613
benperidol analogs, D2 receptor-specific PET tracers, 848(ab)
brain, automated stereotactic transformation, 1007(ab)
brain functional and structural deficits, young alcoholics, 1070(ab)
- C-11 acetate
compared with F-18 fluorodeoxyglucose, recovery after revascularization, 855(ab)
oxidative metabolism, infarcted and periinfarcted myocardium, 953(ab)
- C-11 carazolol, evaluation in pigs, 885(ab)
- C-11 carfentanil, effect of nitrous oxide, endogenous opiate system, 883(ab)
- C-11 CGP 12177, mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
- C-11 cocaine, distribution and kinetics, human body, 521
- C-11 flumazenil
benzodiazepine receptor binding, alcohol-dependent men, 1016(ab)
benzodiazepine receptors, human brain homogenates, 1011(ab)
- C-11 HED, localization of pheochromocytoma, 1125
- C-11 labeled compounds, contribution, labeled carbon dioxide, 581
- C-11 methionine, effective method, imaging of head and neck cancer, 691
- 2-C-11 methyl-amino-2-methyl-3-phenyl-1-propanol, serotonin uptake sites, 861(ab)
- C-11 NMSP, D2 dopamine receptor densities, 848(ab)
- C-11 SAH, myocardial energy balance, 2144
- C-11 tetrabenazine, brain biodistribution, monoaminergic neurons, 870(ab)
- C-11 tetrabenazine and C-11 methoxy derivative, α -dihydrotetrabenazine, monoamine terminals, 983(ab)
- C-11 thymidine, kinetic modeling, DNA synthesis, 1009(ab)
- L-1-C-11 tyrosine and F-18 FDG, radiation-induced inhibition, tumor growth, 373
- cardiac
attenuation scans, three-dimensional registration, 881(ab)
polar map displays, myocardial blood flow, 1628
position paper, 23N(4)
cardiac function in neonates and children, arterial switch operation, 977(ab)
cardiac volumes, delineation of myocardium, 933(ab)
central cholinergic nerve terminals, 1011(ab)
cerebral blood flow
brain perfusion Tc-99m ECD SPECT, 966(ab)
regional variation in statistical maps, 1008(ab)
cerebral glucose metabolism, striatal F-DOPA uptake, patients with chorea, 1015(ab)
cerebral metabolism
epilepsy, effect of disease duration, 1018(ab)
standardized approach, controlled behavioral conditions, 1011(ab)
clinical
bloody future, 620
debate continues, 1587(1e)
science behind it, 1586(1e)
clinical applications in cancer, 330
clinical neurological, interactive computer-based atlas, 1071(ab)
combined with radioimmunoscinigraphy, F-18 monoclonal antibody fragments, 1535
Cu-64 antibodies, 1685
Cu-64 radiopharmaceuticals, scintillating fiber detector module, small animals, 1010(ab)
decline of L-6-[F-18]fluorodopa rate constant K_1 , vs. aging, 964(ab)
-defined targets for stereotaxic brain biopsy, 868(ab)
design features and performance, animal research, 595
discordant twins with Parkinson's disease, 1013(ab)
dopamine D1 and D2 receptor imaging, striatonigral degeneration, Parkinson's disease, 917(ab)
dual-labeling agents, dopamine D-2 receptors, 890(ab)
dual-tracer, lumped constant imaging, 944(ab)
dynamic, 1-aminocyclobutane[C-11]carboxylic acid, 2-compartment model, brain tumors, 922(ab)
dynamic studies of the heart, temporal sampling, kinetic model parameters, 881(ab)
ECG gated, C-11 monoxide, "background" question, 938(ab)
enhanced fluorodeoxyglucose uptake, metabolic design, combination therapy, 1981
evaluation of neural-network classifier, normal and Alzheimer's disease subjects, 1459
examination of visual mental imagery, 908(ab)
extent and severity of ischemic myocardium at risk, predictor of prognosis following thrombolytic therapy, 837(ab)
F-18, bone blood flow and influx rate, 937(ab)
F-18 antimyosin monoclonal antibody fragments, preliminary investigations, canine myocardial infarct model, 575
F-18 biotin, tumor localization, 1026(ab)
F-18 BMY 14802, synthesis and resolution, ba-boons, 830(ab)

- F-18 BT-SCH, synthesis and *in vivo* evaluation, dopamine D1 ligand, 829(ab)
- F-18 deoxyglucose, mediastinal lymph node mapping, 828(ab)
- F-18 FDG
- accuracy in dementia diagnosis, 967(ab)
 - Bayesian regression, metabolic rate of glucose utilization, 944(ab)
 - brain, registered atlas, 1071(ab)
 - brain tumor therapy, 1071(ab)
 - cerebral glucose metabolic rates, 30- and 45-minute acquisitions, 2103
 - chest imaging, 975(ab)
 - cranial and spinal neuromas, 1931
 - decreased cerebral glucose metabolism, Cushing's disease, 834(ab)
 - design of combination therapy, hexadecylphosphocholine and deoxyglucose, 1019(ab)
 - developmental cognitive disorders, 973(ab)
 - differential diagnosis, solitary pulmonary nodule, 836(ab)
 - differentiation of infectious from malignant CNS lesions, AIDS, 838(ab)
 - 3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
 - evaluation of liver tumors, 333
 - fully quantitative neurological studies, without arterial blood sampling, 922(ab)
 - glucose loading or insulin clamp methods, myocardium, 1263
 - HIV-1-infected children, seropositive mothers, 976(ab)
 - increased uptake as prognostic indicator, myocardial infarction, 886(ab)
 - insulin clamp, myocardial glucose utilization, 1255, 1263
 - investigation of olfactory system, 858(ab)
 - late-life depression, 1013(ab)
 - left premotor cortex specialization, finger movements, 857(ab)
 - low grade and anaplastic astrocytomas, brain imaging, 966(ab)
 - lymphoma, 532
 - malignant lymphoma, proliferative activity, 325
 - malignant melanoma, 975(ab)
 - mediastinum, lung cancer, 828(ab)
 - method for correcting myocardium to blood pool spillover, 882(ab)
 - MIHA, myocardial viability, 953(ab)
 - MRI data and, atypical dementia and Alzheimer's disease, 965(ab)
 - multiple systemic atrophy, selective metabolic involvement, 1014(ab)
 - myocardial viability, coronary artery disease, 886(ab)
 - parietal lobe epilepsy, 1017(ab)
 - post-treatment evaluation, genitourinary malignancies, 829(ab)
 - preoperative chemotherapy, locoregionally advanced breast cancer, 828(ab)
 - pre-operative staging, colorectal carcinoma, 975(ab)
 - presurgical localization, epileptogenic zones, 928(ab)
 - prognostic implications, temporal lobe surgery, 929(ab)
 - quantitation, tumor glucose metabolism, 339
 - quantitative dynamic and whole body, breast cancer, 828(ab)
 - radiation-induced response, head and neck carcinoma, 829(ab)
 - recurrent brain tumors, 867(ab)
 - residual or recurrent musculoskeletal sarcoma, 992(ab)
 - temporal lobe metabolism, refractory epilepsy, 928(ab)
 - treatment planning and monitoring, lung tumors, 975(ab)
 - TSH stimulation of thyroid cancer, T4 replacement therapy, 894(ab)
- F-18 FDOPA, nigrostriatal function, ratio method and graphical analyses, 945(ab)
- F-18 fleroxacin, pharmacokinetics in rabbits, 924(ab)
- F-18 fluconazole, pharmacokinetics, humans, 924(ab)
- F-18 fluoride ion, skeletal kinetics, 633
- F-18 fluoro analog of tamoxifen, estrogen receptors, radiosynthesis, 985(ab)
- F-18 fluorocarazolol
- β -adrenergic radiotracer, 984(ab)
 - ligand, β -adrenergic receptors, 983(ab)
- 6-F-18 fluoro-L-dopa kinetics, carbidopa administration, 1472
- F-18 fluoromisonidazole, hypoxia, human gliomas, 2133
- F-18 FMISO, quantification, tumor oxygenation status, 1010(ab)
- F-18 monoclonal antibody fragments, 934(ab)
- F-18 NMSP, benzamide analogs and, 985(ab)
- fast maximum-likelihood reconstruction, 1710
- flumazenil as a ligand, quantification, benzodiazepine receptors, 883(ab)
- fluorinated SCH 38548 derivatives, dopamine D1 receptors, 829(ab)
- forum, 15N(5)
- functional brain scans, evidence in criminal court, 18N(6)
- GABAergic modulation of endogenous dopamine, acetylcholine release, 847(ab)
- Ga-68 platelets, 931(ab)
- heart and brain, use of linear programming, glucose utilization and receptor binding, 944(ab)
- hepatic FDG uptake kinetics, impact of glucose ingestion, 945(ab)
- high count rate cardiac, spatially dependent dead-time losses, 2226
- high-rate, high-resolution module, room temperature photodiodes, crystal identification, 862(ab)
- high resolution image reconstruction, restoration, detector response, 872(ab)
- I-124 3F9, tumor dosimetry, radioimmunotherapy in a child with neuroblastoma, 2020
- I-124 monoclonal antibodies, *c-erbB-2* protein overexpression, breast cancer, 2154
- image reconstruction, artifacts, 1069(ab)
- image reconstruction for volume imaging, axial extent, 871(ab)
- improved quantitation of small objects, restoration and correction algorithms, 872(ab)
- inexpensive high resolution detector, photomultiplier quadrant sharing, 1011(ab)
- intracoronary Doppler probes and, concordant quantification, flow reserve, 836(ab)
- ischemic segments, accelerated clearance, C-11 acetate, 856(ab)
- labeled carbon dioxide, transient metabolite, 585
- ligand, cerebral dopamine D-2 receptors, 847(ab)
- ligand-receptor modeling, multi-injection approach, 943(ab)
- Macintosh programs, 1069(ab)
- maximum-likelihood reconstruction, clinically important characteristics, 1678
- measurement of receptor concentration, instrumental errors, heart, 882(ab)
- model sequences, factor analysis, dynamic structures, 1011(ab)
- MPTP-primate model of Parkinson's disease, glucose metabolism, 965(ab)
- MR brain images and, accuracy of surface fit registration, 921(ab)
- MRI and
- fully automated and robust coordinate matching system, 1009(ab)
 - primary brain tumors, 867(ab)
 - multi-energy maximum-likelihood reconstruction algorithms, 831(ab)
- myocardial, region-of-interest strategy, 1243
- myocardial perfusion, correction for patient motion, automated region definition, 882(ab)
- N-13 ammonia
- adenosine stress, myocardial perfusion images, 825(ab)
 - defect size and severity, 875(ab)
 - left ventricular mass and infarct size, explanted human hearts for validation, 826(ab)
 - methods for quantification, myocardial blood flow, 881(ab)
 - regional perfusion reserve, coronary artery disease, 826(ab)
- N-13 ammonia stress perfusion, objective computerized quantitative method, heart, 1009(ab)
- neurological indications, approval by Blues, 40N(11)
- new generation, performance evaluation, 861(ab)
- nonpeptide substance P analog, 860(ab)
- O-15, intrasubject and intersubject averaging, 1009(ab)
- O-15 butanol, cortical areas in brain, visual imagery in reading, 908(ab)
- O-15 water
- cerebral language area, 2D brain surface map, 857(ab)
 - event-related potentials, auditory cognitive task, 1016(ab)
 - left ventricular time-activity curve, 1669
 - partition coefficient, regional cerebral blood flow, 911(ab)
 - somatosensory stimulation, thalamic lesions, 858(ab)
- octahedral gallium chelate, monoclonal antibodies, immunoscintigraphy, 1366
- offering of little additional value, compared with SPECT, 1586(1e)
- parameter optimization programs, 1069(ab)
- parametric Dopa-decarboxylase imaging, 879(ab)
- pathophysiological evaluation, progressive aphasia, 1016(ab)
- PATLAK analysis, algorithm, estimation of slope, 944(ab)
- primary progressive aphasia, 857(ab)
- probes for cocaine receptors, non-human primate model, 946(ab)
- protein flux measurements, pulmonary blood flow, 1661
- radiolabeled cocaine analogs, receptor imaging agent, 1025(ab)
- Rb-82, vs. Tl-201 SPECT, myocardial perfusion, 1064(ab)
- Rb-82 vs. F-18 FDG, hibernating myocardium, irreversible perfusion defects, 1065(ab)
- real time-weighted integration, rapid calculation, functional images, 1008(ab)
- reoriented cardiac, issues in quantitation, 1235
- resolution, quantification, visual interpretation of FDG brain tumor studies, 872(ab)
- retrospective post-therapy evaluation, cardiac function, coronary artery disease, 885(ab)

Postcholecystectomy

- scanner gantry and bed, on-line repositioning, alignment with prior studies, 921(ab)
- sentence comprehension, grammatical and semantic components, 1012(ab)
- septum-less volume imaging scanner, count rate performance, 861(ab)
- sinogram noise, quantitative assessment, reprojection, 1008(ab)
- spatial low frequency pattern analysis, normals and schizophrenics, 287
- SPECT and, F-18 FDG and TI-201, myocardial viability, 1064(ab)
- staff formulating/dispersing/administering radiopharmaceuticals, regional dose distribution, hands, 1065(ab)
- standardization, cardiac tomographic imaging, 1434
- standardized tests of performance, 1429(le)
- static cardiac, automated three-dimensional analysis, 1008(ab)
- Tc-94m radionuclide purity requirements, pharmacokinetic studies, 850(ab)
- Tc-99m sestamibi, defect size and severity, 875(ab)
- temporal lobe epilepsy, mesial temporal origin, 1014(ab)
- three-dimensional
- MRI image registration, simple device, 1008(ab)
 - scanners with retractable septa, scatter correction, 879(ab)
 - signal-to-noise improvements, bolus O-15 water activity, 1010(ab)
- three-dimensional functional brain images, automated method, rotational correction, 1579
- T-18 labeled ligands, benzodiazepine receptor studies, 883(ab)
- tracers, industry split over approval, 24N(9)
- trans-C-11 McN-5652, serotonin uptake sites, 860(ab)
- transmission and emission scans, myocardial imaging, 1209, 1214
- transmission processing, accuracy, attenuation correction, 862(ab)
- triazolam and central type benzodiazepine receptors, baboons, 973(ab)
- tritium-3-colchicine, *in vivo* identification, tumor multidrug resistance, 1373
- two-dimensional restoration filter, quantitation of amygdala, 921(ab)
- volume imaging, attenuation correction, 862(ab)
- vs. SPECT, Annual Meeting highlights, 13N(8)
- whole-body
- attenuation correction, 862(ab)
 - methods and performance characteristics, 1191
- whole-body imaging, 1069(ab)
- Postcholecystectomy**, noninvasive test, Sphincter of Oddi dysfunction, 1216
- Pregnancy**, testing for, QM program, 30N(9)
- Progestins**, Tc-99m and Re-186 labeled, synthesis and receptor binding, 558
- Propylene amine oxime**, derivatives, glutathione-mediated decomposition, ligand structure, 988(ab)
- Prostate-specific antigen**, serial measurements, radiotherapy, localized cancer, 853(ab)
- Prostatic neoplasms**, F-18 androgens, potential imaging agents, 724
- Protamine**, In-111 DTPA-heparin, radiolabeling, pharmacokinetics, 1028(ab)
- Protein**
- flux measurements, pulmonary blood flow, PET, 1661
 - intestinal loss, In-111 transferrin, inflammatory bowel disease, 919(ab)
- Proteins**
- radiolabeled, biodistribution and kinetics, focal infection, 388
 - targeted, diagnostic imaging, 394
- Proto-oncogenes**
- c-erbB2* overexpression, I-124 monoclonal antibodies and PET, breast cancer, 2154
 - c-kit*, scintigraphic detection, monoclonal F(ab')₂, 893(ab)
 - oncogene-encoded molecules, radiolabeled antibodies, tumor imaging and therapy, 2160
- Psychiatry**
- functional brain SPECT, powerful clinical method, 1888
 - lithium carbonate therapy, hyperthyroidism, 996(ab)
- PTCA**: see Angioplasty, percutaneous transluminal coronary
- Pulmonary embolism**
- atelectasis, infrequent chest X-ray finding, 849(ab)
 - computer-assisted diagnosis, ventilation-perfusion lung scanning, 1003(ab)
 - enhanced V/Q mismatch sign, 1072(ab)
 - likelihood, number of segmental mismatches, ventilation-perfusion lung scans, 849(ab)
 - low probability V/Q scans, routine ventilation imaging, 1022(ab)
 - suspected, D-dimer plasma concentration, 978(ab)
- Putrescine**, experience, value of, 1720
- Pyeloplasty**, pre- and post-, functional assessment, diuretic renogram, 977(ab)
- Pyrrolidinyi acetamide**, derivatives, labeling with F-18, 830(ab)
- Q**
- Quality Management Rule**, override of OMB disapproval, NRC, 32N(10)
- R**
- Radiation**
- induced alterations, location in cell, methionine or thymidine, 841(ab)
 - induced inhibition of tumor growth, L-[1-¹¹C] tyrosine and F-18 FDG, PET, 373
 - induced response, FDG PET, head and neck carcinoma, 829(ab)
 - injury after interstitial injection, iodocholesterol, 1722(le)
 - local and systemic effects, bone metabolism, quantitative SPECT, 1774
 - perceptions of risk, 20N(7)
 - protection, 33N(9)
 - implications, nonuniformity of dose, 384
- safety
- for beginners, 167
 - post-I-131 thyroid cancer therapy, 1402
- synovectomy
- Ho-166 hydroxyapatite, 937(ab)
 - radiolabeling, hydroxyapatite particles, 980(ab)
- Radiation dose**
- absorbed, Tc-99m teboroxime, humans, 88
 - biodistribution and, planar scintigraphic views, radiolabeled monoclonal antibodies, 925(ab)
 - calculation, bone-to-marrow interface, Monte Carlo modeling, 623
 - calculation at bone-to-marrow interface, 1915(le)
 - distribution in thyroid follicle, revised method, 926(ab)
 - dynamic urinary bladder model, MIRD pamphlet No. 14, 783
 - estimates for chimeric monoclonal cT84.88, In-111 labeling, 953(ab)
- I-131 QSPECT of phantom, transfer of CT vols, manual alignment, 925(ab)
- ovaries, radionuclide hysterosalpingography, Tc-99m pertechnetate, 282
- Radiation dosimetry**, In-111 anti-CEA-F(ab')₂ fragments, tissue distribution, rats, 1654
- Radioactive waste**
- agreement states still chafing, NRC compatibility, 27N(3)
 - low-level: see Low-Level Radioactive Waste monitored retrievable storage, 27N(1)
- Radioactive Waste Act**, hearing by Supreme Court, 37N(5)
- Radioactivity**, intravascular, arrival delay of O-15 tracers, brain, 909(ab)
- Radioaerosols**, pulmonary radioaerosol clearance, appropriate background subtraction, 836(ab)
- Radioangiostintigraphy**, renal post-transplanted patients, 991(ab)
- Radiochemistry**
- microwave fields, C-11 alkylations, 1026(ab)
 - pharmacokinetics and, In-111 BAD-Lym-1, 1030(ab)
- Radiocontrast**, -induced acute renal failure, real time monitoring, 948(ab)
- Radiofluorination**, heterogeneous nucleophilic, thermally stable ion exchange resin, 984(ab)
- Radiography**
- computed, dual-isotope autoradiography, 1005(ab)
 - neuro-SPECT imaging, immature third ventricle teratoma, 435
 - osteoid osteoma, 269
- Radioimmunoassay**, novel HAMA, ovarian cancer patients, 852(ab)
- Radioimmunodetection**
- cancer identification, 803
 - lung cancer, monoclonal antibody HB4C5, 958(ab)
- Radioimmunoimaging**
- alkylamine conjugation chemistry, labeling of antibodies, 986(ab)
 - second Sino-American nuclear medicine conference, 16N(4)
- Radioimmunosciintigraphy**
- combined with PET, F-18 monoclonal antibody fragments, 1535
 - I-131 monoclonal antibody, renal cell carcinoma, 913(ab)
 - pretargeted immunosciintigraphy, hapten valency, murine tumor uptake, 2006
 - three-step monoclonal antibody pretargeting technique, uveal melanoma, 959(ab)
- Radioimmunotherapy**
- antibody pretargeting, three-step approach, 880(ab)
 - biotin conjugates, anti-pan-carcinoma NR-LU-10 monoclonal antibodies, 880(ab)
 - cancer, 1110
 - child with neuroblastoma, tumor dosimetry, I-124 3F9 PET, 2020
 - chimeric antibody chCE7, neuroblastoma xenografts, 231
 - efficacy, 5-iododeoxyuridine, human tumors growing in nude mice, 1530
 - efficacy of immunophoresis, reduction of myelosuppression, 863(ab)
 - event loss estimation, 1005(ab)
 - I-131, bone marrow radiation absorbed dose estimation, leukemia, 941(ab)
 - I-131 anti-pan B-cell antibodies, B-cell lymphoma, 863(ab)

- I-131 B1 and BC8 antibodies, trace and therapeutic amounts, 864(ab)
- I-131 CC49 SPECT, CT and, advanced colorectal cancer, 1002(ab)
- I-131 monoclonal antibody, bone marrow suppression, recombinant G-CSF, 933(ab)
- I-131 pan-B-cell monoclonal antibody, B-cell lymphoma, 893(ab)
- intraperitoneal, postural effects, monoclonal antibodies, 959(ab)
- metastatic breast cancer, 862(ab)
- metastatic gastrointestinal cancer, 863(ab)
- micrometastases
 continuing evolution, 2180
 plasmapheresis, mathematical modeling, 941(ab)
- monoclonal antibody, MIRDose dosimetry software protocol, 926(ab)
- plasmapheresis, micrometastases, dosimetry, 2167
- potential of CH2 domain deletion mutant, NR-LU-10, monoclonal antibody and F(ab')₂, 1028
- prospects and problems, anti-antibody, 958(ab)
- reactor-produced Sc-47, 900(ab)
- Re-186 monoclonal antibodies, Phase I trials, 1099
- repeated low-dose, I-131 LL2 monoclonal antibody, lymphoma, 863(ab)
- Re-186 TNT-1 and TNT-1-F(ab')₂ monoclonal antibodies, 987(ab)
- second generation high-affinity anti-CEA monoclonal antibody, 904(ab)
- toxicity of total body irradiation, non-Hodgkin's lymphoma, 960(ab)
- Radiiodindium**, -labeled autologous platelets, MIRD dose estimate No. 15, 777
- Radiiodination**
 B72.3/CC49/CC83 monoclonal antibodies, pharmacokinetics, 960(ab)
- corticotropin-releasing factor, CRF-receptor imaging, 996(ab)
- E2020 analogs, mapping, *sigma* receptors, 890(ab)
- ETAC reagent, cross-linking antibody Fab' fragments, 943(ab)
- I-131 1,2-Pal-3-IPPA, pancreatic lipase, urine analysis, 1028(ab)
- 3-iodophenylisothiocyanate, coupling to monoclonal antibodies, 1029(ab)
- new simple iodination method, 982(ab)
- 2-nitroimidazole derivatives, viable hypoxic tissue, SPECT, 891(ab)
- novel candidate for SPECT imaging, *sigma* receptors, 981(ab)
- Radiiodine**, pelvic uptake, rectal wall teratoma, thyroidectomy for papillary carcinoma, 1848
- Radiiodine-131**, therapy for well-differentiated thyroid cancer, 1132
- Radioisotopes**
 lung scanning, anatomy of, 676
 medical use of, NRC Medical Use Division, 30N(9)
 production and research, questions about future of DOE, 13N(6)
 threatened reactor worker strike, 19N(9)
 Unites States supply of, Congressional subcommittee, 16N(10)
- Radioligands**
 alternate syntheses, I-125 ioxipride and I-125 epidepride, 982(ab)
- C-11 NNC 722, dopamine uptake system, 931(ab)
- radioiodinated 2 β -carboxymethoxy-3 β -(4-chlorophenyl)-8-(3E- and 3Z-iodopropen-2-yl)nortropanes, mapping of cocaine receptor sites, SPECT, 890(ab)
- Radionuclides**
 arthrography and roentgenological contrast, total hip prosthesis loosening, 950(ab)
- bone scan, MRI imaging, detection of spinal metastases, 992(ab)
- cardiac volumes, correction for Compton scatter, buildup factor, 1642
- common bile duct clearance, endoscopic nasobiliary drainage tube, gallbladder stone, 997(ab)
- cystography, vesicoureteral reflux, children and adolescents, 1022(ab)
- dual, Tc-99m and I-123, quantitative brain SPECT, 972(ab)
- evaluation of Ebstein's deformity, symptomatic infants and children, 930(ab)
- four methods, left ventricular volume determination, 763
- hysterosalpingography, Tc-99m pertechnetate, radiation dose to ovaries, 282
- image quantification, scatter correction technique, 888(ab)
- production threatened in Poland, 20N(7)
- stress tests, efficacy, referral bias, 2074
- studies and MRI comparison, osteomyelitis, 992(ab)
- validation of techniques in an animal model, ratio, hepatic arterial-to-portal venous blood flow, 239
- Radiopharmaceuticals**
 absorbed dose calculations, rapidly growing tumors, 277
- bis(dithiocarbamate)nitrido Tc(V), subcellular distribution, male rats, 850(ab)
- chromatofocusing studies, monoclonal Fab', 2148
- development by National Lab and Biotech Firm, 44N(11)
- formulation, phosphorus-nitrogen backbone ligands, 1072(ab)
- Ga-68, myocardium, 931(ab)
- government relations update, 15N(3)
- Hevesy Nuclear Medicine Pioneer Award, Michael J. Welch, 16N(7)
- incidence of adverse reactions, 1025(ab)
- industry seeks speedier reviews, 19N(2)
- industry split over approval, PET tracers, 24N(9)
- In-111-labeled, quantitative autoradiographic study, heterogeneous activity distribution, 1825
- I.V. administration, prevention of contamination, 1027(ab)
- kits, reconstitution and fractionation, 1915(1e)
- preparation of I-125 PAB, malignant melanoma, 889(ab)
- radiotoxicity, I-123/I-125/I-131-labeled compounds, mouse, 2196
- rapid clearance, simulation, dynamic SPECT, 1200
- second Sino-American nuclear medicine conference, 16N(4)
- single kit, radiolabeling human polyclonal IgG, Tc-99m or In-111, 1024(ab)
- staff formulating/dispersing/administering, regional dose distribution to hands, 1065(ab)
- Tc- and Re-labeled progestins, 558
- Tc-99m
 multifunctional phosphorus hydrazides, 1032(ab)
- perfusion agents, 22N(1)
- uptake and dose heterogeneity, quantitative autoradiography, 1833
- Radiopharmacy**, how magic is the bullet, what will it do?, 549
- Radiosynthesis**, imaging estrogen receptors with PET, F-18 fluoro analog, tamoxifen, 985(ab)
- Radiotherapy**
 computers and instrumentation, SNM Mid-Winter Meeting, 23N(1)
- regional, Re-186 cell binding agent, 899(ab)
- regional bone formation and, 1780
- serial measurements, prostate-specific antigen, localized cancer, 853(ab)
- Sr-89, metastatic prostatic carcinoma, 1316
- Radiotoxicity**, lymphocyte labeling, Tc-99m HMPAO, micronucleus assay, 1167
- Radiotracers**
 monoclonal, Tc-99m N₂S₂, synthesis and evaluation, 990(ab)
- rapid washout from the heart, single-headed gamma camera SPECT system, 1146
- targeted proteins for diagnostic imaging, 394
- Reactor**, -produced Sc-47, evaluation for radioimmunotherapy, 900(ab)
- Reading**, visual imagery, cortical areas in brain, PET study with O-15 butanol, 908(ab)
- Receiver operating characteristics (ROC)**
 analysis for optimizing quantitative results, esophageal scintigraphy, 832(ab)
- anatomy of ROC curve, 1068(ab)
- Receptors**
 β -adrenergic
 F-18 fluorocarazolol PET, 984(ab)
- F-18 fluorocarazolol synthesis, 983(ab)
- angiotensin II, ligand distribution, imaging potential, 900(ab)
- benzodiazepine
 activity-related plasticity, adult mouse brain, 883(ab)
- binding of iomazenil, dynamic SPECT, 911(ab)
- C-11 flumazenil binding, chronic alcohol-dependent men, 1016(ab)
- C-11 flumazenil PET, human brain homogenates, 1011(ab)
- F-18 labeled ligands, PET, 883(ab)
- flumazenil as a ligand, PET, 883(ab)
- hypometabolic parietal cortex, Alzheimer's disease, 887(ab)
- interaction with trazolam, PET, 973(ab)
- occupancy, SPECT, 887(ab)
- visualization, C-11 RO 15-4513, 860(ab)
- cocaine
 mapping with radioligands, SPECT, 890(ab)
- PET imaging probes, non-human primate model, 946(ab)
- radiolabeled analogs, PET, 1025(ab)
- corticotropin-releasing factor, radioiodination, potential tracer, 996(ab)
- dopamine
 density measured by C-11 raclopride and NMSP, same living human brain, 847(ab)
- effects of age, SPECT and IBZM, 897(ab)
- dopamine D1, fluorinated SCH 38548 derivatives, PET radiotracers, 829(ab)
- dopamine D2
 alternate syntheses, I-125 ioxipride and I-125 epidepride, 982(ab)
- chemical family of ligand, 981(ab)
- density, C-11 NMSP PET, 848(ab)
- dual-labeling agents, PET and SPECT, 890(ab)
- dynamic SPECT and whole body imaging, I-123 IBZM, 896(ab)
- I-123 IBZM SPECT, 1964
- I-123 IBZM SPECT, haloperidol, 898(ab)

Reconstruction

- I-123 IBZM SPECT, Parkinson's disease, 917(ab)
I-123 IBZM SPECT, Parkinson syndromes, 917(ab)
I-123 IBZM SPECT, unilateral Parkinson's disease, 1016(ab)
I-123 IBZM SPECT, Wilson's disease, 897(ab)
I-123 2'-ISP SPECT, 897(ab)
in vivo SPECT with iodine-iodoluride, supranuclear palsy, 1481
PET tracers, benperidol analogs, 848(ab)
preclinical study, I-123 IBF SPECT, 870(ab)
preparation, F-18 NCQ 616 and C-11 FLB 457, 860(ab)
radioiodinated high-affinity ligands, 848(ab)
specific and non-specific binding of C-11 YM-09151-2, age dependency, 897(ab)
superior PET ligand, 847(ab)
supranuclear palsy, I-123 ILIS SPECT, 1019(ab)
dopamine D1 and D2, striato-nigral degeneration, Parkinson's disease and PET, 917(ab)
glucose utilization and, use of linear programming, PET studies of heart and brain, 944(ab)
hepatic, biochemistry, Ga-68 DF-NGA, 1160
histamine H1
 blocking drugs, distribution of C-11 pyrilamine, 968(ab)
 C-11 pyrilamine and C-11 doxepin, heart, 885(ab)
5-HT₃, potential tracer for imaging, 830(ab)
ligand-, PET, multi-injection approach, 943(ab)
measurement of concentration in the heart, instrumental errors, PET, 882(ab)
muscarinic, synthesis and biodistribution, C-11 2 α -tropanyl benzilate, 423
muscarinic acetylcholine, I-125 QNB, rat brain, 883(ab)
muscarinic cholinergic
 decreased binding of I-123 IDEX, temporal lobe epilepsy, 928(ab)
 tracer kinetic analysis, C-11 NMPB, 882(ab)
opiate kappa, synthesis, F-18 N-(2-(pyrrolidinyl)-1-phenylethyl)acetamide analog, 830(ab)
serotonin, mapping, C-11 methylketanserin, 1026(ab)
serotonin S₂, I-125 altanserin SPECT, 1023(ab)
sigma
 mapping of, radioiodinated E2020 analogs, 890(ab)
 novel candidate for SPECT imaging, radioiodination, 981(ab)
somatostatin
 I-123 TOCT and In-111 DOCT somatostatin analogues, neoplasms, 914(ab)
 scintigraphy, In-111-DTPA-D-Phe-1-octreotide, 652
- Reconstruction**
accelerated, ordered subsets, 960(ab)
algorithm, singular value decomposition, attenuation in SPECT, 831(ab)
Bayesian, registered anatomical images as priors, SPECT, 963(ab)
cardiac SPECT, truncated projections, 831(ab)
cone beam, algorithm, displaced center-of-rotation, 891(ab)
3D ML-EM, improved signal-to-noise, 961(ab)
fan beam convolution, variable focal length collimators, 891(ab)
fast iterative method, basis, functional regions, 831(ab)
fast maximum-likelihood, 1710
high resolution PET image, restoration, detector response, 872(ab)
image, filtered back-projection, iterative linear algorithms, 871(ab)
improved resolution, SPECT, simulation results, 851(ab)
iterative
 algorithm, SPECT grey matter imaging, 1225
 quantification, human basal ganglia, 878(ab)
 maximum-likelihood
 clinically important characteristics, 1678
 improved brain SPECT, 964(ab)
 PET images, artifacts, 1069(ab)
 quantitative method, single-orbit cone beam SPECT, 892(ab)
 quantitative performance of maximum likelihood, image wide resolution convergence, 871(ab)
 three-dimensional iterative, SPECT, 879(ab)
 volume-imaging PET, function of axial extent, 871(ab)
- Red blood cells**
human, reduction of teboroxime extraction, rabbit heart, 864(ab)
serial measurements of cardiac volumes, count-based methods, 1324
UltraTag RBC kit, anticoagulants, reagent volume, 989(ab)
- Reflux**
duodenogastric, significance, diagnosis of acute cholecystitis, 898(ab)
gastroesophageal, abnormal esophageal motility, angina-like chest pain, 955(ab)
vesicoureteral
 cyclic voiding cystography, asymptomatic siblings, 873(ab)
 radionuclide cystography, children and adolescents, 1022(ab)
- Regional wall motion**
choice of stress for diagnostic perfusion, MIBI-SPECT, stress echocardiography, 825(ab)
regional metabolic abnormality, relation to perfusion, myocardial infarction, 659
thrombolytic therapy, Tc-99m sestamibi defect size, 927(ab)
- Regions of interest (ROI)**
anatomy-oriented 3-D ROI definition system, 1006(ab)
maximum likelihood-expectation maximization reconstruction, SPECT, 451
- Rejection**
cardiac allograft, I-123 anti-ICAM-1 imaging, rats, 1000(ab)
cardiac transplantation, antimyosin agents, primates, 1994
- Renography**
captopril
 captopril-stimulated PRA, bilateral renal artery stenosis, 907(ab)
 cortical residual activity, renal artery stenosis, 906(ab)
 segmental branch renal artery stenosis, 266
 diuresis, gravity-assisted drainage view, 1022(ab)
 diuretic
 functional assessment, pre- and post-pyeloplasty, 977(ab)
 natural history, infantile hydronephrosis, 2098
 DTPA, triple radiopharmaceutical renal study, renovascular hypertension, 1034(ab)
 volume expanded diuretic, postnatal assessment, suspected uretero-pelvic junction obstruction, 2094
 "well tempered" diuretic, hydronephrosis or hydroureteronephrosis, asymptomatic neonate, 2047
- Reperfusion**, infarct-related arterial patency, serial tomographic imaging, Tc-99m sestamibi, 2080
- Resins**, thermally stable ion exchange, heterogeneous nucleophilic radiofluorination, 984(ab)
- Resource Based Relative Value Scale (RBRVS)**, PPRC report to Congress, 36N(9)
- Respiration**, effect of cocaine, Tc-99m D,L-HMPAO, rat brain slices, 964(ab)
- Restenosis**, fibrin deposition, coronary artery injury, 845(ab)
- Rhenium-186**
anti-P185HER2 monoclonal antibody, animal tumor model, 934(ab)
cell binding agent, regional radiotherapy, 899(ab)
comparison of bone-seeking agents, mechanistic implications, 899(ab)
direct vs. chelate labeled NR-LU-10 monoclonal antibody, tumored nude mice, 910(ab)
immunocjugates, effective stabilization, 979(ab)
labeling the diaminedithiol ligand system, 1032(ab)
pharmacokinetics after Re-186-HEDP, bone metastases, 646
Tc-99m complexes and
 structural requirements, rapid tubular transport, 900(ab)
 unsymmetrical BAT ligand, 989(ab)
 TNT-1 and TNT-1-F(ab')₂ monoclonal antibodies, radioimmunotherapy, 987(ab)
- Rhenium-186 etidronate**, radiochemical and chemical stability of injection, radiolysis effects, 1024(ab)
- Rhenium-186 HEDP**, treatment of bone pain, 859(ab)
- Rhenium-186 IgG**, metabolic studies, normal and tumor-bearing mice, 979(ab)
- Rhenium-186 monoclonal antibodies**, radioimmunotherapy, Phase I trials, 1099
- Rhenium-186 progesterin**, Tc-99m and, synthesis and receptor binding, 558
- Rhenium-188**
I-131 Mu-9 IgG and, therapeutic potential, single and fractionated doses, 1000(ab)
methylene bridged phosphineoxide-phosphine, versatile chelating agent, 979(ab)
Tc-99m and, bifunctional frameworks, phosphorus hydrazide chelates, 910(ab)
- Rhenium-188 antibody**, generation by direct labeling methods, 909(ab)
- Rhenium-188 Rc(V)-DMSA**, facile synthesis, triphenylphosphine reduction, perrhenate at room temperature, 1024(ab)
- Rheumatic fever**
carditis, importance, scintigraphic diagnosis, 995(ab)
Tc-99m radionuclide angiography, thrombosis detection, left atrial appendage, 365
- Rotor's disease**, scintigraphic aspect, Tc-99m mebrofenin, 1550
- Rubidium-82**
O-15 water and, myocardial perfusion, PET, 884(ab)
PET
 vs. F-18 FDG, hibernating myocardium, 1065(ab)
 vs. Tl-201 SPECT, myocardial perfusion, 1064(ab)

S

- Samarium-153**
comparison of bone-seeking agents, mechanistic

- implications, 899(ab)
- Cu-67 immunoconjugates, tumor therapy, 942(ab)
- intra-arterial microspheres, pre-operative sterilization, kidney cancers, 1024(ab)
- Samarium-153 EDTMP**
- escalating dose schedule, metastatic bone cancer, 1451
- multidose, pain palliation, metastatic bone disease, 992(ab)
- Sarcoidosis**
- acute, In-111 leukocyte and Ga-67 imaging, 2027
- assessment of disease activity, Ga-67 citrate scanning, 751
- uveitis, Ga-67 citrate scanning, 1851
- Sarcoma**
- Ewing's and osteogenic, scintigraphic differentiation, gallium and bone scintigraphy, 1063(ab)
- Kaposi's, Tc-99m DTPA aerosol, Ga-67 scanning, 81
- musculoskeletal, F-18 FDG PET, 992(ab)
- soft-tissue, metastasis, gallium imaging, 1594
- soft tissue and bone, Tl-201 scan patterns, 843(ab)
- Scandium-47**, reactor-produced, evaluation for radioimmunotherapy, 900(ab)
- Scatter**
- acceptance testing and quality assurance, WAM module, 1005(ab)
- attenuation and depth-dependent resolution, 180° myocardial SPECT, 842(ab)
- camera-induced, collimator penetration, I-131 imaging, 889(ab)
- component, SPECT projections, 842(ab)
- Compton**
- deconvolution-fitting, energy and spatial regularization, 842(ab)
- prediction process and cubic spline, SPECT, 888(ab)
- radionuclide cardiac volumes, buildup factor, 1642
- correction**
- attenuation and, SPECT imaging, 2232
- 3D PET studies, scanners with retractable septa, 879(ab)
- dual photopeak window, uniformity, 962(ab)
- dual-photopeak window method, 605
- energy spectra, neural network, 963(ab)
- four methods, Monte Carlo-simulated source distributions, 962(ab)
- radionuclide image quantification, 888(ab)
- semiquantification, I-123 IBZM SPECT, 972(ab)
- spectral imaging, standard acquisition energy window, 888(ab)
- whole-body SPECT, 1007(ab)
- SCH 38548**, fluorinated derivatives, PET radiotracers, dopamine D-1 receptors, 829(ab)
- Schizophrenia**
- depression and, Tc-99m HMPAO SPECT, 972(ab)
- mapping of *sigma* receptors, radioiodinated E2020 analogs, 890(ab)
- spatial low frequency pattern analysis, positron emission tomography, 287
- Schwannoma**, cranial and spinal neuroma, PET-fluorodeoxyglucose, 1931
- Scientific exhibits**, prizes, 19N(2)
- Scintigraphy**
- adenosine thallium, high cardiac risk, patients referred for vascular surgery, 952(ab)
- adenosine Tl-201, lung thallium uptake, 1600
- adrenocortical, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)
- appearance of Alzheimer's disease, Tc-99m HMPAO SPECT, 181
- assessment of MIBG uptake, globally denervated human and canine hearts, 1444
- bile extravasation, presence of ascites, hepatic transplantation, 115
- biliary, grading of hyperperfusion, rim sign, 898(ab)
- bolus transport and contraction parameters, multiple-swallow investigations, 1291
- bone**
- I-131 MIBG and, detection of neuroblastoma, 1735
- intravenous pamidronate, Paget's disease, 1589
- lower extremity pain of unknown origin, pre-school children, 351
- Tc-99m MDP abdominal uptake, continuous ambulatory dialysis, 2052
- captopril-enhanced, renal artery stenosis, en-bloc pediatric renal transplant, 263
- cardiac blood-pool, Tc-99m liposomes, 984(ab)
- detection of overexpressed c-kit protooncogene, monoclonal F(ab')₂ fragments, 893(ab)
- diabetes, gastric motility disturbances, 832(ab)
- differentiation of osteogenic sarcoma, Ewing's sarcoma, gallium and bone scintigraphy, 1063(ab)
- diuretic MAG₃ renal, routine protocol, congenital and acquired renal disorders, 1035(ab)
- dobutamine stress thallium, usefulness and safety, 951(ab)
- esophageal**
- achalasia and achalasia-like disorders, 590
- reproducibility, normal ranges, 2106
- ROC-analysis, 832(ab)
- F-18 FDG, chemotherapeutic impact, malignant lymphoma, 858(ab)
- gastric emptying of liquids, 956(ab)
- hemodynamic-scintigraphic study, myocardial ischemia, adenosine infusion, 952(ab)
- hepatobiliary**
- bile lakes, liver transplant infarcts, 997(ab)
- hepatic transport function, 998(ab)
- intrahepatic vs. extrahepatic cholestasis, 1186
- high-resolution, postnatal maturation, myocardial sympathetic nerves, 935(ab)
- I-123 iodoamphetamine, Budd-Chiari syndrome, 744
- I-123 MIBG and I-123 TOCT, metastatic carcinoma tumors, 1121
- I-131 MIBG
- diagnostic value, kindred with MEN-II, 1065(ab)
- pitfalls, diagnosis of neuroblastoma, 930(ab)
- importance of diagnosis, carditis in rheumatic fever, 995(ab)
- In-111 antimyosin, significance, uncomplicated valvular replacement, 895(ab)
- In-111 antimyosin monoclonal antibody, time course, myocardial infarction, 1501
- In-111 labeled human nonspecific IgG, evaluation, inflammatory bowel disease, 919(ab)
- In-111 pentatreotide, gastro-entero-pancreatic endocrine tumors, 976(ab)
- In-111 somatostatin analogue, visualization, malignant lymphoma, 903(ab)
- leukocyte, diagnosis of mycotic aneurysm, 1486
- location and size of defects, myocardial perfusion, fatal infarction, 251
- marrow changes, hormonal changes, 1427(le)
- MIBG, location of neuroblastoma, opsoclonus-myoclonus, 930(ab)
- MRI and, bone marrow, staging of breast cancer, 914(ab)
- parathyroid, subtraction algorithm, 996(ab)
- phase analysis, consequences, ventricular tachycardia, 994(ab)
- planar, SPECT and, rotating slit collimator, 1005(ab)
- planar bone**
- SPECT, low back pain, 868(ab)
- zygapophyseal joint injection, chronic low back pain, 868(ab)
- plastic detectors, high-resolution I-125 imaging, rat brain blood flow, 1003(ab)
- presurgical HMPAO, patients with medically refractory seizures, 967(ab)
- pulsed Doppler and per-jejunum, portal venous blood flow, liver cirrhosis, 997(ab)
- quantitative tumor, time to metastasis, dogs with osteosarcoma, 1542
- radiolabeled amyloid P-component, 913(ab)
- renal**
- captopril, renal artery stenosis, 2045
- captopril, unexpected pressor responses, 906(ab)
- prognostic value with captopril, renovascular hypertension, 2040
- Rotor's disease, Tc-99m mebrofenin, 1550
- sestamibi, radioisotopic assessment, myocardial viability, 1925
- somatostatin analog, carcinoid tumors, 914(ab)
- somatostatin receptor, In-111-DTPA-D-Phe-1-octreotide, 652
- sphincter of Oddi dysfunction, 1223
- subchondral bone infarctions, acute ligamentous knee injuries, 516
- Tc-99m antifibrin, acute deep venous thrombosis, 848(ab)
- Tc-99m antigranulocyte Fab' fragments, compared to In-111 oxine/Tc-99m HMPAO leukocytes, infectious diseases, 903(ab)
- Tc-99m EHIDA hepatobiliary, diagnostic criteria for biliary atresia, neonatal jaundice, 899(ab)
- Tc-99m HMPAO cerebral cortical activity, 117
- Tc-99m HMPAO cerebral perfusion, timely brain death declaration, 2209
- Tc-99m MAG₃, captopril, renal artery stenosis, 990(ab)
- Tc-99m MIBI, myocardial viability, thallous chloride injection, 906(ab)
- Tc-99m TBI, detection of metastases, thyroid carcinoma, 914(ab)
- thallium**
- incremental diagnostic value and impact, 1727
- incremental value, cost consciousness, 1732
- thrombosis, Tc-99m inhibited recombinant t-PA, 1029(ab)
- Tl-201**
- localization, parathyroid enlargement, 895(ab)
- viable myocardium, chronic coronary artery disease, 505
- tomographic myocardial perfusion, integration of wall kinetic and perfusion data, 933(ab)
- torsion in triorchidism, 1854
- two-phase scrotal, classification of varicoceles, 1034(ab)
- ventilation-perfusion, intermediate likelihood-ratio results, 849(b)
- white blood cell, monoclonal antibodies, septic loosening of endoprostheses, 840(ab)
- Sclerosis**, systemic, left ventricular diastolic function, 68
- Scrotum**, two-phase scintigraphy, classification of varicoceles, 1034(ab)
- Seizures**
- medically refractory, presurgical HMPAO scin-

Self-referral

- tigraphy, 967(ab)
simple and partial, foci localization, Tc-99m HMPAO SPECT, 971(ab)
- Self-referral, bans on, 36N(9)**
- Senescence, accelerated mouse, altered tritiated nicotine accumulation, 1023(ab)**
- Sepsis**
cellular hypoxia, marker F-18 fluoromisonidazole, 924(ab)
loosening of endoprostheses, WBC scintigraphy with monoclonal antibodies, 840(ab)
spread of infectious complications, odontogenic abscess, Tc-99m HMPAO-labeled WBC scan, 254
- Serotonin**
improved preparation, I-123 LSD or I-125 LSD, 982(ab)
presynaptic, synthesis and evaluation, I-125 5-I-6-NQP, 890(ab)
transporter, MIBG uptake, 935(ab)
uptake sites
trans-C-11 McN-5652, 860(ab)
2-[C-11]methyl-amino-2-methyl-3-phenyl-1-propanol PET, 861(ab)
- Shock, cardiogenic, acute onset, normal coronary arteries, 1558**
- Shunt**
left-to-right, quantitation, recirculation subtraction, 1917(le)
portal systemic, fraction quantification, I-123 HIDPM, 997(ab)
- Sincalide, continuous infusion, calculation, gallbladder ejection fraction, 537**
- Single photon emission computed tomography (SPECT)**
180°, spine, patients with LBP, 950(ab)
acquisition, effects, differential tracer washout, 1251(le)
adrenal, without dexamethasone suppression, primary aldosteronism, 834(ab)
anatomy-oriented 3-D ROI definition system, 1006(ab)
attenuation correction
dual-energy X-ray CT, 901(ab)
iterative methods, 962(ab)
basal ganglia uptake, monkey brain phantom, 963(ab)
Bayesian reconstruction, registered anatomical images as priors, 963(ab)
benzodiazepine receptor occupancy, relation to benzodiazepine medication, 887(ab)
blood flow in stroke, clinical prognosis, 878(ab)
brain
attenuation effect, 961(ab)
blood flow, interventional neuroradiology, 826(ab)
cerebral angioplasty, delayed ischemia due to vasospasm, 1789
dual radionuclide data acquisition, Tc-99m and I-123, 972(ab)
extracorporeal membrane oxygenation, neonates, 1943
maximum-likelihood reconstruction, 964(ab)
multimedia multimodality interactive computer tutorial, 1071(ab)
rapid registration, 1005(ab)
transcranial Doppler, acute ischemic stroke therapy, 968(ab)
brain perfusion
cocaine abuse, AIDS dementia complex, 1312, 887(ab)
differential diagnosis, dementia, 1017(ab)
regional cerebral blood flow, PET comparison, 966(ab)
- cardiac
cardiofocal collimator, 852(ab)
defect detection, cone beam geometry, 961(ab)
defect detection, restoration filters, 842(ab)
emission and transmission noise propagation, non-uniform attenuation correction, 902(ab)
reconstructions, truncated projections, 831(ab)
volume, delineation of myocardium, 933(ab)
cerebral blood flow and MRI, differential diagnosis, dementia, 1014(ab)
cerebral perfusion, relative error-estimation, regional analysis, 969(ab)
cerebral perfusion abnormalities, Alzheimer's disease, 973(ab)
clinical, promotion of, 38N(9)
cocaine receptor site mapping, radioligands, 890(ab)
collimation, spatially variant focusing, 891(ab)
compared to PET, 1586(le)
comparison of single/dual/triple-head, 1070(ab)
Compton scatter correction method, prediction process, cubic spline, 888(ab)
computer-directed coregistration, multislice functional and anatomic images, external fiducials, 961(ab)
cone-beam, sampling considerations, 891(ab)
continuous imaging protocol, Tc-99m tebo and Tl-201, 1304
Cramer-Rao bound analysis of effects, attenuation, feature size and activity estimation, 962(ab)
current role, imaging of subdural hematoma, 248
delayed, I-123 IMP, dementia, 1015(ab)
diagnostic accuracy, Alzheimer's disease, 1019(ab)
dual bone and WBC scan imaging, osteomyelitis, cellulitis, 839(ab)
dual-detector, cone beam tomography, 892(ab)
dual isotope, brain, headtome set 031, 1017(ab)
dual isotope immunoscintigraphy, improved demarcation of tumors, occult colorectal carcinoma, 1000(ab)
dual-labeling agents, dopamine D-2 receptors, 890(ab)
dual radionuclide, feasibility with I-123 and Tc-99m, 851(ab)
- dynamic
detection and correction of motion, 911(ab)
iomazenil binding to human benzodiazepine receptor, 911(ab)
kinetic modeling, teboroxime, 878(ab)
simulation, radiopharmaceuticals with rapid clearance, 1200
whole body imaging, I-123 IBZM and dopamine D2 receptors, 896(ab)
equitable reimbursement, 36N(9)
fast maximum-likelihood reconstruction, 1710
four scatter correction methods, Monte Carlo-simulated source distributions, 962(ab)
functional brain, powerful clinical method, 1888
functional brain scans, evidence in criminal court, 18N(6)
fusion with CT/MRI images, radiolabeled monoclonal antibodies, 960(ab)
Ga-67 citrate, biopsy-confirmed residual Hodgkin's disease, mediastinum, 345
gamma camera, image truncation, cone beam CT, 901(ab)
gated, Tc-99m sestamibi, fixed defects as infarct or artifact, 927(ab)
gated blood-pool imaging
parametric display, 3-D biventricular function, 952(ab)
- potential added clinical value, 910(ab)
gated or non-gated Cardiolite, quantitative evaluation, myocardial perfusion abnormalities, 927(ab)
gated Tc-99m sestamibi, left ventricular ejection fractions, 927(ab)
generalized Gibbs prior, maximum *a posteriori*-EM SPECT reconstruction, 832(ab)
grey matter imaging, compensation, iterative reconstruction algorithm, 1225
high-resolution three-head, dual energy acquisition, liver tumor imaging, 976(ab)
hippocampal blood flow, diagnosis, Alzheimer's disease, 940(ab)
I-125 altanserine, potential ligand, serotonin S₂ receptors, 1023(ab)
I-123 CIT, monoamine transporter sites, non-human primate brain, 945(ab)
I-123 IBF, preclinical study, D2 dopamine receptor, 870(ab)
I-123 IBZM
differential diagnosis of Parkinsonism, 917(ab)
dopamine D2 receptors, 1964
dopamine D2 receptors, effects of age, 897(ab)
dopamine D2 receptors, haloperidol, 898(ab)
dopamine D2 receptors, Parkinson's disease, 917(ab)
dopamine D2 receptors, Parkinson syndromes, 917(ab)
dopamine D2 receptors, Wilson's disease, 897(ab)
dopamine D2 receptors, unilateral Parkinson's disease, 1016(ab)
Parkinson's disease, multi-system atrophy and dystonia, 1018(ab)
semiquantification, scatter correction, 972(ab)
I-123 IBZM and Tc-99m HMPAO, subjects with and at risk for Huntington's disease, 970(ab)
I-123 ILIS, dopamine D2 receptors, supranuclear palsy, 1019(ab)
I-123 IMP
cerebral blood flow, no arterial sampling, 969(ab)
cerebral perfusion, progressive supranuclear palsy, 704
nondemented old patients, Down's syndrome, 967(ab)
partition coefficient, regional cerebral blood flow, 911(ab)
I-123 IPPA, myocardial involvement, systemic myopathies, 995(ab)
I-123 2'-ISP, D-2 dopamine receptors, 897(ab)
I-131 CC49 monoclonal antibody, radioimmunotherapy and CT, advanced colorectal cancer, 1002(ab)
imaging and quantitation, spatial factors, 1069(ab)
imaging in small animals, 852(ab)
improved colonic transit procedure, easily prepared marker, 833(ab)
improved reconstructed resolution, simulation results, 851(ab)
in vivo imaging of D2 receptor, iodine-iodolysuride, supranuclear palsy, 1481
liver volume measurement, autopsy and NMR imaging, 1066(ab)
maximum likelihood-expectation maximization reconstruction, ROC analysis, 451
maximum-likelihood important characteristics, clinically important characteristics, 1678
McSPECT prototype, cylindrical brain SPECT system, 852(ab)
measured attenuation map, attenuation correction, simple method, 843(ab)

- MIBI, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
- moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
- multi-energy maximum-likelihood reconstruction algorithms, 831(ab)
- multi-head camera, sensitivity, resolution and image quality, 1859
- multiple gated, myocardial thickening, phase analysis, 926(ab)
- myocardial
- computer-aided diagnosis, coronary artery disease, 272
 - fan-beam collimators, newborn period and early infancy, 930(ab)
- 180° myocardial, scatter, attenuation and depth-dependent resolution, 842(ab)
- myocardial perfusion, Tc-99m MIBI radio-nuclide angiography, dipyridamole, 846(ab)
- neuro-SPECT and radiographic imaging, immature third ventricle teratoma, 435
- N*-isopropyl[¹²³I]IMP, regional cerebral blood flow, 1741
- N*-isopropyl[¹²³I]p-iiodoamphetamine, regional cerebral blood flow, 965(ab)
- perfusion imaging, autopsy-diagnosed dementia, 939(ab)
- PET and, F-18 FDG and Tl-201, myocardial viability, 1064(ab)
- planar bone scintigraphy and, zygapophyseal joint injection, chronic low back pain, 868(ab)
- planar scintigraphy and, rotating slit collimator, 1005(ab)
- projections based on analytical scatter functions, estimate, scatter component, 842(ab)
- project underway, 44N(11)
- prototype emission-transmission CT imaging system, 1881
- qualitative approach to HIV dementia, 1018(ab)
- quantification, attenuation and scatter correction, cardiac imaging, 2232
- quantitative
- I-131, transfer of CT vols, 925(ab)
 - local and systemic effects of radiation, bone metabolism, 1774
- quantitative stress-redistribution Tl-201, prone imaging, validation, 1509
- quantitative vs. visual analysis, Tl-201 defect reversibility and severity, 905(ab)
- radial slices, myocardial perfusion studies, 1070(ab)
- radioiodinated high-affinity dopamine D2 receptor ligands, *in vivo* comparison, 848(ab)
- radioiodinated 2-nitroimidazole derivatives, viable hypoxic tissue, 891(ab)
- radioiodination of sigma receptors, 981(ab)
- rapidly cleared tracers, 1206
- rapid registration and review, brain, 1067(ab)
- reimbursement, 19N(3)
- sequential high resolution, intracranial arterio-venous malformations, Tc-99m RBC and Tc-99m HMPAO, 839(ab)
- simultaneous acquisitions, rCBF and glucose metabolism, 965(ab)
- simultaneous dual-isotope, parathyroid pathology, 131
- simultaneous emission/transmission, scanning line source, attenuation correction, 901(ab)
- simultaneous rest Tl-201/stress Tc-99m sestamibi, myocardial perfusion, 854(ab)
- single-headed gamma camera system, rapid radiotracer washout, heart, 1146
- single-orbit cone beam, quantitative reconstruction method, 892(ab)
- standardization, cardiac tomographic imaging, 1434
- Tc-99m and I-123, validation by phantom studies, brain, 2030
- Tc-99m CEROTEC, interictal localization, epileptic foci, 966(ab)
- Tc-99m DMSA
- three-head rotating gamma camera, renal scan, 1021(ab)
 - triple-head imaging, urinary tract infection, 991(ab)
- Tc-99m DTPA and Tc-99m desferoxamine aerosols, lung ventilation, 835(ab)
- Tc-99m ECD, kinetic behavior, compartment analysis and dynamic SPECT, 909(ab)
- Tc-99m exametazine, unilateral voluntary hand movement, regional cerebral uptake, 1623
- Tc-99m HMPAO
- acetazolamide, cerebrovascular disease, 877(ab)
 - acetazolamide, vascular response and diaschisis, 967(ab)
 - acute aphasia, 970(ab)
 - alternating hemiplegia, childhood, 1021(ab)
 - Barre-Liou syndrome, cervical manipulation, 972(ab)
 - bilateral and symmetrical anomalies, brain, 485
 - brain, 1875
 - carbon dioxide reactivity, cerebrum and cerebellum, 1014(ab)
 - cerebral blood flow, brain tumors and strokes, 971(ab)
 - cerebral blood flow, chronic subdural hematoma, 246
 - cerebral blood flow, choreo-athetoid syndrome, 838(ab)
 - cerebrovascular reserve capacity, carotid artery stenosis, 971(ab)
 - compared to MR/CT, diagnosis of dementia, 972(ab)
 - crossed cerebellar diaschisis, cerebral infarction, 877(ab)
 - 3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
 - feasibility, cortical activation study, 1015(ab)
 - independent aura/ictal/interictal cerebral perfusion, 438
 - kinetic behavior, brain, 135
 - linearization algorithm, cerebral blood flow, 912(ab)
 - localization, epileptic foci, 971(ab)
 - neurofocal imaging, brain, 1070(ab)
 - perfusion change after thrombolytic therapy, ischemic stroke, 877(ab)
 - presurgical evaluation, temporal lobe epilepsy, 929(ab)
 - quantitative perfusion-defect indexes, children with cerebral palsy, 977(ab)
 - regional cerebral blood flow, Down's syndrome, 1013(ab)
 - regional cerebral blood flow, Wisconsin card sorting test, 967(ab)
 - schizophrenia and depression, 972(ab)
 - scintigraphic appearance, Alzheimer's disease, 181, 312
 - sensitivity and specificity, dementia, 1013(ab)
 - status epilepticus, 928(ab)
- Tc-99m HMPAO and I-123 IMP, cerebral blood flow, 1012(ab)
- Tc-99m HMPAO and Tc-99m ECD, kinetics, brain tumors, 969(ab)
- Tc-99m MIBI
- resting and exercise myocardial imaging, children, 929(ab)
 - stability, perfusion defect size, 876(ab)
- Tc-99m monoclonal antibody 174H.64, staging head and neck cancer, 912(ab)
- Tc-99m PPN.1011, clinical evaluation, myocardium, 875(ab)
- Tc-99m sestamibi
- dobutamine, coronary artery disease, 866(ab)
 - F-18 FDG glucose PET, malignancy, 858(ab)
 - myocardial viability, 886(ab)
 - right ventricular ischemia, inferior myocardial infarction, 876(ab)
 - same day, myocardium, 876(ab)
 - spontaneous chest pain, coronary intervention, 875(ab)
- Tc-99m TEBO
- delay of image acquisition, myocardium, 952(ab)
 - preprocessing masking technique, 854(ab)
- three-detector, simultaneous transmission and emission, 901(ab)
- three-dimensional
- cerebral blood flow, obsessive-compulsive disorder, 838(ab)
 - iterative reconstruction, 879(ab)
 - myocardial perfusion, Tc-99m sestamibi stress perfusion, 926(ab)
- three-headed, transmission data acquisition, 901(ab)
- Tl-201
- attenuation correction, 1574
 - brain tumor recurrence, 867(ab)
 - distinction, high-grade from low-grade gliomas, 868(ab)
 - effect of patient motion, 1566
 - exercise-redistribution, myocardial viability after infarction, 906(ab)
 - F-18 FDG PET and MRI, recurrent brain tumors, 867(ab)
 - influence of perfusion defect size, tomographic defect severity, 995(ab)
 - meningioma, prediction of histological type, 971(ab)
 - myasthenia gravis, 1020(ab)
 - myocardial viability, coronary artery disease, 886(ab)
 - of theoretical derivations, empirical evidence, 1578
 - recurrent primary brain tumors, 1071(ab)
 - re-evaluation for brain tumor, 844(ab)
 - reinjection studies, collateralization, 915(ab)
 - sensitivity to patient motion, 1571
 - teboroxime resting washout, coronary disease, 876(ab)
 - vs. Rb-82 PET, myocardial perfusion, 1064(ab)
- Tl-201 and Tc-99m phytate, liver tumor imaging, high-resolution three-head imaging, 918(ab)
- Tl-201 and Tc-99m sestamibi
- heart transplantation, coronary arteriopathy, 951(ab)
 - myocardial viability, 905(ab)
- Tl-201 myocardial, major upward creep of heart, COPD, 1846
- triple-headed DMSA, comparison with ultrasonography, 922(ab)
- triple-head high-resolution
- diagnosis, femoral head avascular necrosis, 936(ab)
 - diagnosis, hepatic hemangioma, 918(ab)
- vs. PET, Annual Meeting highlights, 13N(8)
- vs. planar bone scintigraphy, low back pain, 868(ab)
- whole-body, method for scatter correction,

Skeleton

1007(ab)
Xe-133
cerebral blood flow and predetermined ROIs, children, 977(ab)
surgical outcome, temporal lobe epilepsy, 1018(ab)
Skeleton
axial, bone mineral density, acromegaly, 1608
bone mineral density, dual-energy X-ray absorptiometry, 1137
kinetics, evaluation, F-18 fluoride ion PET, 633
nonvisualization, bone scan, secondary to intravenous etidronate therapy, 748
screening in children, traumatic brain injury, 873(ab)
Sn(II) complexes, macromolecular, direct Tc-99m labeling with antibody, 1029(ab)
Sn(II)-DPEDO kit, Tc-99m labeled brain scanning, elimination of chiral centers, coordination sphere, 920(ab)
Sn-117m, comparison of bone-seeking agents, mechanistic implications, 899(ab)
Society of Nuclear Medicine (SNM)
ACNP and, medicare fee schedule, 18N(1)
actions of the Board of Trustees, 23N(4)
Annual Meeting highlights, molecules with messages, 10N(8)
Annual Meeting preview, 33N(5)
budget testimony, 13N(6)
court upheld nuclear quality management rule, 19N(7)
government relations update, 30N(9), 14N(12)
identifying nuclear medicine's practitioners, 26N(4)
licensing decision, California radioactive waste site, 40N(9)
Mid-Winter Meeting, computers and instrumentation, 23N(1)
new way to order medicine books, 33N(3)
Nuclear Medicine Week goes international, 33N(3)
standardization, cardiac tomographic imaging, 1434
trustees favor central office move to nation's capitol, 27N(8)
Somatostatin, radiolabeled, thyroid and orbital accumulation, Graves' disease, 894(ab)
Somatostatin analogue, Tc-99m and In-111, preparation, preliminary evaluation, 851(ab)
Spasm, infantile, regional cerebral blood flow, 1018(ab)
Species differences, interspecies variation in biodistribution, Tc-99m CPI, 1357
Spheroids, multicellular tumor, radioiodinated MIBG, neuroblastoma micrometastases, 859(ab)
Sphincter of Oddi
dysfunction
noninvasive test, postcholecystectomy, 1216
scintigraphic evaluation, 1223
Spinal cord, injury, renal plasma flow, glomerular filtration rate, 1035(ab)
Spine
fracture, bone mineral density, cyclic oral phosphate and etidronate, 1
neuroma, PET-fluorodeoxyglucose, 1931
Spleen
-liver scan, fatty liver, masquerade as neoplasm, 258
radiolabeled granulocyte kinetics, systemic vasculitis, 491
Starling effect, reduced exercise capacity, cardiac transplantation, 939(ab)
Stenosis

carotid artery, cerebrovascular reserve capacity, thrombendarterectomy, 971(ab)
coronary, adenosine, TI-201 compared to Tc-99m teboroxime, 864(ab)
iliac artery, renal transplant hypertension, 1178
renal artery
captopril-stimulated PRA, 907(ab)
chronic rejection, renal kinetics in transplants, 923(ab)
cortical residual activity, captopril renography, 906(ab)
Tc-99m MAG₃ scintigraphy, captopril, 990(ab)
Stents, coronary, platelet-fibrin deposition, anticoagulation, 845(ab)
Stereotaxy, automated, transformation, functional brain PET images, 1007(ab)
Stomach
antral processing of solid meal, acute and chronic alcohol, 832(ab)
applications of amplitude images, interpretation, gastric bleed studies, 1006(ab)
Fourier approach to gastric motility, 956(ab)
gastric uptake of Ga-67 in AIDS, 643
Streptavidin
biotin and, localization of infection, 1810
imaging infection/inflammation, radiolabeled biotin, 924(ab)
labeled biotin and, tumor localization, substitute for antibody, 934(ab)
Striata, variation of axial recovery, tilt, solution of, 921(ab)
Striatum, loss of 6-[F-18]fluoro-L-dihydroxyphenylalanine metabolites, 916(ab)
Stroke
acute ischemic, transcranial Doppler, brain SPECT, 968(ab)
blood flow, clinical prognosis, SPECT, 878(ab)
brain tumors and, cerebral blood flow, HMPAO-SPECT and MRI technique, 971(ab)
cross cerebellar diaschisis, neurologic imaging, 968(ab)
functional brain SPECT, powerful clinical method, 1888
ischemic, perfusion change after thrombolytic therapy, Tc-99m HMPAO SPECT, 877(ab)
neurologic as an aid in diagnosis and localization, 878(ab)
Strontium-89
different therapeutic doses, metastatic bone pain, 937(ab)
low-dose infusion cisplatin and, hormone refractory prostate carcinoma metastatic to bone, 1437
radiotherapy, metastatic prostatic carcinoma, 1316
Substance P analog, nonpeptide, synthesis of, PET studies, 860(ab)
N-Succinimidyl 4-[F-18]fluorobenzonate, labeling of monoclonal antibodies with F-18, 881(ab)
Sudden death, thallium scan, court litigation, 120
Supranuclear palsy, *in vivo* SPECT with iodine-iodoluride, D2 receptor, 1481
Supreme Court, case against radioactive waste policy amendments act, 33N(3)
Surgery, vs. conservative management, antenatal hydronephrosis, impaired renal function, 873(ab)
Sympathetic nervous system
localization of pheochromocytoma, C-11 HED PET, 1125
MIBG heart and lung extraction fraction, first-pass analysis, 716
myocardial, postnatal maturation, high-resolution scintigraphy, 935(ab)

Synovectomy
radiation
Ho-166 hydroxyapatite, 937(ab)
radiolabeling, hydroxyapatite particles, 980(ab)
radionuclide, polymeric microspheres, neuron-activated holmium-166, 398

T

Tamoxifen, F-18 fluoro analog, radiosynthesis, estrogen receptors and PET, 985(ab)
Taste, dysfunction, thyroid cancer, I-131 treatment, 996(ab)
Teboroxime
extraction in rabbit heart, reduction by incubation with human RBC, 864(ab)
kinetic modeling, dynamic SPECT imaging, 878(ab)
myocardial perfusion imaging, adenosine, accuracy and optimal imaging time, 854(ab)
preprocessing masking technique, SPECT, 854(ab)
resting washout and stress thallium SPECT, coronary disease, 876(ab)
Technetium-94m, radionuclide purity requirements, pharmacokinetic studies, PET, 850(ab)
Technetium-96, comparison of bone-seeking agents, mechanistic implications, 899(ab)
Technetium-96 sestamibi, myocardial blood flow, co-injection technique, 1152
Technetium-99m
alkyl-hydroxyamide complexes, 1033(ab)
anatomy of radioisotope lung scanning, 676
brain scanning agent, elimination of chiral centers, coordination sphere, 920(ab)
cationic complexes, myocardial tissue uptake, 1033(ab)
cell binding agent, 920(ab)
compared to N2S2 chelate labeled NR-LU-10 Fab', tumored nude mice, 909(ab)
complexes and Re, structural requirements, rapid tubular transport, 900(ab)
direct labeling, platelet-binding laminin peptide, 1031(ab)
direct labeling of antibody, macromolecular Sn(II) complexes, 1029(ab)
dual-radioisotopic technique, tumescence, penile blood flow, 41
equilibrium imaging, Kr-81m, right ventricular determination, 932(ab)
evaluation of 12 biotin derivatives, 920(ab)
gated blood-pool imaging, ECG gated PET C-11 monoxide, "background" question, 938(ab)
human immunoglobulin, dendrimers as linker molecules, 986(ab)
hypodermically injected, study on radioactive pathways, 403
I-123 and
dual radionuclide data acquisition, quantitative brain SPECT, 972(ab)
feasibility, dual radionuclide SPECT imaging, 851(ab)
SPECT, brain, 2030
ImmunRAID-CEA, patient response, human anti-mouse antibody, 1002(ab)
inhibited recombinant tissue plasminogen activator, thrombosis scintigraphy, 1029(ab)
-labeled organic cations, synthesis, renal excretion, 2190
labeling of antimyosin Fab', instant kit method, myocardial infarct model, 144
mapping of leukocytes, secondary ion mass spectrometry microscopy, 2162
myocardial imaging agent, kit development,

- Technecard, 850(ab)
 new radiopharmaceuticals, multifunctional phosphorus hydrazides, 1032(ab)
 radionuclide angiography, thrombosis detection, left atrial appendage, 365
 Re-188 and, bifunctional frameworks, phosphorus hydrazide chelates, 910(ab)
 Re complexes and, unsymmetrical BAT ligand, 989(ab)
 renal scan, diagnosis, bleeding mycotic iliac aneurysm, 1548
 second binding site in IgG, relation to histidine groups, 1029(ab)
 serial measurements of cardiac volumes, count-based methods, 1324
 side chain modifications, bis(dithiocarbamate) nitrido technetium(V), myocardial uptake, 1034(ab)
 small molecule neutral-lipophilic agents, functionalized phosphinimines, 851(ab)
 targeted proteins, diagnostic imaging, 394
 Tl-201 and, dual-isotope autoradiography, computed tomography, 1005(ab)
 transmission source, Tl-201 cardiac SPECT, simultaneous acquisition of emission/transmission data, 2238
 two new myocardial perfusion agents, 22N(1)
 Xe-133 and, dual isotope imaging, energy weighted acquisition, 889(ab)
- Technetium-99m D,L-HMPAO**, uptake mechanism in cell cultures, dissociated postnatal rat cerebellum, 108
- Technetium-99m antibody**
 direct and indirect, comparison in mice, 909(ab)
 pharmacokinetic modeling, 958(ab)
- Technetium-99m anti-CEA antibodies**, technical limitations of immunoscintigraphy, 1001(ab)
- Technetium-99m antifibrin**, scintigraphy, acute deep venous thrombosis, 848(ab)
- Technetium-99m antifibrin Fab'**, localization or pharmacokinetics, anticoagulation by heparin, acute venous thrombosis, 978(ab)
- Technetium-99m anti-fibrin monoclonal antibody**, accumulation in inflammatory focus, 1181
- Technetium-99m antigranulocyte antibody**
 clinical usefulness, differential diagnosis, intracranial abscess, 957(ab)
 suspected bone infections, 526
- Technetium-99m antigranulocyte Fab' fragments**, scintigraphy, compared to In-111 oxine/Tc-99m HMPAO leukocytes, infectious diseases, 903(ab)
- Technetium-99m antigranulocyte monoclonal antibody**, fever of unknown origin, 902(ab)
- Technetium-99m antimyosin Fab'**, instant kit method, myocardial infarct model, 144
- Technetium-99m avidin**, kidney uptake, isoelectric point, 986(ab)
- Technetium-99m bicisate**: see Technetium-99m ECD
- Technetium-99m Cerotec**
 brain scan, assessment, brain death, 970(ab)
 SPECT, interictal localization, epileptic foci, 966(ab)
- Technetium-99m colloid**, Tc-99m monoclonal antibodies and, image subtraction analysis, liver lesions, 913(ab)
- Technetium-99m complexes**, properties that facilitate renal tubular transport, 920(ab)
- Technetium-99m CPI**
 human pharmacokinetics and radiopharmacological studies, 1949
 interspecies variation in biodistribution, 1357
- Technetium-99m DACH**, potential new cationic renal tubular agent, normal human volunteers, 923(ab)
- Technetium-99m desferoxamine**, Tc-99m DTPA aerosols and, SPECT lung ventilation, 835(ab)
- Technetium-99m dexamethasone phosphate**, imaging of inflammatory lesions, 1027(ab)
- Technetium-99m dextran**, lymphoscintigraphy, transverse rectus abdominus myocutaneous flap, autogenous breast reconstruction, 859(ab)
- Technetium-99m DISIDA**, utility of cholescintigraphy, laparoscopic cholecystectomy, 898(ab)
- Technetium-99m DMSA**
 elimination of background and kidney-depth correction, compartment modeling, renal uptake rate, 1004(ab)
 febrile urinary tract infections, 976(ab)
 parenchymal renal lesion after ESWL, 990(ab)
 pentavalent, small coordination complexes, tumor imaging, 469(e)
 renal scans, variability, standardized rating scale, 922(ab)
 replacement with Tc-99m MAG₃, exclusion, focal renal defect, 2090
- SPECT**
 three-head rotating gamma camera, renal scan, 1021(ab)
 triple-head imaging, urinary tract infection, 991(ab)
 triple-headed SPECT, comparison with ultrasonography, 922(ab)
- Technetium-99m DTPA**
 aerosol, MIRD dose estimate Report No. 16, 1717
 aerosol and gallium-67 scanning, pulmonary complications, HIV infection, 81
 aerosol clearance, effect of molecular size, 1022(ab)
 bifunctional, macrocyclic ligands, serum stability studies with Y-88, 1031(ab)
 diuresis renography, ureteral status, children, 72
 effects of dipyrindamole, renal function, 355
 incidence of adverse reactions, 1025(ab)
 monofunctional analogs, attachment to peptides and antibodies, 988(ab)
 radiation dosimetry, human biodistribution studies, 33
 renal uptake-plasma volume product, glomerular filtration rate, 1712
 single-injection multi-sample renal clearance methods, optimum sample times, 948(ab)
 Tc-99m desferoxamine aerosols and, SPECT lung ventilation, 835(ab)
 ventilation, effectiveness of PEP mask, cystic fibrosis, 835(ab)
- Technetium-99m DTPA-HSA**, cerebrovascular response to acetazolamide, new method for monitoring, 969(ab)
- Technetium-99m ECD**
 brain perfusion SPECT, cerebral blood flow, PET, 966(ab)
 brain retention, effect of radiolabeled impurities, dosimetry, 989(ab)
 kinetic behavior in human brain, compartment analysis and dynamic SPECT, compared to Tc-99m HMPAO, 909(ab)
 planar imaging, global cerebral blood flow, monkeys, 979(ab)
 SPECT, kinetics, brain tumors, 969(ab)
 synthesis of isomers, brain, monkeys, 979(ab)
 Tc-99m HMPAO and, intrasubject comparison, healthy human subjects, 480
- Technetium-99m EHIDA**, hepatobiliary scintigraphy, diagnostic criteria for biliary atresia, neonatal jaundice, 899(ab)
- Technetium-99m erythrocytes**, modification of labeling technique, effectiveness, 2222
- Technetium-99m exametazine**, regional cerebral uptake, unilateral voluntary hand movement, 1623
- Technetium-99m fragment E₁**, thrombus imaging, preparation, preliminary evaluation, 710
- Technetium-99m 2GAM**, renal imaging, evaluation in humans, 923(ab)
- Technetium-99m glucarate**, Tl-201 and, acute myocardial infarction, rats, 1988
- Technetium-99m glucoheptonate white blood cells**, inflammatory bowel disease, 998(ab)
- Technetium-99m HDP**, incidence of adverse reactions, 1025(ab)
- Technetium-99m HIDA**, hepatic clearance of derivatives, hyperbilirubinemic states, 1551
- Technetium-99m HIG**
 assessment of infectious conditions, musculoskeletal system, 839(ab)
 bone scans and, joint inflammation, rheumatoid arthritis, 840(ab)
 detection of bone and joint inflammation, 839(ab)
 one-step labeling kit, imaging of inflammation and tumors, 1028(ab)
- Technetium-99m HMPAO**
 angiography of the brain, quantitative approach, 877(ab)
 brain perfusion SPECT, acute aphasia, 970(ab)
 brain scans, high-resolution SPECT, neurofocal imaging, 1070(ab)
 brain SPECT
 bilateral and symmetrical anomalies, 485
 cerebral angioplasty, delayed ischemia due to vasospasm, 1789
 cerebral blood flow, choreo-athetoid syndrome, 838(ab)
 r-CBF variability, 826(ab)
 regional cerebral blood flow, Down's syndrome, 1013(ab)
 cerebral cortical activity, scintigraphy, 117
 cerebral perfusion, internal carotid artery occlusion, 969(ab)
 cerebral perfusion scintigraphy, timely brain death declaration, 2209
 comparative study of TcGH and TcHMPAO, diagnosis of brain death, 1016(ab)
 compartment analysis and dynamic SPECT, kinetic behavior, Tc-99m ECD, 909(ab)
 differential diagnosis of dementia, 939(ab)
 I-123 IMP and
 dual-isotope brain imaging, normal volunteers, 827(ab)
 regional cerebral blood flow, drug abuse, 1015(ab)
 regional cerebral blood flow, SPECT and MRI, 1012(ab)
 independent aura/ictal/interictal cerebral perfusion, 438
 intraarterial carotid artery injection, recurrent glioma, 966(ab)
 isomers D,L and effect of cocaine, uptake and respiration, rat brain slices, 964(ab)
 isomers D and L, biological evaluation, 1032(ab)
 kinetic behavior in human brain, cerebral blood flow, dynamic SPECT, 135
 -labeled WBC scan, spread of infectious complications, odontogenic abscess, 254
 lymphocyte labeling, radiotoxicity study, micron-

- ucleus assay, 1167
- presurgical scintigraphy, patients with medically refractory seizures, 967(ab)
- SPECT**
 - acetazolamide, cerebrovascular disease, 877(ab)
 - acetazolamide effect, vascular response and diaschisis, 967(ab)
 - alternating hemiplegia, childhood, 1021(ab)
 - attenuation correction, brain, 1875
 - Barre-Liou syndrome, cervical manipulation, 972(ab)
 - brain blood flow, interventional neuroradiology, 826(ab)
 - carbon dioxide reactivity, cerebrum and cerebellum, 1014(ab)
 - cerebral blood flow, brain tumors and strokes, 971(ab)
 - cerebral blood flow, chronic subdural hematoma, 246
 - cerebrovascular reserve capacity, carotid artery stenosis, 971(ab)
 - cocaine abuse, AIDS dementia complex, 1312
 - crossed cerebellar diaschisis, cerebral infarction, 877(ab)
 - 3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
 - feasibility of cortical activation study, subtraction method, 1015(ab)
 - kinetics, brain tumors, 969(ab)
 - linearization algorithm, cerebral blood flow, 912(ab)
 - localization, epileptic foci, 971(ab)
 - perfusion change after thrombolytic therapy, ischemic stroke, 877(ab)
 - presurgical evaluation, temporal lobe epilepsy, 929(ab)
 - quantitative perfusion-defect indexes, children with cerebral palsy, 977(ab)
 - regional cerebral blood flow, Wisconsin card sorting test, 967(ab)
 - remote history, traumatic brain injury, 52
 - schizophrenia and depression, 972(ab)
 - scintigraphic appearance, Alzheimer's disease, 181, 312
 - sensitivity and specificity, dementia, 1013(ab)
 - status epilepticus, 928(ab)
 - subjects with and at risk for Huntington's disease, 970(ab)
- SPECT compared to MR/CT, diagnosis of dementia, 972(ab)
- Tc-99m ECD and, intrasubject comparison, healthy human subjects, 480
- Tc-99m RBC and, sequential high resolution SPECT, intracranial arteriovenous malformations, 839(ab)
- Technetium-99m HMPAO leukocytes**, Tc-99m anti-granulocyte Fab' fragments, scintigraphy, 903(ab)
- Technetium-99m HMPAO lymphocytes**, fast diagnosis of abdominal infections, 1253(le)
- Technetium-99m hydrazino nicotinamide**, conjugated chemotactic peptides, imaging focal sites of infection, 910(ab)
- Technetium-99m hydroxyamic acids**, tumor imaging agents, 988(ab)
- Technetium-99m IDA**, quantitative cholescintigraphy, differentiation, congenital gallbladder abnormality, 431
- Technetium-99m L,L-EC**, renal imaging agent, 551
- Technetium-99m LDL**, binding to parenchymal and non-parenchymal cells, normal and estradiol-stimulated rat liver, 1028(ab)
- Technetium-99m leukocytes**
 - clinical experience with Tc-99m nanocolloid, 999(ab)
 - diagnosis of sternal wound infection, 59
 - In-111 oxine and, simultaneous imaging, community hospital, 902(ab)
- Technetium-99m liposomes**
 - cardiac blood-pool scintigraphy, 984(ab)
 - newly developed labeling procedure, successful infection detection, rats, 1027(ab)
- Technetium-99m MAG₃**
 - clearance
 - camera-based method, gamma variate fit, 991(ab)
 - optimized camera based method, 948(ab)
 - preliminary "normal" values, infants, 1021(ab)
 - prospective validation, single sample technique, 1620
 - diuretic renal scintigraphy, routine protocol, congenital and acquired renal disorders, 1035(ab)
 - evaluation of new ligands, renal function agents, 988(ab)
 - hepatobiliary excretion, 990(ab)
 - kits, prolonging useful life, 991(ab)
 - modified amide bonds, 1032(ab)
 - potential renal imaging agents, 919(ab)
 - radiation dosimetry, human biodistribution studies, 33
 - renal scans, hepatic activity, 992(ab)
 - replacement of Tc-99m DMSA, exclusion, focal renal defect, 2090
 - scintigraphy, captopril, renal artery stenosis, 990(ab)
 - simplified ERPF determination, 1034(ab)
 - single-injection multi-sample renal clearance methods
 - comparison, 948(ab)
 - optimum sample times, 948(ab)
 - technescan, labeling conditions and QC, 1033(ab)
 - vs. I-131 hippurate, functional and anatomic evaluation, renal transplants, 1035(ab)
- Technetium-99m MDP**
 - accumulation of F-18 FDG, bone fracture, 869(ab)
 - compared to Tc-99m MIBI uptake, benign and malignant bone lesions, 319
 - diffuse abdominal uptake, continuous ambulatory dialysis, bone scintigraphy, 2052
 - extraneous uptake, pathophysiologic approach, 1063(ab)
 - gallium and, scintigraphic differentiation, osteogenic and Ewing's sarcoma, 1063(ab)
 - I-131 MIBG and bone scintigraphy, detection of neuroblastoma, 1735
 - skeletal nonvisualization, bone scan, intravenous etidronate therapy, 748
- Technetium-99m mebrofenin**, scintigraphic aspect, Rotor's disease, 1550
- Technetium-99m medronate**, uptake in hepatic necrosis, Budd-Chiari syndrome, 1390
- Technetium-99m mertiatide**, atlas of renal transplant imaging studies, 1073(ab)
- Technetium-99m MIBI**
 - compared to Tl-201 scintigraphy with reinjection, viable myocardium, chronic coronary artery disease, 505
 - radionuclide angiography, SPECT myocardial perfusion, diprydamole, 846(ab)
 - rest-redistribution Tl-201, chronic coronary artery disease, 905(ab)
 - scintigraphy, myocardial viability, thallos chloride injection, 906(ab)
- SPECT**
 - resting and exercise myocardial imaging, chil-
 - dren, 929(ab)
 - stability, perfusion defect size, 876(ab)
 - subcellular distribution and analysis, perfused rat hearts, 1516
- Tl-201**
 - follow-up, differentiated thyroid carcinoma, 844(ab)
 - and MRI, recurrent brain tumors, 867(ab)
 - Tl-201 chloride and, uptake, primary thyroid lymphoma, 1396
 - Tl-201 scintigraphy and, localization, parathyroid enlargement, 895(ab)
 - Tl-201 SPECT and, childhood brain tumors, 844(ab)
 - uptake in benign and malignant bone lesions, compared to Tc-99m MDP, 319
 - use in peripheral vascular disease, 629(le)
- Technetium-99m monoclonal antibody**
 - CA 125, early detection, ovarian cancer recurrences, 904(ab)
 - F023C5 anti-CEA IgG1, gastrointestinal tumor targeting, role of CEA content, 892(ab)
 - 174H.64, SPECT, staging of head and neck cancer, 912(ab)
 - HPLC, recovery and calibration, 1030(ab)
 - management of colorectal and ovarian cancer, 904(ab)
 - Tc-99m colloid image subtraction analysis and, liver lesions, 913(ab)
- Technetium-99m N₂S₈**, monocationic radiotracers, synthesis and evaluation, 990(ab)
- Technetium-99m nanocolloid**, clinical experience, 999(ab)
- Technetium-99m NGA**, evaluation of local reduced mass, functioning hepatocytes, chronic liver diseases, 998(ab)
- Technetium-99m nitrido dithiocarbamate**, myocardial imaging agents, improved synthesis, 989(ab)
- Technetium-99m 2-nitroimidazole**, imaging regional hypoxia, occlusion of LAD coronary artery, rabbit myocardium, 865(ab)
- Technetium-99m P53**, myocardial imaging agent, structural characterization, 850(ab)
- Technetium-99m pertechnetate**
 - pulmonary mean transit times, teboroxime, 846(ab)
 - radionuclide hysterosalpingography, radiation dose to ovaries, 282
 - thyroid scanning, 1722(le)
- Technetium-99m phytate**
 - high-resolution three-head SPECT, dual energy acquisition, liver tumor imaging, 976(ab)
 - Tl-201 and, liver tumor imaging, high-resolution three-head SPECT, 918(ab)
- Technetium-99m phytate succralfate**, new procedure, advanced ulcer avid agent, 1033(ab)
- Technetium-99m polyclonal IgG**
 - carbohydrate modification, sites of bacterial infection, 1378
 - single radiopharmaceutical kit, 1024(ab)
- Technetium-99m PPN.1011**, SPECT, clinical evaluation, myocardium, 875(ab)
- Technetium-99m progesterin**, Re-186 and, synthesis and receptor binding, 558
- Technetium-99m Q12**, myocardial blood flow in canine heart, 993(ab)
- Technetium-99m red blood cells**
 - gastrointestinal bleeding studies, early negative images, 202
 - penile corporal venous leak, 49
 - preparation with UltraTag RBC kit, evaluation, heparin and anticoagulant citrate dextrose, 306(le)

- Tc-99m HMPAO and, sequential high resolution SPECT, intracranial arteriovenous malformations, 839(ab)
- Technetium-99m sestamibi**
 acute Adriamycin cardiotoxicity, chick heart cells, 864(ab)
 cardiac perfusion abnormalities, Kawasaki syndrome, 929(ab)
 comparison of rest-redistribution Tl-201 uptake, coronary artery disease, 905(ab)
 defect size, thrombolytic therapy, regional wall motion, 927(ab)
 detection of coronary artery disease, 1091
 dobutamine and exercise, coronary artery disease, 951(ab)
 gated SPECT, characterization of fixed defects, infarct or artifact, 927(ab)
 localization of parathyroid adenoma hyperparathyroidism, 1801
 primary hyperparathyroidism, 894(ab)
 lung uptake, correlation with LV ejection fraction, 846(ab)
 multiple gated SPECT, myocardial thickening, phase analysis, 926(ab)
 myocardial distribution, nontransmural infarction, 223
 myocardial imaging, comparison, same-day protocols, 186
 myocardial reperfusion imaging, acute chest pain, non-diagnostic EKG, 876(ab)
 myocardial SPECT imaging
 comparison, short and standard data acquisition, 855(ab)
 early and delayed imaging, 855(ab)
 parathyroid imaging, 313
 perfusion and regional contraction, peak left ventricular ejection fraction, coronary artery disease, 847(ab)
 PET, defect size and severity, 875(ab)
 planar, blinded evaluation, myocardial perfusion studies, 668
 retention characteristics, canine myocardium, 865(ab)
 same-day acquisition protocol, 468(le)
 scintigraphy, radioisotopic assessment, myocardial viability, 1925
 serial tomographic imaging, infarct-related arterial patency, reperfusion therapy, 2080
SPECT
 dobutamine, coronary artery disease, 866(ab)
 F-18 FDG glucose PET, malignancy, 858(ab)
 myocardial viability, 886(ab)
 right ventricular ischemia, inferior myocardial infarction, 876(ab)
 same day, myocardium, 876(ab)
 spontaneous chest pain, coronary intervention, 875(ab)
 Tl-201 and, myocardial viability, 905(ab)
 stress perfusion, myocardial function and viability, 3-D SPECT, 926(ab)
 stress/rest Tl-201 SPECT, myocardial perfusion, 854(ab)
 Tl-201 and
 heart transplantation, coronary arteriopathy, 951(ab)
 imaging, myocardial infarction, 865(ab)
 quantitative dual isotope autoradiography, uptake in rabbits, 993(ab)
 rest/exercise imaging, defect reversibility, 855(ab)
 uptake kinetics, rat heart endothelial and fibroblast-like cells, 102
 viable myocardium, 815
 uptake by recurrent Hurthle cell carcinoma, thyroid, 1393
 vial breakage with microwave oven, 176(le)
- Technetium-99m somatostatin analogue**, In-111 somatostatin analogue and, preparation, preliminary evaluation, 851(ab)
- Technetium-99m sulphur colloid**, dosimetry, cellular level, Kupffer cells, 380
- Technetium-99m T691**, preclinical studies, regional cerebral perfusion, 1836
- Technetium-99m TBI**, scintigraphy, detection of metastases, thyroid carcinoma, 914(ab)
- Technetium-99m TBIDA**, hot spots on liver scan, focal nodular hyperplasia, 918(ab)
- Technetium-99m teboroxime**
 absorbed radiation dose to humans, 88
 detection of coronary artery disease, 1091
 myocardial blood flow, co-injection technique, 1152
 myocardial extraction, interaction with blood, 94
 myocardial SPECT imaging, delay of image acquisition, exercise-induced perfusion defects, 952(ab)
 planar myocardial perfusion imaging, Tl-201 and coronary angiography, 1783
 retention characteristics, canine myocardium, 865(ab)
 Tl-201 and
 continuous SPECT imaging protocol, 1304
 coronary stenosis, vasodilation with adenosine, 864(ab)
- Technetium-99m tetrofosmin**
 biokinetics, myocardial perfusion, one-day imaging, 874(ab)
 clinical efficacy, myocardial imaging agent, 874(ab)
 comparison of defect size, peak exercise, 874(ab)
 effect of coronary blood flow on uptake, rabbit heart, 846(ab)
 myocardial imaging
 coronary heart disease, 875(ab)
 perfusion and blood flow, 993(ab)
 structural characterization, myocardial imaging agent, 850(ab)
- Technetium-99m (V)-DMSA**, facile synthesis of Re-188-labeled Rc(V)-DMSA, triphenylphosphine reduction, perchlorate at room temperature, 1024(ab)
- Technetium-99m (V)-thiocyanate**, gastric emptying and intragastric distribution, oil, presence of liquid or solid meal, 1283
- Technetium-PnAO-nitroimidazole complex**, chemistry of, localization in hypoxic tissue, 919(ab)
- Technology**, coming reform of health care system, 24N(4)
- Telangiectasia**, hereditary hemorrhagic, embolization, hepatic arteriovenous malformations, 260
- Tenascin**, detection of breast tumors, labeled BC-2 monoclonal antibody, 999(ab)
- Teratoma**
 immature third ventricle, radiographic and neuro-SPECT imaging, 435
 rectal wall, pelvic radioiodine uptake, thyroidectomy for papillary carcinoma, 1848
- Testes**
 macro- and microscopic biodistribution, In-111, rats, 954(ab)
 radiotoxicity, I-123/I-125/I-131-labeled compounds, mouse, 2196
- 1,4,7,10-Tetraazacyclododecane**, simple synthesis and activation, immunoconjugation, 942(ab)
- Thakur, Mathew**, Aebersold Award, 34N(5)
- Thallium-201**
 accumulation by epidermoid inclusion cyst, 1857
 adenosine scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
 after brain surgery and irradiation, quantification using an animal model, 964(ab)
 brain SPECT, re-evaluation for brain tumor, 844(ab)
 cardiac SPECT imaging, Tc-99m transmission source, simultaneous acquisition of emission/transmission data, 2238
 -chloride uptake, hypermetabolic bone marrow, granulocyte stimulating factor, 2014
 comparison of digital and analog film display, 1003(ab)
 CT/MRI/angiography in bone and soft tissue sarcoma, 843(ab)
 defect reversibility and severity, quantitative vs. visual analysis, 905(ab)
 delayed post-reinjection, detection of viable myocardium, 1064(ab)
 dipyridamole
 improvement of image quality, walking exercise, 2061
 predictive value, myocardial bridging, 1905
 dipyridamole imaging, dose comparisons, coronary artery disease, 866(ab)
 dobutamine, scintigraphy, usefulness and safety, 951(ab)
 early imaging after PTCA, 866(ab)
 tomographic evaluation, adenosine-induced coronary hyperemia, 2086
 exercise myocardial SPECT, major upward creep of heart, COPD, 1846
 exercise-redistribution SPECT, myocardial viability after infarction, 906(ab)
 exercise whole-body thallium perfusion imaging, peripheral vascular disease, 1797
 high-resolution three-head SPECT, dual energy acquisition, liver tumor imaging, 976(ab)
 I-123 branched fatty acid analogue and, assessment, ischemic but viable myocardium, 885(ab)
 importance of delayed scanning, 463(le)
 influence of perfusion defect size, tomographic defect severity, 995(ab)
 injection, myocardial viability, Tc-99m scintigraphy, 906(ab)
 lack of redistribution, dipyridamole imaging, postoperative and long-term outcome, 951(ab)
 myocardial blood flow, co-injection technique, 1152
 optimal imaging time as a tumor agent, lymphoma, 844(ab)
 planar myocardial perfusion imaging
 detection, coronary artery disease, 1091
 Tc-99m tebo, 1783
 quantitative stress-redistribution SPECT, prone imaging, validation, 1509
 redistribution, FDG PET, increased FDG uptake after myocardial infarction, 886(ab)
 redistribution model, 915(ab)
 reinjection
 enhanced detection of ischemia, quantitative reversibility maps, 916(ab)
 interval between reinjection and imaging, post-MI patients, 915(ab)
 patients without previous myocardial infarction, 916(ab)
 rest-redistribution
 chronic coronary artery disease, relation to Tc-99m MIBI, 905(ab)
 resting sestamibi uptake, coronary artery dis-

ease, 905(ab)
 rest/stress Tc-99m sestamibi SPECT, myocardial perfusion, 854(ab)
 retention characteristics, canine myocardium, 865(ab)
 reversible perfusion defects, incomplete right bundle branch block, normal coronary angiogram, 1556
 scan
 contribution, differentiated thyroid carcinoma, 955(ab)
 interpretation, court litigation, 120
 patterns, bone and soft tissue sarcoma, 843(ab)
 scintigraphy
 adenosine, lung thallium uptake, 1600
 incremental diagnostic value and impact, 1727
 incremental value, cost consciousness, 1732
 localization, parathyroid enlargement, 895(ab)
 scintigraphy with reinjection, viable myocardium, chronic coronary artery disease, 505
 SPECT
 attenuation correction, 1574
 brain tumor recurrence, 867(ab)
 distinction, high-grade from low-grade gliomas, 868(ab)
 heart transplantation, coronary arteriopathy, 951(ab)
 meningioma, prediction of histological type, 971(ab)
 myasthenia gravis, 1020(ab)
 myocardial viability, coronary artery disease, 886(ab)
 of theoretical derivations, empirical evidence, 1578
 recurrent primary brain tumors, 1071(ab)
 reinjection studies, collateralization, 915(ab)
 sensitivity to patient motion, 1571
 teboroxime resting washout, coronary disease, 876(ab)
 vs. Rb-82 PET, myocardial perfusion, 1064(ab)
 SPECT and F-18 FDG PET, MRI, recurrent supratentorial and infratentorial brain tumors, 867(ab)
 stress test, ECG response and perfusion images, 1723(le)
 Tc-99m and, dual-isotope autoradiography, computed tomography, 1005(ab)
 Tc-99m glucarate and, acute myocardial infarction, rats, 1988
 Tc-99m MIBI and
 follow-up, differentiated thyroid carcinoma, 844(ab)
 MRI, recurrent brain tumors, 867(ab)
 Tc-99m MIBI SPECT and, childhood brain tumors, 844(ab)
 Tc-99m phytate and, liver tumor imaging, high-resolution three-head SPECT, 918(ab)
 Tc-99m sestamibi and
 imaging, myocardial infarction, 865(ab)
 quantitative dual isotope autoradiography, uptake in rabbits, 993(ab)
 rest/exercise imaging, defect reversibility, 855(ab)
 uptake kinetics, rat heart endothelial and fibroblast-like cells, 102
 viable myocardium, 815
 Tc-99m sestamibi SPECT and, myocardial viability, 905(ab)
 Tc-99m teboroxime and
 continuous SPECT imaging protocol, 1304
 coronary stenosis, vasodilation with adenosine, 864(ab)
 tomographic perfusion imaging, effect of patient motion, 1566

tomography, pharmacologic stress and, extent and location of CAD, 2067
 transient exercise vs. dipyridamole-induced left ventricular cavity dilatation, 951(ab)
 uptake after reinjection, regional ventricular function, myocardial perfusion, 915(ab)
 uptake pattern in bone lesions, differentiation, benign from malignant processes, 869(ab)
Thallium-201 chloride, Tc-99m MIBI and, uptake, primary thyroid lymphoma, 1396
Thrombendarterectomy, carotid artery stenosis, cerebrovascular reserve capacity, 971(ab)
Thrombocytopenia, hepatic sequestration of In-111 platelets, GM-CSF, 923(ab)
Thrombogenicity, comparative, cellulose-acetate hemodialyzer, 956(ab)
Thrombolytic therapy
 late infarct size and ejection fraction, acute myocardial infarction, 939(ab)
 perfusion change, ischemic stroke, Tc-99m HMPAO SPECT, 877(ab)
 predictor of prognosis, PET, ischemic myocardium at risk, 837(ab)
Thrombosis
 acute deep venous, Tc-99m antifibrin scintigraphy, 848(ab)
 acute venous, anticoagulation by heparin, Tc-99m antifibrin Fab' localization, 978(ab)
 detection in left atrial appendage, Tc-99m radionuclide angiography, 365
 imaging, Tc-99m fragment E₁, preliminary evaluation, 710
 scintigraphy, Tc-99m inhibited recombinant t-PA, 1029(ab)
 thallium scan, court litigation, 120
Thymidine, methionine or, location in cell, radiation-induced alterations, 841(ab)
Thyroglobulin, measurement, I-131 whole-body scan, thyroid carcinoma, 172(le)
Thyroid
 autonomous nodule, treatment, percutaneous ethanol injection, 954(ab)
 follicle, radiation dose distribution, revised method, 926(ab)
 nodule, accuracy of neuronet diagnosis, backpropagation simulator, 954(ab)
 orbital radiolabeled somatostatin accumulation, Graves' disease, Graves' ophthalmopathy, 894(ab)
 post-I-131 cancer therapy, radiation safety considerations, 1402
 primary osteosarcoma, 1399
 radioactive uptake, potential effects, contrast material iodides, 237
 scanning with Tc-99m pertechnetate, 1722(le)
 uptake neck phantoms, 304(le)
 well-differentiated neoplasms, radioiodine-131 therapy, 1132
Thyroidectomy, papillary carcinoma, pelvic radioiodine uptake, rectal wall teratoma, 1848
Thyroid neoplasms
 differentiated, clinical meaning, circulating anti-thyroglobulin antibodies, 1478
 I-131 contamination, 2110
 I-131 therapy, quantitative dosimetric approach, 894(ab)
 surprise findings, Chernobyl, 23N(11)
 taste dysfunction, I-131 treatment, 996(ab)
 TSH stimulation, sequential FDG PET studies, before and after T4 thyroid replacement therapy, 894(ab)
 well-differentiated, chest X-rays and bone scans, I-131 scans, 894(ab)
Title VII, appropriations, 26N(3)

Tomography, cone beam, dual-detector SPECT system, 892(ab)
Tracers, new developments, 16N(8)
Tracheobronchitis, necrotizing, In-111 white blood cell scan, 1704
Transferrin
 hepatic Ga-67 concentration and, Ga-67 distribution, 1701
 IgG and F(ab')₂ conjugates, preparation, characterization, 986(ab)
Transplantation
 cardiac, reduced exercise capacity, Starling effect, 939(ab)
 distribution in cells of In-111 hepatocytes, 918(ab)
 lung, scintigraphy in follow-up, 835(ab)
 renal
 atlas of imaging studies, Tc-99m mertiatide, 1073(ab)
 functional and anatomic evaluation, Tc-99m MAG₃ vs. I-131 hippurate, 1035(ab)
 hypertension, iliac artery stenosis, 1178
 renal kinetics, chronic rejection, renal artery stenosis, 923(ab)
 single lung, quantitative exercise-rest ventilation-perfusion imaging, 835(ab)
Triazolam, interaction with central type benzodiazepine receptors, PET, baboons, 973(ab)
Trionix, lawsuit of ADAC Laboratories, gamma camera technology, 18N(2)
Triorchidism, scintigraphy of torsion, 1854
Tritium-3-colchicine, tumor multidrug resistance, *in vivo* identification, 1373
Tuberculosis, extrapulmonary, Ga-67 scan, computed tomography, 2118
Tumescence, evaluation of penile blood flow, dual-radioisotopic technique, 41
Tumor-associated antigens, similarity and co-expression, recognition, different monoclonal antibodies, 853(ab)
Tumors
 quantitative scintigraphy and time to metastasis, dogs with osteosarcoma, 1542
 rapidly growing, absorbed dose calculations, 277
 solid
 5-iododeoxyuridine, efficacy of radioimmunotherapy, 1530
 localization with streptavidin and labeled biotin, substitute for antibody, 934(ab)
 radiolabeled monoclonal antibody heterogeneous distribution, binding site barrier, 893(ab)
Tyramine cellobiose, radioiodinated monomeric antibody P-67, improved tumor retention, 987(ab)

U

Ulcer, avid agent, new procedure, 1033(ab)
Ultrasonography
 cerebrovascular reserve capacity, carotid artery stenosis, thrombendarterectomy, 971(ab)
 compared to triple-headed DMSA SPECT, 922(ab)
 intracoronary probes and PET, concordant quantification, flow reserve, 836(ab)
 Tc-99m MIBI and Tl-201 scintigraphy, localization, parathyroid enlargement, 895(ab)
 transcranial, brain SPECT, acute ischemic stroke therapy, 968(ab)
Ureter
 function, assessment of hydronephrosis, 78
 kidney washout, Tc-99m DTPA diuresis renography, children, 73
Uretero-pelvic junction

- natural history of infantile hydronephrosis, diuretic renography, 2098
 suspicion of obstruction, postnatal assessment, volume expanded diuretic renography, 2094
- Urinary bladder**, dynamic model for radiation dose calculation, MIRD pamphlet No. 14, 783
- Urinary tract**
 febrile infections, Tc-99m DMSA scanning, children, 976(ab)
 infection, triple-head imaging, Tc-99m DMSA SPECT, 991(ab)
 infection in childhood, 872(ab)
- Urokinase**, lung scan, pulmonary arteriogram improvement, 849(ab)
- U.S. Court of Appeals**, upheld nuclear quality management rule, 19N(7)
- Uveitis**, sarcoid, Ga-67 citrate scanning, 1851
- V**
- Variocoeles**, classification by two-phase scrotal scintigraphy, 1034(ab)
- Vascular disease**, peripheral, use of Tc-99m MIBI, 629(le)
- Vasculitis**, systemic, radiolabeled granulocyte kinetics, 491
- Vasospasm**, delayed ischemia, cerebral angioplasty, brain SPECT, 1789
- Ventilation**
 enhanced V/Q mismatch sign, pulmonary embolism, 1072(ab)
 go with the flow—but how far?, 1939
 lung, Tc-99m DTPA and Tc-99m desferoxamine aerosols, SPECT, 835(ab)
 necrotizing tracheobronchitis, In-111 white blood cell scan, 1704
 perfusion scans, severe diffuse obstructive airway disease, single-breath Xe-133, 1072(ab)
 regional, volume and, separation by Kr-81m, 1935
 routine imaging, PE evaluation, low probability V/Q scans, 1022(ab)
 V/Q frequency distribution, pulmonary diseases, 1023(ab)
- Ventilation-perfusion**
 exercise-rest, single lung transplant, 835(ab)
 lung scanning, computer-assisted diagnosis, pulmonary embolism, 1003(ab)
 lung scans, number of segmental mismatches, likelihood of pulmonary embolism, 849(ab)
 scintigraphy, intermediate likelihood-ratio results, 849(ab)
- Ventricular function**
 biventricular, parametric display, gated blood-pool SPECT, 952(ab)
- left**
 count-based ratio method and volume, first-pass radionuclide angiography, 2124
 diastole, systemic sclerosis, 68
 during exercise, coronary jeopardy score, 938(ab)
 ejection fraction, gated Tc-99m sestamibi SPECT, 927(ab)
 perfusion and performance, single radiopharmaceutical and one camera, 1411
 regions of interest, simulated annealing, 932(ab)
 severely impaired ejection fraction, cardiac peak power, 938(ab)
 time-activity curve, O-15 water PET, 1669
 volume determination, radionuclide methods, 763
- miniature cadmium telluride detector, coronary artery bypass grafting, 441
 myocardial perfusion and, simultaneous assessment, total coronary artery occlusion, 825(ab)
 nuclear probes in cardiology, 448
 right, volume determination, Kr-81m multiple-gated imaging and Tc-99m equilibrium imaging, 932(ab)
 thallium uptake after reinjection, myocardial perfusion, 915(ab)
- Ventriculography**, radionuclide, rest and exercise, active acromegaly, 834(ab)
- Vesamicol**, F-18 labeled acyclic analogues, potential cholinergic neuron markers, 983(ab)
- VEST**, continuous, miniature cadmium telluride detector, coronary artery bypass grafting, 1914(le)
- W**
- WAM module**, acceptance testing and quality assurance, 1005(ab)
- Water**, contraction/relaxation of actomyosin, T2 relaxation behavior, 974(ab)
- Welch, Michael J.**, Hevesy Nuclear Medicine Pioneer Award, 16N(7)
- White blood cells**
 dual bone and WBC scan imaging, osteomyelitis and cellulitis, planar and SPECT imaging, 839(ab)
 monoclonal antibodies, 34N(5)
 scintigraphy with monoclonal antibodies, septic loosening, endoprostheses, 840(ab)
- Wilson's disease**, dopamine D2 receptors, I-123 IBZM, 897(ab)
- Wound healing**, hematopoietic neoplasia, soft-shell clam, 998(ab)
- X**
- Xenografts**
 human epidermoid carcinoma, biodistribution, In-111 B3 monoclonal antibody, 842(ab)
 neuroblastoma
 distribution of I-125 MIBG, electron microscopic autoradiography, 1021(ab)
 radioimmunolocalization, chimeric antibody chCE7, 231
 scintigraphic detection, overexpressed c-kit protooncogene, monoclonal F(ab')₂ fragments, 893(ab)
- Xenon**, dual-radioisotopic technique, tumescence, penile blood flow, 41
- Xenon-127**, economic advantages over Xe-133, 305(le)
- Xenon-133**
 method to evaluate PE, low probability V/Q scans, routine ventilation scans, 1022(ab)
 single-breath, severe diffuse obstructive airway disease, 1072(ab)
- SPECT**
 cerebral blood flow and predetermined ROIs, children, 977(ab)
 surgical outcome, temporal lobe epilepsy, 1018(ab)
 Tc-99m and, dual isotope imaging, energy weighted acquisition, 889(ab)
- X-ray**
 chest
 atelectasis, pulmonary embolism, 849(ab)
 bone and I-131 scans, well-differentiated thyroid cancer, 894(ab)
- Y**
- Young Investigators Symposium**, Computer and Instrumentation Council as sponsor, 32N(10)
- Yttrium-88**, bifunctional DTPA and macrocyclic ligands, serum stability studies, 1031(ab)
- Yttrium-88 immunocjugates**, biodistribution, chelate rigidity and denticity, 1030(ab)
- Yttrium-90**
 attachment to antibody via popular chelators, liver homogenates, 1030(ab)
 microsphere therapy, three-dimensional tumor dosimetry, 735

JNM

DIRECT RESPONSE

The *Journal* is testing a new method to enable you to get information on a more timely basis from our advertisers.

Listed below are the companies that have advertised in this issue, as well as those that have been mentioned in the *New Products* section. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this form to The Society of Nuclear Medicine, Marketing Dept., 136 Madison Ave., New York, NY 10016. FAX: 212/545-0221. We will forward this information to the advertiser(s). Deadline for response is: **March 15, 1993.**

Advertisers:

- | | | | |
|---|---|--|---|
| 1 American College of Nuclear Physicians Washington, DC (202) 857-1135 Pages 9A | 5 Data Spectrum Chapel Hill, NC (919) 732-6300 Page 24A | 9 Encore Medical Systems Palantine, IL (708) 359-4400 Pages 39A | 13 Picker International Bedford, OH (216) 475-1111 Page 56A-Inside Back Cover |
| 2 Biodex Medical Systems Shirley, NY (516) 924-9000 Page 38A | 6 Diversified Diagnostic Products, Inc. Houston, TX (713) 955-5323 Page 53A | 10 Elscint, Inc. Hackensack, NJ (800) 228-7226 Pages 11A-13A, 36A-37A | 14 Quinton Sales Dept. Seattle, WA (800) 426-0337 Page 38A |
| 3 Capintec, Inc. Ramsey, NJ (800) 631-3826 Page 2A | 7 EG&G ORTEC Oak Ridge, TN (615) 482-4411 Page 38A | 11 Medimatic Div. of M.I.D., Inc. New York, NY (212) 688-5620 Back Cover | 15 Siemens Medical Systems, Inc. Hoffman Estates, IL (708) 304-7252 Inside Front Cover-1A |
| 4 CME Video Cherry Hill, NJ (800) 284-8433 Page 38A | 8 Du Pont Company No. Billerica, MA (800) 225-1572 Pages 17A-23A | 12 Olympus Corp. Lake Success, NY (800) 446-5967 Page 38A | 16 SNM Meetings Pages 14A, 46A, 53A |
| | | | 17 SNM Membership Information |

From:

Your Name: _____ Title: _____
 Institution: _____ Dept: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ FAX: _____
 Primary Specialty: _____ Secondary Specialty: _____

Circle One Answer In Each Category:

Employer

1. Hospital:
 - a. 500 patients plus
 - b. 300-499 patients
 - c. 200-299 patients
 - d. 100-199 patients
2. Private Clinic
3. R&D Commercial
4. University
5. Government
6. Other _____

Purchase Authority

1. Recommend
2. Specify
3. Purchase

Reason for Inquiry

1. Immediate Purchase
2. General Information
3. Budgeting Information

SNM Member

1. Yes
2. No

SNM Subscriber

1. Yes
2. No